{"docstore/data": {"41316b80-30ce-400c-8319-4b5b9a65544e": {"__data__": {"id_": "41316b80-30ce-400c-8319-4b5b9a65544e", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "original_text": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. "}, "hash": "c10b5d56b05fa41c34e596be2aa463816eae8d3cff91251c1988503aca82b7f7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58": {"__data__": {"id_": "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "original_text": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41316b80-30ce-400c-8319-4b5b9a65544e", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0508ad65ebc4d2739faa3b2b0307c66a2ab3d05b477f9ea1c0c960b744eebf05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n", "original_text": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.  "}, "hash": "dd023cecb567cf13e82f0ae77f1015f24c4cc954ce09907d339b9a8867ccb34c", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "start_char_idx": 48, "end_char_idx": 177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67": {"__data__": {"id_": "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n", "original_text": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "original_text": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d1239b417a96581d8554a02ddd7acf258b309cdbd89d1c35096f5de556dd8f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88d9e3e4-2d6d-4039-a939-e84930b32699", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome. ", "original_text": "Today's conference is being recorded. "}, "hash": "9e145c87927902b85930067da6606bc310eb8b92c0a50fdd019b0081a1511ac5", "class_name": "RelatedNodeInfo"}}, "text": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "start_char_idx": 177, "end_char_idx": 237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88d9e3e4-2d6d-4039-a939-e84930b32699": {"__data__": {"id_": "88d9e3e4-2d6d-4039-a939-e84930b32699", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n", "original_text": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ed0cb26129d87b9abfc405dea9a2a3b0f43bd739bbeb44025d5b2c2ea8cd85c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  "}, "hash": "f9b3f1d4be3ae08421ff956879756efd1f3337989fe46af1b52c267ef75e488e", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 237, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b": {"__data__": {"id_": "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88d9e3e4-2d6d-4039-a939-e84930b32699", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40e611a23e9354d3b2e54f06dd0262d1b1733fa95a969b11e64683a56bb7e23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6e526e-b38e-4e84-b1fc-5c50219eb411", "node_type": "1", "metadata": {"window": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "original_text": "Please go ahead.  \n \n"}, "hash": "e99daa5167332940935c0dde0762252af742c6bb5aa3c83df94cee4ce761eb59", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "start_char_idx": 275, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6e526e-b38e-4e84-b1fc-5c50219eb411": {"__data__": {"id_": "3c6e526e-b38e-4e84-b1fc-5c50219eb411", "embedding": null, "metadata": {"window": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22367f115dbe8bde5bfe59bde2c9662178cfb68e7565a7864926c545a96c45dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e937027-1041-4c95-b8d5-c12ec234f856", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "original_text": "Kevin Moran:  Good morning, and welcome. "}, "hash": "73db8ae7871ddd83b2c83638aa43bb73be6991ea3c6469e49b7ed92c0b52f4e3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 382, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e937027-1041-4c95-b8d5-c12ec234f856": {"__data__": {"id_": "7e937027-1041-4c95-b8d5-c12ec234f856", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "original_text": "Kevin Moran:  Good morning, and welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6e526e-b38e-4e84-b1fc-5c50219eb411", "node_type": "1", "metadata": {"window": "Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "349e4082aeae101616ccfb2df803253039bd684e8cdd451cbe04ce791841bf8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  "}, "hash": "2cf16811ec6159e39298049476151cd1388bae1517f3a6ebbb72cd7c1a7c5d1d", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Good morning, and welcome. ", "start_char_idx": 403, "end_char_idx": 444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6": {"__data__": {"id_": "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e937027-1041-4c95-b8d5-c12ec234f856", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "original_text": "Kevin Moran:  Good morning, and welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23c95d207741ceb05e808e54d3cfcb84826557d11c623aba23c6b958a871bc28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n "}, "hash": "ec49b7cdc6cf15191ddb5af28096a1a940b18c0b25873430fc2043d550672a8a", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "start_char_idx": 444, "end_char_idx": 564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2": {"__data__": {"id_": "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0506f756a5940f4e2425997150c6225b20ccc8fd0677e359e78979304f5b35f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d448a807-bf5d-4b98-8d68-2f6e0537b1f1", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. "}, "hash": "6ecddee5ce724a96e422546073670069e985875d4a59cb1a757386ccd87f1b42", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "start_char_idx": 564, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d448a807-bf5d-4b98-8d68-2f6e0537b1f1": {"__data__": {"id_": "d448a807-bf5d-4b98-8d68-2f6e0537b1f1", "embedding": null, "metadata": {"window": "Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3439ddf55f8dcc04d0edb7bd067e4582e98723837dacd282f418f7e4f7635c59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da81d20e-9b38-4a6f-9046-728898a30251", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  "}, "hash": "46f305db2b35d7f7796c8a04056e26ccb0a75c1817044e7d94e8eedf467d2cb9", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "start_char_idx": 681, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da81d20e-9b38-4a6f-9046-728898a30251": {"__data__": {"id_": "da81d20e-9b38-4a6f-9046-728898a30251", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d448a807-bf5d-4b98-8d68-2f6e0537b1f1", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and welcome.  Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da77632a8413361529f67ca693f4967cf9260a07f5cdcd40582ceaa2fd91e825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf175af5-9495-4f5d-ad14-a0644b9c7f1a", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  "}, "hash": "171c75a6544ae8eb0e914a1ee324e61650399a72269af2ff3d7135c4e0d8a266", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements.  ", "start_char_idx": 787, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf175af5-9495-4f5d-ad14-a0644b9c7f1a": {"__data__": {"id_": "cf175af5-9495-4f5d-ad14-a0644b9c7f1a", "embedding": null, "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da81d20e-9b38-4a6f-9046-728898a30251", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's second quarter \nfiscal 2021 results along with an update to our FY21 outlook.   You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc64c9275e63cde2d959a253a81f962729c496d0bf51ac381a9fe27129e8d491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n "}, "hash": "523262f0f47af41916ea40b1d2bd73181c99e70761f21dbeab8e8b815004e014", "class_name": "RelatedNodeInfo"}}, "text": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "start_char_idx": 852, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf": {"__data__": {"id_": "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf", "embedding": null, "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf175af5-9495-4f5d-ad14-a0644b9c7f1a", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  \n \n  Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "original_text": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9874cb43a63552be2e5f22682cc25c2d0a509738c8ca3631c91e670f0b2256a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36e972bc-a93e-4e5d-92bb-6fef40446c80", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  "}, "hash": "f3f4d917eb2519879445e2d75f113d67a5f2f341a0e10839c05d3c302832ce25", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "start_char_idx": 1024, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36e972bc-a93e-4e5d-92bb-6fef40446c80": {"__data__": {"id_": "36e972bc-a93e-4e5d-92bb-6fef40446c80", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Ch ief \nFinancial Officer.  During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c93ed7a402f6b200fe5e69772a9765089fd6ed94004d29444e5239e6a0283f65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "482a28d0-e57e-461e-a52c-f5da8d113860", "node_type": "1", "metadata": {"window": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n "}, "hash": "46b7d2731de521b2a2f3db08eb4c3fa74ea6b61a1f811a7ef4c4c555a99d75f6", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "start_char_idx": 1193, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "482a28d0-e57e-461e-a52c-f5da8d113860": {"__data__": {"id_": "482a28d0-e57e-461e-a52c-f5da8d113860", "embedding": null, "metadata": {"window": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36e972bc-a93e-4e5d-92bb-6fef40446c80", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb6c237c351314338324d0d9365d16f779eceb2b320ae092b758ed8bc700e28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdd08179-86fb-4a64-b6b6-d286ef58d146", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. "}, "hash": "43ccb8e3d8665e7460195d9fbd3f691733eab0f44eb3c5a83c738c8c6f224a6c", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "start_char_idx": 1333, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdd08179-86fb-4a64-b6b6-d286ef58d146": {"__data__": {"id_": "cdd08179-86fb-4a64-b6b6-d286ef58d146", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "482a28d0-e57e-461e-a52c-f5da8d113860", "node_type": "1", "metadata": {"window": "The matters \naddressed in the statements are subject to the risks and uncertainties that could cause actual results \nto differ materially from those projected or implied.   Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "383b8b741a4f4d73118b07aed7f4bf9ad4ea627e308651c9fbfa29cbf82cba38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8236c2a3-ae41-4c98-bd37-bf2bff5640a8", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n ", "original_text": "With that, I'll now turn the call over to \nMike.  \n \n"}, "hash": "a321f2dce6754adcb78e51e501ce628f82abdd9793c9ed3523b2d30771e9b852", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "start_char_idx": 1459, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8236c2a3-ae41-4c98-bd37-bf2bff5640a8": {"__data__": {"id_": "8236c2a3-ae41-4c98-bd37-bf2bff5640a8", "embedding": null, "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n ", "original_text": "With that, I'll now turn the call over to \nMike.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdd08179-86fb-4a64-b6b6-d286ef58d146", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -\nlooking statement slide at the beginning of our presentation for a description of these risks and \nuncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "original_text": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a029220736a1eaef94f618c8d0f9f36c286428272ddd5f36cf2343858484388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f63f061-2dc9-4a60-a782-03291bd22955", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. "}, "hash": "bbb3357986d99f78683b1c3d935b809f29073cf713d11b5ddeefeaa20a7cab0b", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn the call over to \nMike.  \n \n", "start_char_idx": 1616, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f63f061-2dc9-4a60-a782-03291bd22955": {"__data__": {"id_": "0f63f061-2dc9-4a60-a782-03291bd22955", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8236c2a3-ae41-4c98-bd37-bf2bff5640a8", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunles s they are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n ", "original_text": "With that, I'll now turn the call over to \nMike.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c1e3e8e40a4166ea7dd459cf51f7647479329215b6f153c420a1efc724fbfbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "original_text": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  "}, "hash": "00bb77eeed18011e7d8cbab61dbe1df213ec4fa45d32aca82bd700c7e81ae75e", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "start_char_idx": 1669, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0": {"__data__": {"id_": "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "original_text": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f63f061-2dc9-4a60-a782-03291bd22955", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found in the schedules attached to our press release.  \n \n  During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf9b01cc670ced2d5d9eb02bf1648d08f4b935f041701aa3535ce2062b14953c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aadeff19-5668-4197-82ff-60e6a403ce95", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "original_text": "I'll close by sharing updates regarding our growth areas.  \n \n "}, "hash": "2c69726740600116718d2026e714b9e01d632b262095910f62ac4284a5193498", "class_name": "RelatedNodeInfo"}}, "text": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "start_char_idx": 1728, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aadeff19-5668-4197-82ff-60e6a403ce95": {"__data__": {"id_": "aadeff19-5668-4197-82ff-60e6a403ce95", "embedding": null, "metadata": {"window": "With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "original_text": "I'll close by sharing updates regarding our growth areas.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we please ask that you try and limit yourself to o ne \nquestion so that we can try and give everyone an opportunity.  With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "original_text": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23b1078002b00c117314b1871f00318ae88440fc497fadfd12a915ad2a74a023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "580a089d-064b-4f95-9f48-ffd1e5b5de2d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "original_text": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  "}, "hash": "2f09faf5abc23fd00201f5e40255f74089abcb91cf6214a4cdc7475a6ff31fd3", "class_name": "RelatedNodeInfo"}}, "text": "I'll close by sharing updates regarding our growth areas.  \n \n ", "start_char_idx": 1907, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "580a089d-064b-4f95-9f48-ffd1e5b5de2d": {"__data__": {"id_": "580a089d-064b-4f95-9f48-ffd1e5b5de2d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "original_text": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aadeff19-5668-4197-82ff-60e6a403ce95", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to \nMike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "original_text": "I'll close by sharing updates regarding our growth areas.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b80e415d1c853f30541e3cd14bccb4af368a8470aeed52d8bb8156b8e6bf2f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13351ad6-18c4-4edf-b783-59cc732822b0", "node_type": "1", "metadata": {"window": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.  ", "original_text": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  "}, "hash": "69422c32e498ffda107a7b96686fabb7572f4cab6869b8e3628fa45f26b53959", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "start_char_idx": 1970, "end_char_idx": 2080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13351ad6-18c4-4edf-b783-59cc732822b0": {"__data__": {"id_": "13351ad6-18c4-4edf-b783-59cc732822b0", "embedding": null, "metadata": {"window": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.  ", "original_text": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "580a089d-064b-4f95-9f48-ffd1e5b5de2d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "original_text": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e63b07d1e00b5274c6386a31187c94a916d99a039ef8a5ebd7dd63809cb9140b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e", "node_type": "1", "metadata": {"window": "I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "original_text": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n "}, "hash": "2c7dd9b6d5af4a9afc32e064bd72e00e4ec8eba1f2502b65c8224f9c6cdfba5e", "class_name": "RelatedNodeInfo"}}, "text": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "start_char_idx": 2080, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e": {"__data__": {"id_": "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e", "embedding": null, "metadata": {"window": "I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "original_text": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13351ad6-18c4-4edf-b783-59cc732822b0", "node_type": "1", "metadata": {"window": "I'll start our discussion with a few high -\nlevel thoughts on our progress so far this year, and then Jason will review our second quarter results \nand our updated FY21 outlook.   I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.  ", "original_text": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ad5d6c035b7833b1140d5b09ff37f082f955eff36003570d101ff269fb83a88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68", "node_type": "1", "metadata": {"window": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n "}, "hash": "a48aebcdcb95c85f402b711aa3f7c7e4175712e37d3067402c9e9ab183466a8c", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "start_char_idx": 2190, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68": {"__data__": {"id_": "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68", "embedding": null, "metadata": {"window": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e", "node_type": "1", "metadata": {"window": "I'll close by sharing updates regarding our growth areas.  \n \n  We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "original_text": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32b3172e9d64f78d4556c77dda3beb0aa183f754ba3a3ea555676763c75ffe70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4dc5b93-bab6-4152-82bc-59fbd5714aa1", "node_type": "1", "metadata": {"window": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "In the second quarter, we saw varying effects of the pan demic on our business.  "}, "hash": "c8a990c8ff0b880174321f5805d586d5cb0b6c9180e7c0f82611f473c07fba1a", "class_name": "RelatedNodeInfo"}}, "text": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "start_char_idx": 2335, "end_char_idx": 2538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4dc5b93-bab6-4152-82bc-59fbd5714aa1": {"__data__": {"id_": "e4dc5b93-bab6-4152-82bc-59fbd5714aa1", "embedding": null, "metadata": {"window": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "In the second quarter, we saw varying effects of the pan demic on our business.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68", "node_type": "1", "metadata": {"window": "We continue to make progress on our strategic plan as we navigate the rapidly changing \nglobal enviro nment.   Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576884c4b6749d5698c466027386f2b84e0f3964f5a12b042091346bc805bddd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d5b8a8-4fde-49c0-8a29-4a256e974224", "node_type": "1", "metadata": {"window": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  "}, "hash": "0a06f70bd06816014483f99c3dbef2cc6317277215f47695525f0f01fefc7e14", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we saw varying effects of the pan demic on our business.  ", "start_char_idx": 2538, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d5b8a8-4fde-49c0-8a29-4a256e974224": {"__data__": {"id_": "81d5b8a8-4fde-49c0-8a29-4a256e974224", "embedding": null, "metadata": {"window": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4dc5b93-bab6-4152-82bc-59fbd5714aa1", "node_type": "1", "metadata": {"window": "Overall, second quarter operating results came in better than our expectations, \nled by the Medical segment.   In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "In the second quarter, we saw varying effects of the pan demic on our business.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6cddfd402d69aa00ab1cc476b97ab9af432666090453eb7dda329e12a5ee03c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e14199d-38a3-4643-9959-9cfd67b9829e", "node_type": "1", "metadata": {"window": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "And in Pharma, although the pandemic continued to "}, "hash": "8e29ad01350aa5fcd5ee4c317295974cb9c0b10fb5f12eb23e63f8233cea6f3a", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "start_char_idx": 2619, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e14199d-38a3-4643-9959-9cfd67b9829e": {"__data__": {"id_": "1e14199d-38a3-4643-9959-9cfd67b9829e", "embedding": null, "metadata": {"window": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "And in Pharma, although the pandemic continued to ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2af9cd0a7e4fab1e44295d6206f45876b0cd6a2ae423288817f8e2ffeae496", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d5b8a8-4fde-49c0-8a29-4a256e974224", "node_type": "1", "metadata": {"window": "In addition, we saw some favorability, including timing below the \noperating line, enabling us to deliver EPS growth of 14% in the quarter.  \n \n  Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.  ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70ffeb394d669eba02bf5ecf8aad8212efcccb245b120f8716805f17f37f1338", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9096962c-e6de-453b-81f0-4f0a7c14c50d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "original_text": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n "}, "hash": "9175d1484c8bd31745d01df7bef572927dabc5f22311275a844b8e5eb4e072cc", "class_name": "RelatedNodeInfo"}}, "text": "And in Pharma, although the pandemic continued to ", "start_char_idx": 2765, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9096962c-e6de-453b-81f0-4f0a7c14c50d": {"__data__": {"id_": "9096962c-e6de-453b-81f0-4f0a7c14c50d", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "original_text": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e14199d-38a3-4643-9959-9cfd67b9829e", "node_type": "1", "metadata": {"window": "Due to our solid first half performance and our improved visibility into the remainder of the \nfiscal year, we are increasing and narrowing our EPS guidance to a range of $5.85 to $6.10 per \nshare.  \n \n  In the second quarter, we saw varying effects of the pan demic on our business.   Our Medical \nsegment saw a net positive impact related to COVID -19 as our lab business and PPE products \ncontinued to experience strong demand.   And in Pharma, although the pandemic continued to ", "original_text": "And in Pharma, although the pandemic continued to ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecf05b2dd2fa6e5fcdaecbd0dc47848e2b4841166c61cd1cd5cc5e6f90dcb5d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e287777-3b67-4fa5-b368-15876ee589bb", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "original_text": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.  "}, "hash": "43466bd92274cfe8f15c60af722135e3dac7c6c6bcb65360da916b49ac1383c0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n ", "start_char_idx": 0, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e287777-3b67-4fa5-b368-15876ee589bb": {"__data__": {"id_": "2e287777-3b67-4fa5-b368-15876ee589bb", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "original_text": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9096962c-e6de-453b-81f0-4f0a7c14c50d", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "original_text": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc458cf11ae81a4960e31acd946781978896800c44a652cbb8017459f969548", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf6f2b5d-02dd-413a-9ec5-9ebe24870787", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "original_text": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.  "}, "hash": "b32296e07c13aaa12866a3d90948577dfd9dfe67e8aefa72c50282653b40a101", "class_name": "RelatedNodeInfo"}}, "text": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.  ", "start_char_idx": 173, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf6f2b5d-02dd-413a-9ec5-9ebe24870787": {"__data__": {"id_": "bf6f2b5d-02dd-413a-9ec5-9ebe24870787", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "original_text": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e287777-3b67-4fa5-b368-15876ee589bb", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "original_text": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "291c59c647aa401e29cf09cd7b85fad1243b83925ea8b35542a71dc2e590108a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0a3dd09-7b76-47ea-b5dc-effc051e43ce", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "original_text": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n "}, "hash": "9f3e1c9ab6e8b64692e220b58c5e9d5affe36dc786831921ee4ed8624216736f", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.  ", "start_char_idx": 275, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0a3dd09-7b76-47ea-b5dc-effc051e43ce": {"__data__": {"id_": "b0a3dd09-7b76-47ea-b5dc-effc051e43ce", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "original_text": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf6f2b5d-02dd-413a-9ec5-9ebe24870787", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "original_text": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b884cbe2235c944a78751efe87d6683efc9ac3b8fd0b6a9cdf1623b605a250dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ee92fb-a909-4e99-ab6a-ddb655a87e1e", "node_type": "1", "metadata": {"window": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "original_text": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  "}, "hash": "1bb10acb48238706d545cbd1205f3743c3a0f7cf0e27d8488bba25ca0996ee71", "class_name": "RelatedNodeInfo"}}, "text": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "start_char_idx": 472, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ee92fb-a909-4e99-ab6a-ddb655a87e1e": {"__data__": {"id_": "74ee92fb-a909-4e99-ab6a-ddb655a87e1e", "embedding": null, "metadata": {"window": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "original_text": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0a3dd09-7b76-47ea-b5dc-effc051e43ce", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "original_text": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662d40bec28c491ca140d8f82913c087b5583474d6f672e5af9f64847c9176a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69", "node_type": "1", "metadata": {"window": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "original_text": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n "}, "hash": "7ea8e99519214fff5ee363b5bd92bce625f7c27bffae142bcced5c8e336d516b", "class_name": "RelatedNodeInfo"}}, "text": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "start_char_idx": 607, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69": {"__data__": {"id_": "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69", "embedding": null, "metadata": {"window": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "original_text": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ee92fb-a909-4e99-ab6a-ddb655a87e1e", "node_type": "1", "metadata": {"window": "Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "original_text": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f49917c278b062c165f6d86ac09b424b023e6f6e268df23589026da8271fa871", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a7cff0c-7255-4537-93cc-ff3310bd5288", "node_type": "1", "metadata": {"window": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "original_text": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n "}, "hash": "ef069f2a97ced6a2b09e40291be7d208e3f741b81b3a6f19d992c3359d89589e", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "start_char_idx": 774, "end_char_idx": 932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a7cff0c-7255-4537-93cc-ff3310bd5288": {"__data__": {"id_": "8a7cff0c-7255-4537-93cc-ff3310bd5288", "embedding": null, "metadata": {"window": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "original_text": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69", "node_type": "1", "metadata": {"window": "In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "original_text": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7578faa83be2180000faa82f8ac0e559d83d7741bc1e5aa36c4714a1ddea001b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "587dd507-70ff-46d1-a6bd-058f34769e68", "node_type": "1", "metadata": {"window": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "original_text": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n"}, "hash": "e2fbd682da319c3b3679776c42d886d93d4ef6c5662b36b144df1fa1945b2e1b", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "start_char_idx": 932, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "587dd507-70ff-46d1-a6bd-058f34769e68": {"__data__": {"id_": "587dd507-70ff-46d1-a6bd-058f34769e68", "embedding": null, "metadata": {"window": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "original_text": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a7cff0c-7255-4537-93cc-ff3310bd5288", "node_type": "1", "metadata": {"window": "And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n  Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "original_text": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10b2cba0817fe46e83a56308c47e6057b5e137e19d261615a9e64bf8ba92d248", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c25b0ce2-4c77-4f2f-ac72-0eede3d16126", "node_type": "1", "metadata": {"window": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone. "}, "hash": "02975d399bdce8f9f1d7004f0ba529de3546901382cf42c61532e31920a85db6", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "start_char_idx": 1146, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c25b0ce2-4c77-4f2f-ac72-0eede3d16126": {"__data__": {"id_": "c25b0ce2-4c77-4f2f-ac72-0eede3d16126", "embedding": null, "metadata": {"window": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "587dd507-70ff-46d1-a6bd-058f34769e68", "node_type": "1", "metadata": {"window": "Regarding PPE, we are utilizing our supply assurance program to manage costs for our \ncustomers and provide consistent, long -range supply in key product categories.   We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "original_text": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7270a1ce36eaa821e23170e4ccd70a49c9fff5eecc27b03f9c38ba6f9305ba9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42f2e63a-9af2-4851-a6d9-996e7650569a", "node_type": "1", "metadata": {"window": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "original_text": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  "}, "hash": "d863d3e86e4fa13007f87ea289cbf922ef1eafe67bbc2b64af90527d6e79d614", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "start_char_idx": 1309, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42f2e63a-9af2-4851-a6d9-996e7650569a": {"__data__": {"id_": "42f2e63a-9af2-4851-a6d9-996e7650569a", "embedding": null, "metadata": {"window": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "original_text": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c25b0ce2-4c77-4f2f-ac72-0eede3d16126", "node_type": "1", "metadata": {"window": "We are seeing \nimproving supply in some of these product categories such as gowns and masks, but continue to see \na challenging market with exam gloves.  \n \n  Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning, everyone. ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e486bb3d0ca6d60dc2613a12b63cf2c7e8b6038c56a99d0e4f6dbfed5b7a328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d42c2ca8-1b82-4989-8530-ce7b204a6eec", "node_type": "1", "metadata": {"window": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "original_text": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  "}, "hash": "a7ed1ff8b9d46ebb63c75fef033e8feb504a0fcc2da7b45cd021af36c6a128b4", "class_name": "RelatedNodeInfo"}}, "text": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "start_char_idx": 1366, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d42c2ca8-1b82-4989-8530-ce7b204a6eec": {"__data__": {"id_": "d42c2ca8-1b82-4989-8530-ce7b204a6eec", "embedding": null, "metadata": {"window": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "original_text": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42f2e63a-9af2-4851-a6d9-996e7650569a", "node_type": "1", "metadata": {"window": "Looking ahead, we remain committed to supporting our customers, patients, government and \ncommunities through the ongoing challenges of the pandemic, and we are ready and willing to help in \nany way possible.  \n \n  Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "original_text": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f140c9fa53284515b55abdb966605dfba5d2393c2c8fdbc5be6b0439a8edd5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "original_text": "Total gross margin was flat at $1.8 billion.  "}, "hash": "be415011283a357e20625f2c567532cf996a510e9f3e75d94b2d605a717b26d0", "class_name": "RelatedNodeInfo"}}, "text": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "start_char_idx": 1521, "end_char_idx": 1642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae": {"__data__": {"id_": "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "original_text": "Total gross margin was flat at $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d42c2ca8-1b82-4989-8530-ce7b204a6eec", "node_type": "1", "metadata": {"window": "Before I provide some updates on our strategic growth areas, I'll turn it over to Jason to share \nmore details on our second quarter and outlook for the year.  \n \n Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "original_text": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29b4df2478763881fe9f34d4a8b52a05e28b7a112cfe27b3f3443e452249c5f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e29ef39a-cf72-4fea-80f8-a3f12b361598", "node_type": "1", "metadata": {"window": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n ", "original_text": "SG&A increased 2% to \n$1.1 billion due to IT investments.  "}, "hash": "5a0d7c9cd70af4193dd0bb804802f6b271c8e19ee3c307fbdf07a893bab5612e", "class_name": "RelatedNodeInfo"}}, "text": "Total gross margin was flat at $1.8 billion.  ", "start_char_idx": 1642, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e29ef39a-cf72-4fea-80f8-a3f12b361598": {"__data__": {"id_": "e29ef39a-cf72-4fea-80f8-a3f12b361598", "embedding": null, "metadata": {"window": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n ", "original_text": "SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning, everyone.  B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "original_text": "Total gross margin was flat at $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4605787e471cde707f943088620634ca858f23a6a7c2711f23845649630e614b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d190be-0f24-4876-aa2a-3539fe9e9fda", "node_type": "1", "metadata": {"window": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "original_text": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n "}, "hash": "6cdd3861dcea68c8b3373b95b0a38e0f7ffd01738796b91e6f9999c4891ba46d", "class_name": "RelatedNodeInfo"}}, "text": "SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "start_char_idx": 1688, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d190be-0f24-4876-aa2a-3539fe9e9fda": {"__data__": {"id_": "f7d190be-0f24-4876-aa2a-3539fe9e9fda", "embedding": null, "metadata": {"window": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "original_text": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e29ef39a-cf72-4fea-80f8-a3f12b361598", "node_type": "1", "metadata": {"window": "B eginning with total company results, \nsecond quarter EPS was $1.74, reflecting a 14% increase driven by discrete tax items and strong \nMedical results.   Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n ", "original_text": "SG&A increased 2% to \n$1.1 billion due to IT investments.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02b2ba18cceea11cd154561043bd1404cdd71dde6f81028d3ffe43e3223a110f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c21ae3a7-6c2f-44ac-9d32-7277f411e55a", "node_type": "1", "metadata": {"window": "Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "original_text": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  "}, "hash": "dc0a8569ec3efede23f67e804ed1b028008f5864e7c92128c9dbebb8958235fe", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "start_char_idx": 1747, "end_char_idx": 1935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c21ae3a7-6c2f-44ac-9d32-7277f411e55a": {"__data__": {"id_": "c21ae3a7-6c2f-44ac-9d32-7277f411e55a", "embedding": null, "metadata": {"window": "Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "original_text": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d190be-0f24-4876-aa2a-3539fe9e9fda", "node_type": "1", "metadata": {"window": "Total second quarter revenue increased 5% to $41.5 billion, driven primarily by sales \ngrowth from existin g customers.   Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "original_text": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbb9586cd12822ba92bc96df2b14fc5e168e76ea3b424000d2c8896c1761d487", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51ed658d-463f-4b41-86d5-e23fe4a5f44c", "node_type": "1", "metadata": {"window": "SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.  ", "original_text": "I will discuss th ese segment impact s shortly.  \n \n "}, "hash": "acc01d3f835fadf014570b21830b1b789506d39b2064e022183e8829fe565302", "class_name": "RelatedNodeInfo"}}, "text": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "start_char_idx": 1935, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51ed658d-463f-4b41-86d5-e23fe4a5f44c": {"__data__": {"id_": "51ed658d-463f-4b41-86d5-e23fe4a5f44c", "embedding": null, "metadata": {"window": "SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.  ", "original_text": "I will discuss th ese segment impact s shortly.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c21ae3a7-6c2f-44ac-9d32-7277f411e55a", "node_type": "1", "metadata": {"window": "Total gross margin was flat at $1.8 billion.   SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "original_text": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a12f6da85347f965f97908d5b52cffc442b5e97a093f2e2161608fcd81432182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f049eb98-69b3-4313-a3bb-7911a343b9f9", "node_type": "1", "metadata": {"window": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "original_text": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  "}, "hash": "420e9b445cf26c91fe5e3f8d0ecc5156928cdcb1a18d297aad7093d60b1be7ff", "class_name": "RelatedNodeInfo"}}, "text": "I will discuss th ese segment impact s shortly.  \n \n ", "start_char_idx": 2079, "end_char_idx": 2132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f049eb98-69b3-4313-a3bb-7911a343b9f9": {"__data__": {"id_": "f049eb98-69b3-4313-a3bb-7911a343b9f9", "embedding": null, "metadata": {"window": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "original_text": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51ed658d-463f-4b41-86d5-e23fe4a5f44c", "node_type": "1", "metadata": {"window": "SG&A increased 2% to \n$1.1 billion due to IT investments.   The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.  ", "original_text": "I will discuss th ese segment impact s shortly.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25e3fcdc5cc61b1af51f76be1e34911b22880786a6f0759b12928967f8d13cca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5", "node_type": "1", "metadata": {"window": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "original_text": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n "}, "hash": "ca9c7350f64127791802094fe12b2fb81657e8474064f3ee25d8bcf07c2ec4eb", "class_name": "RelatedNodeInfo"}}, "text": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "start_char_idx": 2132, "end_char_idx": 2392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5": {"__data__": {"id_": "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5", "embedding": null, "metadata": {"window": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "original_text": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f049eb98-69b3-4313-a3bb-7911a343b9f9", "node_type": "1", "metadata": {"window": "The net result for the quarter was consolidated operating earnings \nof $628 million, a decrease of 3%, which reflects a modest net negative  impact for the enterprise from \nCOVID -19. \n \n  The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "original_text": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2a2e0da79c6cfce5d6aa013f3d6459b81d779f752c4eae49c7d26767790e494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db083297-0a34-460b-b861-a785657f5b09", "node_type": "1", "metadata": {"window": "I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Now, a quick note on the GAAP tax impact during the quarter.  "}, "hash": "a82362ba2d30291f099233283ddbee08e26c0f961e50d22c51bf6986ee704a7d", "class_name": "RelatedNodeInfo"}}, "text": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "start_char_idx": 2392, "end_char_idx": 2510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db083297-0a34-460b-b861-a785657f5b09": {"__data__": {"id_": "db083297-0a34-460b-b861-a785657f5b09", "embedding": null, "metadata": {"window": "I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Now, a quick note on the GAAP tax impact during the quarter.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5", "node_type": "1", "metadata": {"window": "The Pharma segment was adversely affected by COVID -19 during the quarter, and this was \npartially offset by a net positive impact in Medical.   I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "original_text": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3df2ac8130194143c32d74346ee7c6a8c4d3ae54c5541a89a8ac52abc54cc5dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "869540b6-a772-4b4e-a5dc-5751328ee21e", "node_type": "1", "metadata": {"window": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  "}, "hash": "a2a7ab9301b7218ca8b8705972a68e4b1a4e654807485f56c0e8200964569590", "class_name": "RelatedNodeInfo"}}, "text": "Now, a quick note on the GAAP tax impact during the quarter.  ", "start_char_idx": 2510, "end_char_idx": 2572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "869540b6-a772-4b4e-a5dc-5751328ee21e": {"__data__": {"id_": "869540b6-a772-4b4e-a5dc-5751328ee21e", "embedding": null, "metadata": {"window": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db083297-0a34-460b-b861-a785657f5b09", "node_type": "1", "metadata": {"window": "I will discuss th ese segment impact s shortly.  \n \n  Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Now, a quick note on the GAAP tax impact during the quarter.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cadd1f55ea7af9f583d47da9caacdeb97aa15915a7330850937d3d2935753318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0", "node_type": "1", "metadata": {"window": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  "}, "hash": "38693744c13e213cf0cb15fd63ee6641b4e1eb141beeb8174713760e2bab4157", "class_name": "RelatedNodeInfo"}}, "text": "Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "start_char_idx": 2572, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0": {"__data__": {"id_": "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0", "embedding": null, "metadata": {"window": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "869540b6-a772-4b4e-a5dc-5751328ee21e", "node_type": "1", "metadata": {"window": "Interest and other expense decreased 33% versus the prior year to $34 million, driven \nprimarily by lower interest expense as a result of prior year debt reduction, as well as an increase in \nthe value of our company's deferred compensation plan investments.   Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5157f67c19538ed3a5cea3cca35549ee6e068d2680ba557a0c553c1055568989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f170178-284f-4887-835c-f090af1a9e7e", "node_type": "1", "metadata": {"window": "Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n "}, "hash": "e24cd798193dd1e6d85ca3600a95fb0e3170dae14e78b2876e82d14d6a8f5053", "class_name": "RelatedNodeInfo"}}, "text": "As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "start_char_idx": 2752, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f170178-284f-4887-835c-f090af1a9e7e": {"__data__": {"id_": "3f170178-284f-4887-835c-f090af1a9e7e", "embedding": null, "metadata": {"window": "Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4db70c3-3b4b-48f3-84b5-5600da184518", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6f43d3da3b29dc65f629e307ca01ca12d47477517b7ef75dd052c8a65610fac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0", "node_type": "1", "metadata": {"window": "Our non -GAA P effective tax \nrate for the quarter was 13%, which reflects the impact of certain discrete items.  \n \n  Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.  ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb1f5d2fc0d60b792176d6fe02386deca031cd3d5ac43e6a610a76c3a5463336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3030068-d6c7-4974-8aea-f422050d5c81", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "original_text": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.  "}, "hash": "b0368d6f819690127bf18ed282d2a2b085688589620163d32914c7d507ba3aa7", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "start_char_idx": 2875, "end_char_idx": 3022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3030068-d6c7-4974-8aea-f422050d5c81": {"__data__": {"id_": "d3030068-d6c7-4974-8aea-f422050d5c81", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "original_text": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f170178-284f-4887-835c-f090af1a9e7e", "node_type": "1", "metadata": {"window": "Now, a quick note on the GAAP tax impact during the quarter.   Primarily due to a self -\ninsurance loss on our FY20 federal tax return, we will carry back an d recover previously paid federal \ntaxes at rates that were in effect at that time.   As such, in the quarter, we recorded a net GAAP tax \nbenefit of $420 million associated with the recovery of prior taxes.   Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "original_text": "Additionally, we have recorded a \ncorresponding rec eivable of approximately $1 billion, which we expect to receive within the next 12 \nmonths.  \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b280db229e3e1ff9fb5d598596b767cd963698e7a2449e23fd25ee9745c2c81a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c9c3045-d998-45d8-b928-033ebb9598b2", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "original_text": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.  "}, "hash": "9ba34e006dff310bf995ecd18923dbbb8cf1fa292b42502d46410b2eca168732", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.  ", "start_char_idx": 0, "end_char_idx": 64, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c9c3045-d998-45d8-b928-033ebb9598b2": {"__data__": {"id_": "3c9c3045-d998-45d8-b928-033ebb9598b2", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "original_text": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3030068-d6c7-4974-8aea-f422050d5c81", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "original_text": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12800a8f2e2ac6908d8eb18f9249874d9981deeab28a53e3fff77b5b4a53301f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0969bf37-5972-4827-a7fd-cd5926f77f3b", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "original_text": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.  "}, "hash": "979c78162c5ff1930531f2d977d2adcea77b1d5114fc8a420d0eafdc0e638543", "class_name": "RelatedNodeInfo"}}, "text": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.  ", "start_char_idx": 64, "end_char_idx": 142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0969bf37-5972-4827-a7fd-cd5926f77f3b": {"__data__": {"id_": "0969bf37-5972-4827-a7fd-cd5926f77f3b", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "original_text": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c9c3045-d998-45d8-b928-033ebb9598b2", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "original_text": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b82a2856840100f5b237797ef4f0d798fff3c45b288d98a0aafac89c376d126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c6cf285-9348-4999-8ee8-2ee746f96589", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "original_text": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n "}, "hash": "08642385d6f4d3dcb04ef585084537cdd029690bd512d0ed057c11a234170a57", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.  ", "start_char_idx": 142, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c6cf285-9348-4999-8ee8-2ee746f96589": {"__data__": {"id_": "4c6cf285-9348-4999-8ee8-2ee746f96589", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "original_text": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0969bf37-5972-4827-a7fd-cd5926f77f3b", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "original_text": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "931da0589e5156ab0f8d67981cb43f5b69880339cb0f6810e81e95ee53830221", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba9d4dea-6a79-4a05-be69-55c28f812414", "node_type": "1", "metadata": {"window": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.  ", "original_text": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  "}, "hash": "c2e5984a4f6da2fd71396478f9374f6b728f41eb72b05c657521b4c795cfb977", "class_name": "RelatedNodeInfo"}}, "text": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "start_char_idx": 241, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba9d4dea-6a79-4a05-be69-55c28f812414": {"__data__": {"id_": "ba9d4dea-6a79-4a05-be69-55c28f812414", "embedding": null, "metadata": {"window": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.  ", "original_text": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c6cf285-9348-4999-8ee8-2ee746f96589", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "original_text": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7f7b3a7fb1e025b51ae2c48c834c4f23a80782f6bb847d356398032814d33ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37b111a1-83dd-412c-b72d-28b2f6f9e29b", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "original_text": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  "}, "hash": "f6797af0cb3b1a72d3493bc61bd48db0159b829ebf7b8a85813d7aaf8c0daaa9", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "start_char_idx": 370, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37b111a1-83dd-412c-b72d-28b2f6f9e29b": {"__data__": {"id_": "37b111a1-83dd-412c-b72d-28b2f6f9e29b", "embedding": null, "metadata": {"window": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "original_text": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba9d4dea-6a79-4a05-be69-55c28f812414", "node_type": "1", "metadata": {"window": "We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.  ", "original_text": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f987dbf780b8fb22805daad77d7bdc631ada0d930f8d48e145acd779083d7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a0ff9cc-47db-49ac-87c4-df3b18a5d029", "node_type": "1", "metadata": {"window": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "original_text": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n "}, "hash": "09b56ddd23451c5d041b89ff3a5e54768e9b4feef7699af6c7ee9492e34c169c", "class_name": "RelatedNodeInfo"}}, "text": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "start_char_idx": 468, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a0ff9cc-47db-49ac-87c4-df3b18a5d029": {"__data__": {"id_": "6a0ff9cc-47db-49ac-87c4-df3b18a5d029", "embedding": null, "metadata": {"window": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "original_text": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37b111a1-83dd-412c-b72d-28b2f6f9e29b", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "original_text": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1675ef14af38fdaf8e88c0a6a023fe6c47d1154a0c5bd20de0864d59fc4e0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59199d16-ea90-4b4f-92f7-4e8f44f83a26", "node_type": "1", "metadata": {"window": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "original_text": "Now turning to the segments, beginning with Medical on slide 5.  "}, "hash": "acc115d95f0481e8cb6e73caaf8929135f771639a5ec0ac0d5538359eda067be", "class_name": "RelatedNodeInfo"}}, "text": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "start_char_idx": 552, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59199d16-ea90-4b4f-92f7-4e8f44f83a26": {"__data__": {"id_": "59199d16-ea90-4b4f-92f7-4e8f44f83a26", "embedding": null, "metadata": {"window": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "original_text": "Now turning to the segments, beginning with Medical on slide 5.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a0ff9cc-47db-49ac-87c4-df3b18a5d029", "node_type": "1", "metadata": {"window": "We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n  We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "original_text": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca99678f5bad4195cb8e83aef5c38f3530a684d858991acbcb8a39f4b994d1df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aec4e766-d2f5-4b46-a914-74fd7978dd66", "node_type": "1", "metadata": {"window": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "original_text": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  "}, "hash": "9f0835946f2da8ed1281ea1d852c3566aa401fbb2f9bc375ed3c0fbc796a5b50", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to the segments, beginning with Medical on slide 5.  ", "start_char_idx": 760, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aec4e766-d2f5-4b46-a914-74fd7978dd66": {"__data__": {"id_": "aec4e766-d2f5-4b46-a914-74fd7978dd66", "embedding": null, "metadata": {"window": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "original_text": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59199d16-ea90-4b4f-92f7-4e8f44f83a26", "node_type": "1", "metadata": {"window": "We remain focused on taking appropriate action to maintain our investment -grade balance \nsheet.   Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "original_text": "Now turning to the segments, beginning with Medical on slide 5.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eec3c7f769e78337ad8ecf8f78a39e32cb66b94ffdea937ed862c7cc46759b37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c23717cc-1fa0-4021-9ff1-74262d576505", "node_type": "1", "metadata": {"window": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "original_text": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n "}, "hash": "008bb02b776127b133d6d56e86da9b2ab80e7fc84470be10fdb88439a4e09d53", "class_name": "RelatedNodeInfo"}}, "text": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "start_char_idx": 825, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c23717cc-1fa0-4021-9ff1-74262d576505": {"__data__": {"id_": "c23717cc-1fa0-4021-9ff1-74262d576505", "embedding": null, "metadata": {"window": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "original_text": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aec4e766-d2f5-4b46-a914-74fd7978dd66", "node_type": "1", "metadata": {"window": "Our next debt maturity is in June 2022 with approximately $1.4 billion coming due.   By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "original_text": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ba01c998431b7a230bd4a90a4712c6892c50dbfd187ced3a470dcb91b800fb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34987c79-8cca-4fdf-a29c-2e245668fa8b", "node_type": "1", "metadata": {"window": "Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "original_text": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  "}, "hash": "728267fd1e300e15271e6806f023625a9c2e1a26566b7c0285d39601ba0ecc6d", "class_name": "RelatedNodeInfo"}}, "text": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "start_char_idx": 984, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34987c79-8cca-4fdf-a29c-2e245668fa8b": {"__data__": {"id_": "34987c79-8cca-4fdf-a29c-2e245668fa8b", "embedding": null, "metadata": {"window": "Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "original_text": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c23717cc-1fa0-4021-9ff1-74262d576505", "node_type": "1", "metadata": {"window": "By the end \nof FY22, we intend to reduce long -term debt by that amount , though the exact timing and method \nmay vary as we continue to evaluate the econom ics associated with early retirement of debt.  \n \n  Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "original_text": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d96ca4f64147d2a7ecc04908e5ed3485e7ee5c6cab1c05a8cb73f6c348c856fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6daa8ba2-40b6-47f5-9686-8e51b115d42d", "node_type": "1", "metadata": {"window": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "original_text": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n "}, "hash": "c82199982386f0ef807a63e4864170e5619be1127d8802e6c92bedde59bcd5c2", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "start_char_idx": 1232, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6daa8ba2-40b6-47f5-9686-8e51b115d42d": {"__data__": {"id_": "6daa8ba2-40b6-47f5-9686-8e51b115d42d", "embedding": null, "metadata": {"window": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "original_text": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34987c79-8cca-4fdf-a29c-2e245668fa8b", "node_type": "1", "metadata": {"window": "Now turning to the segments, beginning with Medical on slide 5.   Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "original_text": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d75466af0e80f8f2294944c110359936e154bb2699864ba72f55c3f602747bdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac2768c5-a8e2-4526-8833-97045f5abdf2", "node_type": "1", "metadata": {"window": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "original_text": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  "}, "hash": "8d01a8319bc11cf6843c34728a077b2c8105fbc9bc10ccd4ecd6cd1915428f48", "class_name": "RelatedNodeInfo"}}, "text": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "start_char_idx": 1395, "end_char_idx": 1614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac2768c5-a8e2-4526-8833-97045f5abdf2": {"__data__": {"id_": "ac2768c5-a8e2-4526-8833-97045f5abdf2", "embedding": null, "metadata": {"window": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "original_text": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6daa8ba2-40b6-47f5-9686-8e51b115d42d", "node_type": "1", "metadata": {"window": "Medical revenue increased \n7% in the second quarter to $4.3 billion, driven by a net positive revenue impact from COVID -19 and \nsolid execution by our team.   As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "original_text": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dca829d23ee2327efd171ddde7470eccac3848f128fd4249256e2d694748f0af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9a5b043-67f4-4792-80c2-e3505f575fa0", "node_type": "1", "metadata": {"window": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "original_text": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n "}, "hash": "ecb648b48f5a456ad3afce97f90dc5ae7cc3e26b443f3df71c0a518a4f9d8a67", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "start_char_idx": 1614, "end_char_idx": 1729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9a5b043-67f4-4792-80c2-e3505f575fa0": {"__data__": {"id_": "e9a5b043-67f4-4792-80c2-e3505f575fa0", "embedding": null, "metadata": {"window": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "original_text": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac2768c5-a8e2-4526-8833-97045f5abdf2", "node_type": "1", "metadata": {"window": "As we have previously discussed, we saw higher selling prices and \nvolumes regarding PPE and higher volumes in our lab business, partially offset by reduced surgical \nproducts demand resulting from deferred and cancelled elective proc edures.  \n \n  Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "original_text": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d28aaee910e4412f820043474464dad6f00e6bee37c154d128cd90ced77b824d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9ebdb1b-9b8c-4df9-8772-134317c08b75", "node_type": "1", "metadata": {"window": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "original_text": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  "}, "hash": "bde0e986380424456568d7614e1599c3110627554724316bd53240ef265dbd80", "class_name": "RelatedNodeInfo"}}, "text": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "start_char_idx": 1729, "end_char_idx": 1843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9ebdb1b-9b8c-4df9-8772-134317c08b75": {"__data__": {"id_": "d9ebdb1b-9b8c-4df9-8772-134317c08b75", "embedding": null, "metadata": {"window": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "original_text": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9a5b043-67f4-4792-80c2-e3505f575fa0", "node_type": "1", "metadata": {"window": "Segment profit increased 21% to $236 million, driven by a net positive impact from COVID -19 \nand cost savings, which includes global manufacturing efficiencies.   The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "original_text": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a492833a5f9c92045c51e853b3b495cc7f344ab00045939564a6f5f9a722b2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd72bfb2-a138-4d63-a88c-b3a552798d4e", "node_type": "1", "metadata": {"window": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "original_text": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n "}, "hash": "7e6a758f62420673098a2538763d157380cbf8fe43ca8ce58ca855477b7ab766", "class_name": "RelatedNodeInfo"}}, "text": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "start_char_idx": 1843, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd72bfb2-a138-4d63-a88c-b3a552798d4e": {"__data__": {"id_": "fd72bfb2-a138-4d63-a88c-b3a552798d4e", "embedding": null, "metadata": {"window": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "original_text": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9ebdb1b-9b8c-4df9-8772-134317c08b75", "node_type": "1", "metadata": {"window": "The net positive segment profit \nimpact from COVID -19 was primarily due to higher lab volumes as well as increased contributions \nfrom PPE that were offset by the previously -mentioned elective procedure impacts.  \n \n  As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "original_text": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9873bb6901c327358e65f8a32ee51ad52a9cc6982d36bbc5b90159bc8347ef4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aafff343-a23e-4700-a0a6-cf368e04292f", "node_type": "1", "metadata": {"window": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.  ", "original_text": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n "}, "hash": "78f5e65fcbd0d71d9b999edbe8a005b67cd7d3360049d445c5c95433a07aa00e", "class_name": "RelatedNodeInfo"}}, "text": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "start_char_idx": 1951, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aafff343-a23e-4700-a0a6-cf368e04292f": {"__data__": {"id_": "aafff343-a23e-4700-a0a6-cf368e04292f", "embedding": null, "metadata": {"window": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.  ", "original_text": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd72bfb2-a138-4d63-a88c-b3a552798d4e", "node_type": "1", "metadata": {"window": "As it relates to lab, we continue to experience a tailwind from increased demand for COVID -19 \ntesting products.   While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "original_text": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86eabb67ba7fcefc448aa7e35719e8636a5e1d62839aa283501be38e79871397", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16808585-884f-415e-a130-c372c2047d65", "node_type": "1", "metadata": {"window": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "original_text": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  "}, "hash": "941ed72f3e7a0c47e46ffaa6896b53a720a77b934c8c15ee272a49857b593915", "class_name": "RelatedNodeInfo"}}, "text": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "start_char_idx": 2227, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16808585-884f-415e-a130-c372c2047d65": {"__data__": {"id_": "16808585-884f-415e-a130-c372c2047d65", "embedding": null, "metadata": {"window": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "original_text": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aafff343-a23e-4700-a0a6-cf368e04292f", "node_type": "1", "metadata": {"window": "While difficult  to predict, we expect this demand to remain elevated for at least the \nbalance of fiscal 21. \n \n  Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.  ", "original_text": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8ba0c9420e0f13332f58f444afc39aef52512de1bcb910716356d2ac0703bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf10b510-0416-4ad1-a5a5-d34916cc19c6", "node_type": "1", "metadata": {"window": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.  ", "original_text": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n "}, "hash": "51e595e458038b06c2e0b58d5d801fa5d4c9d8ef1ac235d6464ff8e66f3a781a", "class_name": "RelatedNodeInfo"}}, "text": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "start_char_idx": 2476, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf10b510-0416-4ad1-a5a5-d34916cc19c6": {"__data__": {"id_": "cf10b510-0416-4ad1-a5a5-d34916cc19c6", "embedding": null, "metadata": {"window": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.  ", "original_text": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16808585-884f-415e-a130-c372c2047d65", "node_type": "1", "metadata": {"window": "Regarding PPE, we saw both higher volumes and timing favorability related to our cost \nmitigation efforts.   As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "original_text": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd0cb918a8dfab498ef74d6d931e987545511661be5c85a6090cf692e08e4a7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d454cb-6353-4710-bc4e-73b7136ab80a", "node_type": "1", "metadata": {"window": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Transitioning to the Pharma segment on slide 6.  "}, "hash": "b1a123618b3d0cddc45a44576bdecc8b96ee426f00f0a735aac21121526df5eb", "class_name": "RelatedNodeInfo"}}, "text": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "start_char_idx": 2602, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d454cb-6353-4710-bc4e-73b7136ab80a": {"__data__": {"id_": "93d454cb-6353-4710-bc4e-73b7136ab80a", "embedding": null, "metadata": {"window": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Transitioning to the Pharma segment on slide 6.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf10b510-0416-4ad1-a5a5-d34916cc19c6", "node_type": "1", "metadata": {"window": "As previously mentioned, we have incurred significan tly higher procurement costs \nfor select PPE products during the pandemic, and we expect the timing of selling the higher cost \nproducts to vary as we continue to manage our supply assurance program for our customers.  \n \n  On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.  ", "original_text": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e15c31681b93fce0fa2d3a232534f888ed2c19b4a28c52522490824bf5a1ab59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c689f69-0266-43ee-b4f3-fe6b5709ca9d", "node_type": "1", "metadata": {"window": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  "}, "hash": "179fb5dc7a2856d3ae88bfc44651b257dd9a966121d8a4baead0b0afa3b25123", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning to the Pharma segment on slide 6.  ", "start_char_idx": 2828, "end_char_idx": 2877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c689f69-0266-43ee-b4f3-fe6b5709ca9d": {"__data__": {"id_": "7c689f69-0266-43ee-b4f3-fe6b5709ca9d", "embedding": null, "metadata": {"window": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d454cb-6353-4710-bc4e-73b7136ab80a", "node_type": "1", "metadata": {"window": "On electives, although procedure volum es continue to be choppy and still below prior year \nlevels, second quarter volumes were generally consistent with our first quarter exit rate, down mid -\nsingle digits versus our pre -COVID -19 baseline.  \n \n  Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Transitioning to the Pharma segment on slide 6.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f8b512cb3ce50118a962616beda781d0f37d79aa2cdd3afd661a5ec002fd947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e9dd54-3c4c-47c1-bcad-b22c27bb583c", "node_type": "1", "metadata": {"window": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Pharma \nsegment profit decreased 11% to $413  million.  "}, "hash": "495531503733360dcdbe990ddbec67067a80a9069bb457a27794bfacdfe508ba", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "start_char_idx": 2877, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e9dd54-3c4c-47c1-bcad-b22c27bb583c": {"__data__": {"id_": "37e9dd54-3c4c-47c1-bcad-b22c27bb583c", "embedding": null, "metadata": {"window": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Pharma \nsegment profit decreased 11% to $413  million.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c689f69-0266-43ee-b4f3-fe6b5709ca9d", "node_type": "1", "metadata": {"window": "Finally, as in the first quarter, we continue to see s avings resulting from cost containment \nmeasures during the pandemic.   And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d5c8fd657f5a5002f534b7e007bc701926a0e4df9499f5cede730445efd18b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af2f2cd-e31a-4310-8b53-051f33139850", "node_type": "1", "metadata": {"window": "Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n "}, "hash": "3fcd172571c48263126f302e233e65642c198e3e03187e86c94a87dea5faee1d", "class_name": "RelatedNodeInfo"}}, "text": "Pharma \nsegment profit decreased 11% to $413  million.  ", "start_char_idx": 3009, "end_char_idx": 3065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af2f2cd-e31a-4310-8b53-051f33139850": {"__data__": {"id_": "8af2f2cd-e31a-4310-8b53-051f33139850", "embedding": null, "metadata": {"window": "Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "579c53797f648ef006e052c041015ee140eca9fbf51e8bbca6ef28e4ac920d8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e9dd54-3c4c-47c1-bcad-b22c27bb583c", "node_type": "1", "metadata": {"window": "And outside of COVID -19 impacts, we continue to realize benefits \nfrom our efficiency initiatives like our global manufacturing and supply chain transformation, which we \nexpect will conti nue to deliver strong savings.  \n \n  Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "Pharma \nsegment profit decreased 11% to $413  million.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3da2992bdc495375e4bf05671ec0571387ad6ff2bb8f7f8d7618a855f29c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f4c776f-89a2-49ae-871c-13849d846452", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "original_text": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.  "}, "hash": "fb5ffff3109d63db8643a048d3d0da3f7a201e066d77a01eded597ce2c4bea46", "class_name": "RelatedNodeInfo"}}, "text": "This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "start_char_idx": 3065, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f4c776f-89a2-49ae-871c-13849d846452": {"__data__": {"id_": "0f4c776f-89a2-49ae-871c-13849d846452", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "original_text": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af2f2cd-e31a-4310-8b53-051f33139850", "node_type": "1", "metadata": {"window": "Transitioning to the Pharma segment on slide 6.   Revenue increased 4% to $37.2 billion, \ndriven by sales growth from Pharmaceutical Distribution and Specialty Solutions customers.   Pharma \nsegment profit decreased 11% to $413  million.   This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "original_text": "This was driven by COVID -19-related volume \ndeclines in our generics program and Nuclear business and was partially offset by a higher \ncontribution from brand sales mix in the quarter.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ca389934da8f304e194ed5adec11470ea2010f0f4cb5e3d099837501b4bc879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0508242e-50ec-4d43-b991-7c4be367cea7", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "original_text": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n "}, "hash": "8adca0f098c0ff95322b82c0d0d92f0b720880169ca89179dd82103d8ff3e862", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.  ", "start_char_idx": 0, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0508242e-50ec-4d43-b991-7c4be367cea7": {"__data__": {"id_": "0508242e-50ec-4d43-b991-7c4be367cea7", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "original_text": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f4c776f-89a2-49ae-871c-13849d846452", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "original_text": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5323e1a88e06adb79f52d27227f417556f49bad55b256604c387937ce8a58e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.  ", "original_text": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.  "}, "hash": "db271d1b1ebddae8f7d342bdce272624bc73cfc3749a0605441edc6eca935fb1", "class_name": "RelatedNodeInfo"}}, "text": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n ", "start_char_idx": 223, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3": {"__data__": {"id_": "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.  ", "original_text": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0508242e-50ec-4d43-b991-7c4be367cea7", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "original_text": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee33a177133fe037f48b4ab0bcc369ce4d30960303eb3567c8339547c906ba6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62dcb3eb-fe8c-4eb0-a981-222b72a57927", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "original_text": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  "}, "hash": "a127002d5fee472668833849a547b3e43f4422dbc9b82011537609366cc088b5", "class_name": "RelatedNodeInfo"}}, "text": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.  ", "start_char_idx": 381, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62dcb3eb-fe8c-4eb0-a981-222b72a57927": {"__data__": {"id_": "62dcb3eb-fe8c-4eb0-a981-222b72a57927", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "original_text": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.  ", "original_text": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a084ecdb1faf83b5c1577eaaf9fc8661c8a52c2b9297cda016c751c944ab3c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e", "node_type": "1", "metadata": {"window": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "original_text": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n "}, "hash": "983d448c88a19d9e7751b24b3dd922451579ef44ff0c4596d5d7abe6fa8d0a27", "class_name": "RelatedNodeInfo"}}, "text": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "start_char_idx": 452, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e": {"__data__": {"id_": "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e", "embedding": null, "metadata": {"window": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "original_text": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62dcb3eb-fe8c-4eb0-a981-222b72a57927", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "original_text": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "748eba6a5930e957922360f3e8e94949d47238bd29a4ddc14b363ca5b2921c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa9f6497-f7fd-4520-b9ba-0658a714688b", "node_type": "1", "metadata": {"window": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "original_text": "Regarding updates to other corporate a ssumptions.  "}, "hash": "9a43a09516e0b94c13c014dbec63b94536874d0d6d7413908f8aed5bce0fccbe", "class_name": "RelatedNodeInfo"}}, "text": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "start_char_idx": 699, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa9f6497-f7fd-4520-b9ba-0658a714688b": {"__data__": {"id_": "fa9f6497-f7fd-4520-b9ba-0658a714688b", "embedding": null, "metadata": {"window": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "original_text": "Regarding updates to other corporate a ssumptions.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e", "node_type": "1", "metadata": {"window": "Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "original_text": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3430d1754b6618e333d3f833affc96a188bf01200fec31a823b063fdde180a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06ac2717-7976-40eb-a07c-3976c24371fb", "node_type": "1", "metadata": {"window": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "original_text": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  "}, "hash": "fb1d063db6d8185e15419f3c47e0d08fcb0a38b5c8cc91300c282edf7813b53a", "class_name": "RelatedNodeInfo"}}, "text": "Regarding updates to other corporate a ssumptions.  ", "start_char_idx": 822, "end_char_idx": 874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06ac2717-7976-40eb-a07c-3976c24371fb": {"__data__": {"id_": "06ac2717-7976-40eb-a07c-3976c24371fb", "embedding": null, "metadata": {"window": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "original_text": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa9f6497-f7fd-4520-b9ba-0658a714688b", "node_type": "1", "metadata": {"window": "Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "original_text": "Regarding updates to other corporate a ssumptions.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43e630db1aa1a525c87d9a44ed34609bbea7e54dd69e875c9cad40b6c2b1ca0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "627bc1cb-a8cf-4c98-b7ce-216a392f08a4", "node_type": "1", "metadata": {"window": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.  ", "original_text": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n "}, "hash": "76115aab5e4a520afd67157ad75b476da3c724b12ba804fcb2db9fbebeae2a28", "class_name": "RelatedNodeInfo"}}, "text": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "start_char_idx": 874, "end_char_idx": 1055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "627bc1cb-a8cf-4c98-b7ce-216a392f08a4": {"__data__": {"id_": "627bc1cb-a8cf-4c98-b7ce-216a392f08a4", "embedding": null, "metadata": {"window": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.  ", "original_text": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06ac2717-7976-40eb-a07c-3976c24371fb", "node_type": "1", "metadata": {"window": "Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.   This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "original_text": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af06cccb0c68d24e3119ca5fc0ebfa5bb84d39a239d6084d4e3e6fd67108644e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e930669-9bb0-4c86-88f9-cce29285a825", "node_type": "1", "metadata": {"window": "Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "original_text": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n "}, "hash": "6526414ecd3fbc4e122c068fde2e97db7f537939197657b630eb3b71fe83db40", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "start_char_idx": 1055, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e930669-9bb0-4c86-88f9-cce29285a825": {"__data__": {"id_": "8e930669-9bb0-4c86-88f9-cce29285a825", "embedding": null, "metadata": {"window": "Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "original_text": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "627bc1cb-a8cf-4c98-b7ce-216a392f08a4", "node_type": "1", "metadata": {"window": "This improvement is driven by strong performance in our Medical segment as well as \nupdates below the operating line.  \n \n  Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.  ", "original_text": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6a2a87a5a76589b2f972398ff1466c894d7d35fbb0bcc96d7d3d1081d25e9cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e73d18ba-67ae-4668-8c04-67cdd42fcf06", "node_type": "1", "metadata": {"window": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "original_text": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n "}, "hash": "f4d6684d0c3943011bb38d7cdb6990d5491e0e4053fbbcbec1356f7f88936f8a", "class_name": "RelatedNodeInfo"}}, "text": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "start_char_idx": 1182, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e73d18ba-67ae-4668-8c04-67cdd42fcf06": {"__data__": {"id_": "e73d18ba-67ae-4668-8c04-67cdd42fcf06", "embedding": null, "metadata": {"window": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "original_text": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e930669-9bb0-4c86-88f9-cce29285a825", "node_type": "1", "metadata": {"window": "Regarding updates to other corporate a ssumptions.   We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "original_text": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f800d013fa09a0b40a720e64fc0e5764f872ead297d6a160388eeebe749aa779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab1a7588-cf8d-417d-b1c5-03e43c707fdc", "node_type": "1", "metadata": {"window": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "original_text": "Regarding the segment outlooks on slide 9.  "}, "hash": "cbaa4ad35db6972576eeddf8fdebb97052aa5335badb0d47f9637b7f9dd7d153", "class_name": "RelatedNodeInfo"}}, "text": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "start_char_idx": 1429, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab1a7588-cf8d-417d-b1c5-03e43c707fdc": {"__data__": {"id_": "ab1a7588-cf8d-417d-b1c5-03e43c707fdc", "embedding": null, "metadata": {"window": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "original_text": "Regarding the segment outlooks on slide 9.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e73d18ba-67ae-4668-8c04-67cdd42fcf06", "node_type": "1", "metadata": {"window": "We now expect interest and other in the \nrange of $165 million to $185 million, with the improvement primarily driven by the impact of our \ndeferred compensation plan adjustments.   As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "original_text": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3de0074c70a11d5a578fab6b0ded5b169ea1ac3f4fa29489fa611c5ad7f03ba9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b", "node_type": "1", "metadata": {"window": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "original_text": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n "}, "hash": "1ed6425689a488321217684060c55bd085b2657aa218e77e74e5a17713efb2ac", "class_name": "RelatedNodeInfo"}}, "text": "Regarding the segment outlooks on slide 9.  ", "start_char_idx": 1562, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b": {"__data__": {"id_": "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b", "embedding": null, "metadata": {"window": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "original_text": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab1a7588-cf8d-417d-b1c5-03e43c707fdc", "node_type": "1", "metadata": {"window": "As a reminder, deferred compensation adjustments are \nfully offse t in corporate SG&A and net neutral to our bottom line.  \n \n  We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "original_text": "Regarding the segment outlooks on slide 9.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5489884793fcd7187ab1baab697be9fc9c8bf32b2ac23e702ece37f5c0c82347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1af2c304-98c0-4c94-8bf0-5f654b53abd0", "node_type": "1", "metadata": {"window": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "original_text": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n "}, "hash": "fd22035b6b332d5492b22d48b96bcde38d0586c2cc6d0aac0a9538e7e4cd8d05", "class_name": "RelatedNodeInfo"}}, "text": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "start_char_idx": 1606, "end_char_idx": 1822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1af2c304-98c0-4c94-8bf0-5f654b53abd0": {"__data__": {"id_": "1af2c304-98c0-4c94-8bf0-5f654b53abd0", "embedding": null, "metadata": {"window": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "original_text": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b", "node_type": "1", "metadata": {"window": "We are lowering our non -GAAP ETR range for the year to 23% to 25%, which reflects our \nyear-to-date effective tax rate of 18% and higher expected effective tax rates in the back half of the \nfiscal ye ar due to the timing of discrete items.  \n \n  We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "original_text": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f99ec03c828c2236588caea9c3bfc2436b49e282c881e61e4d869d0a825da8cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bcae024-848f-4dfb-b0b8-2368b1495b0b", "node_type": "1", "metadata": {"window": "Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n", "original_text": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  "}, "hash": "34931562b54a4482cc3799d5997090bcea49a8afb6c810507dcae43bf96b32ea", "class_name": "RelatedNodeInfo"}}, "text": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "start_char_idx": 1822, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bcae024-848f-4dfb-b0b8-2368b1495b0b": {"__data__": {"id_": "0bcae024-848f-4dfb-b0b8-2368b1495b0b", "embedding": null, "metadata": {"window": "Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n", "original_text": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1af2c304-98c0-4c94-8bf0-5f654b53abd0", "node_type": "1", "metadata": {"window": "We also now expect dilutive weighted average shares outstanding to finish the year in the \nrange of 294 million to 295 million.  \n \n  Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "original_text": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4247869161f6b0857c5edfc672ce7ce9d9932f435677529754cb32ac257835ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33f89dd-323b-4d77-879c-b625e6f4d2b4", "node_type": "1", "metadata": {"window": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  "}, "hash": "ac3bedb153fe730088168bcb8d0eb08abb63cbdfe56f0c6b097f86f3969645da", "class_name": "RelatedNodeInfo"}}, "text": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "start_char_idx": 1980, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c33f89dd-323b-4d77-879c-b625e6f4d2b4": {"__data__": {"id_": "c33f89dd-323b-4d77-879c-b625e6f4d2b4", "embedding": null, "metadata": {"window": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bcae024-848f-4dfb-b0b8-2368b1495b0b", "node_type": "1", "metadata": {"window": "Regarding the segment outlooks on slide 9.   For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n", "original_text": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d30ac2b438a03b5c7f7908d2108f31dcc7c5acc121c68cf25ecd1aeb6adf731", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb6fde54-0de6-4482-9ff0-d2f319acbb8b", "node_type": "1", "metadata": {"window": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "original_text": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n "}, "hash": "7605df469e29c1e882e19df7d4b76a17fe6226e9ab92bca7ad7caf7a715c5ac6", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "start_char_idx": 2159, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb6fde54-0de6-4482-9ff0-d2f319acbb8b": {"__data__": {"id_": "bb6fde54-0de6-4482-9ff0-d2f319acbb8b", "embedding": null, "metadata": {"window": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "original_text": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33f89dd-323b-4d77-879c-b625e6f4d2b4", "node_type": "1", "metadata": {"window": "For Medical, due to the previously discus sed \ndrivers, we now expect segment profit percentage growth in the low to mid -20s and revenue growth \nfor the year in the range of high -single to low -double digits.  \n \n  Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4423f4adbcff3f0948e1bb8dd8cf6c18de96d2513ce7deb505be866c981a65d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca646af3-1473-4f33-9a63-d9dab9788a7c", "node_type": "1", "metadata": {"window": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'll now turn it back over to M ike. \n \n"}, "hash": "6716b17c1fcfca0690c9366ca33c52a50cd600c773daef2b94f58882b5894f3c", "class_name": "RelatedNodeInfo"}}, "text": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "start_char_idx": 2270, "end_char_idx": 2467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca646af3-1473-4f33-9a63-d9dab9788a7c": {"__data__": {"id_": "ca646af3-1473-4f33-9a63-d9dab9788a7c", "embedding": null, "metadata": {"window": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'll now turn it back over to M ike. \n \n", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb6fde54-0de6-4482-9ff0-d2f319acbb8b", "node_type": "1", "metadata": {"window": "Regarding the Pharma segment, we are maintaining our current guidance ranges of mid -single  \ndigit revenue growth and low -single  digit profit growth.  \n \n  To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "original_text": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6026de71437c135c94ab42fdfe55e29666b95376ecdeb4df2b5dfa1036a7876", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37cbbcfe-fa97-4e6f-9a70-c8e756054618", "node_type": "1", "metadata": {"window": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "Mike Kaufmann:  Thanks, Jason.  "}, "hash": "2e1f804b132704068b55fbfb7f450ca3e1baabbc29fb96c5be962f109bda1ab3", "class_name": "RelatedNodeInfo"}}, "text": "I'll now turn it back over to M ike. \n \n", "start_char_idx": 2467, "end_char_idx": 2507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37cbbcfe-fa97-4e6f-9a70-c8e756054618": {"__data__": {"id_": "37cbbcfe-fa97-4e6f-9a70-c8e756054618", "embedding": null, "metadata": {"window": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca646af3-1473-4f33-9a63-d9dab9788a7c", "node_type": "1", "metadata": {"window": "To conclude, some comments on our enterprise COVID -19 assumptions for the back half of \nthe fiscal year as we begin to lap the initial impact of the pandemic in the prior year.   We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'll now turn it back over to M ike. \n \n", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecf3a769ae1c4c7c86aa226eed2a0e8654045e4793d3435ff72f10b332a02c7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720", "node_type": "1", "metadata": {"window": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  "}, "hash": "2044480bb74b499099d62da767b5931d9a642fa4fdb64ac30ba903071035ecd9", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Jason.  ", "start_char_idx": 2507, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720": {"__data__": {"id_": "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720", "embedding": null, "metadata": {"window": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37cbbcfe-fa97-4e6f-9a70-c8e756054618", "node_type": "1", "metadata": {"window": "We continue to \nexpect utilization to be choppy and to exit the fiscal year at o r near pre -pandemic levels.   And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "511cf09a29ce43cd84f7b2ee6b0ef703f9a75746805a67af3fcf0c202c70ae1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36da6d67-c689-4856-90e3-c2e012572d64", "node_type": "1", "metadata": {"window": "I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "We create this value "}, "hash": "ae659b2beb019d4f1cbd79576f2bf7107d834c9e832e4ace85a5e6248c9f4603", "class_name": "RelatedNodeInfo"}}, "text": "I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "start_char_idx": 2539, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36da6d67-c689-4856-90e3-c2e012572d64": {"__data__": {"id_": "36da6d67-c689-4856-90e3-c2e012572d64", "embedding": null, "metadata": {"window": "I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "We create this value ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1473a07f-b10a-4654-a4f2-9dee46589993", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3e13d7b274281e33c8aba3dd67cc07df039455434fccb44d72a27534218e73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720", "node_type": "1", "metadata": {"window": "And for the \nenterprise in fiscal 21, we continue to expect a year-over-year net negative impact from COVID -19, \nthough less than originally anticipated due to improved medical expectations.  \n \n  I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b3ced9b4787bd1cbf33f4874313b36a0d10d96a4b86b7df546cbb82071f0247", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82385a61-136c-4a8c-86aa-6d6f9db4e4a9", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "original_text": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n "}, "hash": "979522d287f25b46d487c70f75340623224b976fa59a9339852975216264304a", "class_name": "RelatedNodeInfo"}}, "text": "We create this value ", "start_char_idx": 2935, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82385a61-136c-4a8c-86aa-6d6f9db4e4a9": {"__data__": {"id_": "82385a61-136c-4a8c-86aa-6d6f9db4e4a9", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "original_text": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36da6d67-c689-4856-90e3-c2e012572d64", "node_type": "1", "metadata": {"window": "I'll now turn it back over to M ike. \n \n Mike Kaufmann:  Thanks, Jason.   I'd now like to take a moment to elaborate on how this \nunprecedented time has reinforced our critical role in health care and how we see this role evolving \nas we look toward and beyond the second half of the fiscal yea r. \n \n I said last quarter that we aspire to be health care's most trusted partner and create the \ngreatest value for our customers, shareholders, communities and employees.   We create this value ", "original_text": "We create this value ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4315e40fc335697c3c59ecbe1598b0b9cef10ce16674ce200fc08dc419da51a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55982873-aed4-40b1-93a6-9bd3037c9988", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "original_text": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.  "}, "hash": "a91b09e87466ef4efdaaae760d78181beeb3cb26ea1dece46daf4ec7518ef4dc", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n ", "start_char_idx": 0, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55982873-aed4-40b1-93a6-9bd3037c9988": {"__data__": {"id_": "55982873-aed4-40b1-93a6-9bd3037c9988", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "original_text": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82385a61-136c-4a8c-86aa-6d6f9db4e4a9", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "original_text": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30f88afd81ff598915242b252f4e1b1bbe03bc37a58847ee8ead8210139b7eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "original_text": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.  "}, "hash": "a5a0e3fe72120a482653b609ce2eea6af6e0be6b9af02b1d54e3eb7382f0bce4", "class_name": "RelatedNodeInfo"}}, "text": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.  ", "start_char_idx": 209, "end_char_idx": 356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e": {"__data__": {"id_": "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "original_text": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55982873-aed4-40b1-93a6-9bd3037c9988", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "original_text": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adb030f0aac932073ce79e5fc85994c55a0f7a7337bbced5026e5b16184ad95e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "original_text": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n "}, "hash": "1661215cef8d9f983872eb4a3dbbe538b2546397ab30a7e805a36f2c969c2ac1", "class_name": "RelatedNodeInfo"}}, "text": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.  ", "start_char_idx": 356, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185": {"__data__": {"id_": "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "original_text": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "original_text": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac780d06c93298449780a5aad7e096f6ae3bc5f8d65d24fdc320464cc36d2ed4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60a6a31c-124a-4e06-909b-c5359f3bcc4e", "node_type": "1", "metadata": {"window": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "original_text": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  "}, "hash": "c88d7532b6e2e862527dd74bf5ce7428122a6a067eca0a76057041575af26c87", "class_name": "RelatedNodeInfo"}}, "text": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "start_char_idx": 470, "end_char_idx": 695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60a6a31c-124a-4e06-909b-c5359f3bcc4e": {"__data__": {"id_": "60a6a31c-124a-4e06-909b-c5359f3bcc4e", "embedding": null, "metadata": {"window": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "original_text": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "original_text": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0347108d77ecd7844eb220c399d5a37b92ded6cc5534832d9b5cd8a2facb368", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff62620c-20dd-444f-98b8-a16953d0651e", "node_type": "1", "metadata": {"window": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "original_text": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n "}, "hash": "d318324bc175e494da45243a01f54200c3920ca94e9c7ad0b9e50678524fe76d", "class_name": "RelatedNodeInfo"}}, "text": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "start_char_idx": 695, "end_char_idx": 846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff62620c-20dd-444f-98b8-a16953d0651e": {"__data__": {"id_": "ff62620c-20dd-444f-98b8-a16953d0651e", "embedding": null, "metadata": {"window": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "original_text": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60a6a31c-124a-4e06-909b-c5359f3bcc4e", "node_type": "1", "metadata": {"window": "First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "original_text": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "421b577c9880da586746e294dea772ab99f706f30acbbffb0c43d3d0587c94ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daa83d76-489c-478a-b416-9dd833559298", "node_type": "1", "metadata": {"window": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "original_text": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  "}, "hash": "de0b0cec2d2154f973728014170237d94d144d94bfd20778c0b66b21666a487c", "class_name": "RelatedNodeInfo"}}, "text": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "start_char_idx": 846, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daa83d76-489c-478a-b416-9dd833559298": {"__data__": {"id_": "daa83d76-489c-478a-b416-9dd833559298", "embedding": null, "metadata": {"window": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "original_text": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff62620c-20dd-444f-98b8-a16953d0651e", "node_type": "1", "metadata": {"window": "For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "original_text": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e9b0f75db7a9dcf5d4664f7481441b269744dedad45e3bda49d062708575a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c60d57f-beae-473a-aa98-8bcae190d704", "node_type": "1", "metadata": {"window": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "original_text": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. "}, "hash": "b19a91908fdad39debef636e355c21c80b5de7e88d881306a82bdb8390c8d937", "class_name": "RelatedNodeInfo"}}, "text": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "start_char_idx": 982, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c60d57f-beae-473a-aa98-8bcae190d704": {"__data__": {"id_": "5c60d57f-beae-473a-aa98-8bcae190d704", "embedding": null, "metadata": {"window": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "original_text": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daa83d76-489c-478a-b416-9dd833559298", "node_type": "1", "metadata": {"window": "Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n  We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "original_text": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dbce1d6bd82eeb96385efa0b8111cb86d625a2fd6ee335f34b29e3a8687cfef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a418c45-7adf-43a7-8816-48d08c69abb9", "node_type": "1", "metadata": {"window": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "original_text": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n "}, "hash": "73f2162bdf92943b06142bedb031a0be902d807a4628b3e71b97c1798f35348b", "class_name": "RelatedNodeInfo"}}, "text": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "start_char_idx": 1162, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a418c45-7adf-43a7-8816-48d08c69abb9": {"__data__": {"id_": "1a418c45-7adf-43a7-8816-48d08c69abb9", "embedding": null, "metadata": {"window": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "original_text": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c60d57f-beae-473a-aa98-8bcae190d704", "node_type": "1", "metadata": {"window": "We are also enhancing our core Medical and Pharmaceutical distribution and product \ncapabilities as we continue to adapt these models for the future.   We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "original_text": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d330218c4376d515bb7d09db609de985ff62986e0fe662537a6817e96910bd28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09dbee8-9dde-4e62-8db2-4fe248a64a56", "node_type": "1", "metadata": {"window": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail. ", "original_text": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. "}, "hash": "2e2d65d267683d67e5176ed15d049b22eb1a23d15dff35ce3ccdd5c048c43405", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "start_char_idx": 1522, "end_char_idx": 1713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09dbee8-9dde-4e62-8db2-4fe248a64a56": {"__data__": {"id_": "f09dbee8-9dde-4e62-8db2-4fe248a64a56", "embedding": null, "metadata": {"window": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail. ", "original_text": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a418c45-7adf-43a7-8816-48d08c69abb9", "node_type": "1", "metadata": {"window": "We are making str ong progress in \nboth segments on our supply chain work streams and generating near and long -term efficiencies.  \n \n  For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "original_text": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8878586695b9e70965078562e6b818aa2b630f7bb02c938bf477d3cfe9171d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57772ff2-e4fb-42fe-bfa4-3e627a97f57d", "node_type": "1", "metadata": {"window": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "original_text": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. "}, "hash": "3628713f012cce1923f50a53a210a538ac213f615aa30292ee6bac6a37f8ff1d", "class_name": "RelatedNodeInfo"}}, "text": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "start_char_idx": 1713, "end_char_idx": 1960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57772ff2-e4fb-42fe-bfa4-3e627a97f57d": {"__data__": {"id_": "57772ff2-e4fb-42fe-bfa4-3e627a97f57d", "embedding": null, "metadata": {"window": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "original_text": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09dbee8-9dde-4e62-8db2-4fe248a64a56", "node_type": "1", "metadata": {"window": "For example, we began work this quarter on a new 1 million square foot Medical segment \nreplenishment center near Chicago that we expect to be o perational in the fourth quarter.   This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail. ", "original_text": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7550b775efc3f293b9c4c4552800efb2a08265c1684833274b7cb9f8aa1137ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a184cb5-4478-48a4-8970-55bd3cd70df9", "node_type": "1", "metadata": {"window": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "original_text": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n "}, "hash": "1100268721e942db071ea23984f1a3359494552f57de6e58b635425372d9dc87", "class_name": "RelatedNodeInfo"}}, "text": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "start_char_idx": 1960, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a184cb5-4478-48a4-8970-55bd3cd70df9": {"__data__": {"id_": "3a184cb5-4478-48a4-8970-55bd3cd70df9", "embedding": null, "metadata": {"window": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "original_text": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57772ff2-e4fb-42fe-bfa4-3e627a97f57d", "node_type": "1", "metadata": {"window": "This facility \nis the second of its kind in the last year and is part of our multiyear plan to improve the customer \nexperience, consolidate our network and increase  capacity to meet customer  request s for pandemic \nstorag e. \n \n We are also making strategic investments in our IT infrastructure to enhance our customer \nexperience and digital capabilities.  At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "original_text": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b143130997d3648c13ed0894e1b40ff7df2e1547e6a62b80462ef8c8a2a79f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3ef7458-f65a-4914-98ce-62d3a623631c", "node_type": "1", "metadata": {"window": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "original_text": "Let me highlight a few o f these areas in greater detail. "}, "hash": "879806ee8978a73d0ba42744c9ef929eda17058ce4aae7484d449d04169db3bd", "class_name": "RelatedNodeInfo"}}, "text": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "start_char_idx": 2067, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3ef7458-f65a-4914-98ce-62d3a623631c": {"__data__": {"id_": "d3ef7458-f65a-4914-98ce-62d3a623631c", "embedding": null, "metadata": {"window": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "original_text": "Let me highlight a few o f these areas in greater detail. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a184cb5-4478-48a4-8970-55bd3cd70df9", "node_type": "1", "metadata": {"window": "At the same time, we are investing in our differentiated portfolio to \ndrive strategic, long -term growth in key areas and no t only support , but also anticipate our customers' \nneeds.  \n \n  Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "original_text": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25178e6a09cdd0332a54587eaab0dc0236aa10090354cea4c2ee819f85a25e5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12cec106-b471-4f95-b861-33cc4adeec37", "node_type": "1", "metadata": {"window": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "original_text": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. "}, "hash": "e934afc355842f5a04c41d3f5812f470ed8896eae9c72a5fee021c613970ff57", "class_name": "RelatedNodeInfo"}}, "text": "Let me highlight a few o f these areas in greater detail. ", "start_char_idx": 2150, "end_char_idx": 2208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12cec106-b471-4f95-b861-33cc4adeec37": {"__data__": {"id_": "12cec106-b471-4f95-b861-33cc4adeec37", "embedding": null, "metadata": {"window": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "original_text": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3ef7458-f65a-4914-98ce-62d3a623631c", "node_type": "1", "metadata": {"window": "Our investments in the areas of Specialty, at -Home, Medical Services, Nuclear and Connected \nCare will enable us to capture benefits from favorable industry trends and to develop specialized \ncustom er solutions, utilizing our breadth and scale.  Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "original_text": "Let me highlight a few o f these areas in greater detail. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69701b58425b08c5bf56c554826613acb74aee8965bd1e89957c45b912848ff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8958c496-13a0-418e-a2d3-fba6bf1cdaed", "node_type": "1", "metadata": {"window": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "original_text": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n "}, "hash": "c48f3797857f8f1120a905d25389e75db772243430f1a9b7d25b6d0642cb29e3", "class_name": "RelatedNodeInfo"}}, "text": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "start_char_idx": 2208, "end_char_idx": 2412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8958c496-13a0-418e-a2d3-fba6bf1cdaed": {"__data__": {"id_": "8958c496-13a0-418e-a2d3-fba6bf1cdaed", "embedding": null, "metadata": {"window": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "original_text": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12cec106-b471-4f95-b861-33cc4adeec37", "node_type": "1", "metadata": {"window": "Recall, I noted at a recent conference that these \nfive businesses represent $25 billion in total revenue.  And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "original_text": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eda028bbdde813553b8f09f5d44482a44621a0eb3314225147b7b0c2ee6df40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "417e1e19-2ba1-4462-b0f7-3dfcb70790c4", "node_type": "1", "metadata": {"window": "Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. "}, "hash": "c687223c2fd6979b097c612a74cc618199dce1457756251e181aa34becc15449", "class_name": "RelatedNodeInfo"}}, "text": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "start_char_idx": 2412, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "417e1e19-2ba1-4462-b0f7-3dfcb70790c4": {"__data__": {"id_": "417e1e19-2ba1-4462-b0f7-3dfcb70790c4", "embedding": null, "metadata": {"window": "Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8958c496-13a0-418e-a2d3-fba6bf1cdaed", "node_type": "1", "metadata": {"window": "And together, they have a double -digit historical \nthree -year revenue CAGR.  \n \n  Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "original_text": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c277669c8cf57e0bda924996ca90d600eaba14cb408a55994b249832a7e0b198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e5a667e-a179-4730-8119-83894dde3656", "node_type": "1", "metadata": {"window": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n "}, "hash": "de3b49f52149e5c7c39e3f6f0525aa8ef6789842e88918ee02a4df5b36e42f73", "class_name": "RelatedNodeInfo"}}, "text": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "start_char_idx": 2637, "end_char_idx": 2904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e5a667e-a179-4730-8119-83894dde3656": {"__data__": {"id_": "2e5a667e-a179-4730-8119-83894dde3656", "embedding": null, "metadata": {"window": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "417e1e19-2ba1-4462-b0f7-3dfcb70790c4", "node_type": "1", "metadata": {"window": "Let me highlight a few o f these areas in greater detail.  In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers. ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "637c9db4e15f209d19a71cebe1bd967a354a1e26fbb2c109e20d73719f05009d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9851d8d1-32cf-4282-9952-b09fdd4300f5", "node_type": "1", "metadata": {"window": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  "}, "hash": "4c308da07e242757a432a9f575d9f7f3ec6287fead351a2bd98b65a273687821", "class_name": "RelatedNodeInfo"}}, "text": "WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "start_char_idx": 2904, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9851d8d1-32cf-4282-9952-b09fdd4300f5": {"__data__": {"id_": "9851d8d1-32cf-4282-9952-b09fdd4300f5", "embedding": null, "metadata": {"window": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e5a667e-a179-4730-8119-83894dde3656", "node_type": "1", "metadata": {"window": "In Medical Services, which includes our \nOptiFreight Logistics and WaveMark businesses, we are investing in technologies to drive continued \ninnovation that will meet the evolving needs of our customers.  For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7640280f771566d94699fb17e494ee7354965f1c10e48638d1907c7ae18a35a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9", "node_type": "1", "metadata": {"window": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the "}, "hash": "56dcb9c1d068eaea4355c50263942f46994155b59af4e26a1629afb9fbf94a1f", "class_name": "RelatedNodeInfo"}}, "text": "As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "start_char_idx": 3111, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9": {"__data__": {"id_": "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9", "embedding": null, "metadata": {"window": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fd1eb968d7bc06a670d28ca9b6e433e25bf2a68b53f33b6ea851399ecb8cc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9851d8d1-32cf-4282-9952-b09fdd4300f5", "node_type": "1", "metadata": {"window": "For example, with o ur recently \nannounced TotalVue Analytics tool in our OptiFreight business, we are using data to help our \ncustomers drive insights and savings in their health care supply chain logistics management.  \n \n  And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.  ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97ea2db5c18d3c4cc3912bb76c981a4a82cfe8eb9e29509d468b6b1345e7044a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "584a41f2-9a5c-4dc5-9113-e2c32e6d6610", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "original_text": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.  "}, "hash": "bca1128f2c2ebc3990a91705b8d1808a519afcb7331faacfc25b5a33015c80a9", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "start_char_idx": 3283, "end_char_idx": 3392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "584a41f2-9a5c-4dc5-9113-e2c32e6d6610": {"__data__": {"id_": "584a41f2-9a5c-4dc5-9113-e2c32e6d6610", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "original_text": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9", "node_type": "1", "metadata": {"window": "And in WaveMark, which, as a reminder, is a software -as-a-service platform, optimizing supply \nchain and clinical workflow processes for acute care, we have seen growth in both our installations \nand our pipeline as we continue to go live with additional customers.  WaveMark has also recently \ninitiated partnershi p opportunities to explore solutions to help lab managers and supply chain leaders \nmanage the increased demand for critical test kits and lab supplies.  \n \n  As our Nuclear business continues its recovery related to the pandemic, our team remains \nfocused on lo ng-term plans to further strengthen our leading industry position.   We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "original_text": "We continue to build \nout our Center for Theranostics Advancements in Indianapolis and are excited about the ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffe6c5cd6c22f1a7c62a59cacae1aa4f5f48550e5008eb4c9a8ebd780a3366d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0624134-f566-4acc-8dc4-a08bf3cbda84", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "original_text": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n "}, "hash": "4aa296f22a2365e37d545ac35edccae8b297fd1172a50d640c6f729afbd478b8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.  ", "start_char_idx": 0, "end_char_idx": 62, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0624134-f566-4acc-8dc4-a08bf3cbda84": {"__data__": {"id_": "c0624134-f566-4acc-8dc4-a08bf3cbda84", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "original_text": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "584a41f2-9a5c-4dc5-9113-e2c32e6d6610", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "original_text": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c7dc4ae96a7aca2ed0ddc286abec2db9760b5ec13e594573fb425816de3308a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65eabac1-8a23-449c-b09e-e896b7d05b04", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "original_text": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.  "}, "hash": "039a00c809f8822029fd039b5df48a46be0e06a41d811e5aca6fe33a1b7b9e0d", "class_name": "RelatedNodeInfo"}}, "text": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n ", "start_char_idx": 62, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65eabac1-8a23-449c-b09e-e896b7d05b04": {"__data__": {"id_": "65eabac1-8a23-449c-b09e-e896b7d05b04", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "original_text": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0624134-f566-4acc-8dc4-a08bf3cbda84", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "original_text": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68d276b9988a0fc4b20c472f8c5583ef121a6ad65afafc06f7c6aa6608cd7ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32ef4fe9-c622-4ffc-b4bc-44e722853dc5", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.  ", "original_text": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n "}, "hash": "990195b9f1259719631ccb9ac122cc6d37fbc30bc020a902b3b9958d909009c7", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.  ", "start_char_idx": 242, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32ef4fe9-c622-4ffc-b4bc-44e722853dc5": {"__data__": {"id_": "32ef4fe9-c622-4ffc-b4bc-44e722853dc5", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.  ", "original_text": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65eabac1-8a23-449c-b09e-e896b7d05b04", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "original_text": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66ae76f96ba701846b96905204b8c91644f852c9f3ef361905efa5b3d6301e41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9091641-1be6-473d-8401-eee06236cf4e", "node_type": "1", "metadata": {"window": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "original_text": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  "}, "hash": "74a4f202529b69d47da6eb37b0157d222e9cb94b4d378b85960ca6f23f67b667", "class_name": "RelatedNodeInfo"}}, "text": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "start_char_idx": 380, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9091641-1be6-473d-8401-eee06236cf4e": {"__data__": {"id_": "a9091641-1be6-473d-8401-eee06236cf4e", "embedding": null, "metadata": {"window": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "original_text": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32ef4fe9-c622-4ffc-b4bc-44e722853dc5", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.  ", "original_text": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ecff45c30dc4797be05e3392d6a45cd26bb7da2f0a65526ae09a8f193525b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d4e3b31-4f0c-46de-aceb-fed3292ba26e", "node_type": "1", "metadata": {"window": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "original_text": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n "}, "hash": "714ce3c61b05435e161e075fcaf77092ee78397dbff36d2718b8d7f7118b5445", "class_name": "RelatedNodeInfo"}}, "text": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "start_char_idx": 651, "end_char_idx": 972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d4e3b31-4f0c-46de-aceb-fed3292ba26e": {"__data__": {"id_": "3d4e3b31-4f0c-46de-aceb-fed3292ba26e", "embedding": null, "metadata": {"window": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "original_text": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9091641-1be6-473d-8401-eee06236cf4e", "node_type": "1", "metadata": {"window": "From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "original_text": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8f2590451e83b7648705ff4a44789d3398ef4758dfa61f6dc9880124ddd7c05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcce04ec-0644-40cb-a232-1535f70355e3", "node_type": "1", "metadata": {"window": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "original_text": "We are sending more than 400 million texts annually to support medication management.  "}, "hash": "dcb55bbbf2356e841a22d69e4c7d881c8971fcfb2e7a1201562399ef6585cdac", "class_name": "RelatedNodeInfo"}}, "text": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "start_char_idx": 972, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcce04ec-0644-40cb-a232-1535f70355e3": {"__data__": {"id_": "fcce04ec-0644-40cb-a232-1535f70355e3", "embedding": null, "metadata": {"window": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "original_text": "We are sending more than 400 million texts annually to support medication management.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d4e3b31-4f0c-46de-aceb-fed3292ba26e", "node_type": "1", "metadata": {"window": "In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "original_text": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21d76efb7fd8e87e3346b45bb96d0c997df306c432a7a0eb52a113924bd99576", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e917243-f96a-48b8-bfba-9c33c45bf54f", "node_type": "1", "metadata": {"window": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "original_text": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  "}, "hash": "43243704a7e45886a4fea8341e329260cb1a6017b9007508866a9e43cc1b4eb5", "class_name": "RelatedNodeInfo"}}, "text": "We are sending more than 400 million texts annually to support medication management.  ", "start_char_idx": 1119, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e917243-f96a-48b8-bfba-9c33c45bf54f": {"__data__": {"id_": "2e917243-f96a-48b8-bfba-9c33c45bf54f", "embedding": null, "metadata": {"window": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "original_text": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcce04ec-0644-40cb-a232-1535f70355e3", "node_type": "1", "metadata": {"window": "Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n  And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "original_text": "We are sending more than 400 million texts annually to support medication management.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37d3847e5c55cf1973c0d9e79388eefb96a8235a81d6b75972216b72b8dc82ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "186a1907-713c-4e8d-b6a8-448a1269f3b3", "node_type": "1", "metadata": {"window": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "original_text": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n "}, "hash": "6c9624dc2e205d707fc039c0634c3643d6632571dd21ec42044930816b38b0c6", "class_name": "RelatedNodeInfo"}}, "text": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "start_char_idx": 1206, "end_char_idx": 1396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "186a1907-713c-4e8d-b6a8-448a1269f3b3": {"__data__": {"id_": "186a1907-713c-4e8d-b6a8-448a1269f3b3", "embedding": null, "metadata": {"window": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "original_text": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e917243-f96a-48b8-bfba-9c33c45bf54f", "node_type": "1", "metadata": {"window": "And finally, in Connected Care, we are making additional investments in technology solution s \nand actionable data tools to take advantage of the double -digit growth we are seeing and to enable \nmore meaningful, cost -effective and outcomes -driven connections between payers, manufacturers, \npharmacists and patients.   Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "original_text": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "796dda67779b130a1580d99dfcb7693e9da60cbdf4ccb053bf5a316fcb4d1af8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf13a671-f281-4d59-88af-f4bfbe0d43db", "node_type": "1", "metadata": {"window": "We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n", "original_text": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n "}, "hash": "6510290bcc9a891ca8e24f56b5f662ed02ee30cea16b792ac636b01458972f38", "class_name": "RelatedNodeInfo"}}, "text": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "start_char_idx": 1396, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf13a671-f281-4d59-88af-f4bfbe0d43db": {"__data__": {"id_": "cf13a671-f281-4d59-88af-f4bfbe0d43db", "embedding": null, "metadata": {"window": "We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n", "original_text": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "186a1907-713c-4e8d-b6a8-448a1269f3b3", "node_type": "1", "metadata": {"window": "Demand for these solutions continu es to increase with our services \ncurrently reaching 60,000 pharmacies, 23 million patients and 60 payers.  \n \n  We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "original_text": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0a62e2d0df04fd0466ad7cd44765e0ffe0d9301cd4777505051cde5376e539f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6defaba3-963c-4aa1-8785-7b051ad3522a", "node_type": "1", "metadata": {"window": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "original_text": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  "}, "hash": "1835b4336f83c51b0aa0066811ea8110c7be841175fa78ee13c474b83a444829", "class_name": "RelatedNodeInfo"}}, "text": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "start_char_idx": 1550, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6defaba3-963c-4aa1-8785-7b051ad3522a": {"__data__": {"id_": "6defaba3-963c-4aa1-8785-7b051ad3522a", "embedding": null, "metadata": {"window": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "original_text": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf13a671-f281-4d59-88af-f4bfbe0d43db", "node_type": "1", "metadata": {"window": "We are sending more than 400 million texts annually to support medication management.   And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n", "original_text": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "654a0cdc1c5271294c152b0b53470905fb731b2cd05607c9810dde04db8d9a07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e10bc90-db83-4678-b26c-1e67705abba1", "node_type": "1", "metadata": {"window": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "original_text": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n "}, "hash": "d96b0836c50df8db1dd8e853aa64409813fa88919c3ebcf0c51d43ca7d089e89", "class_name": "RelatedNodeInfo"}}, "text": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "start_char_idx": 1751, "end_char_idx": 1865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e10bc90-db83-4678-b26c-1e67705abba1": {"__data__": {"id_": "6e10bc90-db83-4678-b26c-1e67705abba1", "embedding": null, "metadata": {"window": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "original_text": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6defaba3-963c-4aa1-8785-7b051ad3522a", "node_type": "1", "metadata": {"window": "And \nin the last quarter, we have designed, developed and implemented tools to help our pharmacy \ncustomers administer the COVID -19 vaccine with more than 2,500 locations already engaged.   We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "original_text": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9175d8a73e58d2cdabec7240a1819705aa7b7036c26843952b93d7838d92a8a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc1dc365-7c84-4e9b-b0dc-13d304989b2a", "node_type": "1", "metadata": {"window": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "original_text": "With that, I'll pause to open it up for ques tions.  \n \n"}, "hash": "2eb37bf80494a50cefc80bfb1481c62f55cdbe819363a468860523bba948985d", "class_name": "RelatedNodeInfo"}}, "text": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "start_char_idx": 1865, "end_char_idx": 2008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc1dc365-7c84-4e9b-b0dc-13d304989b2a": {"__data__": {"id_": "cc1dc365-7c84-4e9b-b0dc-13d304989b2a", "embedding": null, "metadata": {"window": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "original_text": "With that, I'll pause to open it up for ques tions.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e10bc90-db83-4678-b26c-1e67705abba1", "node_type": "1", "metadata": {"window": "We \nwill continue to share progress in each of these growth areas and in our core capability initiatives as \nthey materialize ov er the coming year.  \n \n  Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "original_text": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c26fb39676e5a58639615daed92e5453752b2194d61aa7f33ca6edf38616bca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "950acf64-ecc9-44a9-b795-924569c9635a", "node_type": "1", "metadata": {"window": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n"}, "hash": "c1b24689d7adcaebcd6958cc64220b52b34ab6fbd836693de2b512dfaac20a5e", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll pause to open it up for ques tions.  \n \n", "start_char_idx": 2008, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "950acf64-ecc9-44a9-b795-924569c9635a": {"__data__": {"id_": "950acf64-ecc9-44a9-b795-924569c9635a", "embedding": null, "metadata": {"window": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc1dc365-7c84-4e9b-b0dc-13d304989b2a", "node_type": "1", "metadata": {"window": "Before I close, I want to thank the team here at Cardinal Health, who continue to do a \ntremendous job adapting and responding to the changing needs of our customers as we navigate the \npandemic.  \n \n  Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "original_text": "With that, I'll pause to open it up for ques tions.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c6ca3f51b2e7792661e2ee4c29e7fae8de80d115aa39a627dae00ace001ec7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "329d4c24-8481-4f4f-b982-5c49a1851d61", "node_type": "1", "metadata": {"window": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.  ", "original_text": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  "}, "hash": "538e0667848ff247ad6e4da35b424a293112ad4c06129e94e137ae76a124077e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "start_char_idx": 2064, "end_char_idx": 2174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "329d4c24-8481-4f4f-b982-5c49a1851d61": {"__data__": {"id_": "329d4c24-8481-4f4f-b982-5c49a1851d61", "embedding": null, "metadata": {"window": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.  ", "original_text": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "950acf64-ecc9-44a9-b795-924569c9635a", "node_type": "1", "metadata": {"window": "Finally, I will reiterate that what we  do matters , to our customers, shareholders, employees and \ncommunities.   As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa65bc49109f1b809433945eb7cf5d089d5825206d06f901d6fa7d39286a451", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c85053ed-cd95-45c1-b42f-30d593254289", "node_type": "1", "metadata": {"window": "With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.  ", "original_text": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n"}, "hash": "7d07e0006e1d23400e705bbbe10807cccbd3aff5387d341b9d9dab6dcb9dfc4e", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "start_char_idx": 2174, "end_char_idx": 2246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c85053ed-cd95-45c1-b42f-30d593254289": {"__data__": {"id_": "c85053ed-cd95-45c1-b42f-30d593254289", "embedding": null, "metadata": {"window": "With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.  ", "original_text": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "329d4c24-8481-4f4f-b982-5c49a1851d61", "node_type": "1", "metadata": {"window": "As we move forward, we are using our breadth, scale and expertise to provide \nproducts and solutions that create value and improve lives.  \n \n  With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.  ", "original_text": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41586953146ec590e7d11b8996f4b90222ee75e34cdcbe93a15e63c1fec96210", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6125400a-dada-4a21-afe5-607aa84d23ba", "node_type": "1", "metadata": {"window": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "a90f99af2a219577416c3843de551bc428460d4fe43a1879529b853eeee2f4ed", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "start_char_idx": 2246, "end_char_idx": 2456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6125400a-dada-4a21-afe5-607aa84d23ba": {"__data__": {"id_": "6125400a-dada-4a21-afe5-607aa84d23ba", "embedding": null, "metadata": {"window": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c85053ed-cd95-45c1-b42f-30d593254289", "node_type": "1", "metadata": {"window": "With that, I'll pause to open it up for ques tions.  \n \n Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.  ", "original_text": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "992f7db58c783cc6912f5254c4cdc70aa0f12b500a7d8be68844e92c005ccc23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c59cdaa-c0cd-4370-a323-28c8b991786b", "node_type": "1", "metadata": {"window": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "original_text": "Thanks for the question, Michael.  "}, "hash": "73b7514eb9d823c67f82745579ccba0f94e135b16d5e1f829fa3982e0d691dc0", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 2456, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c59cdaa-c0cd-4370-a323-28c8b991786b": {"__data__": {"id_": "7c59cdaa-c0cd-4370-a323-28c8b991786b", "embedding": null, "metadata": {"window": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "original_text": "Thanks for the question, Michael.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6125400a-dada-4a21-afe5-607aa84d23ba", "node_type": "1", "metadata": {"window": "Operator:  (Operator Instructions) We'll take our first question from Michael Cherny of Bank of \nAmerica.  \n \n Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1991df4708f05689a34f8cd9069d6a730ee24da0e41c9322b4cc18a47912e562", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9", "node_type": "1", "metadata": {"window": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "original_text": "Appreciate it.  "}, "hash": "470ee035aec3154c2cc3ed1dbbde6569224d9c8ab2b26fc8bf4383be6f71caa3", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Michael.  ", "start_char_idx": 2478, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9": {"__data__": {"id_": "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9", "embedding": null, "metadata": {"window": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "original_text": "Appreciate it.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c59cdaa-c0cd-4370-a323-28c8b991786b", "node_type": "1", "metadata": {"window": "Michael Cherny:  If I can dive a little bit into the Pharma headwinds.   As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "original_text": "Thanks for the question, Michael.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9d95fb0b75d05a9c23a2befbf8ec13d51e7def80d33add220bbd0cf7673922c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "I guess, really a couple of \nthings to keep in mind .  "}, "hash": "8b09bb07242d62bfbeaf72433c03a2cc9fa1f837abe3f0e6dd73efb794167bb3", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate it.  ", "start_char_idx": 2513, "end_char_idx": 2529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f": {"__data__": {"id_": "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "I guess, really a couple of \nthings to keep in mind .  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9", "node_type": "1", "metadata": {"window": "As you think about the outlook \nfor the rest of the year, how do you th ink about the trajectory and the visibility on Nuclear and then \nalso the headwinds on generic s and when they could recover for you?  \n \n Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "original_text": "Appreciate it.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c413487c48fa6514863fe8675ca907faf066c6a8d314ac5c5b1e11bfb9d99401", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2db2c777-ab93-4e3f-9245-7bb93b7c00e3", "node_type": "1", "metadata": {"window": "Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n "}, "hash": "076e3dee56eae5d9c044616ba2a21d0374d4f43cfc4250c2d917a8eef5ca466a", "class_name": "RelatedNodeInfo"}}, "text": "I guess, really a couple of \nthings to keep in mind .  ", "start_char_idx": 2529, "end_char_idx": 2584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2db2c777-ab93-4e3f-9245-7bb93b7c00e3": {"__data__": {"id_": "2db2c777-ab93-4e3f-9245-7bb93b7c00e3", "embedding": null, "metadata": {"window": "Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "I guess, really a couple of \nthings to keep in mind .  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb3067c221f8d1e5b992c02135fde3856dd02116162e5570438717b5e5c2b3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f579b64c-ee96-40f7-a5f3-b347da7bff64", "node_type": "1", "metadata": {"window": "Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  "}, "hash": "4d13b6d27c34334f72170a4bd8362b14a4e4f29f52e70c02d5b007c5465ccd7a", "class_name": "RelatedNodeInfo"}}, "text": "We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "start_char_idx": 2584, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f579b64c-ee96-40f7-a5f3-b347da7bff64": {"__data__": {"id_": "f579b64c-ee96-40f7-a5f3-b347da7bff64", "embedding": null, "metadata": {"window": "Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2db2c777-ab93-4e3f-9245-7bb93b7c00e3", "node_type": "1", "metadata": {"window": "Thanks for the question, Michael.   Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be1448383ef2c34b7401f8b5939c67df3d11ae85de94aebc68c67088445fc5c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "979c5c47-cf00-4c83-800e-7ed052deaf83", "node_type": "1", "metadata": {"window": "I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "It's g ood so far that a lot of the things that might affect the segments such as brand inflation, "}, "hash": "16bb8d1e752940f56931d9949c72966a7df32838850dd56365d95d96287f8328", "class_name": "RelatedNodeInfo"}}, "text": "We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "start_char_idx": 2733, "end_char_idx": 2833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "979c5c47-cf00-4c83-800e-7ed052deaf83": {"__data__": {"id_": "979c5c47-cf00-4c83-800e-7ed052deaf83", "embedding": null, "metadata": {"window": "I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6789be5e-f109-4922-8dd0-a62444fc7156", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa5d369366c647fb162270fd8aff0f96bc1e6dadfd0d6c502375d6bd2525d93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f579b64c-ee96-40f7-a5f3-b347da7bff64", "node_type": "1", "metadata": {"window": "Appreciate it.   I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a84405bb8a7e5553ab4379da21d74bd7d2748e678eb859af0804b3aad60c17fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b767b4bf-7909-4f08-bd49-fbd6a5f53672", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "original_text": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.  "}, "hash": "12cf913430e214a85c6f19b964de797f5a27044f3e37003dff25b22765fde330", "class_name": "RelatedNodeInfo"}}, "text": "It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "start_char_idx": 2833, "end_char_idx": 2932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b767b4bf-7909-4f08-bd49-fbd6a5f53672": {"__data__": {"id_": "b767b4bf-7909-4f08-bd49-fbd6a5f53672", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "original_text": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "979c5c47-cf00-4c83-800e-7ed052deaf83", "node_type": "1", "metadata": {"window": "I guess, really a couple of \nthings to keep in mind .   We're really pleased with the resiliency of our Pharma segment both in the \nPharma Distribution, as well as Specialty and the Nuclear business.  \n \n  We do continue to see really COVID -19 being the main driver of any headwinds we're seeing \nthere.   It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "original_text": "It's g ood so far that a lot of the things that might affect the segments such as brand inflation, ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97a2e1762d8ed652f8637d8de1911a27fd04510e7ef8b8f3ad72f73315c6d9be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "original_text": "We feel like we're executing really well \non all our initiatives.  "}, "hash": "3f4fde11d3d00c89b03126dd03e04974eead223677753aee9845a8448a110d81", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.  ", "start_char_idx": 0, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8": {"__data__": {"id_": "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "original_text": "We feel like we're executing really well \non all our initiatives.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b767b4bf-7909-4f08-bd49-fbd6a5f53672", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "original_text": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "699a29d117816b3ea0075356d041a57437d3a2ca0511f42d1050ece4b283399b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6d330e-c8de-4687-8328-82f580635dfa", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n ", "original_text": "And also, from a cost saving standp oint, we're on track.  "}, "hash": "f44f93203fc9ab49425a3f3ef783acdd738346382f942ba7c8c84107e9bb4f66", "class_name": "RelatedNodeInfo"}}, "text": "We feel like we're executing really well \non all our initiatives.  ", "start_char_idx": 81, "end_char_idx": 148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6d330e-c8de-4687-8328-82f580635dfa": {"__data__": {"id_": "3c6d330e-c8de-4687-8328-82f580635dfa", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n ", "original_text": "And also, from a cost saving standp oint, we're on track.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "original_text": "We feel like we're executing really well \non all our initiatives.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c0ff7c7119e846285bfc7fefcdb4f3db86a69cabd78094d7162113b963cf41e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.  ", "original_text": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n "}, "hash": "e7a0231662f93f810e3c23806e90955872e042118a0397be3c4986ab51c58759", "class_name": "RelatedNodeInfo"}}, "text": "And also, from a cost saving standp oint, we're on track.  ", "start_char_idx": 148, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd": {"__data__": {"id_": "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.  ", "original_text": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6d330e-c8de-4687-8328-82f580635dfa", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n ", "original_text": "And also, from a cost saving standp oint, we're on track.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91b506c0b48e9e771696c3ebcaa38cfddc098ce19f358c62dcb0088f743cb0ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073", "node_type": "1", "metadata": {"window": "We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.  ", "original_text": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  "}, "hash": "2b498c09de851e5c56770f664538e43a43e7964bba28d559ac35723a576ee9ec", "class_name": "RelatedNodeInfo"}}, "text": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "start_char_idx": 207, "end_char_idx": 383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073": {"__data__": {"id_": "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073", "embedding": null, "metadata": {"window": "We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.  ", "original_text": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.  ", "original_text": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0d6ec213edc249582b7cffa08e4a9221f16e6bb501a5cff729c2e27322c8279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "404963e1-9e27-4689-bb67-58e0c5ed8413", "node_type": "1", "metadata": {"window": "And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.  ", "original_text": "But what we really see is COVID being the main swing factor.  \n \n "}, "hash": "e819f589803ec35d180cbd3698df6db73503b0cc3f379575c4c3032755d48321", "class_name": "RelatedNodeInfo"}}, "text": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "start_char_idx": 383, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "404963e1-9e27-4689-bb67-58e0c5ed8413": {"__data__": {"id_": "404963e1-9e27-4689-bb67-58e0c5ed8413", "embedding": null, "metadata": {"window": "And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.  ", "original_text": "But what we really see is COVID being the main swing factor.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073", "node_type": "1", "metadata": {"window": "We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.  ", "original_text": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b23cc5f191becc06c1878ccef6dd168db141c9f15849801121d14022b58a4618", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4", "node_type": "1", "metadata": {"window": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "original_text": "The things I would say there is that we saw a lot of choppiness in the quarter.  "}, "hash": "26a0171ae8692045770b29841296c874f5d7a3357b8f65063dc58f879712d3fb", "class_name": "RelatedNodeInfo"}}, "text": "But what we really see is COVID being the main swing factor.  \n \n ", "start_char_idx": 491, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4": {"__data__": {"id_": "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4", "embedding": null, "metadata": {"window": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "original_text": "The things I would say there is that we saw a lot of choppiness in the quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "404963e1-9e27-4689-bb67-58e0c5ed8413", "node_type": "1", "metadata": {"window": "And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.  ", "original_text": "But what we really see is COVID being the main swing factor.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f02311367bcede9a75b251064bad87439c243c5c3abec2e3f764bb378bbed30e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "852442b4-4eb1-4f0b-b51b-f5d96216af6f", "node_type": "1", "metadata": {"window": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "original_text": "We would \nexpect it to continue to be choppy for the second half of the year.  "}, "hash": "cf416646a316a9fde6e41e7702b44dd940b4e68a8121990715ab87fafd13d464", "class_name": "RelatedNodeInfo"}}, "text": "The things I would say there is that we saw a lot of choppiness in the quarter.  ", "start_char_idx": 557, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "852442b4-4eb1-4f0b-b51b-f5d96216af6f": {"__data__": {"id_": "852442b4-4eb1-4f0b-b51b-f5d96216af6f", "embedding": null, "metadata": {"window": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "original_text": "We would \nexpect it to continue to be choppy for the second half of the year.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4", "node_type": "1", "metadata": {"window": "And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n  So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "original_text": "The things I would say there is that we saw a lot of choppiness in the quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "002093b9eaedac028e08ee3c9f0ce647d9b6fe2ca7128dbcd95f9693380d749e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89a604d9-07bc-497e-a3a4-12c09a62eba7", "node_type": "1", "metadata": {"window": "But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "original_text": "But we still are expecting to exit at \nor near pre -COVID levels.  "}, "hash": "7097b9cc9e30098c85e906381d4c882e2b4b31190360faef5cb9c37661004d29", "class_name": "RelatedNodeInfo"}}, "text": "We would \nexpect it to continue to be choppy for the second half of the year.  ", "start_char_idx": 638, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89a604d9-07bc-497e-a3a4-12c09a62eba7": {"__data__": {"id_": "89a604d9-07bc-497e-a3a4-12c09a62eba7", "embedding": null, "metadata": {"window": "But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "original_text": "But we still are expecting to exit at \nor near pre -COVID levels.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "852442b4-4eb1-4f0b-b51b-f5d96216af6f", "node_type": "1", "metadata": {"window": "So a lot of those swing factors are really off the table when we look at the rest of the year for \nPharma.   But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "original_text": "We would \nexpect it to continue to be choppy for the second half of the year.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9feb4188feb9cfd75ff1a310a7780e85c1d05443b2127f45bf23f0881b7d1be6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb", "node_type": "1", "metadata": {"window": "The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "original_text": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n"}, "hash": "8c65d8f16db66c391170a7e9163bc63205914c5049525e9fe8d2af5e110bc6e0", "class_name": "RelatedNodeInfo"}}, "text": "But we still are expecting to exit at \nor near pre -COVID levels.  ", "start_char_idx": 717, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb": {"__data__": {"id_": "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb", "embedding": null, "metadata": {"window": "The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "original_text": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89a604d9-07bc-497e-a3a4-12c09a62eba7", "node_type": "1", "metadata": {"window": "But what we really see is COVID being the main swing factor.  \n \n  The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "original_text": "But we still are expecting to exit at \nor near pre -COVID levels.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bc53fd5b1250d0e45ea981f75caeabb0fb6fc4d683164ef1c3654a2ac3335ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85a8045a-8d42-48c3-a14b-da87dacb4bf0", "node_type": "1", "metadata": {"window": "We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "original_text": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.  "}, "hash": "5923be1100f7597a24609a516bc70976aa8b46193cf946665c77a2baab3e8433", "class_name": "RelatedNodeInfo"}}, "text": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "start_char_idx": 784, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85a8045a-8d42-48c3-a14b-da87dacb4bf0": {"__data__": {"id_": "85a8045a-8d42-48c3-a14b-da87dacb4bf0", "embedding": null, "metadata": {"window": "We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "original_text": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb", "node_type": "1", "metadata": {"window": "The things I would say there is that we saw a lot of choppiness in the quarter.   We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "original_text": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "596b48be65e5f2d310313317e95de5a1d6bb399672998364451cb87dfe9d8199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db24b76-1eb9-4a4e-9c1e-95548879279d", "node_type": "1", "metadata": {"window": "But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.  ", "original_text": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  "}, "hash": "99b4cf2e7b2679f2d26b0b6d1b581964936ce30ec2e0839d9a65319e0664d873", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "start_char_idx": 876, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db24b76-1eb9-4a4e-9c1e-95548879279d": {"__data__": {"id_": "7db24b76-1eb9-4a4e-9c1e-95548879279d", "embedding": null, "metadata": {"window": "But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.  ", "original_text": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85a8045a-8d42-48c3-a14b-da87dacb4bf0", "node_type": "1", "metadata": {"window": "We would \nexpect it to continue to be choppy for the second half of the year.   But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "original_text": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f2b70e4d1c6fcc315097a531f428fa95cbbb3890423ec5b18c5b32d47a857be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a479eeac-2946-4ed7-a583-4cb723996afd", "node_type": "1", "metadata": {"window": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  "}, "hash": "c9ea0c3dedfc31a0ecefc17f09031fd6d775e618c84865ab3d94edb3c4ba8283", "class_name": "RelatedNodeInfo"}}, "text": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "start_char_idx": 951, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a479eeac-2946-4ed7-a583-4cb723996afd": {"__data__": {"id_": "a479eeac-2946-4ed7-a583-4cb723996afd", "embedding": null, "metadata": {"window": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db24b76-1eb9-4a4e-9c1e-95548879279d", "node_type": "1", "metadata": {"window": "But we still are expecting to exit at \nor near pre -COVID levels.   And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.  ", "original_text": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98f4111d5208eb21807a43ccf5718b59e7124774a89032f5916892fe16e292f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb", "node_type": "1", "metadata": {"window": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "original_text": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n"}, "hash": "efe9fd68e140d98ae4f20a0213331dcc40eed2239ec46301ee071693dccd6370", "class_name": "RelatedNodeInfo"}}, "text": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "start_char_idx": 1083, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb": {"__data__": {"id_": "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb", "embedding": null, "metadata": {"window": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "original_text": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a479eeac-2946-4ed7-a583-4cb723996afd", "node_type": "1", "metadata": {"window": "And as we said, our guidance continues to be low single -digit growth for \nthe segment.  \n \n Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "original_text": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "034928526ea96f122d91a6f16765302c9aeba4b9c4d1ca7c7ab629bad4af5462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2666daaf-2137-44a1-aba5-ad28d20ea76e", "node_type": "1", "metadata": {"window": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "original_text": "Operator:  Thank you.  "}, "hash": "7edc516b5e3562635a062c5dc2b70f8e88dc93b259f7c7ca652da1b9fd645a5a", "class_name": "RelatedNodeInfo"}}, "text": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "start_char_idx": 1244, "end_char_idx": 1320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2666daaf-2137-44a1-aba5-ad28d20ea76e": {"__data__": {"id_": "2666daaf-2137-44a1-aba5-ad28d20ea76e", "embedding": null, "metadata": {"window": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "original_text": "Operator:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb", "node_type": "1", "metadata": {"window": "Jason Hollar:  And if I could just add one point, Michael, this is Jason.   In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "original_text": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07cf05088b88dd778186c6ac5554b00d9521ce07ea2567c9fd473e442580f837", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97eeddee-b96e-416e-8dd1-67e8233fb477", "node_type": "1", "metadata": {"window": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "original_text": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n"}, "hash": "eaa550fc47ec4672cc97003f5c65a5a6efcbbd00ff788da20e110baeabd16ddf", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 1320, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97eeddee-b96e-416e-8dd1-67e8233fb477": {"__data__": {"id_": "97eeddee-b96e-416e-8dd1-67e8233fb477", "embedding": null, "metadata": {"window": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "original_text": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2666daaf-2137-44a1-aba5-ad28d20ea76e", "node_type": "1", "metadata": {"window": "In your point a bout Nuclear, \nwe did see the headwind year -over-year be a little bit less than what we saw in the first quarter.   So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "original_text": "Operator:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c254f8556cc1e0295d2326c89a6b4edd987d86fd75465691a73a617d255ffcb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d566364-47ba-4fbd-97ae-a0b205bb5ae9", "node_type": "1", "metadata": {"window": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.  ", "original_text": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  "}, "hash": "111a7fec66459387c67fd7381754b4b0a4a34ada8f746a6156153fcb3e6243f8", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "start_char_idx": 1343, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d566364-47ba-4fbd-97ae-a0b205bb5ae9": {"__data__": {"id_": "0d566364-47ba-4fbd-97ae-a0b205bb5ae9", "embedding": null, "metadata": {"window": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.  ", "original_text": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97eeddee-b96e-416e-8dd1-67e8233fb477", "node_type": "1", "metadata": {"window": "So \nkind of follows -- continue s to follow a little bit of what we're seeing with electives, a little bit more than \nother elements of the under lying volume.   So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "original_text": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b6e737a803bdaf94eb91447ed73b94903e705a8a9b37fabcc0954a3399f9589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44542133-2a98-412d-b5a6-62802656aa42", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "original_text": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  "}, "hash": "de7485b0f21c8aa5417c8d1a551722e4a02b66d4e54181283a64a691ff1689d5", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "start_char_idx": 1414, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44542133-2a98-412d-b5a6-62802656aa42": {"__data__": {"id_": "44542133-2a98-412d-b5a6-62802656aa42", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "original_text": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d566364-47ba-4fbd-97ae-a0b205bb5ae9", "node_type": "1", "metadata": {"window": "So not a lot of new news there, but a slight improvement \nsequentially.  \n \n Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.  ", "original_text": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68eb8e06df0d0ec66fbe8b4b4dd6bc84edec9513b648a39d5e0ff0148bfd448b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a", "node_type": "1", "metadata": {"window": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "original_text": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n "}, "hash": "61573112e499637520a2a990e7aba4c841d09e48490d34b0f152ac8dfe66423d", "class_name": "RelatedNodeInfo"}}, "text": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "start_char_idx": 1549, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a": {"__data__": {"id_": "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a", "embedding": null, "metadata": {"window": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "original_text": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44542133-2a98-412d-b5a6-62802656aa42", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "original_text": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d13f5341a1738f38c213f965d32c29bce42d34a1acf13825e1989dd3c5980ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc0b8ab-d503-4eaf-b286-8f58f92f27b1", "node_type": "1", "metadata": {"window": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.  ", "original_text": "And I know there's a lot of moving pieces related to COVID.  "}, "hash": "cb7c0a0496c30e373cc035a8f52bed5afd47467433deec05fa3ae7bd2f94299b", "class_name": "RelatedNodeInfo"}}, "text": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "start_char_idx": 1678, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc0b8ab-d503-4eaf-b286-8f58f92f27b1": {"__data__": {"id_": "adc0b8ab-d503-4eaf-b286-8f58f92f27b1", "embedding": null, "metadata": {"window": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.  ", "original_text": "And I know there's a lot of moving pieces related to COVID.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a", "node_type": "1", "metadata": {"window": "We'll take our next question from Robert Jones with Goldman Sachs.  \n \n Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "original_text": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a05f14a17944d81eaf27808f05d5912dab6f2d249b1bcafe5880f2f71ee1bdbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e76b4230-71db-40ce-8eb1-0627e1763d08", "node_type": "1", "metadata": {"window": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n "}, "hash": "532a155c1ba982e9dbcd0067903d1b338ebb4980c9f3683838596dd7707e8e2b", "class_name": "RelatedNodeInfo"}}, "text": "And I know there's a lot of moving pieces related to COVID.  ", "start_char_idx": 1837, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e76b4230-71db-40ce-8eb1-0627e1763d08": {"__data__": {"id_": "e76b4230-71db-40ce-8eb1-0627e1763d08", "embedding": null, "metadata": {"window": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc0b8ab-d503-4eaf-b286-8f58f92f27b1", "node_type": "1", "metadata": {"window": "Robert Jones:  Maybe on the Medical business, I think we all understand that C OVID is having \nsignificant impact across the segment.   But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.  ", "original_text": "And I know there's a lot of moving pieces related to COVID.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "968fc03ea105961e41f5cd06ac616189ed40fa459abea92414a7c22b8dae565b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf67efad-bf21-4e36-a058-f4e07a7c2774", "node_type": "1", "metadata": {"window": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.  ", "original_text": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n"}, "hash": "3ae9d186ff8556ade6535d1ebcfee582c28795ca0f33c3fde34959220df55d19", "class_name": "RelatedNodeInfo"}}, "text": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "start_char_idx": 1898, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf67efad-bf21-4e36-a058-f4e07a7c2774": {"__data__": {"id_": "cf67efad-bf21-4e36-a058-f4e07a7c2774", "embedding": null, "metadata": {"window": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.  ", "original_text": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e76b4230-71db-40ce-8eb1-0627e1763d08", "node_type": "1", "metadata": {"window": "But I was hoping maybe you could help us with what you're \nassuming in the back half in Medical, particularly on the EBIT line.   It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26ab1fa89b1ac03d2277d07753d08395773724c768118fb892f902e317e9d2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f", "node_type": "1", "metadata": {"window": "And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "9f9d43acd17cb03b5cbcf592065bf6aed01574258a9117bbe31b0bcaa3c138b7", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "start_char_idx": 2118, "end_char_idx": 2278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f": {"__data__": {"id_": "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f", "embedding": null, "metadata": {"window": "And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf67efad-bf21-4e36-a058-f4e07a7c2774", "node_type": "1", "metadata": {"window": "It just seems, based on the results \nto date and the updated guidance, you  have to see kind of mid -20 declines in the back half versus the \nfront half.  \n \n  And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.  ", "original_text": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e11661d7fbdf0f1b8bf128131566c08285899d49ec51ad6d804f491c6ac8312", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "747efa13-661f-47c6-8e88-85cc0871027e", "node_type": "1", "metadata": {"window": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "original_text": "This is Jason.  "}, "hash": "4475d238683b0a61d490594512fdc46a9019eafc46317941dbf99fbe5eac0e1a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 2278, "end_char_idx": 2299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "747efa13-661f-47c6-8e88-85cc0871027e": {"__data__": {"id_": "747efa13-661f-47c6-8e88-85cc0871027e", "embedding": null, "metadata": {"window": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "original_text": "This is Jason.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f", "node_type": "1", "metadata": {"window": "And I know there's a lot of moving pieces related to COVID.   But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c066dcf247513982976773031f25b2e787df367610fb9c03c75089542529ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30ba9764-8b55-4d7b-b3eb-171141b95164", "node_type": "1", "metadata": {"window": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "original_text": "Let me start it off.  "}, "hash": "d6b30d188b06ed3262bd1a95fbe6821d54fc87a68a98f8d7ecee96bba010d1b3", "class_name": "RelatedNodeInfo"}}, "text": "This is Jason.  ", "start_char_idx": 2299, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30ba9764-8b55-4d7b-b3eb-171141b95164": {"__data__": {"id_": "30ba9764-8b55-4d7b-b3eb-171141b95164", "embedding": null, "metadata": {"window": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "original_text": "Let me start it off.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "747efa13-661f-47c6-8e88-85cc0871027e", "node_type": "1", "metadata": {"window": "But -- and I think at a high level, \nMike, I would think as you maybe see some of the drivers of the front half poten tially fade, you would \nobviously see the legacy kind of surgery recovery product lines pick up.  \n \n  Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "original_text": "This is Jason.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42719097c0e58c614a281c8b541cecf1d73928bd0c51ee91d98432261df5ce87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "677852d9-6ee1-45d2-b919-fc1e7333add8", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.  ", "original_text": "Yes, like you said, we're really pleased with our \nfirst half performance.  "}, "hash": "00f3389a79455b644b2be1274f9ea15f9439641ce724fb6c50e18f2f4bbda6e1", "class_name": "RelatedNodeInfo"}}, "text": "Let me start it off.  ", "start_char_idx": 2315, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "677852d9-6ee1-45d2-b919-fc1e7333add8": {"__data__": {"id_": "677852d9-6ee1-45d2-b919-fc1e7333add8", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.  ", "original_text": "Yes, like you said, we're really pleased with our \nfirst half performance.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30ba9764-8b55-4d7b-b3eb-171141b95164", "node_type": "1", "metadata": {"window": "Just trying to get a better sense of what you're assuming that could really drive this kind of \nback half decline versus what you've seen in the front half. \n \n Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "original_text": "Let me start it off.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d95596c72c3aa2b5c2d56c28f5c18b4ae2f233a482a74082b484e2e4b29911de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78566e42-6ccc-4cc0-8ec8-813214e13d1c", "node_type": "1", "metadata": {"window": "This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "original_text": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  "}, "hash": "f471def9095d87941c26709dd7d56b4fd83c85ba580e9702aa18dd03c76ac985", "class_name": "RelatedNodeInfo"}}, "text": "Yes, like you said, we're really pleased with our \nfirst half performance.  ", "start_char_idx": 2337, "end_char_idx": 2413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78566e42-6ccc-4cc0-8ec8-813214e13d1c": {"__data__": {"id_": "78566e42-6ccc-4cc0-8ec8-813214e13d1c", "embedding": null, "metadata": {"window": "This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "original_text": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "677852d9-6ee1-45d2-b919-fc1e7333add8", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.  ", "original_text": "Yes, like you said, we're really pleased with our \nfirst half performance.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3888338bf2c58a9e7eb8a23493b7b5d2ed816f09b88ca370c699743dfb4d7183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acd1ff2-dea6-4515-9bce-5c339800f04a", "node_type": "1", "metadata": {"window": "Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "original_text": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n "}, "hash": "8166b4e133a122125cabbecfaaf840dcef79bef4d1413e46d7560a70d7f0e62e", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "start_char_idx": 2413, "end_char_idx": 2516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acd1ff2-dea6-4515-9bce-5c339800f04a": {"__data__": {"id_": "4acd1ff2-dea6-4515-9bce-5c339800f04a", "embedding": null, "metadata": {"window": "Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "original_text": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78566e42-6ccc-4cc0-8ec8-813214e13d1c", "node_type": "1", "metadata": {"window": "This is Jason.   Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "original_text": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a78fbe0f389e4706b5e49702d2c4eded8c8e10579fdf9aea262a7cd0722c5e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd", "node_type": "1", "metadata": {"window": "Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "To the point about the trends, first half versus second half.  "}, "hash": "a5331665f4cb17e8e71ee2150dd8421078cf4fb690e865e79462e51a509c9461", "class_name": "RelatedNodeInfo"}}, "text": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "start_char_idx": 2516, "end_char_idx": 2603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd": {"__data__": {"id_": "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd", "embedding": null, "metadata": {"window": "Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "To the point about the trends, first half versus second half.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acd1ff2-dea6-4515-9bce-5c339800f04a", "node_type": "1", "metadata": {"window": "Let me start it off.   Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "original_text": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1b85567f997c4e944f4e4849d5b8c2dc559d109b28e8e3bd722ccedb03f3a67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1567e5ed-5930-48f9-9bd4-9e62c59b7b32", "node_type": "1", "metadata": {"window": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  "}, "hash": "61458e64772fa330362b6b48e9e06ac2c87ee5dae4855b9e5a0ea8c5d704332b", "class_name": "RelatedNodeInfo"}}, "text": "To the point about the trends, first half versus second half.  ", "start_char_idx": 2603, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1567e5ed-5930-48f9-9bd4-9e62c59b7b32": {"__data__": {"id_": "1567e5ed-5930-48f9-9bd4-9e62c59b7b32", "embedding": null, "metadata": {"window": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd", "node_type": "1", "metadata": {"window": "Yes, like you said, we're really pleased with our \nfirst half performance.   Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "To the point about the trends, first half versus second half.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad995b1de8aa6d53cf9392aad635f871cb670324f3d4cafff0249c9511b68798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe", "node_type": "1", "metadata": {"window": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  "}, "hash": "6942dea5b6ecaab48cd7c924cfbe6c090f10c1786a2e7a89c791f4525bb27377", "class_name": "RelatedNodeInfo"}}, "text": "As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "start_char_idx": 2666, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe": {"__data__": {"id_": "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe", "embedding": null, "metadata": {"window": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1567e5ed-5930-48f9-9bd4-9e62c59b7b32", "node_type": "1", "metadata": {"window": "Certainly, two good quarters here now as well as on top of last year's double -\ndigit growth as well.   And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adbcdc2c0e9b5d1667a73b889f153fdbaa8714cd8b00045d5e109f32694bb40e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08d52977-e156-4f81-9a35-774c0c9df496", "node_type": "1", "metadata": {"window": "To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n "}, "hash": "22a2514595ef8e15e6096446653ad4fd3ee414a9d6b9b10cf7dbd3a1d6430f2b", "class_name": "RelatedNodeInfo"}}, "text": "So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "start_char_idx": 2800, "end_char_idx": 3032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08d52977-e156-4f81-9a35-774c0c9df496": {"__data__": {"id_": "08d52977-e156-4f81-9a35-774c0c9df496", "embedding": null, "metadata": {"window": "To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "862ed3a026f45da2a745b52a9bc8ce6e301422d2c3dc444e212c6740476cbecc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe", "node_type": "1", "metadata": {"window": "And then, stil l guiding to low to mid -20s for the year we feel very good about.  \n \n  To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f92a4892e78ffe2f4ccb62e31309fe523f436890a54acabaf3a9b28c3abf22d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6500bcc3-d258-49d2-a7fe-4d89c2cee269", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "original_text": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.  "}, "hash": "c438c4ae839c18a59516722ab45c22ff2ec90fa0bd1b7692b9c7e1dedd60e07d", "class_name": "RelatedNodeInfo"}}, "text": "And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "start_char_idx": 3032, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6500bcc3-d258-49d2-a7fe-4d89c2cee269": {"__data__": {"id_": "6500bcc3-d258-49d2-a7fe-4d89c2cee269", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "original_text": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08d52977-e156-4f81-9a35-774c0c9df496", "node_type": "1", "metadata": {"window": "To the point about the trends, first half versus second half.   As we stated in the remarks, we \ndid see some Q2 favorability as it relates to our cost mitigation efforts on certain PPE prod ucts.   So \nthat's an element that was a component in addition to the volume strength that we saw in lab and the \nvolume strength that we saw in PPE that drove Medical to actually have a net tailwind associated with \nCOVID in the quarter.   And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "original_text": "And so that's just o ne thing that will continue to vary quarter -to-quarter as we \ngo forward.  \n ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13664b695d1b0b94858be5157d252c1a4660c47f7fc2b707c89c4a9db1e134e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0e05c87-1c2c-4887-8482-0d08efaf78ab", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n", "original_text": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n "}, "hash": "bd04fc54753a2c5c515164765958c788975b63c41b951878987f6b3851b01f0c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.  ", "start_char_idx": 0, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0e05c87-1c2c-4887-8482-0d08efaf78ab": {"__data__": {"id_": "c0e05c87-1c2c-4887-8482-0d08efaf78ab", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n", "original_text": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6500bcc3-d258-49d2-a7fe-4d89c2cee269", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "original_text": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f4460a8d3946f5577c341a748bce6f471592ab3e138f1160de64a65af1f5a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48780eb7-9206-4a6c-b04e-0e4ad9687723", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.  ", "original_text": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.  "}, "hash": "9b24bcf1f0715a8e1126c98fb5cc24632b7f7fa9b660c1e24c5917e7bc997c5e", "class_name": "RelatedNodeInfo"}}, "text": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n ", "start_char_idx": 230, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48780eb7-9206-4a6c-b04e-0e4ad9687723": {"__data__": {"id_": "48780eb7-9206-4a6c-b04e-0e4ad9687723", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.  ", "original_text": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0e05c87-1c2c-4887-8482-0d08efaf78ab", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n", "original_text": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db55ebc308a1ef925b6e2b5fe53db65faf295145a1c012b954b8ab82bc73152e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84434f8d-6ca9-49ad-843a-9fcbcbb401f2", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "original_text": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  "}, "hash": "0c760de4bc5e0f6589a6f0f2ed27355d44fa111b6d2f440d7ab37ae14b0d481c", "class_name": "RelatedNodeInfo"}}, "text": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.  ", "start_char_idx": 342, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84434f8d-6ca9-49ad-843a-9fcbcbb401f2": {"__data__": {"id_": "84434f8d-6ca9-49ad-843a-9fcbcbb401f2", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "original_text": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48780eb7-9206-4a6c-b04e-0e4ad9687723", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.  ", "original_text": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccd512c9f71c83fcb1083f7aeed178f5bf604873857a7874d5e47e9ac74b16dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac", "node_type": "1", "metadata": {"window": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "original_text": "And so we always trade off our level of spend in that \nregard as well.  \n \n"}, "hash": "b96fc633654fdbd1dd77b5255122411cac5e4e193924c3d2f1508c92b1c01c9b", "class_name": "RelatedNodeInfo"}}, "text": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "start_char_idx": 454, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac": {"__data__": {"id_": "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac", "embedding": null, "metadata": {"window": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "original_text": "And so we always trade off our level of spend in that \nregard as well.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84434f8d-6ca9-49ad-843a-9fcbcbb401f2", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "original_text": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab32c5eb83aecf341b38fbb8dd23dcad3ac6defe8608469db6fff613c085350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3450709-6f81-4c93-9394-efc0628c1da5", "node_type": "1", "metadata": {"window": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "original_text": "Operator:  Thank you.  "}, "hash": "0d01cb9b6824d76e017e0b34b26cbd0e7d579ae9f8e66eea22fa91ec5a64ae03", "class_name": "RelatedNodeInfo"}}, "text": "And so we always trade off our level of spend in that \nregard as well.  \n \n", "start_char_idx": 593, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3450709-6f81-4c93-9394-efc0628c1da5": {"__data__": {"id_": "e3450709-6f81-4c93-9394-efc0628c1da5", "embedding": null, "metadata": {"window": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "original_text": "Operator:  Thank you.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac", "node_type": "1", "metadata": {"window": "And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "original_text": "And so we always trade off our level of spend in that \nregard as well.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9af1fddaa8802ff955769be8ad157faf582fd68e2893e023497fe79a39933461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e34e79fa-ead0-4351-adb1-0bf644cbd9d0", "node_type": "1", "metadata": {"window": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "original_text": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n"}, "hash": "9a614ce8fe8478f52c29e15351056cdc2feccdd71d119cc4b6554c7e95f3d38f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 668, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e34e79fa-ead0-4351-adb1-0bf644cbd9d0": {"__data__": {"id_": "e34e79fa-ead0-4351-adb1-0bf644cbd9d0", "embedding": null, "metadata": {"window": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "original_text": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3450709-6f81-4c93-9394-efc0628c1da5", "node_type": "1", "metadata": {"window": "And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "original_text": "Operator:  Thank you.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e63f2fded1393d2a4c9ee95ffcf45d1ef2a624463c51484f593d34fee087d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03256936-c1fd-4080-8381-5d4b15584600", "node_type": "1", "metadata": {"window": "And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.  ", "original_text": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  "}, "hash": "0ac42bbd13d2b9253afbeaf673088484f14c55e8acc4a4225c029ede50af5958", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "start_char_idx": 691, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03256936-c1fd-4080-8381-5d4b15584600": {"__data__": {"id_": "03256936-c1fd-4080-8381-5d4b15584600", "embedding": null, "metadata": {"window": "And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.  ", "original_text": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e34e79fa-ead0-4351-adb1-0bf644cbd9d0", "node_type": "1", "metadata": {"window": "As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.   And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "original_text": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce524bbb7f182d70eabf523b9f35ce0592f0d679d8e22c091b29132ef7adccc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48377fc6-3b71-4c41-a31f-15c29fec9fb6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.  ", "original_text": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  "}, "hash": "5e14e437f1e4885a6b6d2494e932efcf25470b0525793ec846b0581f3ef56a2d", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "start_char_idx": 766, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48377fc6-3b71-4c41-a31f-15c29fec9fb6": {"__data__": {"id_": "48377fc6-3b71-4c41-a31f-15c29fec9fb6", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.  ", "original_text": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03256936-c1fd-4080-8381-5d4b15584600", "node_type": "1", "metadata": {"window": "And so we always trade off our level of spend in that \nregard as well.  \n \n Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.  ", "original_text": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58b83649fbeb183e1f0a4387e5bce8643837539861ea6dd6134d0cefac9b4aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8", "node_type": "1", "metadata": {"window": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "original_text": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n"}, "hash": "50648c435e3f39c3afd1610ada1ee6406c3c3f296cac0ea416e1d0b03e757bf9", "class_name": "RelatedNodeInfo"}}, "text": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "start_char_idx": 859, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8": {"__data__": {"id_": "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8", "embedding": null, "metadata": {"window": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "original_text": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48377fc6-3b71-4c41-a31f-15c29fec9fb6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.  ", "original_text": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9bd0f56664b543ac52de640ea5a97abc47d30af46734edbec89b4558cf085f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a9d2d11-abde-414b-8a90-ce2770153515", "node_type": "1", "metadata": {"window": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "original_text": "Mike Kaufmann:  Thanks.  "}, "hash": "a1f40c4927c13a0a98f847da88cd6561ba22e5b662af03b3acb1cfc435cf137f", "class_name": "RelatedNodeInfo"}}, "text": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "start_char_idx": 966, "end_char_idx": 1130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9d2d11-abde-414b-8a90-ce2770153515": {"__data__": {"id_": "2a9d2d11-abde-414b-8a90-ce2770153515", "embedding": null, "metadata": {"window": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "original_text": "Mike Kaufmann:  Thanks.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8", "node_type": "1", "metadata": {"window": "We'll take our next question from Ja ilendra Singh with Credit Suisse.  \n \n Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "original_text": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "216b1e2ded29b3ddc6905f52bc9542170484f1e6ab99ba72bca9d3a5f317a926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "661b6b29-dd27-4513-99f6-4b7b38d32841", "node_type": "1", "metadata": {"window": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.  ", "original_text": "Appreciate the question.  "}, "hash": "fac7611be14051ec2598912ec7e9e1e41c99790257236eb6592c27fe78de17af", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks.  ", "start_char_idx": 1130, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "661b6b29-dd27-4513-99f6-4b7b38d32841": {"__data__": {"id_": "661b6b29-dd27-4513-99f6-4b7b38d32841", "embedding": null, "metadata": {"window": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.  ", "original_text": "Appreciate the question.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a9d2d11-abde-414b-8a90-ce2770153515", "node_type": "1", "metadata": {"window": "Jailendra Singh:  You mentioned a few things you're doing to help with the vaccine rollout.   I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "original_text": "Mike Kaufmann:  Thanks.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fba4e814a9c1a25a1b2326ceb4cd04f02991cdd85f39857a8a1bec73ce1bdee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb677824-ca51-45ce-b3f8-d9d213a17532", "node_type": "1", "metadata": {"window": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "original_text": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  "}, "hash": "bdc836feafeb418f8eea9b6b14fe2485da8c63d7193f09f014da8f624070d7bf", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate the question.  ", "start_char_idx": 1155, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb677824-ca51-45ce-b3f8-d9d213a17532": {"__data__": {"id_": "fb677824-ca51-45ce-b3f8-d9d213a17532", "embedding": null, "metadata": {"window": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "original_text": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "661b6b29-dd27-4513-99f6-4b7b38d32841", "node_type": "1", "metadata": {"window": "I realize \nthese programs, in and of themselves, aren't going to move the needle for the overall company.   But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.  ", "original_text": "Appreciate the question.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5fd2df7ab96df326881ce5f3b87fc2effe4d0946352512b3435ca97c262beba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "original_text": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  "}, "hash": "6480016f5de29a30924c46285f1ad8e6e3a2d090f1ca15492604d3c115746b71", "class_name": "RelatedNodeInfo"}}, "text": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "start_char_idx": 1181, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b": {"__data__": {"id_": "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "original_text": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb677824-ca51-45ce-b3f8-d9d213a17532", "node_type": "1", "metadata": {"window": "But \njust curious as to  how this work might set the company up for future opportunities for you guys to \nparticipate in future phases of vaccine distribution.  \n \n Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "original_text": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9224cfcb44abf6d70e57656e569a74bfb9b8380925f96f219e2d1fbe5b624126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68a52e8d-5115-4f16-923f-1088fa17dd64", "node_type": "1", "metadata": {"window": "Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "original_text": "And so we continue to do that.  "}, "hash": "7fa9635fbe96fbc77a514866a918133ff7099c72f26c6a945e82fe85c21febe1", "class_name": "RelatedNodeInfo"}}, "text": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "start_char_idx": 1294, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68a52e8d-5115-4f16-923f-1088fa17dd64": {"__data__": {"id_": "68a52e8d-5115-4f16-923f-1088fa17dd64", "embedding": null, "metadata": {"window": "Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "original_text": "And so we continue to do that.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks.   Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "original_text": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "675e71109f863e1356fc5f06a31e596d2c7842852dabe225f6d9f950c381b800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1cc3470-889a-41d3-a2e7-80ccfef5eeae", "node_type": "1", "metadata": {"window": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "original_text": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n "}, "hash": "ed11edaff1822b3c03a4e4cb5be5907868de53d9544042bafd03128e1e8fbb44", "class_name": "RelatedNodeInfo"}}, "text": "And so we continue to do that.  ", "start_char_idx": 1461, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1cc3470-889a-41d3-a2e7-80ccfef5eeae": {"__data__": {"id_": "a1cc3470-889a-41d3-a2e7-80ccfef5eeae", "embedding": null, "metadata": {"window": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "original_text": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68a52e8d-5115-4f16-923f-1088fa17dd64", "node_type": "1", "metadata": {"window": "Appreciate the question.   Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "original_text": "And so we continue to do that.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd3067e7057701904c1b953db9b909b01f729ba3faa7233b00c4f788af6b0e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41", "node_type": "1", "metadata": {"window": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "original_text": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  "}, "hash": "2efdad73cdd86d1f4ac09afeab1c9a5109733fc521c3b6d06441459bed730ab1", "class_name": "RelatedNodeInfo"}}, "text": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "start_char_idx": 1493, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41": {"__data__": {"id_": "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41", "embedding": null, "metadata": {"window": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "original_text": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1cc3470-889a-41d3-a2e7-80ccfef5eeae", "node_type": "1", "metadata": {"window": "Yes, we've been -- continue to be involved and \nstaying up -to-date in everything as it relates to the vaccine.   As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "original_text": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a268363f782b268a5364b9eb70acb19dfceeb68f48a953bb02877587321018c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59db0bd5-c660-453b-a48f-5be24ed9db95", "node_type": "1", "metadata": {"window": "And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "original_text": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n"}, "hash": "1a67a51e0d2e033feaa96b03035c92c85d233b45a990da4dbb283af539ca987d", "class_name": "RelatedNodeInfo"}}, "text": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "start_char_idx": 1582, "end_char_idx": 1941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59db0bd5-c660-453b-a48f-5be24ed9db95": {"__data__": {"id_": "59db0bd5-c660-453b-a48f-5be24ed9db95", "embedding": null, "metadata": {"window": "And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "original_text": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41", "node_type": "1", "metadata": {"window": "As we've said, we are working with the \nstate of Ohio, helping them distribute the vaccine, and we're also a partner with the CDC acting as a \nnetwork administrator.   And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "original_text": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbd57f6aee188eb45409da940fe250cbfa3cdc911f0b2965a4959c4d20ee6b16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6135238c-a6c4-432c-a795-6fefa93112ad", "node_type": "1", "metadata": {"window": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.  ", "original_text": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n"}, "hash": "75a5c7ca2838c95c69ec70498aeb737e41bfe14e2956734462f33320475f4df1", "class_name": "RelatedNodeInfo"}}, "text": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "start_char_idx": 1941, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6135238c-a6c4-432c-a795-6fefa93112ad": {"__data__": {"id_": "6135238c-a6c4-432c-a795-6fefa93112ad", "embedding": null, "metadata": {"window": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.  ", "original_text": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59db0bd5-c660-453b-a48f-5be24ed9db95", "node_type": "1", "metadata": {"window": "And so we continue to do that.   And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "original_text": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77817e9eae9f72216ff030f5d0236c9fd1053af5d842df4084a04b792303a6a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0de47365-6232-4b20-a05d-607fbbe39014", "node_type": "1", "metadata": {"window": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?  ", "original_text": "Eric Percher: Can we dig into the PPE price dynamics a little bit?  "}, "hash": "7f0167b7415acf99ab49d1220b3c9bb78eb22ba9896a9cc9009c04c971ded135", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "start_char_idx": 2090, "end_char_idx": 2175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0de47365-6232-4b20-a05d-607fbbe39014": {"__data__": {"id_": "0de47365-6232-4b20-a05d-607fbbe39014", "embedding": null, "metadata": {"window": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?  ", "original_text": "Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6135238c-a6c4-432c-a795-6fefa93112ad", "node_type": "1", "metadata": {"window": "And there are so me other areas where we are \nhaving some small touch in that area.  \n \n  At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.  ", "original_text": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92e8397cacb1841037eaab5112ecb5b4b49e9bd33de0865ec849e696b00e4e3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a59ad682-c82a-4fa0-a067-9f22ce282b48", "node_type": "1", "metadata": {"window": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "original_text": "I think last quarter, you talked \nabout the abil ity to pass on pricing.  "}, "hash": "1506f70a6b2c77b8787f83f50e362cd2d8ef8d2a3d6c463cee92b9b58089a358", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "start_char_idx": 2175, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a59ad682-c82a-4fa0-a067-9f22ce282b48": {"__data__": {"id_": "a59ad682-c82a-4fa0-a067-9f22ce282b48", "embedding": null, "metadata": {"window": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "original_text": "I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0de47365-6232-4b20-a05d-607fbbe39014", "node_type": "1", "metadata": {"window": "At the end of the day, I believe that -- our belief is that this is the -- one of the most important \nevents in the country's history in that bringing the full scale of the distribution capabilities of all the \ndistributors to the market is going to make the most sense over the long term to be able to effectively \ndistribute and get the vaccines to folks.   And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?  ", "original_text": "Eric Percher: Can we dig into the PPE price dynamics a little bit?  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "958ed5225f097242764e096aab4c13b651ecc09f9d0a80ff811b020b983e8c4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581bd16e-c684-4d57-85a1-7f38ca789722", "node_type": "1", "metadata": {"window": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.  ", "original_text": "In this quarter, I expect that we were going to see some input \ncost increases.  "}, "hash": "997abaa0e0dc0dba85d8c8075813dac252d60a6a2a9387e3fe2b2d7449c50618", "class_name": "RelatedNodeInfo"}}, "text": "I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "start_char_idx": 2243, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581bd16e-c684-4d57-85a1-7f38ca789722": {"__data__": {"id_": "581bd16e-c684-4d57-85a1-7f38ca789722", "embedding": null, "metadata": {"window": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.  ", "original_text": "In this quarter, I expect that we were going to see some input \ncost increases.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a59ad682-c82a-4fa0-a067-9f22ce282b48", "node_type": "1", "metadata": {"window": "And so we continue to make sure that we're doing all the \nthings to make ourselves rea dy to be able to participate and help out however we can.  \n \n Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "original_text": "I think last quarter, you talked \nabout the abil ity to pass on pricing.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "869b1937ed3ebfa38eb0d4fc1ddd08c92c0a72034d52b5c16974ebd3966aadd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8274f430-529d-46a8-a8d6-55043318f5f3", "node_type": "1", "metadata": {"window": "Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": "So can you help square that with the pull forward you just mentioned?  "}, "hash": "a250d50946d11c57f839e757d7b2201fe2661b785c1bd90b851e5040602d5c19", "class_name": "RelatedNodeInfo"}}, "text": "In this quarter, I expect that we were going to see some input \ncost increases.  ", "start_char_idx": 2317, "end_char_idx": 2398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8274f430-529d-46a8-a8d6-55043318f5f3": {"__data__": {"id_": "8274f430-529d-46a8-a8d6-55043318f5f3", "embedding": null, "metadata": {"window": "Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": "So can you help square that with the pull forward you just mentioned?  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581bd16e-c684-4d57-85a1-7f38ca789722", "node_type": "1", "metadata": {"window": "Operator:  We'll take our next question from Eric Percher with Nephron Research.  \n \n Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.  ", "original_text": "In this quarter, I expect that we were going to see some input \ncost increases.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "509f5ab910834d18fd6b93801740c19f3ad11e7254d375573d7186531169d2a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb13e3c4-aa14-4c57-8808-255fcdd7678a", "node_type": "1", "metadata": {"window": "I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.  ", "original_text": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n"}, "hash": "3debaa0fa930580d4d8bd4d0300a622419999b6cf374490444666fd853b9611a", "class_name": "RelatedNodeInfo"}}, "text": "So can you help square that with the pull forward you just mentioned?  ", "start_char_idx": 2398, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb13e3c4-aa14-4c57-8808-255fcdd7678a": {"__data__": {"id_": "bb13e3c4-aa14-4c57-8808-255fcdd7678a", "embedding": null, "metadata": {"window": "I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.  ", "original_text": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8274f430-529d-46a8-a8d6-55043318f5f3", "node_type": "1", "metadata": {"window": "Eric Percher: Can we dig into the PPE price dynamics a little bit?   I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": "So can you help square that with the pull forward you just mentioned?  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7de31b229a118133b68f818b04390a4379039e5dd8e4600c7c4d88ac4d9d13a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "824771c2-87c4-4c03-b465-2d8c6facdb36", "node_type": "1", "metadata": {"window": "In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "7e2262ac3d7959aeaa2de7bf8b6dc7f6d3fe7c17bbbd9792d77d448e255db4f0", "class_name": "RelatedNodeInfo"}}, "text": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "start_char_idx": 2469, "end_char_idx": 2567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "824771c2-87c4-4c03-b465-2d8c6facdb36": {"__data__": {"id_": "824771c2-87c4-4c03-b465-2d8c6facdb36", "embedding": null, "metadata": {"window": "In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb13e3c4-aa14-4c57-8808-255fcdd7678a", "node_type": "1", "metadata": {"window": "I think last quarter, you talked \nabout the abil ity to pass on pricing.   In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.  ", "original_text": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e09fbe3bbcf3d096c276827d0ae29d4b109457e4f5c18f93d4effd60a767877a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b", "node_type": "1", "metadata": {"window": "So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "original_text": "Yes.  "}, "hash": "26c2969c6cfc3974dd91878fd7966b7910d88f61a292ce6b72e475e81954c089", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 2567, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b": {"__data__": {"id_": "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b", "embedding": null, "metadata": {"window": "So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "original_text": "Yes.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "824771c2-87c4-4c03-b465-2d8c6facdb36", "node_type": "1", "metadata": {"window": "In this quarter, I expect that we were going to see some input \ncost increases.   So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174ce74e59b8cb2129ea2e369b2410701d8703f277cad826894e602f14673078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae0f3473-f188-4784-9bc0-34142b6cf3e6", "node_type": "1", "metadata": {"window": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "original_text": "Thanks for the question.  "}, "hash": "245a8aa9e35b514cdcfdf53cf13b1697517837099045376b57f265e03fc8c81a", "class_name": "RelatedNodeInfo"}}, "text": "Yes.  ", "start_char_idx": 2589, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae0f3473-f188-4784-9bc0-34142b6cf3e6": {"__data__": {"id_": "ae0f3473-f188-4784-9bc0-34142b6cf3e6", "embedding": null, "metadata": {"window": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "original_text": "Thanks for the question.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b", "node_type": "1", "metadata": {"window": "So can you help square that with the pull forward you just mentioned?   And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "original_text": "Yes.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cfb6851e666258fb1af4d4b2b5ef9183a400d8b45cf8d4fa3cd3c26fad840d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbf15ee1-fc99-4b88-84f0-6973507a5e89", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.  ", "original_text": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  "}, "hash": "c355a13d867ef1027cafe6b1cdd5bb0c81525c7d6c8eb0052637c8aac632dc46", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 2595, "end_char_idx": 2621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbf15ee1-fc99-4b88-84f0-6973507a5e89": {"__data__": {"id_": "dbf15ee1-fc99-4b88-84f0-6973507a5e89", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.  ", "original_text": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae0f3473-f188-4784-9bc0-34142b6cf3e6", "node_type": "1", "metadata": {"window": "And maybe \nmore broadly, it's price versus COGS Q1 to Q2 and then what's assumed second half?  \n \n Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "original_text": "Thanks for the question.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d0c032624e2495990f9ce1c91ddc9437e991c5217db4a889e4b5575e0b2c6f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e165c5f8-b50e-4e1e-b1d1-421911888872", "node_type": "1", "metadata": {"window": "Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "original_text": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  "}, "hash": "bf4ad145ae38e7f14860c3643525a3c52fc699013027ea74a4e92d2a78f3bee1", "class_name": "RelatedNodeInfo"}}, "text": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "start_char_idx": 2621, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e165c5f8-b50e-4e1e-b1d1-421911888872": {"__data__": {"id_": "e165c5f8-b50e-4e1e-b1d1-421911888872", "embedding": null, "metadata": {"window": "Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "original_text": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbf15ee1-fc99-4b88-84f0-6973507a5e89", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.  ", "original_text": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f9af1ec567716e5e70c49a3db3bfdd95dd5a3243cf885323fb49106f53ae311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b7c67ec-59ec-4ab6-a430-624257ff07cf", "node_type": "1", "metadata": {"window": "Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "original_text": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n "}, "hash": "3f926618e9466d50d196956b085de0a9c03dc03359b6c504c586e54723d3ec81", "class_name": "RelatedNodeInfo"}}, "text": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "start_char_idx": 2726, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b7c67ec-59ec-4ab6-a430-624257ff07cf": {"__data__": {"id_": "0b7c67ec-59ec-4ab6-a430-624257ff07cf", "embedding": null, "metadata": {"window": "Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "original_text": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e165c5f8-b50e-4e1e-b1d1-421911888872", "node_type": "1", "metadata": {"window": "Yes.   Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "original_text": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c42f4d6302699813f8ad14ac22d781e5d783d880928ed68a743760f733989c16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf01853f-4907-4923-b3c2-32d5a38e8dc2", "node_type": "1", "metadata": {"window": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "But certainly, cost remains elevated across all categories.  "}, "hash": "aceddd62005d3e70ecf1c6b172f43235564232ebe8dfde4c8de54a1d6dd84160", "class_name": "RelatedNodeInfo"}}, "text": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "start_char_idx": 2822, "end_char_idx": 2926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf01853f-4907-4923-b3c2-32d5a38e8dc2": {"__data__": {"id_": "cf01853f-4907-4923-b3c2-32d5a38e8dc2", "embedding": null, "metadata": {"window": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "But certainly, cost remains elevated across all categories.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b7c67ec-59ec-4ab6-a430-624257ff07cf", "node_type": "1", "metadata": {"window": "Thanks for the question.   And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "original_text": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7fa4864c1819540db4d7869e07511c6e406e754f886292b9582164c72237987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5", "node_type": "1", "metadata": {"window": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  "}, "hash": "c03ab40d92c1fc5372b6a674219b6eb4dfa8f03241e149229c20eb201a1c9c67", "class_name": "RelatedNodeInfo"}}, "text": "But certainly, cost remains elevated across all categories.  ", "start_char_idx": 2926, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5": {"__data__": {"id_": "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5", "embedding": null, "metadata": {"window": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf01853f-4907-4923-b3c2-32d5a38e8dc2", "node_type": "1", "metadata": {"window": "And let me just kind of step back and talk about \nPPE in general and try to loop in that piece as well.   Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "But certainly, cost remains elevated across all categories.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cbd33189a59be612bfe29aad9525428249460b8b970c2972f4fdad05fc6791a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04755824-ca5b-4c57-9a55-87eb76a6b591", "node_type": "1", "metadata": {"window": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  "}, "hash": "20ef78b560e4c7892353c9e591da21c208c8f959c4bdc93563491d0691138495", "class_name": "RelatedNodeInfo"}}, "text": "It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "start_char_idx": 2987, "end_char_idx": 3093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04755824-ca5b-4c57-9a55-87eb76a6b591": {"__data__": {"id_": "04755824-ca5b-4c57-9a55-87eb76a6b591", "embedding": null, "metadata": {"window": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5", "node_type": "1", "metadata": {"window": "Because certainly, the overall demand dynamic \nhere, obviously, continues to be quite  strong.   And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f4d08f537a6f0b35b06970b961fcdf58c229d7aa6dcafb1990eea3cfad8b3fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a798bde6-ca31-45b8-aef1-ba1e8e44c822", "node_type": "1", "metadata": {"window": "But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "Not only -- so now we're dealing with just the timing of supply, but we're also dealing "}, "hash": "7131a1f83c88d64ca6915c6d9bd82abbcee81abf466f03233525d3ee6c64cbfc", "class_name": "RelatedNodeInfo"}}, "text": "So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "start_char_idx": 3093, "end_char_idx": 3231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a798bde6-ca31-45b8-aef1-ba1e8e44c822": {"__data__": {"id_": "a798bde6-ca31-45b8-aef1-ba1e8e44c822", "embedding": null, "metadata": {"window": "But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495936fd-d685-4b0c-b89c-4b6138ae239d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c0426bc7f0ab52a5ba9afe5db2232ce3bf7933e3f2c9791f2ca5217b6a97e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04755824-ca5b-4c57-9a55-87eb76a6b591", "node_type": "1", "metadata": {"window": "And we are seeing certain components get a little bit \nmore i n balance between supply and demand.  \n \n  But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f0037961ff90dc48171db4108576d438e87b0465956b2b727547db14aedfa3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7ef5d7b-0fe9-487c-b7d2-9cd414622870", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "original_text": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.  "}, "hash": "dea3a9a5643bc9e0d98bd4085b7ad9df3481e57a1a5b41864613503bb436c573", "class_name": "RelatedNodeInfo"}}, "text": "Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "start_char_idx": 3231, "end_char_idx": 3319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7ef5d7b-0fe9-487c-b7d2-9cd414622870": {"__data__": {"id_": "b7ef5d7b-0fe9-487c-b7d2-9cd414622870", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "original_text": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a798bde6-ca31-45b8-aef1-ba1e8e44c822", "node_type": "1", "metadata": {"window": "But certainly, cost remains elevated across all categories.   It's probably even more extreme in \nterms of that supply and demand imbalance remainin g in exam gloves.   So we continue to see that \ndemand just far outstripping that supply, which has created some -- just some supply chain \ninconsistencies.   Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "original_text": "Not only -- so now we're dealing with just the timing of supply, but we're also dealing ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dcbedf67033712fe110791fe7b39fb0e1a4c985b32fba7641d190c0cb3c178c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.  ", "original_text": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n "}, "hash": "0f4625cdd98724de4d731ead1b7b968aca47aeba6007df01edcfdabc0b974d50", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.  ", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a": {"__data__": {"id_": "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.  ", "original_text": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7ef5d7b-0fe9-487c-b7d2-9cd414622870", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "original_text": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63228fc9051d966499012bb6a1dd4720ad8936df338e73e44bfd161333b050ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a42134-88a4-45d4-9d4a-86218d4c55f0", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "original_text": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.  "}, "hash": "57135cef20a4f739bf638414137890a2e748ece382d4add02f3e082b49ac1810", "class_name": "RelatedNodeInfo"}}, "text": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n ", "start_char_idx": 101, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a42134-88a4-45d4-9d4a-86218d4c55f0": {"__data__": {"id_": "43a42134-88a4-45d4-9d4a-86218d4c55f0", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "original_text": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.  ", "original_text": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d06036c44eb3ba59928d03941478cb9a252cfe7f712c9d1a7b7ee09ad95c8ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a26586fe-22b4-41b9-813e-82b5207e2280", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.  ", "original_text": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n"}, "hash": "8a4c05d4d1e8ee084b93f41a20a3c38da35fd35f6c00436fc8e3010a3df67016", "class_name": "RelatedNodeInfo"}}, "text": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.  ", "start_char_idx": 272, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a26586fe-22b4-41b9-813e-82b5207e2280": {"__data__": {"id_": "a26586fe-22b4-41b9-813e-82b5207e2280", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.  ", "original_text": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a42134-88a4-45d4-9d4a-86218d4c55f0", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "original_text": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e598fcb8d33f20cf64568b8cc2288abf1bae9320f4440b262a6098697609c20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0", "node_type": "1", "metadata": {"window": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "f907c01ea2524b8a29da525fc5bba8b1d7aa9bff072ca7c15c0a487fb0888cb7", "class_name": "RelatedNodeInfo"}}, "text": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "start_char_idx": 443, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0": {"__data__": {"id_": "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0", "embedding": null, "metadata": {"window": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a26586fe-22b4-41b9-813e-82b5207e2280", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.  ", "original_text": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ceef2aa11af5936f7518311f622d3415baa79fd8c41651727f994bbbad9c22f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fa038cf-b2f1-432e-839c-afee7c0682ba", "node_type": "1", "metadata": {"window": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "original_text": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n"}, "hash": "85f2ec3c2c9a4624b90f0af821bcf235ef58132ce939c5892ed39e0d09be4e2b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 556, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fa038cf-b2f1-432e-839c-afee7c0682ba": {"__data__": {"id_": "7fa038cf-b2f1-432e-839c-afee7c0682ba", "embedding": null, "metadata": {"window": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "original_text": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0", "node_type": "1", "metadata": {"window": "So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb1278cb3568c7c53eaff2f1c0e5cf5f3bc10d939920776ebeba16f19dee0844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be51034f-c8e0-45f5-aade-f9bfca0ee78a", "node_type": "1", "metadata": {"window": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n ", "original_text": "Operator:  Thank you.  "}, "hash": "7b7490a64f70f3308d3a743ededdabea7912452bd69563b78b471628239a0f61", "class_name": "RelatedNodeInfo"}}, "text": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "start_char_idx": 578, "end_char_idx": 905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be51034f-c8e0-45f5-aade-f9bfca0ee78a": {"__data__": {"id_": "be51034f-c8e0-45f5-aade-f9bfca0ee78a", "embedding": null, "metadata": {"window": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fa038cf-b2f1-432e-839c-afee7c0682ba", "node_type": "1", "metadata": {"window": "So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "original_text": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9b5288a9fbafea0512a6f8f247220f7a7d7506cdca863d3de034777ae94621f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ed4f11-6330-4c00-b71a-24261afcadca", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "original_text": "We'll go next to Lisa Gill, JPMorgan.  \n \n"}, "hash": "15ea744a783766c2bf696a22899ee6b360d9fc2cced4ed875a40b31e5f0b1cba", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 905, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ed4f11-6330-4c00-b71a-24261afcadca": {"__data__": {"id_": "f9ed4f11-6330-4c00-b71a-24261afcadca", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "original_text": "We'll go next to Lisa Gill, JPMorgan.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be51034f-c8e0-45f5-aade-f9bfca0ee78a", "node_type": "1", "metadata": {"window": "But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b65e35c5956ce20138cab19127de4ccec589d77d20a1f5ef9e6cacff08e6d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0ac6557-84bb-4216-9f17-67d8fec97d43", "node_type": "1", "metadata": {"window": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?  ", "original_text": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  "}, "hash": "925fff7d5de9ff8060f4900a5a31f9aa13390e4641ada07c83047578ffaf12e3", "class_name": "RelatedNodeInfo"}}, "text": "We'll go next to Lisa Gill, JPMorgan.  \n \n", "start_char_idx": 928, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0ac6557-84bb-4216-9f17-67d8fec97d43": {"__data__": {"id_": "b0ac6557-84bb-4216-9f17-67d8fec97d43", "embedding": null, "metadata": {"window": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?  ", "original_text": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ed4f11-6330-4c00-b71a-24261afcadca", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "original_text": "We'll go next to Lisa Gill, JPMorgan.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a8df2933e5d5f5ce49bf8c6f590e6e039a687cae7ef997f09c6f76cd19f4f40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79944b41-e5ed-4ffe-a777-f7befdf08eb8", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?  ", "original_text": "One, are you seeing an impact with less cough, cold and flu?  \n \n "}, "hash": "028dbe28b92777756562e3932028b2c3481238849d07c84f8f0e942e9bbb785e", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "start_char_idx": 970, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79944b41-e5ed-4ffe-a777-f7befdf08eb8": {"__data__": {"id_": "79944b41-e5ed-4ffe-a777-f7befdf08eb8", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?  ", "original_text": "One, are you seeing an impact with less cough, cold and flu?  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0ac6557-84bb-4216-9f17-67d8fec97d43", "node_type": "1", "metadata": {"window": "The only thing I would add is that while the PPE is clearly a driver, our lab \nbusiness really was a big driver for us this quarter in the Medical segment, and we continue to be \nexcited about its\u2019 growth and its\u2019 ability to continue to maintain that growth, at least for the remainder \nof FY21, is our current assumption.  \n \n Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?  ", "original_text": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9ea953aba2973226caccd6695a50e32cef3f89a24f204101dc750fb933dc925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bf65428-a692-47f9-b168-914a72c9b078", "node_type": "1", "metadata": {"window": "We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.  ", "original_text": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  "}, "hash": "35978b8412cec7bf95299e179b3fc46921009a0a08f3595a34e341bf6a41e8e9", "class_name": "RelatedNodeInfo"}}, "text": "One, are you seeing an impact with less cough, cold and flu?  \n \n ", "start_char_idx": 1118, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bf65428-a692-47f9-b168-914a72c9b078": {"__data__": {"id_": "6bf65428-a692-47f9-b168-914a72c9b078", "embedding": null, "metadata": {"window": "We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.  ", "original_text": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79944b41-e5ed-4ffe-a777-f7befdf08eb8", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?  ", "original_text": "One, are you seeing an impact with less cough, cold and flu?  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1ef57971a2bd80eb1685141b63f5013d4e8a3e4d55dae6a152c301f5934a86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f3c956c-50a2-4017-9b32-16415d483311", "node_type": "1", "metadata": {"window": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?  ", "original_text": "What are you seeing?  "}, "hash": "62d424a8716083d3afbf1a5f81dfd25f7de58bf7444034ebca9e6124ca75e6b4", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "start_char_idx": 1184, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f3c956c-50a2-4017-9b32-16415d483311": {"__data__": {"id_": "0f3c956c-50a2-4017-9b32-16415d483311", "embedding": null, "metadata": {"window": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?  ", "original_text": "What are you seeing?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bf65428-a692-47f9-b168-914a72c9b078", "node_type": "1", "metadata": {"window": "We'll go next to Lisa Gill, JPMorgan.  \n \n Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.  ", "original_text": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba899e563e1bb3e64db671a92c0e46553c12a34dd59a09f71cc24c49f53fda21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "524ad625-806e-4290-a862-182ebfe79eb4", "node_type": "1", "metadata": {"window": "One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "original_text": "Is it more of a tren d?  "}, "hash": "fcefc9e3381ef3d83f3b5f9b8240c70d0d71eb2a4f008365ed944a05fccadb2a", "class_name": "RelatedNodeInfo"}}, "text": "What are you seeing?  ", "start_char_idx": 1286, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "524ad625-806e-4290-a862-182ebfe79eb4": {"__data__": {"id_": "524ad625-806e-4290-a862-182ebfe79eb4", "embedding": null, "metadata": {"window": "One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "original_text": "Is it more of a tren d?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f3c956c-50a2-4017-9b32-16415d483311", "node_type": "1", "metadata": {"window": "Lisa Gill:  Mike, I just wanted to get an understanding of how you're thinking about utilization  as we go \ninto the back half of the fiscal year.   One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?  ", "original_text": "What are you seeing?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4770ceb3a665c9f3f4692b5e47b37f8825603c805031462c6cdf96c4db3c2e9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf27e2df-038a-4e9f-a039-df186e497372", "node_type": "1", "metadata": {"window": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n ", "original_text": "You said branding.  "}, "hash": "a78e81f3d7fd154a47a38b2991d229aac0b968a53391a08639966d75189458a6", "class_name": "RelatedNodeInfo"}}, "text": "Is it more of a tren d?  ", "start_char_idx": 1308, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf27e2df-038a-4e9f-a039-df186e497372": {"__data__": {"id_": "bf27e2df-038a-4e9f-a039-df186e497372", "embedding": null, "metadata": {"window": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n ", "original_text": "You said branding.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "524ad625-806e-4290-a862-182ebfe79eb4", "node_type": "1", "metadata": {"window": "One, are you seeing an impact with less cough, cold and flu?  \n \n  And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "original_text": "Is it more of a tren d?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a1d86a47c25fb84d6630ccbf45ed20f1748bd3e31b7929d1cd4f08b4d256801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5684aec6-6fd9-4d4a-958a-bf7bdb628e07", "node_type": "1", "metadata": {"window": "What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "original_text": "What kind of came in line \nor was that positive?  "}, "hash": "8952121e53baedf8e5980dd20baad2e9121521037488f590179b8b2a61a6ffbe", "class_name": "RelatedNodeInfo"}}, "text": "You said branding.  ", "start_char_idx": 1333, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5684aec6-6fd9-4d4a-958a-bf7bdb628e07": {"__data__": {"id_": "5684aec6-6fd9-4d4a-958a-bf7bdb628e07", "embedding": null, "metadata": {"window": "What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "original_text": "What kind of came in line \nor was that positive?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf27e2df-038a-4e9f-a039-df186e497372", "node_type": "1", "metadata": {"window": "And then secondly, you talked about the Rx segment in the quarter having an impact due to \ngenerics.   What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n ", "original_text": "You said branding.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deddaf37238bf31d8f84a5c07ad1871347179380f9dcb1158180177ed2116666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "015ed896-be11-4f80-9e07-f909b872e9ab", "node_type": "1", "metadata": {"window": "Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  "}, "hash": "ecfe661ec5e57b5ac33332beb7451e3463b1bec7333945988fbbf8f0838788ce", "class_name": "RelatedNodeInfo"}}, "text": "What kind of came in line \nor was that positive?  ", "start_char_idx": 1353, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "015ed896-be11-4f80-9e07-f909b872e9ab": {"__data__": {"id_": "015ed896-be11-4f80-9e07-f909b872e9ab", "embedding": null, "metadata": {"window": "Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5684aec6-6fd9-4d4a-958a-bf7bdb628e07", "node_type": "1", "metadata": {"window": "What are you seeing?   Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "original_text": "What kind of came in line \nor was that positive?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d02a438822d0f7909df08c0ce61a414934c1d2d74a2123896b25c2227b0b060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14eb0e67-f4fc-4338-8c33-5679b5d669ce", "node_type": "1", "metadata": {"window": "You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.  ", "original_text": "Is there anything going on with your buying group?  \n \n "}, "hash": "30896cbfeace1d91faafe51e31b7445d6ff6c6b3cb130d7f9f91c6fe5586d975", "class_name": "RelatedNodeInfo"}}, "text": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "start_char_idx": 1403, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14eb0e67-f4fc-4338-8c33-5679b5d669ce": {"__data__": {"id_": "14eb0e67-f4fc-4338-8c33-5679b5d669ce", "embedding": null, "metadata": {"window": "You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.  ", "original_text": "Is there anything going on with your buying group?  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "015ed896-be11-4f80-9e07-f909b872e9ab", "node_type": "1", "metadata": {"window": "Is it more of a tren d?   You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ca9149aebc70570d959c39823ceca3b7545b79312ab2ce7640c089f992772f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae", "node_type": "1", "metadata": {"window": "What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say. ", "original_text": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n"}, "hash": "f6c1b56a4ce8494e9e20fc9833a18879ae14818f0259ad341c9f9f198c21e01a", "class_name": "RelatedNodeInfo"}}, "text": "Is there anything going on with your buying group?  \n \n ", "start_char_idx": 1508, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae": {"__data__": {"id_": "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae", "embedding": null, "metadata": {"window": "What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say. ", "original_text": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14eb0e67-f4fc-4338-8c33-5679b5d669ce", "node_type": "1", "metadata": {"window": "You said branding.   What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.  ", "original_text": "Is there anything going on with your buying group?  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b87a97f37a4a53b2a96f16109f85aae1273420b255deb5832027101a57270c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3335f1-f7c1-443c-a3b1-ae18c97cc756", "node_type": "1", "metadata": {"window": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "ae25810abeeceb4c7b299e11ed83c9e9d7679e264edee7b89808f9d436b583ba", "class_name": "RelatedNodeInfo"}}, "text": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "start_char_idx": 1564, "end_char_idx": 1743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3335f1-f7c1-443c-a3b1-ae18c97cc756": {"__data__": {"id_": "dd3335f1-f7c1-443c-a3b1-ae18c97cc756", "embedding": null, "metadata": {"window": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae", "node_type": "1", "metadata": {"window": "What kind of came in line \nor was that positive?   Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say. ", "original_text": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13747444d00ead3d75672fe13d271d1f5d88cbe5bc9b99cb921c1b422b898a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16321123-a2df-43e0-84da-cb7aabe33548", "node_type": "1", "metadata": {"window": "Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "original_text": "Thanks, Lisa.  "}, "hash": "ba248cc8ab342fd7b44461a5ebf9d6d3a03aca6f8a7b151eb78259035c0a922a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 556, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16321123-a2df-43e0-84da-cb7aabe33548": {"__data__": {"id_": "16321123-a2df-43e0-84da-cb7aabe33548", "embedding": null, "metadata": {"window": "Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "original_text": "Thanks, Lisa.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3335f1-f7c1-443c-a3b1-ae18c97cc756", "node_type": "1", "metadata": {"window": "Is it that new prescription volumes continue to be down, at least based on the \ndata we see with IQVIA?   Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b022421cbee30299b392449bcb427435ae2b6e703ca074091142608ac32599e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bac13b59-cd26-4523-8a49-40b24646ecae", "node_type": "1", "metadata": {"window": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "original_text": "A couple of things I would say. "}, "hash": "6c39a74efd061876040a812da542b85a2a6c4dcac74ae8807f0f17a7d63fff95", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Lisa.  ", "start_char_idx": 1765, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bac13b59-cd26-4523-8a49-40b24646ecae": {"__data__": {"id_": "bac13b59-cd26-4523-8a49-40b24646ecae", "embedding": null, "metadata": {"window": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "original_text": "A couple of things I would say. ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16321123-a2df-43e0-84da-cb7aabe33548", "node_type": "1", "metadata": {"window": "Is there anything going on with your buying group?  \n \n  Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "original_text": "Thanks, Lisa.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa99356b2353d4e4e54cb6d7ab4d0ba1ca047e1ca4323e6e81e3a5faf0aeec2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "281ab47f-4467-46cc-beaa-64ab3a12696d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n ", "original_text": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  "}, "hash": "72ab1644224e22de36e0d5831e7e52bc8a40d224d6c58851ebb169f43eaf2cf4", "class_name": "RelatedNodeInfo"}}, "text": "A couple of things I would say. ", "start_char_idx": 1780, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "281ab47f-4467-46cc-beaa-64ab3a12696d": {"__data__": {"id_": "281ab47f-4467-46cc-beaa-64ab3a12696d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n ", "original_text": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bac13b59-cd26-4523-8a49-40b24646ecae", "node_type": "1", "metadata": {"window": "Just how do we think about  utilization and any other comments you can give us around how to \nthink about the Pharma Distribution component of your business in the back half?  \n \n Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "original_text": "A couple of things I would say. ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a56f3749db899638244342dc72e155e079a8a1723d83c0407c900643eda3525f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eb59cff-035f-4e43-869c-6a9b91d6941f", "node_type": "1", "metadata": {"window": "Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.  ", "original_text": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  "}, "hash": "9751ed00ac267edf37d3fc69cc4cc6fda54570943b848a099ceba886746bf88c", "class_name": "RelatedNodeInfo"}}, "text": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "start_char_idx": 1812, "end_char_idx": 1993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eb59cff-035f-4e43-869c-6a9b91d6941f": {"__data__": {"id_": "2eb59cff-035f-4e43-869c-6a9b91d6941f", "embedding": null, "metadata": {"window": "Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.  ", "original_text": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "281ab47f-4467-46cc-beaa-64ab3a12696d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n ", "original_text": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "947f08ff455500ea3b18f4aba5229104b86bf3e65ab20b0b56ed187fcc0bce21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a11f3730-11a6-4cac-879c-2abaa6e7ce0c", "node_type": "1", "metadata": {"window": "A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.  ", "original_text": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  "}, "hash": "5328165625b561ac2821729cac8093d5eadc1d359ded0427f3ab6d97f3fa1c01", "class_name": "RelatedNodeInfo"}}, "text": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "start_char_idx": 1993, "end_char_idx": 2132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a11f3730-11a6-4cac-879c-2abaa6e7ce0c": {"__data__": {"id_": "a11f3730-11a6-4cac-879c-2abaa6e7ce0c", "embedding": null, "metadata": {"window": "A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.  ", "original_text": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eb59cff-035f-4e43-869c-6a9b91d6941f", "node_type": "1", "metadata": {"window": "Thanks, Lisa.   A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.  ", "original_text": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67a0be667a994cf7bfaf85062c5e56a4637ef4218922bfac6b08c5395b7facfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9e472ad-a285-420e-b319-80669bb2646d", "node_type": "1", "metadata": {"window": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "original_text": "It's really just the volumes as it relates to COVID -19. \n \n "}, "hash": "a133a582dd662cf5a48c3e2338b21d2a01f6c0f206e27f080ecbda8f9aaeee6c", "class_name": "RelatedNodeInfo"}}, "text": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "start_char_idx": 2132, "end_char_idx": 2258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9e472ad-a285-420e-b319-80669bb2646d": {"__data__": {"id_": "f9e472ad-a285-420e-b319-80669bb2646d", "embedding": null, "metadata": {"window": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "original_text": "It's really just the volumes as it relates to COVID -19. \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a11f3730-11a6-4cac-879c-2abaa6e7ce0c", "node_type": "1", "metadata": {"window": "A couple of things I would say.  I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.  ", "original_text": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3702ee8be4f78fb39ffac1ed58fc009e397a6e5f84816d1e49e2358e2b08521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b", "node_type": "1", "metadata": {"window": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "original_text": "So -- and as we said, we expect that to continue to be  choppy.  "}, "hash": "da8c4875def69da6c60b417d94e8c93cf475b7d77b52194ed383a1c6934d7ce9", "class_name": "RelatedNodeInfo"}}, "text": "It's really just the volumes as it relates to COVID -19. \n \n ", "start_char_idx": 2258, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b": {"__data__": {"id_": "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b", "embedding": null, "metadata": {"window": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "original_text": "So -- and as we said, we expect that to continue to be  choppy.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9e472ad-a285-420e-b319-80669bb2646d", "node_type": "1", "metadata": {"window": "I guess, first of all, it's important \nto know that sequentially, there's really not a lot of difference between what we saw in volumes \nbetween Q1 and Q2 for our Pharma business.   And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "original_text": "It's really just the volumes as it relates to COVID -19. \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52116219b10b5655f29e77c080bb539a24d2b73918b82c990401dc8e39c10a90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0be2b1c-97bb-4404-80ed-92c03901b070", "node_type": "1", "metadata": {"window": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.  ", "original_text": "We saw a lot of up and down \nover the last six months.  "}, "hash": "d96b92883e8fcbfc6f50e80587e740e7d0c42e6aa731ae3d0a99830217272b0f", "class_name": "RelatedNodeInfo"}}, "text": "So -- and as we said, we expect that to continue to be  choppy.  ", "start_char_idx": 2319, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0be2b1c-97bb-4404-80ed-92c03901b070": {"__data__": {"id_": "f0be2b1c-97bb-4404-80ed-92c03901b070", "embedding": null, "metadata": {"window": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.  ", "original_text": "We saw a lot of up and down \nover the last six months.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b", "node_type": "1", "metadata": {"window": "And also, I would say that all the impact that we're \nseeing on volumes in generics is really, from our view, just re lated to COVID -19.   So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "original_text": "So -- and as we said, we expect that to continue to be  choppy.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e790185658f2ec2cc96cc5623638d9f77b9346883867f6df7d1910c00d4e298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84803eda-274b-49ea-97b8-13c942415c7f", "node_type": "1", "metadata": {"window": "It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.  ", "original_text": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n "}, "hash": "9f6ac1a545d22b414a26aeaa243f6a06e73889643d6474ad225b0cffba7d9539", "class_name": "RelatedNodeInfo"}}, "text": "We saw a lot of up and down \nover the last six months.  ", "start_char_idx": 2384, "end_char_idx": 2440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84803eda-274b-49ea-97b8-13c942415c7f": {"__data__": {"id_": "84803eda-274b-49ea-97b8-13c942415c7f", "embedding": null, "metadata": {"window": "It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.  ", "original_text": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0be2b1c-97bb-4404-80ed-92c03901b070", "node_type": "1", "metadata": {"window": "So we're not seeing \nany other dynamics such as buying groups or other challenges like that impacting our generics \nprogram.   It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.  ", "original_text": "We saw a lot of up and down \nover the last six months.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11fd8c5d7aa8219f0861c16046a9fa944754971948841aaf9dd21d73f3cae9da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26", "node_type": "1", "metadata": {"window": "So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.  ", "original_text": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  "}, "hash": "086c3f3e338c5c507616bdce31e74f3b0ab053148fa9f9132cb8caeab8975645", "class_name": "RelatedNodeInfo"}}, "text": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "start_char_idx": 2440, "end_char_idx": 2588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26": {"__data__": {"id_": "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26", "embedding": null, "metadata": {"window": "So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.  ", "original_text": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84803eda-274b-49ea-97b8-13c942415c7f", "node_type": "1", "metadata": {"window": "It's really just the volumes as it relates to COVID -19. \n \n  So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.  ", "original_text": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "068c69ba0bcd89a4f8283011a9a3326ee1e1de8c079a3a82f3479f88dd8c78e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ec4829-a75f-4ea9-ac82-07ffa4d3916e", "node_type": "1", "metadata": {"window": "We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "original_text": "It \ncan be a small driver.  "}, "hash": "df65910b6007d1a6c3bf2fbedd8ccab918a5b4edb5c796034a5957cbea2852d8", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "start_char_idx": 2588, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16ec4829-a75f-4ea9-ac82-07ffa4d3916e": {"__data__": {"id_": "16ec4829-a75f-4ea9-ac82-07ffa4d3916e", "embedding": null, "metadata": {"window": "We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "original_text": "It \ncan be a small driver.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26", "node_type": "1", "metadata": {"window": "So -- and as we said, we expect that to continue to be  choppy.   We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.  ", "original_text": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b752ec034154f8af54ea21aa7aec90c14b9714f6d26c30ab100c95274c4b6fd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d63d601e-7e8d-406e-bb1e-18a084747c37", "node_type": "1", "metadata": {"window": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "original_text": "And as far as the flu goes, we've hardly seen much at all.  "}, "hash": "99b93c7e0d11d7ab27ea399e2800763a7916d79fb2aec238dc819196edd542bb", "class_name": "RelatedNodeInfo"}}, "text": "It \ncan be a small driver.  ", "start_char_idx": 2686, "end_char_idx": 2714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d63d601e-7e8d-406e-bb1e-18a084747c37": {"__data__": {"id_": "d63d601e-7e8d-406e-bb1e-18a084747c37", "embedding": null, "metadata": {"window": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "original_text": "And as far as the flu goes, we've hardly seen much at all.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ec4829-a75f-4ea9-ac82-07ffa4d3916e", "node_type": "1", "metadata": {"window": "We saw a lot of up and down \nover the last six months.   We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "original_text": "It \ncan be a small driver.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36acae2de5f98093db1d85e696c29e808e45d186fd4dd2829488a0d1d15a7b91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8043fc55-be49-498a-9447-1002d39af3e2", "node_type": "1", "metadata": {"window": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.  ", "original_text": "So in terms of \nvaccine distribution, it has been a little higher.  "}, "hash": "b9d721d654edd44d6c3b98dce8c435d958832ad387588e2fbe7435bb21193d10", "class_name": "RelatedNodeInfo"}}, "text": "And as far as the flu goes, we've hardly seen much at all.  ", "start_char_idx": 2714, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8043fc55-be49-498a-9447-1002d39af3e2": {"__data__": {"id_": "8043fc55-be49-498a-9447-1002d39af3e2", "embedding": null, "metadata": {"window": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.  ", "original_text": "So in terms of \nvaccine distribution, it has been a little higher.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d63d601e-7e8d-406e-bb1e-18a084747c37", "node_type": "1", "metadata": {"window": "We would expect that for the second half of the year, but do expect to still \nget back to at or near pre -COVID levels by the end of the year.  \n \n  As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "original_text": "And as far as the flu goes, we've hardly seen much at all.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b31f2234d574ac0e3b9232c40d5724c82a2e81abfd0f4cebcce2ffb12ca740a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d785f811-648a-47f3-ae7d-28617c1026d4", "node_type": "1", "metadata": {"window": "It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  "}, "hash": "132eb886cb8c0bf66f1f438da9250a2660a559af7b5897a7aa718c35f30582fb", "class_name": "RelatedNodeInfo"}}, "text": "So in terms of \nvaccine distribution, it has been a little higher.  ", "start_char_idx": 2774, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d785f811-648a-47f3-ae7d-28617c1026d4": {"__data__": {"id_": "d785f811-648a-47f3-ae7d-28617c1026d4", "embedding": null, "metadata": {"window": "It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8043fc55-be49-498a-9447-1002d39af3e2", "node_type": "1", "metadata": {"window": "As it relates to flu, as you know, this has beco me less and less of a driver in general for us.   It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.  ", "original_text": "So in terms of \nvaccine distribution, it has been a little higher.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c3a840263636593b59c5a90ae2d3c64b5aa8c6fb8511efc93d18fd9889885e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58dfc7d5-0d29-4dac-aa84-fa08b73f9112", "node_type": "1", "metadata": {"window": "And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n"}, "hash": "116da3cf12389199235c704ec9c7a1a018f596e0ef226f8cebcdad6ad93a8309", "class_name": "RelatedNodeInfo"}}, "text": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "start_char_idx": 2842, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58dfc7d5-0d29-4dac-aa84-fa08b73f9112": {"__data__": {"id_": "58dfc7d5-0d29-4dac-aa84-fa08b73f9112", "embedding": null, "metadata": {"window": "And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d785f811-648a-47f3-ae7d-28617c1026d4", "node_type": "1", "metadata": {"window": "It \ncan be a small driver.   And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1262a8044ea63e3eeb0fedb7f4a020a7b8230a4463e97960de320c2b58caaf02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b51bd7-1b03-46ca-b8c7-75ee66846cee", "node_type": "1", "metadata": {"window": "So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "Operator:  Thank you.  "}, "hash": "0226b553120099631182a5006328da668c4898143bdc771a6ccc16effcf666bb", "class_name": "RelatedNodeInfo"}}, "text": "But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "start_char_idx": 2974, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8b51bd7-1b03-46ca-b8c7-75ee66846cee": {"__data__": {"id_": "b8b51bd7-1b03-46ca-b8c7-75ee66846cee", "embedding": null, "metadata": {"window": "So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58dfc7d5-0d29-4dac-aa84-fa08b73f9112", "node_type": "1", "metadata": {"window": "And as far as the flu goes, we've hardly seen much at all.   So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69879ed2e9d54650737e945f85b99cf5ed08baa12ca84db1d0032a7a48b6c760", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd4fd7ba-58c8-4329-b0fc-900a4251de92", "node_type": "1", "metadata": {"window": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "We'll go next to Glen Santangelo with Guggenheim.  "}, "hash": "46787c0b7377933987436d677d5ed7038fe6206f53673dd61bed400d3dd89b9f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 905, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd4fd7ba-58c8-4329-b0fc-900a4251de92": {"__data__": {"id_": "cd4fd7ba-58c8-4329-b0fc-900a4251de92", "embedding": null, "metadata": {"window": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "We'll go next to Glen Santangelo with Guggenheim.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "583a4136-95fa-435e-b272-086d888555aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90947df224c147edbb5568515d12982594e8b96b6ce4ee52d4a7c1ff60859e97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8b51bd7-1b03-46ca-b8c7-75ee66846cee", "node_type": "1", "metadata": {"window": "So in terms of \nvaccine distribution, it has been a little higher.   But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2278d88ddad8c73757f9f39cd42db67a2bf87bc54bd8d3202216ad5f63ecdd9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "def37c16-d276-4ad1-ae81-b89f9e3467de", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "original_text": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance. "}, "hash": "ac9d847e4332f4ef854cccfefd86f24172b5b631d919df553410a606bdd16597", "class_name": "RelatedNodeInfo"}}, "text": "We'll go next to Glen Santangelo with Guggenheim.  ", "start_char_idx": 3211, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "def37c16-d276-4ad1-ae81-b89f9e3467de": {"__data__": {"id_": "def37c16-d276-4ad1-ae81-b89f9e3467de", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "original_text": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance. ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd4fd7ba-58c8-4329-b0fc-900a4251de92", "node_type": "1", "metadata": {"window": "But all of the other type of ancillary products, such  as \nthe Tamiflus and those types of things, they have been down, obviously.   But again, it's an incredibly \ntiny driver for us and was not something that is driving any of the concern or any challenges that we \nmight be looking at in Pharma, which, again, we  just are focused on COVID.  \n \n Operator:  Thank you.   We'll go next to Glen Santangelo with Guggenheim.  ", "original_text": "We'll go next to Glen Santangelo with Guggenheim.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a775d6496e1e71f81c1f2ada0e13b8706fc6262955fac230b04a2f485a5568e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c131b54-ad6c-4f1b-aa46-deead7cca7c8", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "original_text": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.  "}, "hash": "de2999d031558c40ca25bca9b97c2f833a3c13723a0427a7a9f33c2e53111bc5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance. ", "start_char_idx": 0, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c131b54-ad6c-4f1b-aa46-deead7cca7c8": {"__data__": {"id_": "0c131b54-ad6c-4f1b-aa46-deead7cca7c8", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "original_text": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "def37c16-d276-4ad1-ae81-b89f9e3467de", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "original_text": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance. ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eda035ed1afe22ad56acef6c37ce24ec2111b5424c83904682a751b40bf66cd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba58b63-1740-47e0-bf0a-5d7f854214b8", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.  ", "original_text": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.  "}, "hash": "de24b2819deedd1efcfb066e857966f03e5892885c1af2a2b409f8e20f21e44d", "class_name": "RelatedNodeInfo"}}, "text": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.  ", "start_char_idx": 153, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba58b63-1740-47e0-bf0a-5d7f854214b8": {"__data__": {"id_": "bba58b63-1740-47e0-bf0a-5d7f854214b8", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.  ", "original_text": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c131b54-ad6c-4f1b-aa46-deead7cca7c8", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "original_text": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2088c8aa21a5a7f66f3b1317fb48f897d810ce3a3c2425e98629f4c3cf279d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f588fc84-d775-4752-911d-afded57ab07a", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.  ", "original_text": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  "}, "hash": "ccc92e46cc7979dc39481a3de8d263b426ee5cc08573f2be852ae7a38367bed3", "class_name": "RelatedNodeInfo"}}, "text": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.  ", "start_char_idx": 253, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f588fc84-d775-4752-911d-afded57ab07a": {"__data__": {"id_": "f588fc84-d775-4752-911d-afded57ab07a", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.  ", "original_text": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba58b63-1740-47e0-bf0a-5d7f854214b8", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.  ", "original_text": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a70d2dbd42ddbee6c603aaf3fe1741f6912d9fa1da5dc16fc6adeb788e4c3644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a50d428-8016-4dc0-babc-eb73dc2c4fc4", "node_type": "1", "metadata": {"window": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.  ", "original_text": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n"}, "hash": "64b4a2d3f926841ad2bfb8c84398a7a0d1b174ed8aba03d81f38972fc1784c11", "class_name": "RelatedNodeInfo"}}, "text": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "start_char_idx": 341, "end_char_idx": 446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a50d428-8016-4dc0-babc-eb73dc2c4fc4": {"__data__": {"id_": "5a50d428-8016-4dc0-babc-eb73dc2c4fc4", "embedding": null, "metadata": {"window": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.  ", "original_text": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f588fc84-d775-4752-911d-afded57ab07a", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.  ", "original_text": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "630ec45dec6308c9ea2c2b0196ef76267ae78d30a8919cebb87f588749099d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40e27841-fe33-4032-ad35-bf01cb593dfa", "node_type": "1", "metadata": {"window": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "original_text": "Jason Hollar:  Okay, great.  "}, "hash": "56ccc2c52e3f5c58f91152a09d5307d035316366a52ba269a8c288f9ddebec34", "class_name": "RelatedNodeInfo"}}, "text": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "start_char_idx": 446, "end_char_idx": 597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40e27841-fe33-4032-ad35-bf01cb593dfa": {"__data__": {"id_": "40e27841-fe33-4032-ad35-bf01cb593dfa", "embedding": null, "metadata": {"window": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "original_text": "Jason Hollar:  Okay, great.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a50d428-8016-4dc0-babc-eb73dc2c4fc4", "node_type": "1", "metadata": {"window": "It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.  ", "original_text": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba11deb6a741c9ada1396d2019834bf64f8950e3267ac2f655a34bc44d5aa883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5385341e-847d-4c20-a4da-2901cc6bb15a", "node_type": "1", "metadata": {"window": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "original_text": "So in terms of interest, let's start there.  "}, "hash": "fc3f194dcad25515a935b8073e113165d9e27b67713c9b61c451f76f6118ef15", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Okay, great.  ", "start_char_idx": 597, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5385341e-847d-4c20-a4da-2901cc6bb15a": {"__data__": {"id_": "5385341e-847d-4c20-a4da-2901cc6bb15a", "embedding": null, "metadata": {"window": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "original_text": "So in terms of interest, let's start there.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40e27841-fe33-4032-ad35-bf01cb593dfa", "node_type": "1", "metadata": {"window": "And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "original_text": "Jason Hollar:  Okay, great.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e666acbb0d06b4ceaaea98e7db2b1cf1bc695667f1b46be20ca09e80446b64bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db677e2-289a-476f-9dbb-617376b26f4a", "node_type": "1", "metadata": {"window": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.  ", "original_text": "Yes, you're right.  "}, "hash": "331ad1988fa8afacb8417514d622edc5b751d8aed05a2667879797100cb05dac", "class_name": "RelatedNodeInfo"}}, "text": "So in terms of interest, let's start there.  ", "start_char_idx": 626, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db677e2-289a-476f-9dbb-617376b26f4a": {"__data__": {"id_": "4db677e2-289a-476f-9dbb-617376b26f4a", "embedding": null, "metadata": {"window": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.  ", "original_text": "Yes, you're right.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5385341e-847d-4c20-a4da-2901cc6bb15a", "node_type": "1", "metadata": {"window": "But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?   And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "original_text": "So in terms of interest, let's start there.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5bfa09432c77c67d6772641b2a2572a6a1e6b2c412943530ac5a24fe5a67649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2137b0f3-044a-44eb-91bf-91f7e9e82908", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "original_text": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  "}, "hash": "3242b09425cb0a131e1ad2619fa13d943ded470db67ba495ad4ca00084468456", "class_name": "RelatedNodeInfo"}}, "text": "Yes, you're right.  ", "start_char_idx": 671, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2137b0f3-044a-44eb-91bf-91f7e9e82908": {"__data__": {"id_": "2137b0f3-044a-44eb-91bf-91f7e9e82908", "embedding": null, "metadata": {"window": "Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "original_text": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db677e2-289a-476f-9dbb-617376b26f4a", "node_type": "1", "metadata": {"window": "And secondly to that, is a potential opioid settlement at all in consideration in your \ncapital deployment priorities for the balance of the year?  \n \n Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.  ", "original_text": "Yes, you're right.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07836f26d8260b5672e253542e658b5fbf0ae406ce1178527a9af0285ad9a7d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f569bcc-cf3b-465d-8484-b9014538d57f", "node_type": "1", "metadata": {"window": "So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "original_text": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  "}, "hash": "2963e6143af288fdf4530c72f61ae1640cb3f3f04288e22dd4c687de67acfc49", "class_name": "RelatedNodeInfo"}}, "text": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "start_char_idx": 691, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f569bcc-cf3b-465d-8484-b9014538d57f": {"__data__": {"id_": "2f569bcc-cf3b-465d-8484-b9014538d57f", "embedding": null, "metadata": {"window": "So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "original_text": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2137b0f3-044a-44eb-91bf-91f7e9e82908", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay, great.   So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "original_text": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45620d04ac2628e16ff05e9d4b34967135f9edab010c074be538e808cb04c907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fba4314-dda4-4dbf-9838-40044393d3ab", "node_type": "1", "metadata": {"window": "Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.  ", "original_text": "So there's no \nnet EPS change associated with that.  "}, "hash": "ada62a29396305e3b3221a6e42ef93fed48b61d020a18f26eea6c8e21281597a", "class_name": "RelatedNodeInfo"}}, "text": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "start_char_idx": 794, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fba4314-dda4-4dbf-9838-40044393d3ab": {"__data__": {"id_": "1fba4314-dda4-4dbf-9838-40044393d3ab", "embedding": null, "metadata": {"window": "Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.  ", "original_text": "So there's no \nnet EPS change associated with that.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f569bcc-cf3b-465d-8484-b9014538d57f", "node_type": "1", "metadata": {"window": "So in terms of interest, let's start there.   Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "original_text": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bdc773c66774d5b5ef87352ba3c6d451a3c40168603920e866aae2817b48832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fa02a4f-0fe7-4407-89db-009c1d8edee6", "node_type": "1", "metadata": {"window": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?  ", "original_text": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  "}, "hash": "6fcb8c8433b6a87766b8b1b1beb094d7e60aaa2c3cb28925e6c8afcaefb8ead2", "class_name": "RelatedNodeInfo"}}, "text": "So there's no \nnet EPS change associated with that.  ", "start_char_idx": 894, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fa02a4f-0fe7-4407-89db-009c1d8edee6": {"__data__": {"id_": "9fa02a4f-0fe7-4407-89db-009c1d8edee6", "embedding": null, "metadata": {"window": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?  ", "original_text": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fba4314-dda4-4dbf-9838-40044393d3ab", "node_type": "1", "metadata": {"window": "Yes, you're right.   As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.  ", "original_text": "So there's no \nnet EPS change associated with that.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e436dc57608b9da20a0acd4b22a7d65c49c6e8b413bb5e3a4755b383b61c105", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ec18aa-9e91-4618-9da7-12a4da0dae46", "node_type": "1", "metadata": {"window": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n", "original_text": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n "}, "hash": "149bec57fecb8395a4fbc4c42d78ce9e0eac462e999497f67e3642af1983b25f", "class_name": "RelatedNodeInfo"}}, "text": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "start_char_idx": 947, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ec18aa-9e91-4618-9da7-12a4da0dae46": {"__data__": {"id_": "d6ec18aa-9e91-4618-9da7-12a4da0dae46", "embedding": null, "metadata": {"window": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n", "original_text": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fa02a4f-0fe7-4407-89db-009c1d8edee6", "node_type": "1", "metadata": {"window": "As co nsistent \nwith my comments, it's the deferred comp element that is driving the guidance change.   And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?  ", "original_text": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c35ae6c54764a830442fa6401cff60f2d38566bd6f93457a3691cc3eee514b8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55408135-3a12-4b26-9e8d-1d90298c703f", "node_type": "1", "metadata": {"window": "So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.  ", "original_text": "And so then -- I'm sorry, there are three parts.  "}, "hash": "b78531d8525b431c8d357df2e81b6479836f2701a5f02dbb310a46bcfe0e0a7b", "class_name": "RelatedNodeInfo"}}, "text": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "start_char_idx": 1054, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55408135-3a12-4b26-9e8d-1d90298c703f": {"__data__": {"id_": "55408135-3a12-4b26-9e8d-1d90298c703f", "embedding": null, "metadata": {"window": "So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.  ", "original_text": "And so then -- I'm sorry, there are three parts.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ec18aa-9e91-4618-9da7-12a4da0dae46", "node_type": "1", "metadata": {"window": "And as I \nhighlighted, that's entirely a flip -flop between interest and other and corporate SG&A.   So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n", "original_text": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e47e745842272cec34c2f922ade61aa5a2795105c37bebec4a90e829db0cfecf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22822b91-5e8c-4d16-ab69-90b535e94c1e", "node_type": "1", "metadata": {"window": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.  ", "original_text": "What was the second part?  "}, "hash": "4853e87c8f3cde7b21b264211e953771d77c007727970547d95e64a91aefaa64", "class_name": "RelatedNodeInfo"}}, "text": "And so then -- I'm sorry, there are three parts.  ", "start_char_idx": 1140, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22822b91-5e8c-4d16-ab69-90b535e94c1e": {"__data__": {"id_": "22822b91-5e8c-4d16-ab69-90b535e94c1e", "embedding": null, "metadata": {"window": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.  ", "original_text": "What was the second part?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55408135-3a12-4b26-9e8d-1d90298c703f", "node_type": "1", "metadata": {"window": "So there's no \nnet EPS change associated with that.   And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.  ", "original_text": "And so then -- I'm sorry, there are three parts.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1a8a87c5d5068060e5fecfcee62edfa682bb1af6eaaa670e7e9c62d912d149c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f54897e-ca86-4872-9354-37c4516ba08d", "node_type": "1", "metadata": {"window": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.  ", "original_text": "Sh are count.  \n"}, "hash": "9542e26e1b2710e07413d1874648c48aea79e885faa989535c58bb00265f812d", "class_name": "RelatedNodeInfo"}}, "text": "What was the second part?  ", "start_char_idx": 1190, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f54897e-ca86-4872-9354-37c4516ba08d": {"__data__": {"id_": "7f54897e-ca86-4872-9354-37c4516ba08d", "embedding": null, "metadata": {"window": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.  ", "original_text": "Sh are count.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22822b91-5e8c-4d16-ab69-90b535e94c1e", "node_type": "1", "metadata": {"window": "And of cou rse, interest rates, although low, we have a \nsubstantial part of our capital structure fixed.   So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.  ", "original_text": "What was the second part?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26c29906c03d7841753e4763db435b1b6e19466804539d847852a6f38aaa7be9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c", "node_type": "1", "metadata": {"window": "And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.  ", "original_text": "Okay.  "}, "hash": "c444f757e4f14c27954c9ce28b25a02cbb44a8944875778f6edac25bad958712", "class_name": "RelatedNodeInfo"}}, "text": "Sh are count.  \n", "start_char_idx": 1217, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c": {"__data__": {"id_": "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c", "embedding": null, "metadata": {"window": "And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.  ", "original_text": "Okay.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f54897e-ca86-4872-9354-37c4516ba08d", "node_type": "1", "metadata": {"window": "So we just don't see a lot of variation as it relates to \nwhere rates have been.  \n \n  And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.  ", "original_text": "Sh are count.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a25a949e51338821d58203f5e8cddd6d4f9ad5e5dcdf24a4794df14c798e659d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21c7a587-bc07-4ec2-b848-f56dbf1e40f6", "node_type": "1", "metadata": {"window": "What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.  ", "original_text": "So the share count, we're still within the guidance range of what we had before.  "}, "hash": "20530ae8d81d445b9c868f92cbedc6ba770f20cd0c257583be501155f728c38c", "class_name": "RelatedNodeInfo"}}, "text": "Okay.  ", "start_char_idx": 1233, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21c7a587-bc07-4ec2-b848-f56dbf1e40f6": {"__data__": {"id_": "21c7a587-bc07-4ec2-b848-f56dbf1e40f6", "embedding": null, "metadata": {"window": "What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.  ", "original_text": "So the share count, we're still within the guidance range of what we had before.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c", "node_type": "1", "metadata": {"window": "And so then -- I'm sorry, there are three parts.   What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.  ", "original_text": "Okay.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0120eba7687e7587d01e6295dd23220994dc60cf8dfe8d0bd29a5c134b450e9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207da6bf-a917-4608-929f-e92119385a3f", "node_type": "1", "metadata": {"window": "Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n", "original_text": "It is slightly at \nthe high end, to your point.  "}, "hash": "8e5834a6cca97d7be833cc516fbaf0977f6623396e092a68378d2ea7c4f5b688", "class_name": "RelatedNodeInfo"}}, "text": "So the share count, we're still within the guidance range of what we had before.  ", "start_char_idx": 1240, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207da6bf-a917-4608-929f-e92119385a3f": {"__data__": {"id_": "207da6bf-a917-4608-929f-e92119385a3f", "embedding": null, "metadata": {"window": "Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n", "original_text": "It is slightly at \nthe high end, to your point.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21c7a587-bc07-4ec2-b848-f56dbf1e40f6", "node_type": "1", "metadata": {"window": "What was the second part?   Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.  ", "original_text": "So the share count, we're still within the guidance range of what we had before.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f203e358089d7d652411a438d021b75f651099619cc92729107efa6e0d871f91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850e71d0-4d08-4f77-a5e5-01ea008a65eb", "node_type": "1", "metadata": {"window": "Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.  ", "original_text": "As you can see, in the first quarter, we didn't do any share repo.  "}, "hash": "1d78d0fb2d51f7976ed63a80d9c85bc68223c4e60301ed27138d30e6a1133f25", "class_name": "RelatedNodeInfo"}}, "text": "It is slightly at \nthe high end, to your point.  ", "start_char_idx": 1322, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "850e71d0-4d08-4f77-a5e5-01ea008a65eb": {"__data__": {"id_": "850e71d0-4d08-4f77-a5e5-01ea008a65eb", "embedding": null, "metadata": {"window": "Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.  ", "original_text": "As you can see, in the first quarter, we didn't do any share repo.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207da6bf-a917-4608-929f-e92119385a3f", "node_type": "1", "metadata": {"window": "Sh are count.  \n Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n", "original_text": "It is slightly at \nthe high end, to your point.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ae60397d20143ca1d9d09e6933006f4eaae34fa3457ad6feae31f74a49d133f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77880587-1b8a-4afc-a128-e1d4ee80c9dc", "node_type": "1", "metadata": {"window": "So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n ", "original_text": "We \ndidn't do any in the second quarter as well.  "}, "hash": "0e2ebdf8f30fdfa44b003257cd95fe2476a2312fd4c07bfc3592ae72e15f6e6e", "class_name": "RelatedNodeInfo"}}, "text": "As you can see, in the first quarter, we didn't do any share repo.  ", "start_char_idx": 1371, "end_char_idx": 1439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77880587-1b8a-4afc-a128-e1d4ee80c9dc": {"__data__": {"id_": "77880587-1b8a-4afc-a128-e1d4ee80c9dc", "embedding": null, "metadata": {"window": "So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n ", "original_text": "We \ndidn't do any in the second quarter as well.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "850e71d0-4d08-4f77-a5e5-01ea008a65eb", "node_type": "1", "metadata": {"window": "Okay.   So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.  ", "original_text": "As you can see, in the first quarter, we didn't do any share repo.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90715834c5273c3def4e66bbbcd55dfcc2f53c5669d5c4c8e9339b633096b0f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a8a0f9-df24-4d1f-b064-b06846f538e1", "node_type": "1", "metadata": {"window": "It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "original_text": "But the high end of that share count would imply no repo.  \n"}, "hash": "5028305e50ad6054a88e8abdc64ff85020deb36237d3ce60b2c3ef466c42d59b", "class_name": "RelatedNodeInfo"}}, "text": "We \ndidn't do any in the second quarter as well.  ", "start_char_idx": 1439, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a8a0f9-df24-4d1f-b064-b06846f538e1": {"__data__": {"id_": "b1a8a0f9-df24-4d1f-b064-b06846f538e1", "embedding": null, "metadata": {"window": "It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "original_text": "But the high end of that share count would imply no repo.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77880587-1b8a-4afc-a128-e1d4ee80c9dc", "node_type": "1", "metadata": {"window": "So the share count, we're still within the guidance range of what we had before.   It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n ", "original_text": "We \ndidn't do any in the second quarter as well.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7af5134b59ff938062e89da6f84df970fdc1835598b3e2f700feec76c0760f3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430256e5-a139-4570-9f17-7a97615b6ff2", "node_type": "1", "metadata": {"window": "As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.  ", "original_text": "The low end of this new range would be a modest amount of repo.  "}, "hash": "0a21c3acd35ac12fe8fab2bcabb2d3ffc49568368dc53b07a1b636f5648bc00f", "class_name": "RelatedNodeInfo"}}, "text": "But the high end of that share count would imply no repo.  \n", "start_char_idx": 1489, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430256e5-a139-4570-9f17-7a97615b6ff2": {"__data__": {"id_": "430256e5-a139-4570-9f17-7a97615b6ff2", "embedding": null, "metadata": {"window": "As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.  ", "original_text": "The low end of this new range would be a modest amount of repo.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a8a0f9-df24-4d1f-b064-b06846f538e1", "node_type": "1", "metadata": {"window": "It is slightly at \nthe high end, to your point.   As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "original_text": "But the high end of that share count would imply no repo.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc7d71ea7cded00bd7144a79c61777778a6f178cfdfa43ba33014657e10c1d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a6eff8-5261-4d1c-a682-41313d7a8ec0", "node_type": "1", "metadata": {"window": "We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "original_text": "So that's what's baked within that \nassumption.  \n \n "}, "hash": "c82fe3739107a1c09697136cf0fdf1dcf2a0a9d519d73b268958d0366c1bf149", "class_name": "RelatedNodeInfo"}}, "text": "The low end of this new range would be a modest amount of repo.  ", "start_char_idx": 1549, "end_char_idx": 1614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a6eff8-5261-4d1c-a682-41313d7a8ec0": {"__data__": {"id_": "29a6eff8-5261-4d1c-a682-41313d7a8ec0", "embedding": null, "metadata": {"window": "We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "original_text": "So that's what's baked within that \nassumption.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430256e5-a139-4570-9f17-7a97615b6ff2", "node_type": "1", "metadata": {"window": "As you can see, in the first quarter, we didn't do any share repo.   We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.  ", "original_text": "The low end of this new range would be a modest amount of repo.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec848f3883e91215fe4bb2ae6f4143b57aef86e9719b8d0dc16687684da6f082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a", "node_type": "1", "metadata": {"window": "But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "original_text": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  "}, "hash": "2f7e6c5b25962afc55ab3420f937cdb2e13732c1bd4e8a32df218c1e8b42cc19", "class_name": "RelatedNodeInfo"}}, "text": "So that's what's baked within that \nassumption.  \n \n ", "start_char_idx": 1614, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a": {"__data__": {"id_": "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a", "embedding": null, "metadata": {"window": "But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "original_text": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a6eff8-5261-4d1c-a682-41313d7a8ec0", "node_type": "1", "metadata": {"window": "We \ndidn't do any in the second quarter as well.   But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "original_text": "So that's what's baked within that \nassumption.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b82d51a35c0f73b4b50cce5f5c3870bd4ebd6e4bc4452f4618104e1acb03949", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90", "node_type": "1", "metadata": {"window": "The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "original_text": "Of course, \nwe work within those priorities.  "}, "hash": "9f0ed551fcbbc9581dc59d53cf80ed52299de20d64a52a5ab5e978f2a9ad1f45", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "start_char_idx": 1667, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90": {"__data__": {"id_": "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90", "embedding": null, "metadata": {"window": "The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "original_text": "Of course, \nwe work within those priorities.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a", "node_type": "1", "metadata": {"window": "But the high end of that share count would imply no repo.  \n The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "original_text": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d55db1f9d9709bc41d0aa1b45b626ce9dbf2a21cc934551fa679ed60a751c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f87d9b6b-a7e4-438b-ae94-8473f12883c6", "node_type": "1", "metadata": {"window": "So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "original_text": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n"}, "hash": "4dd5348e3be53679cb5dc818e4c17abfcbb34bfaca3074b300da86fe6c31e319", "class_name": "RelatedNodeInfo"}}, "text": "Of course, \nwe work within those priorities.  ", "start_char_idx": 1756, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f87d9b6b-a7e4-438b-ae94-8473f12883c6": {"__data__": {"id_": "f87d9b6b-a7e4-438b-ae94-8473f12883c6", "embedding": null, "metadata": {"window": "So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "original_text": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90", "node_type": "1", "metadata": {"window": "The low end of this new range would be a modest amount of repo.   So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "original_text": "Of course, \nwe work within those priorities.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fd405d39be57edbc4e696ea52ca63c1b49a9e172bdffa358c44536b9f3b1424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5b6caeb-ee9a-42c2-ada3-967333509e14", "node_type": "1", "metadata": {"window": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "original_text": "And you saw that this quarter with the Medical global manufacturing and supply chain work.  "}, "hash": "ad3d341321f38d165baec0896b9ff81a2a206a4100f72ac2c8d9c5c1ae3710ce", "class_name": "RelatedNodeInfo"}}, "text": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "start_char_idx": 1802, "end_char_idx": 1978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5b6caeb-ee9a-42c2-ada3-967333509e14": {"__data__": {"id_": "e5b6caeb-ee9a-42c2-ada3-967333509e14", "embedding": null, "metadata": {"window": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "original_text": "And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f87d9b6b-a7e4-438b-ae94-8473f12883c6", "node_type": "1", "metadata": {"window": "So that's what's baked within that \nassumption.  \n \n  As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "original_text": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae060d4215cc21803e6f346f194edaf11328546df9237b33c11b733486bab7ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "681058e1-63f8-4bb3-946b-65cb06b59392", "node_type": "1", "metadata": {"window": "Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.  ", "original_text": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n "}, "hash": "ecdc5b53920c072fed26e493cc4cadf47968cbb3c1f4f5bf490a3ad9668a2cac", "class_name": "RelatedNodeInfo"}}, "text": "And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "start_char_idx": 1978, "end_char_idx": 2070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "681058e1-63f8-4bb3-946b-65cb06b59392": {"__data__": {"id_": "681058e1-63f8-4bb3-946b-65cb06b59392", "embedding": null, "metadata": {"window": "Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.  ", "original_text": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5b6caeb-ee9a-42c2-ada3-967333509e14", "node_type": "1", "metadata": {"window": "As it relates to the capital deployment, certainly, we haven't changed ou r priorities.   Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "original_text": "And you saw that this quarter with the Medical global manufacturing and supply chain work.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84fd0cb96214ea29ace36a599f336914d2131903bf0d5059818bcefe083d6849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb46e28-e8b5-49c5-a994-117427e95dfd", "node_type": "1", "metadata": {"window": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "original_text": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  "}, "hash": "f30668b635261446e7d40d5728285b24419acb156092c67e2b58e8063199ee02", "class_name": "RelatedNodeInfo"}}, "text": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "start_char_idx": 2070, "end_char_idx": 2166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb46e28-e8b5-49c5-a994-117427e95dfd": {"__data__": {"id_": "1cb46e28-e8b5-49c5-a994-117427e95dfd", "embedding": null, "metadata": {"window": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "original_text": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "681058e1-63f8-4bb3-946b-65cb06b59392", "node_type": "1", "metadata": {"window": "Of course, \nwe work within those priorities.   And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.  ", "original_text": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "874df9b2460289d015f1c036a45d66e33ae6e1c07d98b776e04a2add9613e1cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca772f96-9383-4668-a97e-ab1b043de843", "node_type": "1", "metadata": {"window": "And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.  ", "original_text": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  "}, "hash": "97831d2433d6102667b75b6816003aa97a8d43177c6f813492d022561775712b", "class_name": "RelatedNodeInfo"}}, "text": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "start_char_idx": 2166, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca772f96-9383-4668-a97e-ab1b043de843": {"__data__": {"id_": "ca772f96-9383-4668-a97e-ab1b043de843", "embedding": null, "metadata": {"window": "And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.  ", "original_text": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb46e28-e8b5-49c5-a994-117427e95dfd", "node_type": "1", "metadata": {"window": "And just to reinforce that, we continue to invest in our business, first \nand foremost, as we are really confident with that strong pipeline of organic growth opportunities.  \n And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "original_text": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7bbd025725e09aa7dad97b55d4b17c2e46e0b7dd4f654ee5abc589a46165e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51e785c9-4590-4bac-9966-7a7706034a7d", "node_type": "1", "metadata": {"window": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "original_text": "And we think that's \nconsistent with that priority.  "}, "hash": "3885b3069811692254fb09e7d5fbb08263afffda4f772decdb13f482faeda9e0", "class_name": "RelatedNodeInfo"}}, "text": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "start_char_idx": 2324, "end_char_idx": 2446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e785c9-4590-4bac-9966-7a7706034a7d": {"__data__": {"id_": "51e785c9-4590-4bac-9966-7a7706034a7d", "embedding": null, "metadata": {"window": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "original_text": "And we think that's \nconsistent with that priority.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca772f96-9383-4668-a97e-ab1b043de843", "node_type": "1", "metadata": {"window": "And you saw that this quarter with the Medical global manufacturing and supply chain work.   We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.  ", "original_text": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73b72068de3710ef687d798ab087dc7b96941fbd09338306b01e5941b7e3daba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d", "node_type": "1", "metadata": {"window": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "original_text": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n "}, "hash": "5f1b990e01de3cbfba4abd0de4f994de554dabab17a683ca11e35ee31109ef2e", "class_name": "RelatedNodeInfo"}}, "text": "And we think that's \nconsistent with that priority.  ", "start_char_idx": 2446, "end_char_idx": 2499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d": {"__data__": {"id_": "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d", "embedding": null, "metadata": {"window": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "original_text": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51e785c9-4590-4bac-9966-7a7706034a7d", "node_type": "1", "metadata": {"window": "We're \nmaking some great progress there, and we want to continue to feed those activities.  \n \n  The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "original_text": "And we think that's \nconsistent with that priority.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5cc29f4d8c6bcdfd98c79146dc95f57841e87e1471c02d4c66c65338fd83323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530", "node_type": "1", "metadata": {"window": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "original_text": "After that, it is repo and other bolt -on strategic M&A.  "}, "hash": "45e3271dd80e5845b67bdabc6392c6264bf17f0466c89e7fe139aba610c82b71", "class_name": "RelatedNodeInfo"}}, "text": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "start_char_idx": 2499, "end_char_idx": 2615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530": {"__data__": {"id_": "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530", "embedding": null, "metadata": {"window": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "original_text": "After that, it is repo and other bolt -on strategic M&A.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d", "node_type": "1", "metadata": {"window": "The other point that I referenced in my commentary is consistent with the second priority, \nwhich is to maintain our strong investment -grade balance sheet.   So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "original_text": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de78d57ac9a2d9c42702bf7043c8ba034ac5c463b6960005625778a91207e4a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d724f73-612b-4981-beba-a16f626e574d", "node_type": "1", "metadata": {"window": "And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n", "original_text": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  "}, "hash": "61e09c84106f6b3224c9a50f328466a88f791e6381c281a7f6558fae7aeb6d00", "class_name": "RelatedNodeInfo"}}, "text": "After that, it is repo and other bolt -on strategic M&A.  ", "start_char_idx": 2615, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d724f73-612b-4981-beba-a16f626e574d": {"__data__": {"id_": "3d724f73-612b-4981-beba-a16f626e574d", "embedding": null, "metadata": {"window": "And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n", "original_text": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530", "node_type": "1", "metadata": {"window": "So I did highlight that we intend to \nreduce our debt by about $1.4 billion as it comes due at the end of our fiscal 22.   And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "original_text": "After that, it is repo and other bolt -on strategic M&A.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e606d9de8a4a4a5914a1c7cae1dd8da2bc7b8ef10851b23cb15feb0a927678e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2537069-940b-43a0-848f-b07ab4309033", "node_type": "1", "metadata": {"window": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.  ", "original_text": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  "}, "hash": "8c72033468b1200437b64cfb0cdfd23dbe61133ef8399102a8b4a6ca9454fc09", "class_name": "RelatedNodeInfo"}}, "text": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "start_char_idx": 2673, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2537069-940b-43a0-848f-b07ab4309033": {"__data__": {"id_": "a2537069-940b-43a0-848f-b07ab4309033", "embedding": null, "metadata": {"window": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.  ", "original_text": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d724f73-612b-4981-beba-a16f626e574d", "node_type": "1", "metadata": {"window": "And we think that's \nconsistent with that priority.   And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n", "original_text": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cae9f7e8444a5a59fa43453b94943b08bbe00adfb68cef7392d47a46f3fa245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fc98085-ec85-4375-be24-0a7fd7086067", "node_type": "1", "metadata": {"window": "After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n", "original_text": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  "}, "hash": "450c26521272666de3cc2f785df217807d9856f4fc9c39929c5db93b03bd877b", "class_name": "RelatedNodeInfo"}}, "text": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "start_char_idx": 2842, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fc98085-ec85-4375-be24-0a7fd7086067": {"__data__": {"id_": "9fc98085-ec85-4375-be24-0a7fd7086067", "embedding": null, "metadata": {"window": "After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n", "original_text": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2537069-940b-43a0-848f-b07ab4309033", "node_type": "1", "metadata": {"window": "And then, of course, we return the cash to shareholders primarily through \nthe dividend as our third priority.  \n \n  After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.  ", "original_text": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77670a8319b43da25cf9cc6495b1558d93036604077f86a6cfcc8966c7664fbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455", "node_type": "1", "metadata": {"window": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "But we continue to balance all those each and \nevery day.  \n \n"}, "hash": "06976917c41d0a591100c3c4a6c4b0782cc66b27572c58566c83bd4470b2b662", "class_name": "RelatedNodeInfo"}}, "text": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "start_char_idx": 2958, "end_char_idx": 3055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455": {"__data__": {"id_": "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455", "embedding": null, "metadata": {"window": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "But we continue to balance all those each and \nevery day.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fc98085-ec85-4375-be24-0a7fd7086067", "node_type": "1", "metadata": {"window": "After that, it is repo and other bolt -on strategic M&A.   But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n", "original_text": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efd74d4f1692897fbdd08c3231668706b031c040946caf01644e655d985e2a56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5ccafa7-8092-4a3c-9e0e-9667b919818d", "node_type": "1", "metadata": {"window": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "Operator:  Thank you.  "}, "hash": "6b2e5a00d9d0a60e30ac7a47b9f9a79fd7f072b1187d06e5fb8c1a2b9c3be8db", "class_name": "RelatedNodeInfo"}}, "text": "But we continue to balance all those each and \nevery day.  \n \n", "start_char_idx": 3055, "end_char_idx": 3117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5ccafa7-8092-4a3c-9e0e-9667b919818d": {"__data__": {"id_": "a5ccafa7-8092-4a3c-9e0e-9667b919818d", "embedding": null, "metadata": {"window": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "Operator:  Thank you.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455", "node_type": "1", "metadata": {"window": "But we'll continue to look at that \nopportunistically as we get more confidence on variables such as opioids is certainly one of the \nelements we look at all the time.   And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "But we continue to balance all those each and \nevery day.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa2a94bcad915793aa2f600f095d0bd687578404c72603d892e1f35c9d10ee19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a59edbc-163a-496f-a952-cf50693d10c3", "node_type": "1", "metadata": {"window": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "We'll take our next question from George Hill with Deutsche Bank.  \n \n"}, "hash": "d87a5242cd48d02d1944d128801177429de8f1bceb449f287ade873af4182eca", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 3117, "end_char_idx": 3140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a59edbc-163a-496f-a952-cf50693d10c3": {"__data__": {"id_": "7a59edbc-163a-496f-a952-cf50693d10c3", "embedding": null, "metadata": {"window": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "We'll take our next question from George Hill with Deutsche Bank.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5ccafa7-8092-4a3c-9e0e-9667b919818d", "node_type": "1", "metadata": {"window": "And as our confidence increases and we make more progress, \nunderstanding it, what the framing of that looks like.   Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "Operator:  Thank you.  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f36f5ca68d3d4b22624eb7fc26983f8135a7d38a79231d95a206b6f5e002b62b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4dc3cef-6bda-4af2-9438-df6cfc763d6d", "node_type": "1", "metadata": {"window": "But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  "}, "hash": "bc4b5b4a078916d899983d9c8c09eab86d47bcb15a5d4d82f3af78e08a1b70f6", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from George Hill with Deutsche Bank.  \n \n", "start_char_idx": 3140, "end_char_idx": 3210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4dc3cef-6bda-4af2-9438-df6cfc763d6d": {"__data__": {"id_": "e4dc3cef-6bda-4af2-9438-df6cfc763d6d", "embedding": null, "metadata": {"window": "But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6ed88ecae921afe4394ea5c5cdd1582403cc16b7be9fb4f640f3d1fabc02f34", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a59edbc-163a-496f-a952-cf50693d10c3", "node_type": "1", "metadata": {"window": "Then we'll continue to evaluate if we can be \nmore aggressive on any of those other components.   But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "We'll take our next question from George Hill with Deutsche Bank.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9467b6b1c0842b2da922ab31ab32a8ff56feb339a765ee13765d1469f6ced3ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba54a53a-eec6-499e-a23f-392ddb84db11", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.  ", "original_text": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.  "}, "hash": "863d70b58a3ba63125bc90099594a3fccb43397613413e7969c5ba71cb527810", "class_name": "RelatedNodeInfo"}}, "text": "George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "start_char_idx": 3210, "end_char_idx": 3426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba54a53a-eec6-499e-a23f-392ddb84db11": {"__data__": {"id_": "ba54a53a-eec6-499e-a23f-392ddb84db11", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.  ", "original_text": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4dc3cef-6bda-4af2-9438-df6cfc763d6d", "node_type": "1", "metadata": {"window": "But we continue to balance all those each and \nevery day.  \n \n Operator:  Thank you.   We'll take our next question from George Hill with Deutsche Bank.  \n \n George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "original_text": "George Hill: I kind of wanted to go back to Eric's topic a little bit on PPE pricin g. I was wondering if \nyou guys would be willing to kind of call out the positive impact of pricing in the first half of the year?  ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df16226f7340bc6e65253a077a1aa7fac9e647250df7a5765d5edec015d3773e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666f21a7-2dc6-4fbc-aba1-2a17af784435", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.  ", "original_text": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n"}, "hash": "84340dd52cfd49aa9f6d7665d6b9659dcaa2bc0adbf37c0989676c4c1e3083f4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.  ", "start_char_idx": 0, "end_char_idx": 112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666f21a7-2dc6-4fbc-aba1-2a17af784435": {"__data__": {"id_": "666f21a7-2dc6-4fbc-aba1-2a17af784435", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.  ", "original_text": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba54a53a-eec6-499e-a23f-392ddb84db11", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.  ", "original_text": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6f6910fc6d54cb6862af8eda16691f2cf2c88757ba377d9c855bf9332025011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "99823ad1a79e3357c246bdc11ed4b6b1d46900e865706574d7120463f124e391", "class_name": "RelatedNodeInfo"}}, "text": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n", "start_char_idx": 112, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e": {"__data__": {"id_": "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666f21a7-2dc6-4fbc-aba1-2a17af784435", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.  ", "original_text": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9073f26ef256aa53e53bc72cb656de835ae6a8e3cfb689f4321ad6142daac7a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f82180-d4bd-42ce-8daa-bfb51b93189f", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n ", "original_text": "So let me start, at least with the first part.  "}, "hash": "eb38ac2a81eface83ff9489204b6bc91ab2078e43bd3317986998b1f7c9cec0e", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 242, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f82180-d4bd-42ce-8daa-bfb51b93189f": {"__data__": {"id_": "62f82180-d4bd-42ce-8daa-bfb51b93189f", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n ", "original_text": "So let me start, at least with the first part.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7ef771e472d4d6552dd35087c43f567406cb610d0439253857e151f9c92db9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a064290d-f47e-4a38-932f-9987b00dcaec", "node_type": "1", "metadata": {"window": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "original_text": "We're not going to break out explicitly \nthe pricing separately.  "}, "hash": "428d32b3316d648bcf71728591fc2cef59feb8de9922d51fd0910288000e2efe", "class_name": "RelatedNodeInfo"}}, "text": "So let me start, at least with the first part.  ", "start_char_idx": 263, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a064290d-f47e-4a38-932f-9987b00dcaec": {"__data__": {"id_": "a064290d-f47e-4a38-932f-9987b00dcaec", "embedding": null, "metadata": {"window": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "original_text": "We're not going to break out explicitly \nthe pricing separately.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f82180-d4bd-42ce-8daa-bfb51b93189f", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n ", "original_text": "So let me start, at least with the first part.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf2233eeecbe01930782defbe8d1ff6bc23c265a6f5a92fc9289a29eef958528", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdd175dd-4391-4024-bfc2-84fc6498b356", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "original_text": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  "}, "hash": "49e095fef34b2744f069a61719b00c279078b01e034ba2243f99b56f721a685a", "class_name": "RelatedNodeInfo"}}, "text": "We're not going to break out explicitly \nthe pricing separately.  ", "start_char_idx": 311, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdd175dd-4391-4024-bfc2-84fc6498b356": {"__data__": {"id_": "bdd175dd-4391-4024-bfc2-84fc6498b356", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "original_text": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a064290d-f47e-4a38-932f-9987b00dcaec", "node_type": "1", "metadata": {"window": "Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "original_text": "We're not going to break out explicitly \nthe pricing separately.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26c1948f37c6b2e1f77a831c97f154aff627dda3c94c12532352e89e25f58111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaddef56-5007-4d25-8172-6cc173aa9e46", "node_type": "1", "metadata": {"window": "So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "original_text": "And so that's what we're balancing there.  \n \n "}, "hash": "ebfb40bfb8b8f18f5cf010312aa28d728504b7de5520f5593bdb29ad314a4a30", "class_name": "RelatedNodeInfo"}}, "text": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "start_char_idx": 377, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaddef56-5007-4d25-8172-6cc173aa9e46": {"__data__": {"id_": "eaddef56-5007-4d25-8172-6cc173aa9e46", "embedding": null, "metadata": {"window": "So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "original_text": "And so that's what we're balancing there.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdd175dd-4391-4024-bfc2-84fc6498b356", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "original_text": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ad393f6a36c60cbf77bf7fbbaa800e7fa3881ce24503dc161a7acdfc9551ad1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61f8ee6a-9aa1-4424-a3f3-1a093a73532f", "node_type": "1", "metadata": {"window": "We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n"}, "hash": "04c9a80f2f96bb6ad7beadd8a7ab4c0bf2ce41326449497c4b85b010faff7422", "class_name": "RelatedNodeInfo"}}, "text": "And so that's what we're balancing there.  \n \n ", "start_char_idx": 489, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61f8ee6a-9aa1-4424-a3f3-1a093a73532f": {"__data__": {"id_": "61f8ee6a-9aa1-4424-a3f3-1a093a73532f", "embedding": null, "metadata": {"window": "We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaddef56-5007-4d25-8172-6cc173aa9e46", "node_type": "1", "metadata": {"window": "So let me start, at least with the first part.   We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "original_text": "And so that's what we're balancing there.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "816ed31edd4d5bc36a84514785ed672b3b70d7dd61e58395e4839950d1e7ab9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46f368f2-6567-4762-aa50-b18707f5219b", "node_type": "1", "metadata": {"window": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "original_text": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. "}, "hash": "8d07a42acb5183b1a223b7d7766457f2749bee78506ee09961b3ac607dea40ef", "class_name": "RelatedNodeInfo"}}, "text": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "start_char_idx": 536, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f368f2-6567-4762-aa50-b18707f5219b": {"__data__": {"id_": "46f368f2-6567-4762-aa50-b18707f5219b", "embedding": null, "metadata": {"window": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "original_text": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61f8ee6a-9aa1-4424-a3f3-1a093a73532f", "node_type": "1", "metadata": {"window": "We're not going to break out explicitly \nthe pricing separately.   First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f70ce630b683f0088818a54f35d273ca36746da673a38cc29052d8abd1cc599", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7da9b68e-9992-485b-8f78-b09bc4de6448", "node_type": "1", "metadata": {"window": "And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "original_text": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n"}, "hash": "23739d9edc4ad6d33a3597a9215722c79badf87ef2fd454b9a0f2ed0d4484e4f", "class_name": "RelatedNodeInfo"}}, "text": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "start_char_idx": 734, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7da9b68e-9992-485b-8f78-b09bc4de6448": {"__data__": {"id_": "7da9b68e-9992-485b-8f78-b09bc4de6448", "embedding": null, "metadata": {"window": "And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "original_text": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f368f2-6567-4762-aa50-b18707f5219b", "node_type": "1", "metadata": {"window": "First of all, it's just really  important to highlight that the pricing is meant to \ncover that cost increase.   And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "original_text": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges. ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "776b21ae9f60919ac5a5814ac8a5db42f0412ffd65ebb4e4572ea79e0dd3a49c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cff6925c-2e5e-41bf-9b81-290e36d24fd3", "node_type": "1", "metadata": {"window": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "1fdb0ace25ce04c8367f19ff868fd4d33e029dd9f60af42f3a00b880127890de", "class_name": "RelatedNodeInfo"}}, "text": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "start_char_idx": 935, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cff6925c-2e5e-41bf-9b81-290e36d24fd3": {"__data__": {"id_": "cff6925c-2e5e-41bf-9b81-290e36d24fd3", "embedding": null, "metadata": {"window": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7da9b68e-9992-485b-8f78-b09bc4de6448", "node_type": "1", "metadata": {"window": "And so that's what we're balancing there.  \n \n  We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "original_text": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebb56c83c14c6d871c827e0b657caa39d3e1341f6e96722852ed23e8f4557e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "480e2e63-0ecb-4af8-bdb8-f31d9e7283de", "node_type": "1", "metadata": {"window": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "original_text": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  "}, "hash": "6e642d45e4231822fe83cb9e71ab5b277ae7eba9ddefd4c281355e4989b9f6d7", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1086, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "480e2e63-0ecb-4af8-bdb8-f31d9e7283de": {"__data__": {"id_": "480e2e63-0ecb-4af8-bdb8-f31d9e7283de", "embedding": null, "metadata": {"window": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "original_text": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cff6925c-2e5e-41bf-9b81-290e36d24fd3", "node_type": "1", "metadata": {"window": "We did, however, say, in our last guidance update in Q1, that the vast majority of that revenue \nguidance increase for Medical was du e to pricing, which was due to that cost that was increasing.  \n With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70f1bafc9e3c429715b699bbf49f7efb51fce2dd42a2922837b95f623c0c5c24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "178a3e5d-0b17-46cc-8b08-95a1936b54e3", "node_type": "1", "metadata": {"window": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.  ", "original_text": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  "}, "hash": "150baf063a1725f74a59b2ca5c6040a16bba3eb8bfdb15930d2e6f8efa3ce428", "class_name": "RelatedNodeInfo"}}, "text": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "start_char_idx": 1108, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "178a3e5d-0b17-46cc-8b08-95a1936b54e3": {"__data__": {"id_": "178a3e5d-0b17-46cc-8b08-95a1936b54e3", "embedding": null, "metadata": {"window": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.  ", "original_text": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "480e2e63-0ecb-4af8-bdb8-f31d9e7283de", "node_type": "1", "metadata": {"window": "With this update, it's definitely more balanced, more weighted towards volume increases in the lab \nbusiness as well as volume increases in PPE and then to a lesser extent, any type of price cha nges.  I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "original_text": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54587c90b1ce53d98f4222955709b27eef4ecba6891c49e6d8d242ff5c8cc41b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a41c38bf-efcc-4113-9e73-3d63337ceb3e", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "original_text": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n"}, "hash": "50c85ee1f0b2992c395ab94c50b77e663c6c54123c84e880e28a03c3dcdfedcb", "class_name": "RelatedNodeInfo"}}, "text": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "start_char_idx": 1251, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a41c38bf-efcc-4113-9e73-3d63337ceb3e": {"__data__": {"id_": "a41c38bf-efcc-4113-9e73-3d63337ceb3e", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "original_text": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "178a3e5d-0b17-46cc-8b08-95a1936b54e3", "node_type": "1", "metadata": {"window": "I \nwould just go back to the last guidance increase, and it gives you a better understanding of what that \nPPE pricing dynamic is being driven by.  \n \n Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.  ", "original_text": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d1d8ffb2d78478b4e6b9ef83a3638873d942564d2ab201e43050119738867e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6128da6c-4227-47dd-bc17-0cb49dd915ba", "node_type": "1", "metadata": {"window": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here. ", "original_text": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n"}, "hash": "43cbd6ebff3e1af5325fbd85a7991d7686f7081e13b97ca184cf461ea6942f70", "class_name": "RelatedNodeInfo"}}, "text": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "start_char_idx": 1369, "end_char_idx": 1482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6128da6c-4227-47dd-bc17-0cb49dd915ba": {"__data__": {"id_": "6128da6c-4227-47dd-bc17-0cb49dd915ba", "embedding": null, "metadata": {"window": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here. ", "original_text": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a41c38bf-efcc-4113-9e73-3d63337ceb3e", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "original_text": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4aeec7ba3d98fd2add1385655a0cea30abfcd4f07dd26cfced155963d1c5ef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "131a347d-87fe-4960-bb0d-a63c9021cb86", "node_type": "1", "metadata": {"window": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.  ", "original_text": "Operator:  Thank you.  "}, "hash": "1ec8495f4d6bdc20e5afdc68bb12cbe3c23d0fdd660d537adae730de79070a02", "class_name": "RelatedNodeInfo"}}, "text": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "start_char_idx": 1482, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "131a347d-87fe-4960-bb0d-a63c9021cb86": {"__data__": {"id_": "131a347d-87fe-4960-bb0d-a63c9021cb86", "embedding": null, "metadata": {"window": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.  ", "original_text": "Operator:  Thank you.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6128da6c-4227-47dd-bc17-0cb49dd915ba", "node_type": "1", "metadata": {"window": "The only thing I would emphasize, just to make sure that it's clear, is th at as \nthe cost of the PPE comes down, our revenue will come down.   But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here. ", "original_text": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "344789fe692bbaf957c41895762dbb41f7be4d03d15f95714fe9c843a9f27019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d847bdf-2b40-41bd-9b43-829fc294ffbb", "node_type": "1", "metadata": {"window": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "original_text": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n"}, "hash": "7f86a109b4695d7cac47f39c34a501b79e2e92911e089b22f6c484461f40f55e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 1657, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d847bdf-2b40-41bd-9b43-829fc294ffbb": {"__data__": {"id_": "4d847bdf-2b40-41bd-9b43-829fc294ffbb", "embedding": null, "metadata": {"window": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "original_text": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "131a347d-87fe-4960-bb0d-a63c9021cb86", "node_type": "1", "metadata": {"window": "But again, our goal has always been \nto maintain margin dollars and work with our customers on an assurance program.   And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.  ", "original_text": "Operator:  Thank you.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4de5840e32b1532e249c5dfd68ac898d3b5a2db8b8075d206596c9ee46d3c809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a3f1674-f812-4b3b-abad-d614a6cb07f5", "node_type": "1", "metadata": {"window": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "original_text": "Ricky Goldwasser:  So two questions here. "}, "hash": "af125d8d6276b78d26be59fe970a06e9b6309911d77c4b9d3a112fe3cb3176fd", "class_name": "RelatedNodeInfo"}}, "text": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "start_char_idx": 1680, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a3f1674-f812-4b3b-abad-d614a6cb07f5": {"__data__": {"id_": "7a3f1674-f812-4b3b-abad-d614a6cb07f5", "embedding": null, "metadata": {"window": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "original_text": "Ricky Goldwasser:  So two questions here. ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d847bdf-2b40-41bd-9b43-829fc294ffbb", "node_type": "1", "metadata": {"window": "And so you \nshouldn't think about declining PPE costs necessarily being a headw ind for us other than revenue.  \n And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "original_text": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd3d22379e161a88f267e5e1da7f9087bb61f2cef62bb85640d715ad76e06cac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97614a4b-bcd1-47c6-b491-3180efb18d06", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "original_text": "One on the Pharma Distribution segment.  "}, "hash": "d89584f03f2df068119e22afd07b38c1aad1e79dae222b9ff71a5121c3365799", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  So two questions here. ", "start_char_idx": 1740, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97614a4b-bcd1-47c6-b491-3180efb18d06": {"__data__": {"id_": "97614a4b-bcd1-47c6-b491-3180efb18d06", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "original_text": "One on the Pharma Distribution segment.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a3f1674-f812-4b3b-abad-d614a6cb07f5", "node_type": "1", "metadata": {"window": "And as Jason said, but the timing of when you have the actual sale price and the cost as they flow \nthrough, that can create a little bit of lumpiness in the recognition.  \n \n Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "original_text": "Ricky Goldwasser:  So two questions here. ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c2d20d5a45291ca1c9595f4dc3d3b4dcfaca644d14e91bf80fdedf0fb10e69e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "755a1a7b-e848-45b1-ba41-26d5b1f2d961", "node_type": "1", "metadata": {"window": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "original_text": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  "}, "hash": "87bc56b6699c0939cb05da346b968af6574a0e2051c7bdedddf9d052bf7ad7ff", "class_name": "RelatedNodeInfo"}}, "text": "One on the Pharma Distribution segment.  ", "start_char_idx": 1782, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "755a1a7b-e848-45b1-ba41-26d5b1f2d961": {"__data__": {"id_": "755a1a7b-e848-45b1-ba41-26d5b1f2d961", "embedding": null, "metadata": {"window": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "original_text": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97614a4b-bcd1-47c6-b491-3180efb18d06", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "original_text": "One on the Pharma Distribution segment.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541cfd95be373ec476c34914a9fa0c01cd0e6ff6510e7f42a7ec0c5b81ffdd68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6a8785c-9c80-432c-aff7-cc9c33c5e89e", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "original_text": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  "}, "hash": "c03172dd782edb420fe07da29e83d8fd5f88946ef1efebc0f76903b1506e142f", "class_name": "RelatedNodeInfo"}}, "text": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "start_char_idx": 1823, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6a8785c-9c80-432c-aff7-cc9c33c5e89e": {"__data__": {"id_": "e6a8785c-9c80-432c-aff7-cc9c33c5e89e", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "original_text": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "755a1a7b-e848-45b1-ba41-26d5b1f2d961", "node_type": "1", "metadata": {"window": "We'll go next to Ricky Goldwas ser with Morgan Stanley.  \n \n Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "original_text": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc3f7be24783a97207d77c69e30f1821309529639fb61713b17752cd5e19940a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91f25c31-cc07-4555-8649-d01bb9e43541", "node_type": "1", "metadata": {"window": "One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "original_text": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n "}, "hash": "4cb5990de40eb903e188d9676bd1ff89c2bbebc094900f5f0c1fc141a0831b0c", "class_name": "RelatedNodeInfo"}}, "text": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "start_char_idx": 1914, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91f25c31-cc07-4555-8649-d01bb9e43541": {"__data__": {"id_": "91f25c31-cc07-4555-8649-d01bb9e43541", "embedding": null, "metadata": {"window": "One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "original_text": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6a8785c-9c80-432c-aff7-cc9c33c5e89e", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  So two questions here.  One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "original_text": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1df43c7763a28a0ffdbf79437130ac02c1b77e5ec2778e4cb1516359b19b1b42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a78a1031-1173-4cdf-8f95-23c9b160d829", "node_type": "1", "metadata": {"window": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  "}, "hash": "2ae3d1c672961a2b8754e09ab61adcac086a2a3f37cbc073fdf58a414f1e2b47", "class_name": "RelatedNodeInfo"}}, "text": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "start_char_idx": 2004, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a78a1031-1173-4cdf-8f95-23c9b160d829": {"__data__": {"id_": "a78a1031-1173-4cdf-8f95-23c9b160d829", "embedding": null, "metadata": {"window": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91f25c31-cc07-4555-8649-d01bb9e43541", "node_type": "1", "metadata": {"window": "One on the Pharma Distribution segment.   When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "original_text": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa26ab0630126be0f1c9fbc598484de12b6f13e4d165df01993b4aa71a1cd3bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe", "node_type": "1", "metadata": {"window": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.  ", "original_text": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n"}, "hash": "a4f55193fe511bd3b881b0cefee1599af780cb8c94324a63eeefbd482e175dce", "class_name": "RelatedNodeInfo"}}, "text": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "start_char_idx": 2076, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe": {"__data__": {"id_": "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe", "embedding": null, "metadata": {"window": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.  ", "original_text": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a78a1031-1173-4cdf-8f95-23c9b160d829", "node_type": "1", "metadata": {"window": "When we look \nat the implied growth for second half, EBIT is growing faster than revenue.   Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "947c4f187ed0b7c27dc7af59db8c5c1c2c44a4ea20ef57cb790bf0c1f5de21f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad62c846-5cdc-406b-bfb6-7faf6387d93e", "node_type": "1", "metadata": {"window": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "original_text": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n"}, "hash": "c9e0745e370427158894c656e574453decfe1b9dfd1cdb042562b8208ba2ce18", "class_name": "RelatedNodeInfo"}}, "text": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "start_char_idx": 2230, "end_char_idx": 2381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad62c846-5cdc-406b-bfb6-7faf6387d93e": {"__data__": {"id_": "ad62c846-5cdc-406b-bfb6-7faf6387d93e", "embedding": null, "metadata": {"window": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "original_text": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe", "node_type": "1", "metadata": {"window": "Now clearly, there's some \neasy year -over-year comps versu s the same period last year.   But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.  ", "original_text": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1af28bd9393efbf20aaada18201687de50975aadb5c4e1877bdda1c60dfa3f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2492aecd-f9d3-447e-a904-836f3f5efb97", "node_type": "1", "metadata": {"window": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.  ", "original_text": "Mike Kaufmann:  Sure.  "}, "hash": "eb450596dac23dcd6e6b843c24c9bb315c7c759f694056988d3d12c76fecc1e0", "class_name": "RelatedNodeInfo"}}, "text": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "start_char_idx": 2381, "end_char_idx": 2481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2492aecd-f9d3-447e-a904-836f3f5efb97": {"__data__": {"id_": "2492aecd-f9d3-447e-a904-836f3f5efb97", "embedding": null, "metadata": {"window": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad62c846-5cdc-406b-bfb6-7faf6387d93e", "node_type": "1", "metadata": {"window": "But as we think -- and I know it's too \nearly to think about 2022.  \n \n  But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "original_text": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69e0e0a10ac94326ea33cad2aca71a8a5624bea77a1c8a77bcc52d442b39f193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beaa8262-c155-42fb-9d66-45351f293e72", "node_type": "1", "metadata": {"window": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "original_text": "As far as -- I'll just cover the opioids quickly.  "}, "hash": "f8283e59c34ccbabe266fefa6b104f5006e4bfb6372f355faa4a4be924192511", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Sure.  ", "start_char_idx": 2481, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beaa8262-c155-42fb-9d66-45351f293e72": {"__data__": {"id_": "beaa8262-c155-42fb-9d66-45351f293e72", "embedding": null, "metadata": {"window": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "original_text": "As far as -- I'll just cover the opioids quickly.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2492aecd-f9d3-447e-a904-836f3f5efb97", "node_type": "1", "metadata": {"window": "But really, if we think about the different drivers, that expectation that generic volumes are \ngoing to come back, and Nuclear, which is higher margin.   Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fd01d015b8925285592ea97d93eed0041a5204d4fbff3e7cc88f850e225c04f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f84127c-147b-4aa0-a89a-c5e823a2326e", "node_type": "1", "metadata": {"window": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.  ", "original_text": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n "}, "hash": "012e63a4d7fefcfd798364d4eeedf96000bff9a01d20e6fa2b76d1b6800ebd39", "class_name": "RelatedNodeInfo"}}, "text": "As far as -- I'll just cover the opioids quickly.  ", "start_char_idx": 2504, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f84127c-147b-4aa0-a89a-c5e823a2326e": {"__data__": {"id_": "4f84127c-147b-4aa0-a89a-c5e823a2326e", "embedding": null, "metadata": {"window": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.  ", "original_text": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beaa8262-c155-42fb-9d66-45351f293e72", "node_type": "1", "metadata": {"window": "Is it  sustainable for us to think that we'll be \nable to model EBIT continuing to grow faster than revenues for the [Pharma ] distribution segment?  \n And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "original_text": "As far as -- I'll just cover the opioids quickly.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2301e5fcd11e1cea66ac199481cf72bcb8c6a55445d124cd7a3484e30b35ee3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b793907-f13b-477b-88bc-c79bc4a09328", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "original_text": "As far as on the Pharma guidance goes or though ts there.  "}, "hash": "9b6c1a39ae27a937c7fef66a6030811b27e4c5a4b3065cae056650fedb39fd24", "class_name": "RelatedNodeInfo"}}, "text": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "start_char_idx": 2555, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b793907-f13b-477b-88bc-c79bc4a09328": {"__data__": {"id_": "5b793907-f13b-477b-88bc-c79bc4a09328", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "original_text": "As far as on the Pharma guidance goes or though ts there.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f84127c-147b-4aa0-a89a-c5e823a2326e", "node_type": "1", "metadata": {"window": "And my other question was just if you can give us a quick update on opioids and where we stand?  \n \n Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.  ", "original_text": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f72b0d424b31b143fc0647cf1d424d3f682e6884d9669d0698fc5db304fa2246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f016554-57bd-404c-abbe-131a6d053cc1", "node_type": "1", "metadata": {"window": "As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.  ", "original_text": "We -- obviously, we can't talk about \nit at this time, fiscal 22.  "}, "hash": "ef77d50ea3131afa10dbb6ef61daa25e3deb6fc99739d9d7b89a5a57e2ebea43", "class_name": "RelatedNodeInfo"}}, "text": "As far as on the Pharma guidance goes or though ts there.  ", "start_char_idx": 2711, "end_char_idx": 2770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f016554-57bd-404c-abbe-131a6d053cc1": {"__data__": {"id_": "8f016554-57bd-404c-abbe-131a6d053cc1", "embedding": null, "metadata": {"window": "As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.  ", "original_text": "We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b793907-f13b-477b-88bc-c79bc4a09328", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "original_text": "As far as on the Pharma guidance goes or though ts there.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "489b5054c895faff0a42503c2a5661eea42316a879d193d1d260a815670f2b08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca184415-b10d-4660-be4a-f5cd66172646", "node_type": "1", "metadata": {"window": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "But you're right on those components.  "}, "hash": "8db012f5c77f7b643f0bbe8413279dd0463f499b381331381f721afa4e351c6d", "class_name": "RelatedNodeInfo"}}, "text": "We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "start_char_idx": 2770, "end_char_idx": 2837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca184415-b10d-4660-be4a-f5cd66172646": {"__data__": {"id_": "ca184415-b10d-4660-be4a-f5cd66172646", "embedding": null, "metadata": {"window": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "But you're right on those components.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f016554-57bd-404c-abbe-131a6d053cc1", "node_type": "1", "metadata": {"window": "As far as -- I'll just cover the opioids quickly.   As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.  ", "original_text": "We -- obviously, we can't talk about \nit at this time, fiscal 22.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1988181ebd1f55c5b3593ca0bc32385e3f27901994acd9e4dcab8ec202ba053c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77b827a6-cf68-4bec-b49c-f7dba7447068", "node_type": "1", "metadata": {"window": "As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  "}, "hash": "6423025ef0370210e69b64852092de9f10b09308adacae72fd1eee61c34f5645", "class_name": "RelatedNodeInfo"}}, "text": "But you're right on those components.  ", "start_char_idx": 2837, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77b827a6-cf68-4bec-b49c-f7dba7447068": {"__data__": {"id_": "77b827a6-cf68-4bec-b49c-f7dba7447068", "embedding": null, "metadata": {"window": "As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca184415-b10d-4660-be4a-f5cd66172646", "node_type": "1", "metadata": {"window": "As I've said in the past, it \ncontinues to be, as you know, complex negotiations, a lot of moving parts, but we're continuing to \nmake progress there.  \n \n  As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "But you're right on those components.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "811b36366462602ae0c82116b4b70ceccf1ad2f97e130c09a4e875b666a42a89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4517ada-2091-4e40-90c0-f2499f64b50a", "node_type": "1", "metadata": {"window": "We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "And we have a lot of confidence in that business.  "}, "hash": "2faee338958f9e0662a54884beae0229c3782b698a1d2dda4edab15e11c5fca6", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "start_char_idx": 2876, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4517ada-2091-4e40-90c0-f2499f64b50a": {"__data__": {"id_": "a4517ada-2091-4e40-90c0-f2499f64b50a", "embedding": null, "metadata": {"window": "We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "And we have a lot of confidence in that business.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77b827a6-cf68-4bec-b49c-f7dba7447068", "node_type": "1", "metadata": {"window": "As far as on the Pharma guidance goes or though ts there.   We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31c9ad2aef81e32320b88ca50ff48030ba96d91e5bcbbb23f6806d2e29e7c2de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668", "node_type": "1", "metadata": {"window": "But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  "}, "hash": "e29f34a0cad0df50201c1ffd316c0285ca1f6159c16234d81369e3919011450d", "class_name": "RelatedNodeInfo"}}, "text": "And we have a lot of confidence in that business.  ", "start_char_idx": 3037, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668": {"__data__": {"id_": "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668", "embedding": null, "metadata": {"window": "But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32fdabc7-6624-46ed-8dba-39e6300a793c", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdc4ca03f3bcdb5136b6c38f0601a1f83d207415b355687a4629fba68ffacad8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4517ada-2091-4e40-90c0-f2499f64b50a", "node_type": "1", "metadata": {"window": "We -- obviously, we can't talk about \nit at this time, fiscal 22.   But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "And we have a lot of confidence in that business.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "687e2793701e0e02ff6a1a0fb4f22b87e15df022487617b6e03224c35dcdac47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "612d97bf-75a9-4cec-9b5f-454b2ae5102b", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.  "}, "hash": "af171f61362fd7dc934fd855253141910049888a6fa4aeea61089b78e80b7a91", "class_name": "RelatedNodeInfo"}}, "text": "As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "start_char_idx": 3088, "end_char_idx": 3342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "612d97bf-75a9-4cec-9b5f-454b2ae5102b": {"__data__": {"id_": "612d97bf-75a9-4cec-9b5f-454b2ae5102b", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668", "node_type": "1", "metadata": {"window": "But you're right on those components.   First of all, we would expect, if we exit \nat or near pre -COVID levels, that our Nuclear business would continue to improve sequentially as  it \ngoes forward.   And we have a lot of confidence in that business.   As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "original_text": "As you know, I highlighted it in my \ncomments, around not only how they're performing well in the current situation, but also the \ninvestments we've made to be able to see growth in that b usiness over the mid and long term in the \ntheranostic s space.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d30ee0bfb4f1e2b2bdcb8000769fd43a0f0d3b70eec2b46241f34fdb8619d7fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "944cf015-7afe-4e31-8e65-6ce68cdadb05", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "original_text": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.  "}, "hash": "e0ce79e55a0aabd031132af3257efb57b8f98f61f6db66519d617b294c714b66", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.  ", "start_char_idx": 0, "end_char_idx": 156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "944cf015-7afe-4e31-8e65-6ce68cdadb05": {"__data__": {"id_": "944cf015-7afe-4e31-8e65-6ce68cdadb05", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "original_text": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "612d97bf-75a9-4cec-9b5f-454b2ae5102b", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "586398dae7032cb1dfa0de706881fa8c72cdeea166310cc747957966038f9e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a464662-7c18-4007-b0a4-51a3390446d0", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "original_text": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n"}, "hash": "8720670a6886aec5ca2acd99def9a0af20425f28bdd6760d6977c1e2197d294f", "class_name": "RelatedNodeInfo"}}, "text": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.  ", "start_char_idx": 156, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a464662-7c18-4007-b0a4-51a3390446d0": {"__data__": {"id_": "6a464662-7c18-4007-b0a4-51a3390446d0", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "original_text": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "944cf015-7afe-4e31-8e65-6ce68cdadb05", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "original_text": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06e7c8a73529a01323370d17feea998354c0db87f5e3ed5e9fccf85f16497549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "8c572d38037b872e76914b7f903a917290b5a1be0fe96d2f8775c50f7e838d50", "class_name": "RelatedNodeInfo"}}, "text": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n", "start_char_idx": 372, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd": {"__data__": {"id_": "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a464662-7c18-4007-b0a4-51a3390446d0", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "original_text": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27f41e0a272598f5aa79029b90a8e0e1c2e5f9dee87f7812f3c1d83e8e0afc0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73277778-cfcf-4ffb-93c2-572503da11e8", "node_type": "1", "metadata": {"window": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n ", "original_text": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  "}, "hash": "a4ba2bb7156b30ed67c9a1ee0eccd835150c54e613a43e088367af7db845c242", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 503, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73277778-cfcf-4ffb-93c2-572503da11e8": {"__data__": {"id_": "73277778-cfcf-4ffb-93c2-572503da11e8", "embedding": null, "metadata": {"window": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n ", "original_text": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71b1c52045efc5c43442ef82eec80f651e85ff6203ea6996dd67a25f38471d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4aa8797-5214-44a1-864c-7ea819abcd79", "node_type": "1", "metadata": {"window": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "original_text": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  "}, "hash": "7a9b6ac02d9e2b97e26cbe472d5131662b8eafa90a21085d1903e90c94b17bcc", "class_name": "RelatedNodeInfo"}}, "text": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "start_char_idx": 524, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4aa8797-5214-44a1-864c-7ea819abcd79": {"__data__": {"id_": "f4aa8797-5214-44a1-864c-7ea819abcd79", "embedding": null, "metadata": {"window": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "original_text": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73277778-cfcf-4ffb-93c2-572503da11e8", "node_type": "1", "metadata": {"window": "And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n ", "original_text": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4c2689e52f70a7c194254171f06b4279a45c1c3a0deb7cf1a22ff2fa7b3093b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "original_text": "Nuclear is a high -margin business.  "}, "hash": "597fdb28c560761f23723497258577cbc73162df785f91538401d97ca52074d3", "class_name": "RelatedNodeInfo"}}, "text": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "start_char_idx": 648, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff": {"__data__": {"id_": "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "original_text": "Nuclear is a high -margin business.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4aa8797-5214-44a1-864c-7ea819abcd79", "node_type": "1", "metadata": {"window": "So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "original_text": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d498596158f413922dc8b99cbf2eb01c99b8cf7d3b0de4219ce40b58a6f9fb7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3c4cb82-c175-48ba-8578-ae97724b7526", "node_type": "1", "metadata": {"window": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "original_text": "It is \nalso a high fixed cost business.  \n \n "}, "hash": "f76325c76289a6110a26fd7a01456740da7d005e97ea6d3e31e4bdc76525cf69", "class_name": "RelatedNodeInfo"}}, "text": "Nuclear is a high -margin business.  ", "start_char_idx": 777, "end_char_idx": 814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3c4cb82-c175-48ba-8578-ae97724b7526": {"__data__": {"id_": "b3c4cb82-c175-48ba-8578-ae97724b7526", "embedding": null, "metadata": {"window": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "original_text": "It is \nalso a high fixed cost business.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "original_text": "Nuclear is a high -margin business.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe47f9e62835559394aeeb8c7798dbe63030690067e7bdfdf03d947de2e89c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01f559af-c498-49df-bb21-73491491933f", "node_type": "1", "metadata": {"window": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.  ", "original_text": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  "}, "hash": "556b83bfc147cd0ed81d5428236d4db54e8b35ee1ae1b6ced995fb72f157b0a2", "class_name": "RelatedNodeInfo"}}, "text": "It is \nalso a high fixed cost business.  \n \n ", "start_char_idx": 814, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01f559af-c498-49df-bb21-73491491933f": {"__data__": {"id_": "01f559af-c498-49df-bb21-73491491933f", "embedding": null, "metadata": {"window": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.  ", "original_text": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3c4cb82-c175-48ba-8578-ae97724b7526", "node_type": "1", "metadata": {"window": "The other thing I'll add is relative to the Nuclear comment, Ricky, as it relates to \nthe revenue and margin balance here.   I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "original_text": "It is \nalso a high fixed cost business.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4c7a9ffe8afaf28f4d4d6b79e33c46c1e7b58e5e21499209977159ea325e3b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ce9421c-4dff-40a5-8839-79e40ed409fe", "node_type": "1", "metadata": {"window": "Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n", "original_text": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n "}, "hash": "c6881f85d23da8d4cf6c4ac4eed5f048bafd2ee3d7e1be7a0e1cf0674cb53af2", "class_name": "RelatedNodeInfo"}}, "text": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "start_char_idx": 859, "end_char_idx": 972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ce9421c-4dff-40a5-8839-79e40ed409fe": {"__data__": {"id_": "8ce9421c-4dff-40a5-8839-79e40ed409fe", "embedding": null, "metadata": {"window": "Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n", "original_text": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01f559af-c498-49df-bb21-73491491933f", "node_type": "1", "metadata": {"window": "I think you're on the right point that, as we talked, especially in \nQ4 of last y ear, when the volumes were declining quickly.   Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.  ", "original_text": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72c4c5e01f5df1ecc2af28d9267d78576ce0dce3e1f75fefdf9bbc8b41e17cf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c9b484-13f2-483a-aeae-8c6663e7744f", "node_type": "1", "metadata": {"window": "It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "original_text": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n"}, "hash": "8e32f8f6afe20864656b68f01661722ff152d835a3c78b8c710bcd85fccef618", "class_name": "RelatedNodeInfo"}}, "text": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "start_char_idx": 972, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c9b484-13f2-483a-aeae-8c6663e7744f": {"__data__": {"id_": "67c9b484-13f2-483a-aeae-8c6663e7744f", "embedding": null, "metadata": {"window": "It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "original_text": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ce9421c-4dff-40a5-8839-79e40ed409fe", "node_type": "1", "metadata": {"window": "Nuclear is a high -margin business.   It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n", "original_text": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "129c28653e6dc0b2e765898d0515e20efadd54df6567e95da1a775d4b3982245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1904f48a-436f-45eb-9529-c875b7462db0", "node_type": "1", "metadata": {"window": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "original_text": "Operator:  Thank you.  "}, "hash": "8ed78296407d508c53840b53fc76a884ee47849f10bba8eee55d23a18e135e02", "class_name": "RelatedNodeInfo"}}, "text": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "start_char_idx": 1111, "end_char_idx": 1376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1904f48a-436f-45eb-9529-c875b7462db0": {"__data__": {"id_": "1904f48a-436f-45eb-9529-c875b7462db0", "embedding": null, "metadata": {"window": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "original_text": "Operator:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c9b484-13f2-483a-aeae-8c6663e7744f", "node_type": "1", "metadata": {"window": "It is \nalso a high fixed cost business.  \n \n  So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "original_text": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a385bb6407695ed1ffa9af25fde1b6460601d5e417abf412a3b8ccc87f16539", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da", "node_type": "1", "metadata": {"window": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "original_text": "We'll take our next question from Charles Rhyee with Cowen.  \n \n"}, "hash": "298853084b2e2f3a62716c4d433b86da28fd9fff6da14188be3bff8874eadda3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 1376, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da": {"__data__": {"id_": "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da", "embedding": null, "metadata": {"window": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "original_text": "We'll take our next question from Charles Rhyee with Cowen.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1904f48a-436f-45eb-9529-c875b7462db0", "node_type": "1", "metadata": {"window": "So it creates a very high contribution margins that we saw certainly create a headwind in that \nfourth quarter.   And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "original_text": "Operator:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae386a2bd68371ff5a08779dd725f1084f340e819be195afb04aa23016182672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1", "node_type": "1", "metadata": {"window": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n", "original_text": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  "}, "hash": "024f13b0626c174f00b7b415ed7ac8648748852b95dbbfc398606aabdde2fa1d", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Charles Rhyee with Cowen.  \n \n", "start_char_idx": 1399, "end_char_idx": 1463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1": {"__data__": {"id_": "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1", "embedding": null, "metadata": {"window": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n", "original_text": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da", "node_type": "1", "metadata": {"window": "And so as we anniver sary that in this fourth quarter, especially if our guidance is \naccurate with the at or near pre -COVID levels.  \n \n  By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "original_text": "We'll take our next question from Charles Rhyee with Cowen.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e0bade5e005526b215360c9ef132218b2ff66e1472c11a154f1e9b50600cc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  "}, "hash": "673d274e397a126d45b257649ed4646160975486cf94f4014bb7e728ea362ff7", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "start_char_idx": 1463, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c": {"__data__": {"id_": "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1", "node_type": "1", "metadata": {"window": "By the time we exit the fiscal year, then you would expect there to be -- for that piece of it, an \nimprovement in earnings relative to revenue as one of the key components that probably needs to be \nplugged into your model to make that whole thing make sense.  \n \n Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n", "original_text": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9755c956d9b6c729cc4864bf24832eea4fa70bd7e0e617857467a6ab09220c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4549a4f-861d-4de8-a316-0a9a8fe5449b", "node_type": "1", "metadata": {"window": "We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.  ", "original_text": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  "}, "hash": "ba165de3116aa2a896f6148ed7fc77d2bb4e531075ed9646e9e196804357bbe7", "class_name": "RelatedNodeInfo"}}, "text": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "start_char_idx": 1584, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4549a4f-861d-4de8-a316-0a9a8fe5449b": {"__data__": {"id_": "c4549a4f-861d-4de8-a316-0a9a8fe5449b", "embedding": null, "metadata": {"window": "We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.  ", "original_text": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b6865e26c7c5cb75c5b2633fe69767b151a151b8aa7e1bd38798d96f23abfee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3508fe72-9527-4348-b20d-7d4e7b4abf90", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.  ", "original_text": "And then -- yes, that's basically it.  \n \n"}, "hash": "5963174818dc726ae821f46ed6c5c353161da9c384a07c70c054b0b9581d9c50", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "start_char_idx": 1695, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3508fe72-9527-4348-b20d-7d4e7b4abf90": {"__data__": {"id_": "3508fe72-9527-4348-b20d-7d4e7b4abf90", "embedding": null, "metadata": {"window": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.  ", "original_text": "And then -- yes, that's basically it.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4549a4f-861d-4de8-a316-0a9a8fe5449b", "node_type": "1", "metadata": {"window": "We'll take our next question from Charles Rhyee with Cowen.  \n \n Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.  ", "original_text": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e037a85ec90a309629778016be1c5f28391fafa708b70211fec2c173a35208e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c189852-af7f-46d2-8a13-59f605c869bd", "node_type": "1", "metadata": {"window": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "962e427dd3bcd706fd6ecb2e0790e3716e8b2175e10a42045c25d72f801ed2ac", "class_name": "RelatedNodeInfo"}}, "text": "And then -- yes, that's basically it.  \n \n", "start_char_idx": 1793, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c189852-af7f-46d2-8a13-59f605c869bd": {"__data__": {"id_": "3c189852-af7f-46d2-8a13-59f605c869bd", "embedding": null, "metadata": {"window": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3508fe72-9527-4348-b20d-7d4e7b4abf90", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Just on the Pharma side, can yo u talk about biosimilars and to the extent that they've \nhad an impact?   Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.  ", "original_text": "And then -- yes, that's basically it.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8a0a1090527fa2a115528d00a9d514c8911d73d57d6b075a4d219206013c25c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f4f168-2162-47bf-88ea-7d49ddcb1b89", "node_type": "1", "metadata": {"window": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "original_text": "Biosimilars continues to be an area we're also excited about.  "}, "hash": "719fa3be7a9d14e9816434733eb2baa29efdf961a5385928328b2f797cce78d1", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1835, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f4f168-2162-47bf-88ea-7d49ddcb1b89": {"__data__": {"id_": "d6f4f168-2162-47bf-88ea-7d49ddcb1b89", "embedding": null, "metadata": {"window": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "original_text": "Biosimilars continues to be an area we're also excited about.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c189852-af7f-46d2-8a13-59f605c869bd", "node_type": "1", "metadata": {"window": "Commentary from some of your peers would suggest that it's starting to become a \nmore meaningful contributor.   I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07340b3d37834123111e1587b03788972b0d3db0e355aa34ad3ae6580c7f3abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a23bf6-5eb1-4652-bda6-e3d026292e2a", "node_type": "1", "metadata": {"window": "And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.  ", "original_text": "We are seeing \npositive contributions from biosimilars.  "}, "hash": "58cdc2a1f5b8ccf98ffc925dc51142aebf7755ab4ffa852cf3a71d6913559e31", "class_name": "RelatedNodeInfo"}}, "text": "Biosimilars continues to be an area we're also excited about.  ", "start_char_idx": 1857, "end_char_idx": 1920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a23bf6-5eb1-4652-bda6-e3d026292e2a": {"__data__": {"id_": "61a23bf6-5eb1-4652-bda6-e3d026292e2a", "embedding": null, "metadata": {"window": "And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.  ", "original_text": "We are seeing \npositive contributions from biosimilars.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f4f168-2162-47bf-88ea-7d49ddcb1b89", "node_type": "1", "metadata": {"window": "I just wanted to get a sense within -- in the Pharma segment, how much \nthat's having an impact?   And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "original_text": "Biosimilars continues to be an area we're also excited about.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "496c16eae6945de96d175394bb5b16d53514e1f1d03e77825df413d687ee9f8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0e24a25-4e59-4877-9d4e-3000964918ef", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n", "original_text": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n "}, "hash": "070a3dab74dad6f4115deb4fc49605094a53283b1c439092f0b4dde992a2a4fc", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing \npositive contributions from biosimilars.  ", "start_char_idx": 1920, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0e24a25-4e59-4877-9d4e-3000964918ef": {"__data__": {"id_": "b0e24a25-4e59-4877-9d4e-3000964918ef", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n", "original_text": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a23bf6-5eb1-4652-bda6-e3d026292e2a", "node_type": "1", "metadata": {"window": "And then -- yes, that's basically it.  \n \n Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.  ", "original_text": "We are seeing \npositive contributions from biosimilars.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "062fa07842339d02acec75d8719ffe87954600e726844d85b208282644b52ff6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "747b3b2b-6d17-4912-853a-f5aa15d4af0b", "node_type": "1", "metadata": {"window": "Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "original_text": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n"}, "hash": "1f92606b240906d73e437be793671d1cd432b3690f23066e3f4800c0d5985cef", "class_name": "RelatedNodeInfo"}}, "text": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "start_char_idx": 1977, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "747b3b2b-6d17-4912-853a-f5aa15d4af0b": {"__data__": {"id_": "747b3b2b-6d17-4912-853a-f5aa15d4af0b", "embedding": null, "metadata": {"window": "Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "original_text": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0e24a25-4e59-4877-9d4e-3000964918ef", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n", "original_text": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37c667b141d6afe8c6f0b6309ef9988ed9f5ce323ed4e05ce0c1dfd67a1ee620", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f54027e8-c12c-4409-a95a-2b297e60416d", "node_type": "1", "metadata": {"window": "We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "original_text": "Operator:  Thank you.  "}, "hash": "11177ed6d851a7a1500af8f54494d12ba22b4aa61b58b4fdc925dc4f45c6c440", "class_name": "RelatedNodeInfo"}}, "text": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "start_char_idx": 2151, "end_char_idx": 2349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f54027e8-c12c-4409-a95a-2b297e60416d": {"__data__": {"id_": "f54027e8-c12c-4409-a95a-2b297e60416d", "embedding": null, "metadata": {"window": "We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "original_text": "Operator:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "747b3b2b-6d17-4912-853a-f5aa15d4af0b", "node_type": "1", "metadata": {"window": "Biosimilars continues to be an area we're also excited about.   We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "original_text": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b672137a1a92549bd47d48c7c2f0992c7038c3ef4431f5c0dcceb20c7c2bf8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4dd4516-e597-44db-8737-44d59108ea4a", "node_type": "1", "metadata": {"window": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "original_text": "We'll take our next question from Steven Valiquette with Barclays.  \n \n"}, "hash": "86f45476873facce4d021991c6ca18de4507be7bae9661280ffe3cca7ad33f8c", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 1376, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4dd4516-e597-44db-8737-44d59108ea4a": {"__data__": {"id_": "e4dd4516-e597-44db-8737-44d59108ea4a", "embedding": null, "metadata": {"window": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "original_text": "We'll take our next question from Steven Valiquette with Barclays.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f54027e8-c12c-4409-a95a-2b297e60416d", "node_type": "1", "metadata": {"window": "We are seeing \npositive contributions from biosimilars.   It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "original_text": "Operator:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "268e65daa2d98814483be8eecf67262b62d916659009ab206529a945c40ddc6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf6520f4-2049-462e-87d9-dc0d16f2dcd9", "node_type": "1", "metadata": {"window": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "original_text": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  "}, "hash": "0202d7924e35a537950fc17c4c16fec3c8be0cd07d3844939bec96518e6fa319", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Steven Valiquette with Barclays.  \n \n", "start_char_idx": 2372, "end_char_idx": 2443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf6520f4-2049-462e-87d9-dc0d16f2dcd9": {"__data__": {"id_": "bf6520f4-2049-462e-87d9-dc0d16f2dcd9", "embedding": null, "metadata": {"window": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "original_text": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4dd4516-e597-44db-8737-44d59108ea4a", "node_type": "1", "metadata": {"window": "It just doesn't -- it's not at the level to be callin g it out as \nnecessarily a driver at this point in time, but it's something that we do continue to participate in.  \n \n  We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "original_text": "We'll take our next question from Steven Valiquette with Barclays.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d044322cbeaa5f81b1ca80f47bb0ae7a4e6f4a9fdea984fe75eafb47db96f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29123dc7-4108-44c0-b518-2add9d8ffb27", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  "}, "hash": "1bd4658f69570c289c881ce425a8dd196e801543fb3f2f47d768dc2b5e7f4a70", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "start_char_idx": 2443, "end_char_idx": 2687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29123dc7-4108-44c0-b518-2add9d8ffb27": {"__data__": {"id_": "29123dc7-4108-44c0-b518-2add9d8ffb27", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf6520f4-2049-462e-87d9-dc0d16f2dcd9", "node_type": "1", "metadata": {"window": "We're very well positioned to be able to help manufacturers and customers with biosimilars, \nand we do see that as something that should be a  tailwind for us as we look forward, going forward.  \n \n Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "original_text": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0945f3feec62ca56160febd5dbb53556a05eda2c4c15258535cc67b27c85c5fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "496b1b1c-3428-445a-9e75-061e97e26b34", "node_type": "1", "metadata": {"window": "We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n "}, "hash": "b63bea5257e0254704ee5b92f5171bfb95069521a6c0d01ea43f1e7a06cd94a6", "class_name": "RelatedNodeInfo"}}, "text": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "start_char_idx": 2687, "end_char_idx": 2798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "496b1b1c-3428-445a-9e75-061e97e26b34": {"__data__": {"id_": "496b1b1c-3428-445a-9e75-061e97e26b34", "embedding": null, "metadata": {"window": "We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29123dc7-4108-44c0-b518-2add9d8ffb27", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "550b430c53d6cf1d5cf4b031cc12ac0d772d734c9a9906cd92d1207e94396498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23a483d7-ca9c-4ff7-b740-d3a452f5e783", "node_type": "1", "metadata": {"window": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  "}, "hash": "1bbe979f09d9b95be227cff66323bb18fd4d6ccf67e2b365de0ff5deb413df96", "class_name": "RelatedNodeInfo"}}, "text": "And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "start_char_idx": 2798, "end_char_idx": 2984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23a483d7-ca9c-4ff7-b740-d3a452f5e783": {"__data__": {"id_": "23a483d7-ca9c-4ff7-b740-d3a452f5e783", "embedding": null, "metadata": {"window": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "496b1b1c-3428-445a-9e75-061e97e26b34", "node_type": "1", "metadata": {"window": "We'll take our next question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c05675ceec15d9f9638d91ec1ac9289d704829bba1d3014d1bba2e8e41767877", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3f9fa52-28ba-4743-8553-ef0bc830ad86", "node_type": "1", "metadata": {"window": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "Or is it just maybe there was something else that made the "}, "hash": "55c9665d3aec0d04f0572706b3f214eb756843a8815815c584788c200f88aa42", "class_name": "RelatedNodeInfo"}}, "text": "I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "start_char_idx": 2984, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3f9fa52-28ba-4743-8553-ef0bc830ad86": {"__data__": {"id_": "f3f9fa52-28ba-4743-8553-ef0bc830ad86", "embedding": null, "metadata": {"window": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "Or is it just maybe there was something else that made the ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57fb6302-0f70-41bd-974c-4700d10f9792", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74104d874ae85ee11ce2a79d056a0f0c2a302273890389a6cd90f6eb65790c79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23a483d7-ca9c-4ff7-b740-d3a452f5e783", "node_type": "1", "metadata": {"window": "Steven Valiquette:  I think in the Pharma segment, we're all just kind of looking at the trend line where \nthe se gment operating profit grew 1% year -over-year back in the fiscal first quarter, but then they \nwere down 11% here in fiscal 2Q.   And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d7e54c36d46ad4fdcb236bbfb15db131f39abfd17a1a28aa27ac82cd77c53e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "original_text": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?  "}, "hash": "b130e2f3ac1357da987f46053109cc8af9ba325e4602d096cf55f6dee3efdbb5", "class_name": "RelatedNodeInfo"}}, "text": "Or is it just maybe there was something else that made the ", "start_char_idx": 3125, "end_char_idx": 3184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c": {"__data__": {"id_": "7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "original_text": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3f9fa52-28ba-4743-8553-ef0bc830ad86", "node_type": "1", "metadata": {"window": "And you mentioned that the Nuclear Pharmacy headwind was \nactually a little bit less in the December quarter.   And I think you sa id in the Q&A that for the generics, \nyou're not seeing anything inconsistent there from what you saw in the prior quarter despite the \nCOVID impact on generics.  \n \n  I guess just the question is, is there anything else you'd call out that may have gotten a lit tle bit \nworse sequentially in that segment?   Or is it just maybe there was something else that made the ", "original_text": "Or is it just maybe there was something else that made the ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1462526a73b7eb956bc8a0df1e1f54cf2b4ac7e8d163c1029fe04510bd3808bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff20df27-6df0-4ae9-bd90-6b1afa72c3be", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "original_text": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n"}, "hash": "39b82f005b8a892e3f04c66c4841ba298731e5cae984e947be36d55e77cce3e2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?  ", "start_char_idx": 0, "end_char_idx": 90, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff20df27-6df0-4ae9-bd90-6b1afa72c3be": {"__data__": {"id_": "ff20df27-6df0-4ae9-bd90-6b1afa72c3be", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "original_text": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "original_text": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d65ea37648479d339484471a97e5c8e524c32d0d3271689194534f09229bef25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bef3c43-0093-4113-b853-9b368900720e", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "original_text": "Jason Hollar:  Yes.  "}, "hash": "27e0efc03a6b7020492a71fb011549dc7f9ce06286e632b215118d71d79d2005", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n", "start_char_idx": 90, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bef3c43-0093-4113-b853-9b368900720e": {"__data__": {"id_": "7bef3c43-0093-4113-b853-9b368900720e", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "original_text": "Jason Hollar:  Yes.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff20df27-6df0-4ae9-bd90-6b1afa72c3be", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "original_text": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a304d25d3b06d23da5aeb4f355492d8c27edd4792a666bab492ca37a72fa288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.  ", "original_text": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n "}, "hash": "c2b6c336bb3d28390decd766bea318391a47a635d661522e65e74a0a84a91209", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 187, "end_char_idx": 208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d": {"__data__": {"id_": "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.  ", "original_text": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bef3c43-0093-4113-b853-9b368900720e", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "original_text": "Jason Hollar:  Yes.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcb6c15bb13eb6f8005553497e1a341cc9f1b67bfa483239a0aa5f327e4a9b1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32fd547b-0885-419a-8850-a1f8a41ee111", "node_type": "1", "metadata": {"window": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  "}, "hash": "d507d9429d017105fd9235386211d127e1a3ffc9532f20add5f69558b9ff0b7c", "class_name": "RelatedNodeInfo"}}, "text": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "start_char_idx": 208, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32fd547b-0885-419a-8850-a1f8a41ee111": {"__data__": {"id_": "32fd547b-0885-419a-8850-a1f8a41ee111", "embedding": null, "metadata": {"window": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.  ", "original_text": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efcf6cc61dad56e10b75b526b45c80075df7a0d8bd11a5ee4d6a91e38e353e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c725811a-a895-4ea2-b866-580b299b2d75", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "original_text": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n"}, "hash": "2ea42a60fccaa22392d49e21f1bc4fac25e3f2c4e6d4fbe55e4a14f755fd33f8", "class_name": "RelatedNodeInfo"}}, "text": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "start_char_idx": 443, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c725811a-a895-4ea2-b866-580b299b2d75": {"__data__": {"id_": "c725811a-a895-4ea2-b866-580b299b2d75", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "original_text": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32fd547b-0885-419a-8850-a1f8a41ee111", "node_type": "1", "metadata": {"window": "Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "original_text": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c74db1ce6a736009c93eb6a7f2b23e870de832e8e4933c35f15638cfbb65d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72206fe9-11cd-4f9e-98b7-7df419eaad72", "node_type": "1", "metadata": {"window": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "original_text": "Operator:  Thank you.  "}, "hash": "ab19327a1b61ecf82209f70369ee9f1659b5b073421a5f477368c2e8176bca06", "class_name": "RelatedNodeInfo"}}, "text": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "start_char_idx": 681, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72206fe9-11cd-4f9e-98b7-7df419eaad72": {"__data__": {"id_": "72206fe9-11cd-4f9e-98b7-7df419eaad72", "embedding": null, "metadata": {"window": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "original_text": "Operator:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c725811a-a895-4ea2-b866-580b299b2d75", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "original_text": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c12965907593f4a8e8f7b87b3bff432003ef0e8ea3715793846c841d6d3420ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82fbff9a-80a5-4575-a4e0-4cc02f6f383d", "node_type": "1", "metadata": {"window": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n"}, "hash": "1f4a04ac8588753781b266d773cd86a1a20652f8021031311421ba0fad20314e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 782, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82fbff9a-80a5-4575-a4e0-4cc02f6f383d": {"__data__": {"id_": "82fbff9a-80a5-4575-a4e0-4cc02f6f383d", "embedding": null, "metadata": {"window": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72206fe9-11cd-4f9e-98b7-7df419eaad72", "node_type": "1", "metadata": {"window": "As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n  So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "original_text": "Operator:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1162b26ac22524c192a292d26b67a16cef4ef60cabcf8c8dab4bab5bfc9526", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b9ae79-2b3b-43a0-8476-4596d517b24e", "node_type": "1", "metadata": {"window": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "original_text": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  "}, "hash": "6a1416fee1af5f5c8de4b7e82e0116056eed270a529211a0b1c1c340ebecec53", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "start_char_idx": 805, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b9ae79-2b3b-43a0-8476-4596d517b24e": {"__data__": {"id_": "18b9ae79-2b3b-43a0-8476-4596d517b24e", "embedding": null, "metadata": {"window": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "original_text": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82fbff9a-80a5-4575-a4e0-4cc02f6f383d", "node_type": "1", "metadata": {"window": "So you do need to go back to look at the Q2 of the prior year, where that's where the generics \nprogram overall was fairly strong, and we talked at that point about not only volume but some mix  \nimpacts that were going on at that time.   So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a1646027f62c4d1a6d9ffa33168a974c1885c8a6c7a3dfc49e7f5dda584a5e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4932a5fb-f4a2-4b4b-bc20-dca4d5727026", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.  ", "original_text": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n"}, "hash": "d1dfb885fa969dcb71b2f255b04e18221d3c97795668af7c60e3a6aa1871e2e7", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "start_char_idx": 877, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4932a5fb-f4a2-4b4b-bc20-dca4d5727026": {"__data__": {"id_": "4932a5fb-f4a2-4b4b-bc20-dca4d5727026", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.  ", "original_text": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b9ae79-2b3b-43a0-8476-4596d517b24e", "node_type": "1", "metadata": {"window": "So I think it 's very much a comp as well as consistency in the \nquarter -to-quarter sequential.  \n \n Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "original_text": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f8bd1b8f978920abb7e586f90178923a84a5b13acbf80bcc8df44e7ebfa66b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c1c902-0d22-4467-8a63-3717faa3a227", "node_type": "1", "metadata": {"window": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "original_text": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  "}, "hash": "a0d70a0758a27cda811191828199c0552ac6dd3c1be21de0c24281d3c61bdbf5", "class_name": "RelatedNodeInfo"}}, "text": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "start_char_idx": 1046, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c1c902-0d22-4467-8a63-3717faa3a227": {"__data__": {"id_": "51c1c902-0d22-4467-8a63-3717faa3a227", "embedding": null, "metadata": {"window": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "original_text": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4932a5fb-f4a2-4b4b-bc20-dca4d5727026", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.  ", "original_text": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81a17fbc604783e5d42493d788bec6163084956cee1a57b0b8d572d9b449dd76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47e19cdb-37bf-4e2d-949c-f10a6ea8a320", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.  ", "original_text": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n "}, "hash": "8006339500a3c1fbbf1bb9b2763c99a48401e80455b0f947a9ca436b77e07c5a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "start_char_idx": 1146, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47e19cdb-37bf-4e2d-949c-f10a6ea8a320": {"__data__": {"id_": "47e19cdb-37bf-4e2d-949c-f10a6ea8a320", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.  ", "original_text": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c1c902-0d22-4467-8a63-3717faa3a227", "node_type": "1", "metadata": {"window": "We'll take our next question from Elizabeth Anderson with Evercore.  \n \n Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "original_text": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf2b2f8cda6d9e365561620aeaf146232e757f653d26e07d5216f784492e05b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa921067-a722-4ea3-a846-919959761dda", "node_type": "1", "metadata": {"window": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.  ", "original_text": "We are making some large investments in our IT systems that will be going online here.  "}, "hash": "da434ad8815b0bf33915028dc6eeea6427e1f1ce294db527560d04fd39da5d15", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "start_char_idx": 1227, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa921067-a722-4ea3-a846-919959761dda": {"__data__": {"id_": "fa921067-a722-4ea3-a846-919959761dda", "embedding": null, "metadata": {"window": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.  ", "original_text": "We are making some large investments in our IT systems that will be going online here.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47e19cdb-37bf-4e2d-949c-f10a6ea8a320", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  I just want to ask about the different -- in terms of y our home health business, \ncan you talk about how that has been performing in the quarter?   And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.  ", "original_text": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faf9dd23dd7254a3d73389ff923d83882bc8db50a8ec98876e35ea5a81c19146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f32bb6a0-bc45-4ad1-9602-0e02774e66be", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "original_text": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  "}, "hash": "5a94e1e406230a45abcfeaa7885dc445c04c3c216529d3f0159c2226fed2103c", "class_name": "RelatedNodeInfo"}}, "text": "We are making some large investments in our IT systems that will be going online here.  ", "start_char_idx": 1453, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f32bb6a0-bc45-4ad1-9602-0e02774e66be": {"__data__": {"id_": "f32bb6a0-bc45-4ad1-9602-0e02774e66be", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "original_text": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa921067-a722-4ea3-a846-919959761dda", "node_type": "1", "metadata": {"window": "And then maybe sort of your \nexpectations as we like move through the rest of COVID and beyond?  \n \n Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.  ", "original_text": "We are making some large investments in our IT systems that will be going online here.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f35ba1c55c39d0d9c44066774594e2a14f01902f96bdcfd8aab1915bbe29ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c5bfb79-9635-4836-be0a-d5e1a903f1f7", "node_type": "1", "metadata": {"window": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.  ", "original_text": "But it's a business that w e continue to \nremain very positive on.  "}, "hash": "1057b192cd581ffa3f27afb2bf0504bb91b18bfb7494c80838b0b16f3371e05e", "class_name": "RelatedNodeInfo"}}, "text": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "start_char_idx": 1541, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c5bfb79-9635-4836-be0a-d5e1a903f1f7": {"__data__": {"id_": "1c5bfb79-9635-4836-be0a-d5e1a903f1f7", "embedding": null, "metadata": {"window": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.  ", "original_text": "But it's a business that w e continue to \nremain very positive on.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f32bb6a0-bc45-4ad1-9602-0e02774e66be", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, we continue to be very pleased with our at -Home business.   We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "original_text": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cc952b12111de80850ad8565d2f6434ca22f9a55e90c89fd7e2ea0576539526", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4fd3a87-1655-4e54-9a70-e930f20ecfd9", "node_type": "1", "metadata": {"window": "We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "original_text": "We believe the trends continue to be in our favor in that business.  "}, "hash": "96349b8724adc3bd072bc9f9e1ed1b7ea5c98f0907179069f1b09a93769dfb1f", "class_name": "RelatedNodeInfo"}}, "text": "But it's a business that w e continue to \nremain very positive on.  ", "start_char_idx": 1710, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4fd3a87-1655-4e54-9a70-e930f20ecfd9": {"__data__": {"id_": "d4fd3a87-1655-4e54-9a70-e930f20ecfd9", "embedding": null, "metadata": {"window": "We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "original_text": "We believe the trends continue to be in our favor in that business.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c5bfb79-9635-4836-be0a-d5e1a903f1f7", "node_type": "1", "metadata": {"window": "We're continuing \nto see growth in overall number of customers that we're serving, the types of product lines that we're \nworking with and driving our mix, all of those types of things , getting after our cost structure.  \n \n  We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.  ", "original_text": "But it's a business that w e continue to \nremain very positive on.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df87dd04c47108984cc5a5a26aba5706d5a686e6d07515a2975d3f0aeb98b490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e2abed-964b-40ef-9b6a-50d8fc645db2", "node_type": "1", "metadata": {"window": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "original_text": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n"}, "hash": "98fc48bf164e79fe73ed307ce955aa9f0f099bc7d405a0caa2bd07ce0d57f406", "class_name": "RelatedNodeInfo"}}, "text": "We believe the trends continue to be in our favor in that business.  ", "start_char_idx": 1778, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e2abed-964b-40ef-9b6a-50d8fc645db2": {"__data__": {"id_": "a4e2abed-964b-40ef-9b6a-50d8fc645db2", "embedding": null, "metadata": {"window": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "original_text": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4fd3a87-1655-4e54-9a70-e930f20ecfd9", "node_type": "1", "metadata": {"window": "We are making some large investments in our IT systems that will be going online here.   So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "original_text": "We believe the trends continue to be in our favor in that business.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18822a051c09b795c1fa2f352964cd9c09c02a912c6a7df7957f907044d88744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd13549-6823-45fd-9b32-9d42b50c33f5", "node_type": "1", "metadata": {"window": "But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "original_text": "Operator:  Thank you.  "}, "hash": "9ee9ccab3f1e7b7b4774d2f937e59f86eca54bdab8e3c30b29a5263f421ae11b", "class_name": "RelatedNodeInfo"}}, "text": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "start_char_idx": 1847, "end_char_idx": 2002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd13549-6823-45fd-9b32-9d42b50c33f5": {"__data__": {"id_": "efd13549-6823-45fd-9b32-9d42b50c33f5", "embedding": null, "metadata": {"window": "But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "original_text": "Operator:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e2abed-964b-40ef-9b6a-50d8fc645db2", "node_type": "1", "metadata": {"window": "So a \nlittle increased SG&A as we drive to improve our systems there to be able to improve the customer \nexperience, and as we grow, be able to do it more effectively.   But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "original_text": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3adbef316424a209a6478a6dd5338b302cc878561184bd83dd7e10a231a0064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eba1b936-d3d1-4472-94c3-0513de876214", "node_type": "1", "metadata": {"window": "We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "original_text": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n"}, "hash": "af52f2a45f52f42f4b9d21e1423a59892867785a8020ac2b153c37d797f6e0de", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 782, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eba1b936-d3d1-4472-94c3-0513de876214": {"__data__": {"id_": "eba1b936-d3d1-4472-94c3-0513de876214", "embedding": null, "metadata": {"window": "We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "original_text": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd13549-6823-45fd-9b32-9d42b50c33f5", "node_type": "1", "metadata": {"window": "But it's a business that w e continue to \nremain very positive on.   We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "original_text": "Operator:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2714754e5b4b678463919291078ed18ccb52e26e907da5251ca64a6b247466f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed", "node_type": "1", "metadata": {"window": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.  ", "original_text": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  "}, "hash": "ca55a1579dd8fc1c5cfc157c6eee231c05407a54782408ab30c654e060c044b7", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "start_char_idx": 2025, "end_char_idx": 2091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed": {"__data__": {"id_": "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed", "embedding": null, "metadata": {"window": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.  ", "original_text": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eba1b936-d3d1-4472-94c3-0513de876214", "node_type": "1", "metadata": {"window": "We believe the trends continue to be in our favor in that business.   And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "original_text": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d344988386ef199843811301989965942a2c7af19f6942ab67ad5cc6463f9ec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6528133f-d847-431f-9a79-6ac8841602a6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.  ", "original_text": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  "}, "hash": "f758349ac81163771ce188c426ca30653c1ce04cda88b3705a62e05a3be544c8", "class_name": "RelatedNodeInfo"}}, "text": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "start_char_idx": 2091, "end_char_idx": 2184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6528133f-d847-431f-9a79-6ac8841602a6": {"__data__": {"id_": "6528133f-d847-431f-9a79-6ac8841602a6", "embedding": null, "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.  ", "original_text": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed", "node_type": "1", "metadata": {"window": "And \nbeing one of the leaders in that space, I think, enables us to invest in various activities and \nopportunities to continue to grow that business . \n \n Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.  ", "original_text": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff6fe828d1900669d06bc2964616829ebb1a1c2d80c36529d8805145ac496ed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016dedb5-df60-4e72-97b4-4189389e59b2", "node_type": "1", "metadata": {"window": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.  ", "original_text": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n"}, "hash": "c70cf37891dd664789ce8ef75803062a91a76d77df02084a77f426dbca43bcdd", "class_name": "RelatedNodeInfo"}}, "text": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "start_char_idx": 2184, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016dedb5-df60-4e72-97b4-4189389e59b2": {"__data__": {"id_": "016dedb5-df60-4e72-97b4-4189389e59b2", "embedding": null, "metadata": {"window": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.  ", "original_text": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6528133f-d847-431f-9a79-6ac8841602a6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.  ", "original_text": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce9b7f0bfbeec157b111680255f1a76629e9bf8e471d44223c7f5a1e14954e6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daf780bd-38cd-4868-9d6e-a2b090817655", "node_type": "1", "metadata": {"window": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "056031d5d38051cbd03b8be72eb793cfc715a6d792d100bc00b7aec0333d08d3", "class_name": "RelatedNodeInfo"}}, "text": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "start_char_idx": 2315, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daf780bd-38cd-4868-9d6e-a2b090817655": {"__data__": {"id_": "daf780bd-38cd-4868-9d6e-a2b090817655", "embedding": null, "metadata": {"window": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016dedb5-df60-4e72-97b4-4189389e59b2", "node_type": "1", "metadata": {"window": "We'll take our next question from Eugene Kim, Wolfe Research.  \n \n Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.  ", "original_text": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39db64ade9c5fbae21fb22f8c09d346c79eee5b8354361946485253c29c0eb2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25d3a672-04d5-437f-ba9a-22b77d55bbe0", "node_type": "1", "metadata": {"window": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "original_text": "So within the quarter, we called out two key items.  "}, "hash": "5f0dcb7c3d0a59c9575bc98d1179871f0f771c3b09c737a165631b5ff96f07b7", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 187, "end_char_idx": 208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25d3a672-04d5-437f-ba9a-22b77d55bbe0": {"__data__": {"id_": "25d3a672-04d5-437f-ba9a-22b77d55bbe0", "embedding": null, "metadata": {"window": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "original_text": "So within the quarter, we called out two key items.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daf780bd-38cd-4868-9d6e-a2b090817655", "node_type": "1", "metadata": {"window": "Eugene Kim:  I would like to get some color on cost savings benefit in the Medical segment.   And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f28a161eca32b1a33df09d8af20c48188b78818683ea84dbc3019e6ebdaf5bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2", "node_type": "1", "metadata": {"window": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "original_text": "One is this topic, cost savings \nas well as the COVID impacts.  "}, "hash": "1022b37b395c46507c5910dd3df08f15d21166e2500a5a8e9388286389f87eb8", "class_name": "RelatedNodeInfo"}}, "text": "So within the quarter, we called out two key items.  ", "start_char_idx": 2426, "end_char_idx": 2479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2": {"__data__": {"id_": "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2", "embedding": null, "metadata": {"window": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "original_text": "One is this topic, cost savings \nas well as the COVID impacts.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25d3a672-04d5-437f-ba9a-22b77d55bbe0", "node_type": "1", "metadata": {"window": "And can \nyou maybe quantify the benefit you saw for the quarter and share how much of th e savings are more \ntemporary in nature?   And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "original_text": "So within the quarter, we called out two key items.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a8968dede19c356fa6ea34b3f2fdbf12b1543c42554f628a0b8a81dd7f2cf05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ef14a0f-9cbd-4293-8d20-e75729a1394e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "original_text": "And they were both the most significant items that are driving our \nyear-over-year performance.  "}, "hash": "4650330c01fa0c97651e3c834eaf94915cf1bb1561527257f47f82ba5955ef85", "class_name": "RelatedNodeInfo"}}, "text": "One is this topic, cost savings \nas well as the COVID impacts.  ", "start_char_idx": 2479, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ef14a0f-9cbd-4293-8d20-e75729a1394e": {"__data__": {"id_": "6ef14a0f-9cbd-4293-8d20-e75729a1394e", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "original_text": "And they were both the most significant items that are driving our \nyear-over-year performance.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2", "node_type": "1", "metadata": {"window": "And also if you are expecting those temporary savings to come back in the \nback half?  \n \n Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "original_text": "One is this topic, cost savings \nas well as the COVID impacts.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaf85e939222f85965d725f48daf99bee258c05ff459e5495ffaa05ab740b303", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbe74d38-7c39-45d3-8f95-26b658e64121", "node_type": "1", "metadata": {"window": "So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "original_text": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n "}, "hash": "fee0f650b723ec3b69a5f5bc1fd6a39e466088f4a203ce437c743f2b6003e65c", "class_name": "RelatedNodeInfo"}}, "text": "And they were both the most significant items that are driving our \nyear-over-year performance.  ", "start_char_idx": 2543, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbe74d38-7c39-45d3-8f95-26b658e64121": {"__data__": {"id_": "fbe74d38-7c39-45d3-8f95-26b658e64121", "embedding": null, "metadata": {"window": "So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "original_text": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ef14a0f-9cbd-4293-8d20-e75729a1394e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "original_text": "And they were both the most significant items that are driving our \nyear-over-year performance.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d9b5b0cfafc6260869bb504eb9da149c397f6491857f130203beb6e1b1a4969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1", "node_type": "1", "metadata": {"window": "One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n"}, "hash": "0d4a46479918260d0807b597826e67c2c686dbee0a6729913ed600c4131ef542", "class_name": "RelatedNodeInfo"}}, "text": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "start_char_idx": 2640, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1": {"__data__": {"id_": "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1", "embedding": null, "metadata": {"window": "One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbe74d38-7c39-45d3-8f95-26b658e64121", "node_type": "1", "metadata": {"window": "So within the quarter, we called out two key items.   One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "original_text": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c8fe6097faa235cfc6c586844667082146562b1a25a15bfd62d7a19af5e59a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a180df14-e7e2-4617-81e9-f23c86ecdf7b", "node_type": "1", "metadata": {"window": "And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  "}, "hash": "3bd6f79ba9a9c98ebc92d0e8446e4daa740b94b66c821e99aa93443dbf02f759", "class_name": "RelatedNodeInfo"}}, "text": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "start_char_idx": 2788, "end_char_idx": 2883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a180df14-e7e2-4617-81e9-f23c86ecdf7b": {"__data__": {"id_": "a180df14-e7e2-4617-81e9-f23c86ecdf7b", "embedding": null, "metadata": {"window": "And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1", "node_type": "1", "metadata": {"window": "One is this topic, cost savings \nas well as the COVID impacts.   And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "537a6e502be1fef6839d0870e8058adfc48b46ff1f8a705ad27b9a2c185b4e1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1cd7436-46c9-4e52-8be2-d3ee66470ed5", "node_type": "1", "metadata": {"window": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  "}, "hash": "664d34e0334000c0c76ce2c888100a30e8bf5a27007918cc60e8376b56cf09d3", "class_name": "RelatedNodeInfo"}}, "text": "Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "start_char_idx": 2883, "end_char_idx": 3001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1cd7436-46c9-4e52-8be2-d3ee66470ed5": {"__data__": {"id_": "d1cd7436-46c9-4e52-8be2-d3ee66470ed5", "embedding": null, "metadata": {"window": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a180df14-e7e2-4617-81e9-f23c86ecdf7b", "node_type": "1", "metadata": {"window": "And they were both the most significant items that are driving our \nyear-over-year performance.   So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70e5e03fb8661b576c41b679c81c541b32a781e3538d587bac5488205700d146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70fbc380-241f-4491-ac19-29b784f5ac37", "node_type": "1", "metadata": {"window": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "It's  "}, "hash": "7de7918731fac7b6c0579ecbc668ec4ef92a941f0d6c73b9ca448a3262ee8634", "class_name": "RelatedNodeInfo"}}, "text": "So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "start_char_idx": 3001, "end_char_idx": 3178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70fbc380-241f-4491-ac19-29b784f5ac37": {"__data__": {"id_": "70fbc380-241f-4491-ac19-29b784f5ac37", "embedding": null, "metadata": {"window": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "It's  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1e3904173aff3996957e58ac896103af5c7c0aaffbcd3827b33758ea078f2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1cd7436-46c9-4e52-8be2-d3ee66470ed5", "node_type": "1", "metadata": {"window": "So in terms of the o rder of magnitude, you should think of that as a \nlarge driver of this performance and consistent with that other driver.  \n \n  How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "104880bc5cb5f1170c5af3d293eb8ccce4cfd970300cdff8667f8cb6de602094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44441188-4fbe-4a00-a3c5-2c777b6ffae9", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "original_text": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.  "}, "hash": "46da0d22203814e811e2fa70992411800264d47f11e6eca0420aad3cc445a590", "class_name": "RelatedNodeInfo"}}, "text": "It's  ", "start_char_idx": 3178, "end_char_idx": 3184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44441188-4fbe-4a00-a3c5-2c777b6ffae9": {"__data__": {"id_": "44441188-4fbe-4a00-a3c5-2c777b6ffae9", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "original_text": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70fbc380-241f-4491-ac19-29b784f5ac37", "node_type": "1", "metadata": {"window": "How we break out our cost savings is that they would, by their nature, be largely permanent.  \n Anything that's temporary and only beca use of COVID or COVID -related matters, we would put into \nthe COVID bucket.   So we do see this as a continuous improvement and deep into our DNA and that \nwe aren't just squeezing out costs temporarily, but truly transformational foundational elements.   It's  ", "original_text": "It's  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "592b81bd83510f46dff56c3736c12a161ace577c9f906dee9111e797891095b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "original_text": "And as such, \nwe'd expect it to be permanent.  \n \n"}, "hash": "1c1cd21c69f03f5a2b700594a2d75b80af322264c720d841a495a291ccc056a7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.  ", "start_char_idx": 0, "end_char_idx": 104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67": {"__data__": {"id_": "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "original_text": "And as such, \nwe'd expect it to be permanent.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44441188-4fbe-4a00-a3c5-2c777b6ffae9", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "original_text": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ed1f810bd9c94db835eb162ff6772c2b6e220972e6e6fce319068661edb859f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31d94e98-6604-445d-95f7-ee093c450ba9", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "c30f0784ce050b3fbd91995d7af4dc25e684d5b2533fb8507f9bba10eebedd70", "class_name": "RelatedNodeInfo"}}, "text": "And as such, \nwe'd expect it to be permanent.  \n \n", "start_char_idx": 104, "end_char_idx": 154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31d94e98-6604-445d-95f7-ee093c450ba9": {"__data__": {"id_": "31d94e98-6604-445d-95f7-ee093c450ba9", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "original_text": "And as such, \nwe'd expect it to be permanent.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "062d3d5ba1f54c5840a063fb355648e9532fcd91531e37ac202a4621d83a8dd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a9bc0b-b0e0-4278-a26b-73796eb904e7", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n", "original_text": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n "}, "hash": "a14724ade489367e94640d62cd96b0a0908dfe28a8c0281e2b726ae4e33fe84a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 154, "end_char_idx": 176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a9bc0b-b0e0-4278-a26b-73796eb904e7": {"__data__": {"id_": "64a9bc0b-b0e0-4278-a26b-73796eb904e7", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n", "original_text": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31d94e98-6604-445d-95f7-ee093c450ba9", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4b80a16d0a2fa69ea399dc241711e6c7424ea3cb291ad30588aa19cc8e18d98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66092dcb-b49f-46bc-9a5e-ad05e856ee8a", "node_type": "1", "metadata": {"window": "And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "original_text": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  "}, "hash": "3a9805475634ab76868370616a7a181fc95ec2d9905dc6f68747307f333c2340", "class_name": "RelatedNodeInfo"}}, "text": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "start_char_idx": 176, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66092dcb-b49f-46bc-9a5e-ad05e856ee8a": {"__data__": {"id_": "66092dcb-b49f-46bc-9a5e-ad05e856ee8a", "embedding": null, "metadata": {"window": "And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "original_text": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a9bc0b-b0e0-4278-a26b-73796eb904e7", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n", "original_text": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67d7f7ba5a0a218b4de895b7f72f3a20d428405ccae65d915912f5a2b498bbf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47061b9b-8e56-4f13-8aac-fe4338696347", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "original_text": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  "}, "hash": "3647fffd15fbf8783190727a7f02a46770be6b69eb993db3e889cabff4b068af", "class_name": "RelatedNodeInfo"}}, "text": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "start_char_idx": 502, "end_char_idx": 592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47061b9b-8e56-4f13-8aac-fe4338696347": {"__data__": {"id_": "47061b9b-8e56-4f13-8aac-fe4338696347", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "original_text": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66092dcb-b49f-46bc-9a5e-ad05e856ee8a", "node_type": "1", "metadata": {"window": "And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "original_text": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f2f6b86005e33045ba2ef4d4b42d9c557e4f1a29f8342594be3c0ecd1a4a5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb58f66f-4abf-4546-ac8d-f9842ed657d0", "node_type": "1", "metadata": {"window": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.  ", "original_text": "So we would expect them to be a little higher in the second half.  \n"}, "hash": "26c15853672ae2e3730106aee8aa25db1d564e905e2d1907b17a7dc9fd142123", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "start_char_idx": 592, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb58f66f-4abf-4546-ac8d-f9842ed657d0": {"__data__": {"id_": "eb58f66f-4abf-4546-ac8d-f9842ed657d0", "embedding": null, "metadata": {"window": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.  ", "original_text": "So we would expect them to be a little higher in the second half.  \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47061b9b-8e56-4f13-8aac-fe4338696347", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "original_text": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "059ef1786499dcaedfe86110802b3f4c58639c1c9ce76469720eb834fc56d7b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dd1aee6-6f40-4299-8d79-24895b066a43", "node_type": "1", "metadata": {"window": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n", "original_text": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.  "}, "hash": "11963d8ea38033f59d1911f19e6a1798c04993b5129760167d8b858a2a057ec2", "class_name": "RelatedNodeInfo"}}, "text": "So we would expect them to be a little higher in the second half.  \n", "start_char_idx": 731, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dd1aee6-6f40-4299-8d79-24895b066a43": {"__data__": {"id_": "1dd1aee6-6f40-4299-8d79-24895b066a43", "embedding": null, "metadata": {"window": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n", "original_text": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb58f66f-4abf-4546-ac8d-f9842ed657d0", "node_type": "1", "metadata": {"window": "And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n  I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.  ", "original_text": "So we would expect them to be a little higher in the second half.  \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aee5ebf0f454f31ebfe292e7710cbfef97a62ed08bee5525901ff52cb714df93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4c450ba-e362-4427-8e36-f1a4c6c18d9e", "node_type": "1", "metadata": {"window": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "original_text": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n"}, "hash": "b337ae18d672b1e8473804cb4f0c23cd9ae3ab68819b478574760f7ad35a3512", "class_name": "RelatedNodeInfo"}}, "text": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "start_char_idx": 799, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4c450ba-e362-4427-8e36-f1a4c6c18d9e": {"__data__": {"id_": "c4c450ba-e362-4427-8e36-f1a4c6c18d9e", "embedding": null, "metadata": {"window": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "original_text": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dd1aee6-6f40-4299-8d79-24895b066a43", "node_type": "1", "metadata": {"window": "I just mentioned the IT systems in at -Home, and we're also looking at some other areas.   So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n", "original_text": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fb3e8000c8cf21804513905ecb7b86dbf55ec4dfcd2544d5418ee85fb857034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc", "node_type": "1", "metadata": {"window": "So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.  ", "original_text": "Opera tor:  Thank you.  "}, "hash": "e472aa6837f73e8c55f8272d8c4078cf6f509574ff8b5bcde938fb127f393bf2", "class_name": "RelatedNodeInfo"}}, "text": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "start_char_idx": 893, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc": {"__data__": {"id_": "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc", "embedding": null, "metadata": {"window": "So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.  ", "original_text": "Opera tor:  Thank you.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4c450ba-e362-4427-8e36-f1a4c6c18d9e", "node_type": "1", "metadata": {"window": "So \nwe are ramping up some of our expenses that -- in the area of making investments in growing the \nbusiness over the mid to short term.   So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "original_text": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad1fb25a4cd283fdf3508cfa48ebaaa3bbb93d5a45c3eac82a86f7c026236710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ff218e9-ca17-4d4c-b1fd-b39c8098467d", "node_type": "1", "metadata": {"window": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.  ", "original_text": "We'll take our next question from Eric Coldwell with Baird.  \n \n"}, "hash": "0b5983c1e5ba9ded666b80e38ea69ee30453636b4f38c7c888684e7bb1e3d12b", "class_name": "RelatedNodeInfo"}}, "text": "Opera tor:  Thank you.  ", "start_char_idx": 1058, "end_char_idx": 1082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ff218e9-ca17-4d4c-b1fd-b39c8098467d": {"__data__": {"id_": "5ff218e9-ca17-4d4c-b1fd-b39c8098467d", "embedding": null, "metadata": {"window": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.  ", "original_text": "We'll take our next question from Eric Coldwell with Baird.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc", "node_type": "1", "metadata": {"window": "So we would expect them to be a little higher in the second half.  \n But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.  ", "original_text": "Opera tor:  Thank you.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa6497b72506afd754fe6928ec8b20cfacba02b4d0f26089861c23bbe351bdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "093e9060-ee6e-40d9-adf2-0a3bf20a9aae", "node_type": "1", "metadata": {"window": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?  ", "original_text": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n "}, "hash": "b7969c94912a13adef31e94a5631fd5c5599c6d5a6c6273a15dc0b7076641d06", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Eric Coldwell with Baird.  \n \n", "start_char_idx": 1082, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "093e9060-ee6e-40d9-adf2-0a3bf20a9aae": {"__data__": {"id_": "093e9060-ee6e-40d9-adf2-0a3bf20a9aae", "embedding": null, "metadata": {"window": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?  ", "original_text": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ff218e9-ca17-4d4c-b1fd-b39c8098467d", "node_type": "1", "metadata": {"window": "But to our $500 million five -year goal, those are seen as permanent expenses that come out.   But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.  ", "original_text": "We'll take our next question from Eric Coldwell with Baird.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa07622270dc0cd706a43f9548b388dac2b9eb19cb0d21004153d6fea57503e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f", "node_type": "1", "metadata": {"window": "Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n", "original_text": "I'm just curious, it sounds like you're doing some similar things here.  "}, "hash": "9dcf83418250dd35db2f5fe98ecbb90acd3377b60a5941ccc46c5ad541987c5c", "class_name": "RelatedNodeInfo"}}, "text": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "start_char_idx": 1146, "end_char_idx": 1377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f": {"__data__": {"id_": "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f", "embedding": null, "metadata": {"window": "Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n", "original_text": "I'm just curious, it sounds like you're doing some similar things here.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "093e9060-ee6e-40d9-adf2-0a3bf20a9aae", "node_type": "1", "metadata": {"window": "But \nwhat we're talking about is ramping back up the type of investments based on how we feel strongly \nabout the performance of the business for the full year.  \n \n Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?  ", "original_text": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d3bc3251af7e6e270107614348939570745f335c337b1974a85b4f2f1ec60d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c9208e2-7ac9-4be3-8551-f480d53ab37e", "node_type": "1", "metadata": {"window": "We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?  ", "original_text": "And I'm curious what the \nmodel looks like with that business.  "}, "hash": "86359233efdfd28f1321d5c56e77eb801cf7274a878e086a9f5434cc482994b3", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious, it sounds like you're doing some similar things here.  ", "start_char_idx": 1377, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c9208e2-7ac9-4be3-8551-f480d53ab37e": {"__data__": {"id_": "4c9208e2-7ac9-4be3-8551-f480d53ab37e", "embedding": null, "metadata": {"window": "We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?  ", "original_text": "And I'm curious what the \nmodel looks like with that business.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f", "node_type": "1", "metadata": {"window": "Opera tor:  Thank you.   We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n", "original_text": "I'm just curious, it sounds like you're doing some similar things here.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34d4c0e5ac20b713517ed1c788280708418f712c9b42644206f3d72bb361fd95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c30dd8de-33f3-4369-8cdf-a1be278dd7d4", "node_type": "1", "metadata": {"window": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "original_text": "Is this more like a 3PL fee?  "}, "hash": "832ed450c29afd7f1c7eab7eccfd904137d159a05dfdc8feacb42689a24186de", "class_name": "RelatedNodeInfo"}}, "text": "And I'm curious what the \nmodel looks like with that business.  ", "start_char_idx": 1450, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c30dd8de-33f3-4369-8cdf-a1be278dd7d4": {"__data__": {"id_": "c30dd8de-33f3-4369-8cdf-a1be278dd7d4", "embedding": null, "metadata": {"window": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "original_text": "Is this more like a 3PL fee?  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c9208e2-7ac9-4be3-8551-f480d53ab37e", "node_type": "1", "metadata": {"window": "We'll take our next question from Eric Coldwell with Baird.  \n \n Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?  ", "original_text": "And I'm curious what the \nmodel looks like with that business.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e53380d27dcd8ae4222eaa9d96d29cb9dbec8721b86522d30aaca2abb62c434", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a96f82a1-0894-4548-a329-1c2578aaa006", "node_type": "1", "metadata": {"window": "I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.  ", "original_text": "Or how exactly does that work?  \n"}, "hash": "1d320d2c0b46b9f0309a22e8c1720d909f02fee41f62ff9c1c001bb2930df4fd", "class_name": "RelatedNodeInfo"}}, "text": "Is this more like a 3PL fee?  ", "start_char_idx": 1514, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a96f82a1-0894-4548-a329-1c2578aaa006": {"__data__": {"id_": "a96f82a1-0894-4548-a329-1c2578aaa006", "embedding": null, "metadata": {"window": "I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.  ", "original_text": "Or how exactly does that work?  \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c30dd8de-33f3-4369-8cdf-a1be278dd7d4", "node_type": "1", "metadata": {"window": "Eric Coldwell:  We've been hearing a lot about stockpile -as-a-service or storage -as-a-service in \nmedical and perhaps even in certain areas of pharma or therapeutics, mission -critical items that are \noften in short supply.  \n \n  I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "original_text": "Is this more like a 3PL fee?  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4663c3309e193483069a671c5a83a6a183c9c458e4ff2bba629619e94f0c4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098c25e3-9a80-40d2-b16e-441dd8309ed5", "node_type": "1", "metadata": {"window": "And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "original_text": "When does th e customer buy the product from you?  "}, "hash": "bafe53a7bf955f699543310d9b857edfa2350ac86aca91d95be16843bd1c4312", "class_name": "RelatedNodeInfo"}}, "text": "Or how exactly does that work?  \n", "start_char_idx": 1544, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098c25e3-9a80-40d2-b16e-441dd8309ed5": {"__data__": {"id_": "098c25e3-9a80-40d2-b16e-441dd8309ed5", "embedding": null, "metadata": {"window": "And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "original_text": "When does th e customer buy the product from you?  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a96f82a1-0894-4548-a329-1c2578aaa006", "node_type": "1", "metadata": {"window": "I'm just curious, it sounds like you're doing some similar things here.   And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.  ", "original_text": "Or how exactly does that work?  \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "152d204ea968c4f4e5272339da2606e752ea6f9c74a4100ea909dc1fe7f58e90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e8f9477-67b8-4762-88d3-7eb3df3f7142", "node_type": "1", "metadata": {"window": "Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n ", "original_text": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n"}, "hash": "fff12e7fb645d48d278a7674cab37ce48cb9666a3e6fa9272d4ea32e8708bc5c", "class_name": "RelatedNodeInfo"}}, "text": "When does th e customer buy the product from you?  ", "start_char_idx": 1577, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e8f9477-67b8-4762-88d3-7eb3df3f7142": {"__data__": {"id_": "7e8f9477-67b8-4762-88d3-7eb3df3f7142", "embedding": null, "metadata": {"window": "Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n ", "original_text": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098c25e3-9a80-40d2-b16e-441dd8309ed5", "node_type": "1", "metadata": {"window": "And I'm curious what the \nmodel looks like with that business.   Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "original_text": "When does th e customer buy the product from you?  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52eaab21cc8a50a979edd50ab30d26fbeb85f32890730fc4ebcac22a05177af4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138c20d5-9e10-4c2c-8bb4-8540f7c23885", "node_type": "1", "metadata": {"window": "Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "original_text": "Mike Kaufmann:  I think a couple of things.  "}, "hash": "103f0b58449e58554a10b113df8b2ec72076d8454fdc0233801f553a45f800b8", "class_name": "RelatedNodeInfo"}}, "text": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "start_char_idx": 1628, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138c20d5-9e10-4c2c-8bb4-8540f7c23885": {"__data__": {"id_": "138c20d5-9e10-4c2c-8bb4-8540f7c23885", "embedding": null, "metadata": {"window": "Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "original_text": "Mike Kaufmann:  I think a couple of things.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e8f9477-67b8-4762-88d3-7eb3df3f7142", "node_type": "1", "metadata": {"window": "Is this more like a 3PL fee?   Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n ", "original_text": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28568f067aad16c1a100c1c4879fb0c429004e0df6b89885e64273d738215348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c208bd-0207-49b6-86f1-6f50d1778c74", "node_type": "1", "metadata": {"window": "When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "original_text": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  "}, "hash": "3f5c28e2ffc096036d4918ca07484c036b9534019188405c5721d6f931847673", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  I think a couple of things.  ", "start_char_idx": 1720, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c208bd-0207-49b6-86f1-6f50d1778c74": {"__data__": {"id_": "67c208bd-0207-49b6-86f1-6f50d1778c74", "embedding": null, "metadata": {"window": "When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "original_text": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138c20d5-9e10-4c2c-8bb4-8540f7c23885", "node_type": "1", "metadata": {"window": "Or how exactly does that work?  \n When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "original_text": "Mike Kaufmann:  I think a couple of things.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cf14c9ffa8753105a0a5a3072afe4c001ae6cb6351f12fb91dff8b4fbac4e7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9043d293-8809-41d2-9fcf-846b2036490f", "node_type": "1", "metadata": {"window": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "original_text": "So that's \nimportant to note.  \n \n "}, "hash": "589c4cc349f55846b57870ca6aaf8ad02d955e8220687b29476f2100e046ef73", "class_name": "RelatedNodeInfo"}}, "text": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "start_char_idx": 1765, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9043d293-8809-41d2-9fcf-846b2036490f": {"__data__": {"id_": "9043d293-8809-41d2-9fcf-846b2036490f", "embedding": null, "metadata": {"window": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "original_text": "So that's \nimportant to note.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c208bd-0207-49b6-86f1-6f50d1778c74", "node_type": "1", "metadata": {"window": "When does th e customer buy the product from you?   How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "original_text": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b889f9eff3a165cf0ac51dd4c5ea86c4a5ca3688aaee04f6e771eaba88a1b8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9467f47-d6c9-4f85-b216-1bdb79529f0f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n "}, "hash": "a7dadae78e3333cd424d89920a95ed08a5cc3cf964723b95e232a9632438eda9", "class_name": "RelatedNodeInfo"}}, "text": "So that's \nimportant to note.  \n \n ", "start_char_idx": 2111, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9467f47-d6c9-4f85-b216-1bdb79529f0f": {"__data__": {"id_": "a9467f47-d6c9-4f85-b216-1bdb79529f0f", "embedding": null, "metadata": {"window": "Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9043d293-8809-41d2-9fcf-846b2036490f", "node_type": "1", "metadata": {"window": "How are you compensated for the facilities, the \ncapital costs, the storage, et cetera?  \n \n Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "original_text": "So that's \nimportant to note.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e992d3049f4390fec1118d6ce7ed661018cde465e41d4853a991e5af53844052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68e74cea-1f89-4c05-8a07-ee61687ce22c", "node_type": "1", "metadata": {"window": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  "}, "hash": "93d08ee0f10a677d10a01096ba0b91dd3eacf66b52202ee9fae1db747495a3a4", "class_name": "RelatedNodeInfo"}}, "text": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "start_char_idx": 2146, "end_char_idx": 2325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68e74cea-1f89-4c05-8a07-ee61687ce22c": {"__data__": {"id_": "68e74cea-1f89-4c05-8a07-ee61687ce22c", "embedding": null, "metadata": {"window": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9467f47-d6c9-4f85-b216-1bdb79529f0f", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  I think a couple of things.   First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "905e7f4d5d42bce7a43ba14607ebaae80b512fa32fc2efe991a09cd069a7c27d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "391b8bff-c6b7-435d-a581-950984f8686b", "node_type": "1", "metadata": {"window": "So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n "}, "hash": "de31729a5f3e336aaa75dc1f9555d23613221f5a1e5105277f9ec4da7678b52f", "class_name": "RelatedNodeInfo"}}, "text": "I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "start_char_idx": 2325, "end_char_idx": 2741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "391b8bff-c6b7-435d-a581-950984f8686b": {"__data__": {"id_": "391b8bff-c6b7-435d-a581-950984f8686b", "embedding": null, "metadata": {"window": "So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68e74cea-1f89-4c05-8a07-ee61687ce22c", "node_type": "1", "metadata": {"window": "First of all, the last thing you said is important is that we \nwould intend to be prop erly compensated for that, as with any investment, we\u2019re working with \ncustomers to make sure that the services that we provide, we're getting compensated for not only \nfrom an income statement, but appropriately looking at our balance sheet and the return.   So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ca8d93573c7288109769b524afe0827a70432188db0f123258561eea335bc96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ec43f19-d7a0-4fe9-b02b-39c429e8727f", "node_type": "1", "metadata": {"window": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  "}, "hash": "456d29c414d6cfbbab9b941a04d8c64c217f2a0fc3b742f3f8dc16cce64df79a", "class_name": "RelatedNodeInfo"}}, "text": "And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "start_char_idx": 2741, "end_char_idx": 2838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ec43f19-d7a0-4fe9-b02b-39c429e8727f": {"__data__": {"id_": "3ec43f19-d7a0-4fe9-b02b-39c429e8727f", "embedding": null, "metadata": {"window": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1ae1264-4732-4177-936b-cd28f69fb016", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4899247b56f13a87604beed853c798542cc2c402815a99254fb5a701b3ce93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "391b8bff-c6b7-435d-a581-950984f8686b", "node_type": "1", "metadata": {"window": "So that's \nimportant to note.  \n \n  To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4ed6aa70daee7c25902d41ab6f9d431c2f2b8f55381abc801f7e7b7935deb11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6391cc6e-a3f9-4e81-899e-61bbcf8b081f", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "original_text": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n"}, "hash": "d0361f8ef28e391dd9b88022596bfdc2d02c94b709728e44bbe79d43bf6cf278", "class_name": "RelatedNodeInfo"}}, "text": "And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "start_char_idx": 2838, "end_char_idx": 3107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6391cc6e-a3f9-4e81-899e-61bbcf8b081f": {"__data__": {"id_": "6391cc6e-a3f9-4e81-899e-61bbcf8b081f", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "original_text": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ec43f19-d7a0-4fe9-b02b-39c429e8727f", "node_type": "1", "metadata": {"window": "To give you specifically on how it would work, that's a little more complicated because I think \nit's -- we're going to see inventory changes across the entire supply chain.  \n \n  I think you're obviously, one, going to see suppl y changes in the way that probably the \nmanufacturers work and the amount of inventory they're carrying to be able to get through these \ntypes of things; the location of our supply chain and where we -- the percentage of what we self -\nmanufacture versus what we source, we continue to increase our capacity, for instance, to \nmanufacture our own drapes and gowns.   And so the ability to ramp that up, store inventory and \nmanaging it that way would be one.  \n \n  And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "original_text": "And then as I mentioned, we are building some larger distr ibution centers so we have the \ncapacity to do that on our end, both to make sure our service levels are where our customers expect \nthem to be, but also, in certain cases, carry that inventory for customers.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73952189a56c2722aaa78d3996e08a0d22088d56fc01d44a3d9b787c7117e277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56d0b7b8-962b-4304-b5b5-c8a192fb22a6", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.  ", "original_text": "And that can create some different opportunities for us to work with them.  \n \n "}, "hash": "ebe250aa1277c50125064d42b8e6a2f951fcc0da1e029de4dcd1515f3d3a002a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n", "start_char_idx": 0, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56d0b7b8-962b-4304-b5b5-c8a192fb22a6": {"__data__": {"id_": "56d0b7b8-962b-4304-b5b5-c8a192fb22a6", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.  ", "original_text": "And that can create some different opportunities for us to work with them.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6391cc6e-a3f9-4e81-899e-61bbcf8b081f", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "original_text": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07a46490df30547123773b7a59501a2f54d2aaa8f1b9995ed10efd5a3fa87932", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd5a41bf-06b5-49f5-9eed-96778e2c539d", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "original_text": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.  "}, "hash": "ec79de3df813f2ef75d982d6c169c639e35b85f79f68a08a0ee443fc309f4152", "class_name": "RelatedNodeInfo"}}, "text": "And that can create some different opportunities for us to work with them.  \n \n ", "start_char_idx": 215, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd5a41bf-06b5-49f5-9eed-96778e2c539d": {"__data__": {"id_": "dd5a41bf-06b5-49f5-9eed-96778e2c539d", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "original_text": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56d0b7b8-962b-4304-b5b5-c8a192fb22a6", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.  ", "original_text": "And that can create some different opportunities for us to work with them.  \n \n ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d558274d8aaa327a6187776aecccff50c8eedc45cc1d64a5f51b1631a2f74ebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ed43fc5-438d-4444-b527-f1f1c4944086", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "original_text": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n"}, "hash": "6862805ce4479505c3e2707fa67b7510aed646603ff9f963af4649bd88f87a1c", "class_name": "RelatedNodeInfo"}}, "text": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.  ", "start_char_idx": 295, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ed43fc5-438d-4444-b527-f1f1c4944086": {"__data__": {"id_": "6ed43fc5-438d-4444-b527-f1f1c4944086", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "original_text": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd5a41bf-06b5-49f5-9eed-96778e2c539d", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "original_text": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e33f09c07b5360e164e23c1789c5bce141b4c6caed8e66eb8629f12f1bc72c99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2767d92-6822-4469-9706-fc9752cae448", "node_type": "1", "metadata": {"window": "And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents. ", "original_text": "Operator:  Thank you.  "}, "hash": "2ea58d4b9893cebbab261c7e766c07ca9c14b100dcebccf3ab03765befb3b676", "class_name": "RelatedNodeInfo"}}, "text": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "start_char_idx": 405, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2767d92-6822-4469-9706-fc9752cae448": {"__data__": {"id_": "b2767d92-6822-4469-9706-fc9752cae448", "embedding": null, "metadata": {"window": "And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents. ", "original_text": "Operator:  Thank you.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ed43fc5-438d-4444-b527-f1f1c4944086", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "original_text": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c9914ad69dc0395dee3aebf17a4f138b75d78c0890524028f12921d029e26c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "388a9fab-9edb-46d5-b2ac-062f48b004c3", "node_type": "1", "metadata": {"window": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "original_text": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n"}, "hash": "80b9c756efd678e8af7c5336fb16e536083a1f5e7e95f8d4ca1e9fd1647088fe", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 604, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "388a9fab-9edb-46d5-b2ac-062f48b004c3": {"__data__": {"id_": "388a9fab-9edb-46d5-b2ac-062f48b004c3", "embedding": null, "metadata": {"window": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "original_text": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2767d92-6822-4469-9706-fc9752cae448", "node_type": "1", "metadata": {"window": "And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents. ", "original_text": "Operator:  Thank you.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c8378ea0a60ec88955e98ccf4dcdfe81a87b626b8fc2722478b3ce36df79f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de", "node_type": "1", "metadata": {"window": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  "}, "hash": "9f55684fdb087bb7040ccd8a107fab5b42ab587d280fa1f7a39fcdafe25ebd45", "class_name": "RelatedNodeInfo"}}, "text": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "start_char_idx": 627, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de": {"__data__": {"id_": "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de", "embedding": null, "metadata": {"window": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "388a9fab-9edb-46d5-b2ac-062f48b004c3", "node_type": "1", "metadata": {"window": "So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "original_text": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2b4564a51169921e15936304d6e74e94b074a681f242752428194925c402aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd668294-fd5a-4eae-ad7f-45a833e0f2cc", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "original_text": "I know you said you're taking \ncare of small chain pharmacies and the independents. "}, "hash": "10ff20672c0380e91448a84030552da036032f5f6adb7dab9ce547487a6f5155", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "start_char_idx": 704, "end_char_idx": 779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd668294-fd5a-4eae-ad7f-45a833e0f2cc": {"__data__": {"id_": "dd668294-fd5a-4eae-ad7f-45a833e0f2cc", "embedding": null, "metadata": {"window": "Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "original_text": "I know you said you're taking \ncare of small chain pharmacies and the independents. ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de", "node_type": "1", "metadata": {"window": "But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86aff152052a37bcf3fb2b0bf46499bda6936efc5b687729655159dcf63ec71c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cad9f854-3fea-498b-8840-e802193963ab", "node_type": "1", "metadata": {"window": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.  ", "original_text": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n"}, "hash": "d7ea5a457444489dda1f6cea2ea229d0561efe2f5aa3ac657378d4dbe2ee381e", "class_name": "RelatedNodeInfo"}}, "text": "I know you said you're taking \ncare of small chain pharmacies and the independents. ", "start_char_idx": 779, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cad9f854-3fea-498b-8840-e802193963ab": {"__data__": {"id_": "cad9f854-3fea-498b-8840-e802193963ab", "embedding": null, "metadata": {"window": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.  ", "original_text": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd668294-fd5a-4eae-ad7f-45a833e0f2cc", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "original_text": "I know you said you're taking \ncare of small chain pharmacies and the independents. ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cac94a7360e3e419b16a8cdf7a7b373aefad56dec07f45016d011c1851371f89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7", "node_type": "1", "metadata": {"window": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "c8aa91d97c8affac6fe4bc608b8b2b3beca7d2b01e32894c599c214a4da6bc55", "class_name": "RelatedNodeInfo"}}, "text": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "start_char_idx": 863, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7": {"__data__": {"id_": "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7", "embedding": null, "metadata": {"window": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cad9f854-3fea-498b-8840-e802193963ab", "node_type": "1", "metadata": {"window": "And we will take our final question from Brian Tanquilut with Jefferies.  \n \n Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.  ", "original_text": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b60c57982e749d5885607261febdfd4299f4ec4bfe3da55925af02725dc7071e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac3102f3-46be-49b0-a729-17e49e6fd950", "node_type": "1", "metadata": {"window": "I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.  ", "original_text": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  "}, "hash": "310ca2205043c76a4c68e5bc52b774464ac42ca1e61f2731808000819991efb7", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1056, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac3102f3-46be-49b0-a729-17e49e6fd950": {"__data__": {"id_": "ac3102f3-46be-49b0-a729-17e49e6fd950", "embedding": null, "metadata": {"window": "I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.  ", "original_text": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7", "node_type": "1", "metadata": {"window": "Brian Tanquilut:  Mike, just a question on the vaccine distribution side.   I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f43f52f56a2ce2393e64946a299c57b6eac622e4bac314c2b1d1d3528a3425e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4493bf71-1160-4700-85ff-495850095cc4", "node_type": "1", "metadata": {"window": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.  ", "original_text": "So I don't really have any good insights on to how to help you on that.  "}, "hash": "d235f047663c2bac60e0cb4cae676930475d81a4ba49f0d56c3e17f2d3241f72", "class_name": "RelatedNodeInfo"}}, "text": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "start_char_idx": 1078, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4493bf71-1160-4700-85ff-495850095cc4": {"__data__": {"id_": "4493bf71-1160-4700-85ff-495850095cc4", "embedding": null, "metadata": {"window": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.  ", "original_text": "So I don't really have any good insights on to how to help you on that.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac3102f3-46be-49b0-a729-17e49e6fd950", "node_type": "1", "metadata": {"window": "I know you said you're taking \ncare of small chain pharmacies and the independents.  So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.  ", "original_text": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e352fdae7900798248ce1b9bfa62c33aa34889bfaa097b3c6c7cb4789512322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38561a4e-0e5b-4625-bd28-f02d52c88a11", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.  ", "original_text": "I would tell you \nthat we continue to be there for our customers.  "}, "hash": "c43ef7d6862fbac101ebb49d77c54fa34c9e3a971499f175048be7c85ced6367", "class_name": "RelatedNodeInfo"}}, "text": "So I don't really have any good insights on to how to help you on that.  ", "start_char_idx": 1175, "end_char_idx": 1248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38561a4e-0e5b-4625-bd28-f02d52c88a11": {"__data__": {"id_": "38561a4e-0e5b-4625-bd28-f02d52c88a11", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.  ", "original_text": "I would tell you \nthat we continue to be there for our customers.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4493bf71-1160-4700-85ff-495850095cc4", "node_type": "1", "metadata": {"window": "So is there any sort of sizing that you can put \nthere or in terms of like what your clients are thinking in terms of the percentage of overall \nvaccinations that they will get as a group?  \n \n Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.  ", "original_text": "So I don't really have any good insights on to how to help you on that.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eefcc72979bf98b44d45be6d787993fb78a17dccf50c3c196434f7e69da44ab1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b813436-5deb-470e-94b4-c7fe0aa1b1c2", "node_type": "1", "metadata": {"window": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "original_text": "We're going to continue to help them be ready to do \nit.  "}, "hash": "72a5ed3e77cdb5ef4e21d86fa83424d1ba4ed387e2b404bc1ab53fb0f9a77791", "class_name": "RelatedNodeInfo"}}, "text": "I would tell you \nthat we continue to be there for our customers.  ", "start_char_idx": 1248, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b813436-5deb-470e-94b4-c7fe0aa1b1c2": {"__data__": {"id_": "9b813436-5deb-470e-94b4-c7fe0aa1b1c2", "embedding": null, "metadata": {"window": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "original_text": "We're going to continue to help them be ready to do \nit.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38561a4e-0e5b-4625-bd28-f02d52c88a11", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.  ", "original_text": "I would tell you \nthat we continue to be there for our customers.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79687cad3b9d44015289ba1e7f8f3a008be5dce31f385345c26eb1c7023393b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "435950b2-528c-4a4b-8478-c60a73877603", "node_type": "1", "metadata": {"window": "So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.  ", "original_text": "It's not a driver at all for our financial statements one way or the other.  "}, "hash": "f22be7411cd9eccbd4c76356ffd2ba7643746102b72efcf08f0dfba0c9010c04", "class_name": "RelatedNodeInfo"}}, "text": "We're going to continue to help them be ready to do \nit.  ", "start_char_idx": 1315, "end_char_idx": 1373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "435950b2-528c-4a4b-8478-c60a73877603": {"__data__": {"id_": "435950b2-528c-4a4b-8478-c60a73877603", "embedding": null, "metadata": {"window": "So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.  ", "original_text": "It's not a driver at all for our financial statements one way or the other.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b813436-5deb-470e-94b4-c7fe0aa1b1c2", "node_type": "1", "metadata": {"window": "At this point in time, it's -- as you know, it's state by state, it changes on a \nweekly basis.   So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "original_text": "We're going to continue to help them be ready to do \nit.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79d086df345b8b03812ec1c9f24b91667e3b6032b16723a751bc031f493fffe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ed75657-793d-452f-b727-a495283ffc07", "node_type": "1", "metadata": {"window": "I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "original_text": "So from a financial driver, \nit's not material.  "}, "hash": "048064dedd10809000c21db81f9693946652b4c458795bb62060fc65f4378a4c", "class_name": "RelatedNodeInfo"}}, "text": "It's not a driver at all for our financial statements one way or the other.  ", "start_char_idx": 1373, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ed75657-793d-452f-b727-a495283ffc07": {"__data__": {"id_": "0ed75657-793d-452f-b727-a495283ffc07", "embedding": null, "metadata": {"window": "I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "original_text": "So from a financial driver, \nit's not material.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "435950b2-528c-4a4b-8478-c60a73877603", "node_type": "1", "metadata": {"window": "So I don't really have any good insights on to how to help you on that.   I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.  ", "original_text": "It's not a driver at all for our financial statements one way or the other.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ef91143bc286d0c240297d835363603350e07c92e8c5e3e5124ce8061d656a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118", "node_type": "1", "metadata": {"window": "We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "original_text": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n"}, "hash": "ca6d5f8f0755a6882a3a38b45630753ea8f17fcc9a04552e59161bcf07fada7d", "class_name": "RelatedNodeInfo"}}, "text": "So from a financial driver, \nit's not material.  ", "start_char_idx": 1450, "end_char_idx": 1499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118": {"__data__": {"id_": "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118", "embedding": null, "metadata": {"window": "We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "original_text": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ed75657-793d-452f-b727-a495283ffc07", "node_type": "1", "metadata": {"window": "I would tell you \nthat we continue to be there for our customers.   We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "original_text": "So from a financial driver, \nit's not material.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c87ae4cc6dfa2c818f4fb2b377875132d8ed1deeb95cdd8d378be6e0c5e4c85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "551b90ae-1d33-42a1-83cb-518d1f058c71", "node_type": "1", "metadata": {"window": "It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "original_text": "Operator:  That will conclude our question -and-answer session.  "}, "hash": "df6f60a43152160b268a74c3d83c5314fd2b24ed84eb056ed7262af3f2a5fe6e", "class_name": "RelatedNodeInfo"}}, "text": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "start_char_idx": 1499, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "551b90ae-1d33-42a1-83cb-518d1f058c71": {"__data__": {"id_": "551b90ae-1d33-42a1-83cb-518d1f058c71", "embedding": null, "metadata": {"window": "It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "original_text": "Operator:  That will conclude our question -and-answer session.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118", "node_type": "1", "metadata": {"window": "We're going to continue to help them be ready to do \nit.   It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "original_text": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90b015e58dfe681bb58b3516452b3ed7dee6f7994d11a73c65d72db79bbadb46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caebd90e-6b8a-4221-8c8d-b965932e6e18", "node_type": "1", "metadata": {"window": "So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.  ", "original_text": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n"}, "hash": "8775f88b31fefcd552248716c88062ba21ee140c139bea34c039560b75924419", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  That will conclude our question -and-answer session.  ", "start_char_idx": 1654, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caebd90e-6b8a-4221-8c8d-b965932e6e18": {"__data__": {"id_": "caebd90e-6b8a-4221-8c8d-b965932e6e18", "embedding": null, "metadata": {"window": "So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.  ", "original_text": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "551b90ae-1d33-42a1-83cb-518d1f058c71", "node_type": "1", "metadata": {"window": "It's not a driver at all for our financial statements one way or the other.   So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "original_text": "Operator:  That will conclude our question -and-answer session.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b0a2c2a1e8c6344c3b9ad347e9c5e5eddfb8dfe408ac0740a35d0c9280a0067", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74163fee-ee65-478a-b3a7-3bf4c0b75042", "node_type": "1", "metadata": {"window": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.  ", "original_text": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  "}, "hash": "2e45012a419178f44bbcee08fbcaf963ac4a747b71a954bb92e4474320d07b18", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "start_char_idx": 1719, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74163fee-ee65-478a-b3a7-3bf4c0b75042": {"__data__": {"id_": "74163fee-ee65-478a-b3a7-3bf4c0b75042", "embedding": null, "metadata": {"window": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.  ", "original_text": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caebd90e-6b8a-4221-8c8d-b965932e6e18", "node_type": "1", "metadata": {"window": "So from a financial driver, \nit's not material.   But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.  ", "original_text": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e92a157c5741772cd8c16fd4cfefe2fa86d7de4465ec58ae69903061cbb23af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46c12372-93b9-48b1-8d50-be880a060783", "node_type": "1", "metadata": {"window": "Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n"}, "hash": "1a2681b2e525d3f851a85ec8b9a1720415a994b90669cfefd96f7f28e55f3e70", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "start_char_idx": 1830, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46c12372-93b9-48b1-8d50-be880a060783": {"__data__": {"id_": "46c12372-93b9-48b1-8d50-be880a060783", "embedding": null, "metadata": {"window": "Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74163fee-ee65-478a-b3a7-3bf4c0b75042", "node_type": "1", "metadata": {"window": "But it'd be really hard for me to even give you anything there because of the \nchoppiness of the amount of vaccines that we're s eeing state by state.  \n \n Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.  ", "original_text": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8101e31b642ec9e2a79b14ea708f2b99dcb44c93c3e194b2de5582061814d393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6863459-7f7a-4e15-a14b-9afc3210dd96", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "Operator:  Thank you.  "}, "hash": "4e455c7424eee2ca5d33e67c34de51deb56dc7422ce7ccdcf87bfc0c16a01234", "class_name": "RelatedNodeInfo"}}, "text": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "start_char_idx": 1915, "end_char_idx": 2074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6863459-7f7a-4e15-a14b-9afc3210dd96": {"__data__": {"id_": "d6863459-7f7a-4e15-a14b-9afc3210dd96", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "Operator:  Thank you.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46c12372-93b9-48b1-8d50-be880a060783", "node_type": "1", "metadata": {"window": "Operator:  That will conclude our question -and-answer session.   At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02124a865bee75ff1f56c94dcd5640871ac4e7d78a152ebedfedb6a33a0b36dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c7aece8-2d1b-4bd1-bd77-4af203362e97", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "That concludes today's call.  "}, "hash": "93a1a8f0397522ccd242202ffaa372831773de8bc0f0297002b254ddb731618d", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 604, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c7aece8-2d1b-4bd1-bd77-4af203362e97": {"__data__": {"id_": "3c7aece8-2d1b-4bd1-bd77-4af203362e97", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "That concludes today's call.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6863459-7f7a-4e15-a14b-9afc3210dd96", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call \nback over to Mike Kaufmann for any additional or closing remarks.  \n \n Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "Operator:  Thank you.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db56efbf085b643701ea3beff196c1e8883cfe762d66c1fe52aa151f696db284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "963c4d3c-0cff-4257-b200-c5e80e57edfc", "node_type": "1", "metadata": {"window": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "We appreciate your particip ation.  "}, "hash": "c323df106819b84b08108819f51b35e04282fad3369faf6dcae5791ba2706f9d", "class_name": "RelatedNodeInfo"}}, "text": "That concludes today's call.  ", "start_char_idx": 2097, "end_char_idx": 2127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "963c4d3c-0cff-4257-b200-c5e80e57edfc": {"__data__": {"id_": "963c4d3c-0cff-4257-b200-c5e80e57edfc", "embedding": null, "metadata": {"window": "And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "We appreciate your particip ation.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a744e44c-75af-453a-8c6d-baf9da576fd5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baef0e9e1879c080e01b778e409ac14fdf110690093cd80794ddc3ebc791d6ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c7aece8-2d1b-4bd1-bd77-4af203362e97", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, I really want to thank everybody for join ing us this morning.   And on behalf of \nall of us at Cardinal Health, I hope you and your families are safe and well, and we look forward to \nspeaking to all of you again soon.  \n \n Operator:  Thank you.   That concludes today's call.   We appreciate your particip ation.  ", "original_text": "That concludes today's call.  ", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0a105c162995ed9a8f2f5a109dad393c72f8eb1345cfe1cc0219283e5c76f07", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate your particip ation.  ", "start_char_idx": 2127, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"41316b80-30ce-400c-8319-4b5b9a65544e": {"doc_hash": "0508ad65ebc4d2739faa3b2b0307c66a2ab3d05b477f9ea1c0c960b744eebf05", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58": {"doc_hash": "6d1239b417a96581d8554a02ddd7acf258b309cdbd89d1c35096f5de556dd8f7", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67": {"doc_hash": "7ed0cb26129d87b9abfc405dea9a2a3b0f43bd739bbeb44025d5b2c2ea8cd85c", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "88d9e3e4-2d6d-4039-a939-e84930b32699": {"doc_hash": "b40e611a23e9354d3b2e54f06dd0262d1b1733fa95a969b11e64683a56bb7e23", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b": {"doc_hash": "22367f115dbe8bde5bfe59bde2c9662178cfb68e7565a7864926c545a96c45dc", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "3c6e526e-b38e-4e84-b1fc-5c50219eb411": {"doc_hash": "349e4082aeae101616ccfb2df803253039bd684e8cdd451cbe04ce791841bf8b", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "7e937027-1041-4c95-b8d5-c12ec234f856": {"doc_hash": "23c95d207741ceb05e808e54d3cfcb84826557d11c623aba23c6b958a871bc28", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6": {"doc_hash": "0506f756a5940f4e2425997150c6225b20ccc8fd0677e359e78979304f5b35f5", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2": {"doc_hash": "3439ddf55f8dcc04d0edb7bd067e4582e98723837dacd282f418f7e4f7635c59", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "d448a807-bf5d-4b98-8d68-2f6e0537b1f1": {"doc_hash": "da77632a8413361529f67ca693f4967cf9260a07f5cdcd40582ceaa2fd91e825", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "da81d20e-9b38-4a6f-9046-728898a30251": {"doc_hash": "fc64c9275e63cde2d959a253a81f962729c496d0bf51ac381a9fe27129e8d491", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "cf175af5-9495-4f5d-ad14-a0644b9c7f1a": {"doc_hash": "9874cb43a63552be2e5f22682cc25c2d0a509738c8ca3631c91e670f0b2256a1", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf": {"doc_hash": "c93ed7a402f6b200fe5e69772a9765089fd6ed94004d29444e5239e6a0283f65", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "36e972bc-a93e-4e5d-92bb-6fef40446c80": {"doc_hash": "4eb6c237c351314338324d0d9365d16f779eceb2b320ae092b758ed8bc700e28", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "482a28d0-e57e-461e-a52c-f5da8d113860": {"doc_hash": "383b8b741a4f4d73118b07aed7f4bf9ad4ea627e308651c9fbfa29cbf82cba38", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "cdd08179-86fb-4a64-b6b6-d286ef58d146": {"doc_hash": "3a029220736a1eaef94f618c8d0f9f36c286428272ddd5f36cf2343858484388", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "8236c2a3-ae41-4c98-bd37-bf2bff5640a8": {"doc_hash": "3c1e3e8e40a4166ea7dd459cf51f7647479329215b6f153c420a1efc724fbfbb", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "0f63f061-2dc9-4a60-a782-03291bd22955": {"doc_hash": "cf9b01cc670ced2d5d9eb02bf1648d08f4b935f041701aa3535ce2062b14953c", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0": {"doc_hash": "23b1078002b00c117314b1871f00318ae88440fc497fadfd12a915ad2a74a023", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "aadeff19-5668-4197-82ff-60e6a403ce95": {"doc_hash": "b80e415d1c853f30541e3cd14bccb4af368a8470aeed52d8bb8156b8e6bf2f39", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "580a089d-064b-4f95-9f48-ffd1e5b5de2d": {"doc_hash": "e63b07d1e00b5274c6386a31187c94a916d99a039ef8a5ebd7dd63809cb9140b", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "13351ad6-18c4-4edf-b783-59cc732822b0": {"doc_hash": "0ad5d6c035b7833b1140d5b09ff37f082f955eff36003570d101ff269fb83a88", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e": {"doc_hash": "32b3172e9d64f78d4556c77dda3beb0aa183f754ba3a3ea555676763c75ffe70", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68": {"doc_hash": "576884c4b6749d5698c466027386f2b84e0f3964f5a12b042091346bc805bddd", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "e4dc5b93-bab6-4152-82bc-59fbd5714aa1": {"doc_hash": "a6cddfd402d69aa00ab1cc476b97ab9af432666090453eb7dda329e12a5ee03c", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "81d5b8a8-4fde-49c0-8a29-4a256e974224": {"doc_hash": "70ffeb394d669eba02bf5ecf8aad8212efcccb245b120f8716805f17f37f1338", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "1e14199d-38a3-4643-9959-9cfd67b9829e": {"doc_hash": "ecf05b2dd2fa6e5fcdaecbd0dc47848e2b4841166c61cd1cd5cc5e6f90dcb5d0", "ref_doc_id": "4dcfea83-8c8b-4f2d-ab1e-40de6beee828"}, "9096962c-e6de-453b-81f0-4f0a7c14c50d": {"doc_hash": "3dc458cf11ae81a4960e31acd946781978896800c44a652cbb8017459f969548", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "2e287777-3b67-4fa5-b368-15876ee589bb": {"doc_hash": "291c59c647aa401e29cf09cd7b85fad1243b83925ea8b35542a71dc2e590108a", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "bf6f2b5d-02dd-413a-9ec5-9ebe24870787": {"doc_hash": "b884cbe2235c944a78751efe87d6683efc9ac3b8fd0b6a9cdf1623b605a250dd", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "b0a3dd09-7b76-47ea-b5dc-effc051e43ce": {"doc_hash": "662d40bec28c491ca140d8f82913c087b5583474d6f672e5af9f64847c9176a0", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "74ee92fb-a909-4e99-ab6a-ddb655a87e1e": {"doc_hash": "f49917c278b062c165f6d86ac09b424b023e6f6e268df23589026da8271fa871", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69": {"doc_hash": "7578faa83be2180000faa82f8ac0e559d83d7741bc1e5aa36c4714a1ddea001b", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "8a7cff0c-7255-4537-93cc-ff3310bd5288": {"doc_hash": "10b2cba0817fe46e83a56308c47e6057b5e137e19d261615a9e64bf8ba92d248", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "587dd507-70ff-46d1-a6bd-058f34769e68": {"doc_hash": "7270a1ce36eaa821e23170e4ccd70a49c9fff5eecc27b03f9c38ba6f9305ba9f", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "c25b0ce2-4c77-4f2f-ac72-0eede3d16126": {"doc_hash": "2e486bb3d0ca6d60dc2613a12b63cf2c7e8b6038c56a99d0e4f6dbfed5b7a328", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "42f2e63a-9af2-4851-a6d9-996e7650569a": {"doc_hash": "5f140c9fa53284515b55abdb966605dfba5d2393c2c8fdbc5be6b0439a8edd5b", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "d42c2ca8-1b82-4989-8530-ce7b204a6eec": {"doc_hash": "29b4df2478763881fe9f34d4a8b52a05e28b7a112cfe27b3f3443e452249c5f7", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae": {"doc_hash": "4605787e471cde707f943088620634ca858f23a6a7c2711f23845649630e614b", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "e29ef39a-cf72-4fea-80f8-a3f12b361598": {"doc_hash": "02b2ba18cceea11cd154561043bd1404cdd71dde6f81028d3ffe43e3223a110f", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "f7d190be-0f24-4876-aa2a-3539fe9e9fda": {"doc_hash": "dbb9586cd12822ba92bc96df2b14fc5e168e76ea3b424000d2c8896c1761d487", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "c21ae3a7-6c2f-44ac-9d32-7277f411e55a": {"doc_hash": "a12f6da85347f965f97908d5b52cffc442b5e97a093f2e2161608fcd81432182", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "51ed658d-463f-4b41-86d5-e23fe4a5f44c": {"doc_hash": "25e3fcdc5cc61b1af51f76be1e34911b22880786a6f0759b12928967f8d13cca", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "f049eb98-69b3-4313-a3bb-7911a343b9f9": {"doc_hash": "d2a2e0da79c6cfce5d6aa013f3d6459b81d779f752c4eae49c7d26767790e494", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5": {"doc_hash": "3df2ac8130194143c32d74346ee7c6a8c4d3ae54c5541a89a8ac52abc54cc5dc", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "db083297-0a34-460b-b861-a785657f5b09": {"doc_hash": "cadd1f55ea7af9f583d47da9caacdeb97aa15915a7330850937d3d2935753318", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "869540b6-a772-4b4e-a5dc-5751328ee21e": {"doc_hash": "5157f67c19538ed3a5cea3cca35549ee6e068d2680ba557a0c553c1055568989", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0": {"doc_hash": "cb1f5d2fc0d60b792176d6fe02386deca031cd3d5ac43e6a610a76c3a5463336", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "3f170178-284f-4887-835c-f090af1a9e7e": {"doc_hash": "b280db229e3e1ff9fb5d598596b767cd963698e7a2449e23fd25ee9745c2c81a", "ref_doc_id": "d4db70c3-3b4b-48f3-84b5-5600da184518"}, "d3030068-d6c7-4974-8aea-f422050d5c81": {"doc_hash": "12800a8f2e2ac6908d8eb18f9249874d9981deeab28a53e3fff77b5b4a53301f", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "3c9c3045-d998-45d8-b928-033ebb9598b2": {"doc_hash": "5b82a2856840100f5b237797ef4f0d798fff3c45b288d98a0aafac89c376d126", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "0969bf37-5972-4827-a7fd-cd5926f77f3b": {"doc_hash": "931da0589e5156ab0f8d67981cb43f5b69880339cb0f6810e81e95ee53830221", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "4c6cf285-9348-4999-8ee8-2ee746f96589": {"doc_hash": "a7f7b3a7fb1e025b51ae2c48c834c4f23a80782f6bb847d356398032814d33ac", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "ba9d4dea-6a79-4a05-be69-55c28f812414": {"doc_hash": "12f987dbf780b8fb22805daad77d7bdc631ada0d930f8d48e145acd779083d7b", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "37b111a1-83dd-412c-b72d-28b2f6f9e29b": {"doc_hash": "c1675ef14af38fdaf8e88c0a6a023fe6c47d1154a0c5bd20de0864d59fc4e0e1", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "6a0ff9cc-47db-49ac-87c4-df3b18a5d029": {"doc_hash": "ca99678f5bad4195cb8e83aef5c38f3530a684d858991acbcb8a39f4b994d1df", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "59199d16-ea90-4b4f-92f7-4e8f44f83a26": {"doc_hash": "eec3c7f769e78337ad8ecf8f78a39e32cb66b94ffdea937ed862c7cc46759b37", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "aec4e766-d2f5-4b46-a914-74fd7978dd66": {"doc_hash": "6ba01c998431b7a230bd4a90a4712c6892c50dbfd187ced3a470dcb91b800fb4", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "c23717cc-1fa0-4021-9ff1-74262d576505": {"doc_hash": "d96ca4f64147d2a7ecc04908e5ed3485e7ee5c6cab1c05a8cb73f6c348c856fe", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "34987c79-8cca-4fdf-a29c-2e245668fa8b": {"doc_hash": "d75466af0e80f8f2294944c110359936e154bb2699864ba72f55c3f602747bdd", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "6daa8ba2-40b6-47f5-9686-8e51b115d42d": {"doc_hash": "dca829d23ee2327efd171ddde7470eccac3848f128fd4249256e2d694748f0af", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "ac2768c5-a8e2-4526-8833-97045f5abdf2": {"doc_hash": "d28aaee910e4412f820043474464dad6f00e6bee37c154d128cd90ced77b824d", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "e9a5b043-67f4-4792-80c2-e3505f575fa0": {"doc_hash": "3a492833a5f9c92045c51e853b3b495cc7f344ab00045939564a6f5f9a722b2c", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "d9ebdb1b-9b8c-4df9-8772-134317c08b75": {"doc_hash": "9873bb6901c327358e65f8a32ee51ad52a9cc6982d36bbc5b90159bc8347ef4e", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "fd72bfb2-a138-4d63-a88c-b3a552798d4e": {"doc_hash": "86eabb67ba7fcefc448aa7e35719e8636a5e1d62839aa283501be38e79871397", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "aafff343-a23e-4700-a0a6-cf368e04292f": {"doc_hash": "db8ba0c9420e0f13332f58f444afc39aef52512de1bcb910716356d2ac0703bb", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "16808585-884f-415e-a130-c372c2047d65": {"doc_hash": "bd0cb918a8dfab498ef74d6d931e987545511661be5c85a6090cf692e08e4a7d", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "cf10b510-0416-4ad1-a5a5-d34916cc19c6": {"doc_hash": "e15c31681b93fce0fa2d3a232534f888ed2c19b4a28c52522490824bf5a1ab59", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "93d454cb-6353-4710-bc4e-73b7136ab80a": {"doc_hash": "4f8b512cb3ce50118a962616beda781d0f37d79aa2cdd3afd661a5ec002fd947", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "7c689f69-0266-43ee-b4f3-fe6b5709ca9d": {"doc_hash": "2d5c8fd657f5a5002f534b7e007bc701926a0e4df9499f5cede730445efd18b3", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "37e9dd54-3c4c-47c1-bcad-b22c27bb583c": {"doc_hash": "c2e3da2992bdc495375e4bf05671ec0571387ad6ff2bb8f7f8d7618a855f29c4", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "8af2f2cd-e31a-4310-8b53-051f33139850": {"doc_hash": "7ca389934da8f304e194ed5adec11470ea2010f0f4cb5e3d099837501b4bc879", "ref_doc_id": "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74"}, "0f4c776f-89a2-49ae-871c-13849d846452": {"doc_hash": "a5323e1a88e06adb79f52d27227f417556f49bad55b256604c387937ce8a58e0", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "0508242e-50ec-4d43-b991-7c4be367cea7": {"doc_hash": "ee33a177133fe037f48b4ab0bcc369ce4d30960303eb3567c8339547c906ba6d", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3": {"doc_hash": "a084ecdb1faf83b5c1577eaaf9fc8661c8a52c2b9297cda016c751c944ab3c6b", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "62dcb3eb-fe8c-4eb0-a981-222b72a57927": {"doc_hash": "748eba6a5930e957922360f3e8e94949d47238bd29a4ddc14b363ca5b2921c90", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e": {"doc_hash": "1c3430d1754b6618e333d3f833affc96a188bf01200fec31a823b063fdde180a", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "fa9f6497-f7fd-4520-b9ba-0658a714688b": {"doc_hash": "43e630db1aa1a525c87d9a44ed34609bbea7e54dd69e875c9cad40b6c2b1ca0f", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "06ac2717-7976-40eb-a07c-3976c24371fb": {"doc_hash": "af06cccb0c68d24e3119ca5fc0ebfa5bb84d39a239d6084d4e3e6fd67108644e", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "627bc1cb-a8cf-4c98-b7ce-216a392f08a4": {"doc_hash": "c6a2a87a5a76589b2f972398ff1466c894d7d35fbb0bcc96d7d3d1081d25e9cc", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "8e930669-9bb0-4c86-88f9-cce29285a825": {"doc_hash": "f800d013fa09a0b40a720e64fc0e5764f872ead297d6a160388eeebe749aa779", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "e73d18ba-67ae-4668-8c04-67cdd42fcf06": {"doc_hash": "3de0074c70a11d5a578fab6b0ded5b169ea1ac3f4fa29489fa611c5ad7f03ba9", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "ab1a7588-cf8d-417d-b1c5-03e43c707fdc": {"doc_hash": "5489884793fcd7187ab1baab697be9fc9c8bf32b2ac23e702ece37f5c0c82347", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b": {"doc_hash": "f99ec03c828c2236588caea9c3bfc2436b49e282c881e61e4d869d0a825da8cf", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "1af2c304-98c0-4c94-8bf0-5f654b53abd0": {"doc_hash": "4247869161f6b0857c5edfc672ce7ce9d9932f435677529754cb32ac257835ac", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "0bcae024-848f-4dfb-b0b8-2368b1495b0b": {"doc_hash": "3d30ac2b438a03b5c7f7908d2108f31dcc7c5acc121c68cf25ecd1aeb6adf731", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "c33f89dd-323b-4d77-879c-b625e6f4d2b4": {"doc_hash": "4423f4adbcff3f0948e1bb8dd8cf6c18de96d2513ce7deb505be866c981a65d6", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "bb6fde54-0de6-4482-9ff0-d2f319acbb8b": {"doc_hash": "c6026de71437c135c94ab42fdfe55e29666b95376ecdeb4df2b5dfa1036a7876", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "ca646af3-1473-4f33-9a63-d9dab9788a7c": {"doc_hash": "ecf3a769ae1c4c7c86aa226eed2a0e8654045e4793d3435ff72f10b332a02c7a", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "37cbbcfe-fa97-4e6f-9a70-c8e756054618": {"doc_hash": "511cf09a29ce43cd84f7b2ee6b0ef703f9a75746805a67af3fcf0c202c70ae1a", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720": {"doc_hash": "0b3ced9b4787bd1cbf33f4874313b36a0d10d96a4b86b7df546cbb82071f0247", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "36da6d67-c689-4856-90e3-c2e012572d64": {"doc_hash": "b4315e40fc335697c3c59ecbe1598b0b9cef10ce16674ce200fc08dc419da51a", "ref_doc_id": "1473a07f-b10a-4654-a4f2-9dee46589993"}, "82385a61-136c-4a8c-86aa-6d6f9db4e4a9": {"doc_hash": "30f88afd81ff598915242b252f4e1b1bbe03bc37a58847ee8ead8210139b7eab", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "55982873-aed4-40b1-93a6-9bd3037c9988": {"doc_hash": "adb030f0aac932073ce79e5fc85994c55a0f7a7337bbced5026e5b16184ad95e", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e": {"doc_hash": "ac780d06c93298449780a5aad7e096f6ae3bc5f8d65d24fdc320464cc36d2ed4", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185": {"doc_hash": "c0347108d77ecd7844eb220c399d5a37b92ded6cc5534832d9b5cd8a2facb368", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "60a6a31c-124a-4e06-909b-c5359f3bcc4e": {"doc_hash": "421b577c9880da586746e294dea772ab99f706f30acbbffb0c43d3d0587c94ff", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "ff62620c-20dd-444f-98b8-a16953d0651e": {"doc_hash": "98e9b0f75db7a9dcf5d4664f7481441b269744dedad45e3bda49d062708575a5", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "daa83d76-489c-478a-b416-9dd833559298": {"doc_hash": "4dbce1d6bd82eeb96385efa0b8111cb86d625a2fd6ee335f34b29e3a8687cfef", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "5c60d57f-beae-473a-aa98-8bcae190d704": {"doc_hash": "d330218c4376d515bb7d09db609de985ff62986e0fe662537a6817e96910bd28", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "1a418c45-7adf-43a7-8816-48d08c69abb9": {"doc_hash": "f8878586695b9e70965078562e6b818aa2b630f7bb02c938bf477d3cfe9171d6", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "f09dbee8-9dde-4e62-8db2-4fe248a64a56": {"doc_hash": "7550b775efc3f293b9c4c4552800efb2a08265c1684833274b7cb9f8aa1137ae", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "57772ff2-e4fb-42fe-bfa4-3e627a97f57d": {"doc_hash": "8b143130997d3648c13ed0894e1b40ff7df2e1547e6a62b80462ef8c8a2a79f6", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "3a184cb5-4478-48a4-8970-55bd3cd70df9": {"doc_hash": "25178e6a09cdd0332a54587eaab0dc0236aa10090354cea4c2ee819f85a25e5a", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "d3ef7458-f65a-4914-98ce-62d3a623631c": {"doc_hash": "69701b58425b08c5bf56c554826613acb74aee8965bd1e89957c45b912848ff4", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "12cec106-b471-4f95-b861-33cc4adeec37": {"doc_hash": "9eda028bbdde813553b8f09f5d44482a44621a0eb3314225147b7b0c2ee6df40", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "8958c496-13a0-418e-a2d3-fba6bf1cdaed": {"doc_hash": "c277669c8cf57e0bda924996ca90d600eaba14cb408a55994b249832a7e0b198", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "417e1e19-2ba1-4462-b0f7-3dfcb70790c4": {"doc_hash": "637c9db4e15f209d19a71cebe1bd967a354a1e26fbb2c109e20d73719f05009d", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "2e5a667e-a179-4730-8119-83894dde3656": {"doc_hash": "7640280f771566d94699fb17e494ee7354965f1c10e48638d1907c7ae18a35a1", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "9851d8d1-32cf-4282-9952-b09fdd4300f5": {"doc_hash": "97ea2db5c18d3c4cc3912bb76c981a4a82cfe8eb9e29509d468b6b1345e7044a", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9": {"doc_hash": "ffe6c5cd6c22f1a7c62a59cacae1aa4f5f48550e5008eb4c9a8ebd780a3366d3", "ref_doc_id": "6f219db7-eaf2-4ecb-badd-b6060efd6a1c"}, "584a41f2-9a5c-4dc5-9113-e2c32e6d6610": {"doc_hash": "9c7dc4ae96a7aca2ed0ddc286abec2db9760b5ec13e594573fb425816de3308a", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "c0624134-f566-4acc-8dc4-a08bf3cbda84": {"doc_hash": "68d276b9988a0fc4b20c472f8c5583ef121a6ad65afafc06f7c6aa6608cd7ae3", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "65eabac1-8a23-449c-b09e-e896b7d05b04": {"doc_hash": "66ae76f96ba701846b96905204b8c91644f852c9f3ef361905efa5b3d6301e41", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "32ef4fe9-c622-4ffc-b4bc-44e722853dc5": {"doc_hash": "b1ecff45c30dc4797be05e3392d6a45cd26bb7da2f0a65526ae09a8f193525b0", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "a9091641-1be6-473d-8401-eee06236cf4e": {"doc_hash": "a8f2590451e83b7648705ff4a44789d3398ef4758dfa61f6dc9880124ddd7c05", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "3d4e3b31-4f0c-46de-aceb-fed3292ba26e": {"doc_hash": "21d76efb7fd8e87e3346b45bb96d0c997df306c432a7a0eb52a113924bd99576", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "fcce04ec-0644-40cb-a232-1535f70355e3": {"doc_hash": "37d3847e5c55cf1973c0d9e79388eefb96a8235a81d6b75972216b72b8dc82ef", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "2e917243-f96a-48b8-bfba-9c33c45bf54f": {"doc_hash": "796dda67779b130a1580d99dfcb7693e9da60cbdf4ccb053bf5a316fcb4d1af8", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "186a1907-713c-4e8d-b6a8-448a1269f3b3": {"doc_hash": "e0a62e2d0df04fd0466ad7cd44765e0ffe0d9301cd4777505051cde5376e539f", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "cf13a671-f281-4d59-88af-f4bfbe0d43db": {"doc_hash": "654a0cdc1c5271294c152b0b53470905fb731b2cd05607c9810dde04db8d9a07", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "6defaba3-963c-4aa1-8785-7b051ad3522a": {"doc_hash": "9175d8a73e58d2cdabec7240a1819705aa7b7036c26843952b93d7838d92a8a7", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "6e10bc90-db83-4678-b26c-1e67705abba1": {"doc_hash": "c26fb39676e5a58639615daed92e5453752b2194d61aa7f33ca6edf38616bca9", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "cc1dc365-7c84-4e9b-b0dc-13d304989b2a": {"doc_hash": "4c6ca3f51b2e7792661e2ee4c29e7fae8de80d115aa39a627dae00ace001ec7f", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "950acf64-ecc9-44a9-b795-924569c9635a": {"doc_hash": "faa65bc49109f1b809433945eb7cf5d089d5825206d06f901d6fa7d39286a451", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "329d4c24-8481-4f4f-b982-5c49a1851d61": {"doc_hash": "41586953146ec590e7d11b8996f4b90222ee75e34cdcbe93a15e63c1fec96210", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "c85053ed-cd95-45c1-b42f-30d593254289": {"doc_hash": "992f7db58c783cc6912f5254c4cdc70aa0f12b500a7d8be68844e92c005ccc23", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "6125400a-dada-4a21-afe5-607aa84d23ba": {"doc_hash": "1991df4708f05689a34f8cd9069d6a730ee24da0e41c9322b4cc18a47912e562", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "7c59cdaa-c0cd-4370-a323-28c8b991786b": {"doc_hash": "d9d95fb0b75d05a9c23a2befbf8ec13d51e7def80d33add220bbd0cf7673922c", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9": {"doc_hash": "c413487c48fa6514863fe8675ca907faf066c6a8d314ac5c5b1e11bfb9d99401", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f": {"doc_hash": "cb3067c221f8d1e5b992c02135fde3856dd02116162e5570438717b5e5c2b3c0", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "2db2c777-ab93-4e3f-9245-7bb93b7c00e3": {"doc_hash": "be1448383ef2c34b7401f8b5939c67df3d11ae85de94aebc68c67088445fc5c3", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "f579b64c-ee96-40f7-a5f3-b347da7bff64": {"doc_hash": "a84405bb8a7e5553ab4379da21d74bd7d2748e678eb859af0804b3aad60c17fa", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "979c5c47-cf00-4c83-800e-7ed052deaf83": {"doc_hash": "97a2e1762d8ed652f8637d8de1911a27fd04510e7ef8b8f3ad72f73315c6d9be", "ref_doc_id": "6789be5e-f109-4922-8dd0-a62444fc7156"}, "b767b4bf-7909-4f08-bd49-fbd6a5f53672": {"doc_hash": "699a29d117816b3ea0075356d041a57437d3a2ca0511f42d1050ece4b283399b", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8": {"doc_hash": "8c0ff7c7119e846285bfc7fefcdb4f3db86a69cabd78094d7162113b963cf41e", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "3c6d330e-c8de-4687-8328-82f580635dfa": {"doc_hash": "91b506c0b48e9e771696c3ebcaa38cfddc098ce19f358c62dcb0088f743cb0ff", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd": {"doc_hash": "c0d6ec213edc249582b7cffa08e4a9221f16e6bb501a5cff729c2e27322c8279", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073": {"doc_hash": "b23cc5f191becc06c1878ccef6dd168db141c9f15849801121d14022b58a4618", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "404963e1-9e27-4689-bb67-58e0c5ed8413": {"doc_hash": "f02311367bcede9a75b251064bad87439c243c5c3abec2e3f764bb378bbed30e", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4": {"doc_hash": "002093b9eaedac028e08ee3c9f0ce647d9b6fe2ca7128dbcd95f9693380d749e", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "852442b4-4eb1-4f0b-b51b-f5d96216af6f": {"doc_hash": "9feb4188feb9cfd75ff1a310a7780e85c1d05443b2127f45bf23f0881b7d1be6", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "89a604d9-07bc-497e-a3a4-12c09a62eba7": {"doc_hash": "7bc53fd5b1250d0e45ea981f75caeabb0fb6fc4d683164ef1c3654a2ac3335ee", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb": {"doc_hash": "596b48be65e5f2d310313317e95de5a1d6bb399672998364451cb87dfe9d8199", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "85a8045a-8d42-48c3-a14b-da87dacb4bf0": {"doc_hash": "4f2b70e4d1c6fcc315097a531f428fa95cbbb3890423ec5b18c5b32d47a857be", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "7db24b76-1eb9-4a4e-9c1e-95548879279d": {"doc_hash": "98f4111d5208eb21807a43ccf5718b59e7124774a89032f5916892fe16e292f6", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "a479eeac-2946-4ed7-a583-4cb723996afd": {"doc_hash": "034928526ea96f122d91a6f16765302c9aeba4b9c4d1ca7c7ab629bad4af5462", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb": {"doc_hash": "07cf05088b88dd778186c6ac5554b00d9521ce07ea2567c9fd473e442580f837", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "2666daaf-2137-44a1-aba5-ad28d20ea76e": {"doc_hash": "c254f8556cc1e0295d2326c89a6b4edd987d86fd75465691a73a617d255ffcb7", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "97eeddee-b96e-416e-8dd1-67e8233fb477": {"doc_hash": "1b6e737a803bdaf94eb91447ed73b94903e705a8a9b37fabcc0954a3399f9589", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "0d566364-47ba-4fbd-97ae-a0b205bb5ae9": {"doc_hash": "68eb8e06df0d0ec66fbe8b4b4dd6bc84edec9513b648a39d5e0ff0148bfd448b", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "44542133-2a98-412d-b5a6-62802656aa42": {"doc_hash": "1d13f5341a1738f38c213f965d32c29bce42d34a1acf13825e1989dd3c5980ca", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a": {"doc_hash": "a05f14a17944d81eaf27808f05d5912dab6f2d249b1bcafe5880f2f71ee1bdbb", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "adc0b8ab-d503-4eaf-b286-8f58f92f27b1": {"doc_hash": "968fc03ea105961e41f5cd06ac616189ed40fa459abea92414a7c22b8dae565b", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "e76b4230-71db-40ce-8eb1-0627e1763d08": {"doc_hash": "b26ab1fa89b1ac03d2277d07753d08395773724c768118fb892f902e317e9d2f", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "cf67efad-bf21-4e36-a058-f4e07a7c2774": {"doc_hash": "8e11661d7fbdf0f1b8bf128131566c08285899d49ec51ad6d804f491c6ac8312", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f": {"doc_hash": "2c066dcf247513982976773031f25b2e787df367610fb9c03c75089542529ea8", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "747efa13-661f-47c6-8e88-85cc0871027e": {"doc_hash": "42719097c0e58c614a281c8b541cecf1d73928bd0c51ee91d98432261df5ce87", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "30ba9764-8b55-4d7b-b3eb-171141b95164": {"doc_hash": "d95596c72c3aa2b5c2d56c28f5c18b4ae2f233a482a74082b484e2e4b29911de", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "677852d9-6ee1-45d2-b919-fc1e7333add8": {"doc_hash": "3888338bf2c58a9e7eb8a23493b7b5d2ed816f09b88ca370c699743dfb4d7183", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "78566e42-6ccc-4cc0-8ec8-813214e13d1c": {"doc_hash": "a78fbe0f389e4706b5e49702d2c4eded8c8e10579fdf9aea262a7cd0722c5e0e", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "4acd1ff2-dea6-4515-9bce-5c339800f04a": {"doc_hash": "f1b85567f997c4e944f4e4849d5b8c2dc559d109b28e8e3bd722ccedb03f3a67", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd": {"doc_hash": "ad995b1de8aa6d53cf9392aad635f871cb670324f3d4cafff0249c9511b68798", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "1567e5ed-5930-48f9-9bd4-9e62c59b7b32": {"doc_hash": "adbcdc2c0e9b5d1667a73b889f153fdbaa8714cd8b00045d5e109f32694bb40e", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe": {"doc_hash": "7f92a4892e78ffe2f4ccb62e31309fe523f436890a54acabaf3a9b28c3abf22d", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "08d52977-e156-4f81-9a35-774c0c9df496": {"doc_hash": "13664b695d1b0b94858be5157d252c1a4660c47f7fc2b707c89c4a9db1e134e0", "ref_doc_id": "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf"}, "6500bcc3-d258-49d2-a7fe-4d89c2cee269": {"doc_hash": "5f4460a8d3946f5577c341a748bce6f471592ab3e138f1160de64a65af1f5a22", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "c0e05c87-1c2c-4887-8482-0d08efaf78ab": {"doc_hash": "db55ebc308a1ef925b6e2b5fe53db65faf295145a1c012b954b8ab82bc73152e", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "48780eb7-9206-4a6c-b04e-0e4ad9687723": {"doc_hash": "ccd512c9f71c83fcb1083f7aeed178f5bf604873857a7874d5e47e9ac74b16dc", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "84434f8d-6ca9-49ad-843a-9fcbcbb401f2": {"doc_hash": "5ab32c5eb83aecf341b38fbb8dd23dcad3ac6defe8608469db6fff613c085350", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac": {"doc_hash": "9af1fddaa8802ff955769be8ad157faf582fd68e2893e023497fe79a39933461", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "e3450709-6f81-4c93-9394-efc0628c1da5": {"doc_hash": "6e63f2fded1393d2a4c9ee95ffcf45d1ef2a624463c51484f593d34fee087d17", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "e34e79fa-ead0-4351-adb1-0bf644cbd9d0": {"doc_hash": "ce524bbb7f182d70eabf523b9f35ce0592f0d679d8e22c091b29132ef7adccc6", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "03256936-c1fd-4080-8381-5d4b15584600": {"doc_hash": "58b83649fbeb183e1f0a4387e5bce8643837539861ea6dd6134d0cefac9b4aa1", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "48377fc6-3b71-4c41-a31f-15c29fec9fb6": {"doc_hash": "f9bd0f56664b543ac52de640ea5a97abc47d30af46734edbec89b4558cf085f4", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8": {"doc_hash": "216b1e2ded29b3ddc6905f52bc9542170484f1e6ab99ba72bca9d3a5f317a926", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "2a9d2d11-abde-414b-8a90-ce2770153515": {"doc_hash": "8fba4e814a9c1a25a1b2326ceb4cd04f02991cdd85f39857a8a1bec73ce1bdee", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "661b6b29-dd27-4513-99f6-4b7b38d32841": {"doc_hash": "f5fd2df7ab96df326881ce5f3b87fc2effe4d0946352512b3435ca97c262beba", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "fb677824-ca51-45ce-b3f8-d9d213a17532": {"doc_hash": "9224cfcb44abf6d70e57656e569a74bfb9b8380925f96f219e2d1fbe5b624126", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b": {"doc_hash": "675e71109f863e1356fc5f06a31e596d2c7842852dabe225f6d9f950c381b800", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "68a52e8d-5115-4f16-923f-1088fa17dd64": {"doc_hash": "cd3067e7057701904c1b953db9b909b01f729ba3faa7233b00c4f788af6b0e52", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "a1cc3470-889a-41d3-a2e7-80ccfef5eeae": {"doc_hash": "0a268363f782b268a5364b9eb70acb19dfceeb68f48a953bb02877587321018c", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41": {"doc_hash": "fbd57f6aee188eb45409da940fe250cbfa3cdc911f0b2965a4959c4d20ee6b16", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "59db0bd5-c660-453b-a48f-5be24ed9db95": {"doc_hash": "77817e9eae9f72216ff030f5d0236c9fd1053af5d842df4084a04b792303a6a5", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "6135238c-a6c4-432c-a795-6fefa93112ad": {"doc_hash": "92e8397cacb1841037eaab5112ecb5b4b49e9bd33de0865ec849e696b00e4e3d", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "0de47365-6232-4b20-a05d-607fbbe39014": {"doc_hash": "958ed5225f097242764e096aab4c13b651ecc09f9d0a80ff811b020b983e8c4a", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "a59ad682-c82a-4fa0-a067-9f22ce282b48": {"doc_hash": "869b1937ed3ebfa38eb0d4fc1ddd08c92c0a72034d52b5c16974ebd3966aadd5", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "581bd16e-c684-4d57-85a1-7f38ca789722": {"doc_hash": "509f5ab910834d18fd6b93801740c19f3ad11e7254d375573d7186531169d2a9", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "8274f430-529d-46a8-a8d6-55043318f5f3": {"doc_hash": "7de31b229a118133b68f818b04390a4379039e5dd8e4600c7c4d88ac4d9d13a1", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "bb13e3c4-aa14-4c57-8808-255fcdd7678a": {"doc_hash": "e09fbe3bbcf3d096c276827d0ae29d4b109457e4f5c18f93d4effd60a767877a", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "824771c2-87c4-4c03-b465-2d8c6facdb36": {"doc_hash": "174ce74e59b8cb2129ea2e369b2410701d8703f277cad826894e602f14673078", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b": {"doc_hash": "8cfb6851e666258fb1af4d4b2b5ef9183a400d8b45cf8d4fa3cd3c26fad840d3", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "ae0f3473-f188-4784-9bc0-34142b6cf3e6": {"doc_hash": "2d0c032624e2495990f9ce1c91ddc9437e991c5217db4a889e4b5575e0b2c6f3", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "dbf15ee1-fc99-4b88-84f0-6973507a5e89": {"doc_hash": "2f9af1ec567716e5e70c49a3db3bfdd95dd5a3243cf885323fb49106f53ae311", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "e165c5f8-b50e-4e1e-b1d1-421911888872": {"doc_hash": "c42f4d6302699813f8ad14ac22d781e5d783d880928ed68a743760f733989c16", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "0b7c67ec-59ec-4ab6-a430-624257ff07cf": {"doc_hash": "e7fa4864c1819540db4d7869e07511c6e406e754f886292b9582164c72237987", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "cf01853f-4907-4923-b3c2-32d5a38e8dc2": {"doc_hash": "7cbd33189a59be612bfe29aad9525428249460b8b970c2972f4fdad05fc6791a", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5": {"doc_hash": "3f4d08f537a6f0b35b06970b961fcdf58c229d7aa6dcafb1990eea3cfad8b3fb", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "04755824-ca5b-4c57-9a55-87eb76a6b591": {"doc_hash": "2f0037961ff90dc48171db4108576d438e87b0465956b2b727547db14aedfa3b", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "a798bde6-ca31-45b8-aef1-ba1e8e44c822": {"doc_hash": "5dcbedf67033712fe110791fe7b39fb0e1a4c985b32fba7641d190c0cb3c178c", "ref_doc_id": "495936fd-d685-4b0c-b89c-4b6138ae239d"}, "b7ef5d7b-0fe9-487c-b7d2-9cd414622870": {"doc_hash": "63228fc9051d966499012bb6a1dd4720ad8936df338e73e44bfd161333b050ff", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a": {"doc_hash": "7d06036c44eb3ba59928d03941478cb9a252cfe7f712c9d1a7b7ee09ad95c8ef", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "43a42134-88a4-45d4-9d4a-86218d4c55f0": {"doc_hash": "0e598fcb8d33f20cf64568b8cc2288abf1bae9320f4440b262a6098697609c20", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "a26586fe-22b4-41b9-813e-82b5207e2280": {"doc_hash": "8ceef2aa11af5936f7518311f622d3415baa79fd8c41651727f994bbbad9c22f", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0": {"doc_hash": "fb1278cb3568c7c53eaff2f1c0e5cf5f3bc10d939920776ebeba16f19dee0844", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "7fa038cf-b2f1-432e-839c-afee7c0682ba": {"doc_hash": "d9b5288a9fbafea0512a6f8f247220f7a7d7506cdca863d3de034777ae94621f", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "be51034f-c8e0-45f5-aade-f9bfca0ee78a": {"doc_hash": "c9b65e35c5956ce20138cab19127de4ccec589d77d20a1f5ef9e6cacff08e6d4", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "f9ed4f11-6330-4c00-b71a-24261afcadca": {"doc_hash": "1a8df2933e5d5f5ce49bf8c6f590e6e039a687cae7ef997f09c6f76cd19f4f40", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "b0ac6557-84bb-4216-9f17-67d8fec97d43": {"doc_hash": "a9ea953aba2973226caccd6695a50e32cef3f89a24f204101dc750fb933dc925", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "79944b41-e5ed-4ffe-a777-f7befdf08eb8": {"doc_hash": "7d1ef57971a2bd80eb1685141b63f5013d4e8a3e4d55dae6a152c301f5934a86", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "6bf65428-a692-47f9-b168-914a72c9b078": {"doc_hash": "ba899e563e1bb3e64db671a92c0e46553c12a34dd59a09f71cc24c49f53fda21", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "0f3c956c-50a2-4017-9b32-16415d483311": {"doc_hash": "4770ceb3a665c9f3f4692b5e47b37f8825603c805031462c6cdf96c4db3c2e9b", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "524ad625-806e-4290-a862-182ebfe79eb4": {"doc_hash": "4a1d86a47c25fb84d6630ccbf45ed20f1748bd3e31b7929d1cd4f08b4d256801", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "bf27e2df-038a-4e9f-a039-df186e497372": {"doc_hash": "deddaf37238bf31d8f84a5c07ad1871347179380f9dcb1158180177ed2116666", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "5684aec6-6fd9-4d4a-958a-bf7bdb628e07": {"doc_hash": "4d02a438822d0f7909df08c0ce61a414934c1d2d74a2123896b25c2227b0b060", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "015ed896-be11-4f80-9e07-f909b872e9ab": {"doc_hash": "5ca9149aebc70570d959c39823ceca3b7545b79312ab2ce7640c089f992772f4", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "14eb0e67-f4fc-4338-8c33-5679b5d669ce": {"doc_hash": "2b87a97f37a4a53b2a96f16109f85aae1273420b255deb5832027101a57270c9", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae": {"doc_hash": "13747444d00ead3d75672fe13d271d1f5d88cbe5bc9b99cb921c1b422b898a73", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "dd3335f1-f7c1-443c-a3b1-ae18c97cc756": {"doc_hash": "b022421cbee30299b392449bcb427435ae2b6e703ca074091142608ac32599e5", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "16321123-a2df-43e0-84da-cb7aabe33548": {"doc_hash": "aa99356b2353d4e4e54cb6d7ab4d0ba1ca047e1ca4323e6e81e3a5faf0aeec2a", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "bac13b59-cd26-4523-8a49-40b24646ecae": {"doc_hash": "a56f3749db899638244342dc72e155e079a8a1723d83c0407c900643eda3525f", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "281ab47f-4467-46cc-beaa-64ab3a12696d": {"doc_hash": "947f08ff455500ea3b18f4aba5229104b86bf3e65ab20b0b56ed187fcc0bce21", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "2eb59cff-035f-4e43-869c-6a9b91d6941f": {"doc_hash": "67a0be667a994cf7bfaf85062c5e56a4637ef4218922bfac6b08c5395b7facfd", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "a11f3730-11a6-4cac-879c-2abaa6e7ce0c": {"doc_hash": "d3702ee8be4f78fb39ffac1ed58fc009e397a6e5f84816d1e49e2358e2b08521", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "f9e472ad-a285-420e-b319-80669bb2646d": {"doc_hash": "52116219b10b5655f29e77c080bb539a24d2b73918b82c990401dc8e39c10a90", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b": {"doc_hash": "9e790185658f2ec2cc96cc5623638d9f77b9346883867f6df7d1910c00d4e298", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "f0be2b1c-97bb-4404-80ed-92c03901b070": {"doc_hash": "11fd8c5d7aa8219f0861c16046a9fa944754971948841aaf9dd21d73f3cae9da", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "84803eda-274b-49ea-97b8-13c942415c7f": {"doc_hash": "068c69ba0bcd89a4f8283011a9a3326ee1e1de8c079a3a82f3479f88dd8c78e3", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26": {"doc_hash": "b752ec034154f8af54ea21aa7aec90c14b9714f6d26c30ab100c95274c4b6fd2", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "16ec4829-a75f-4ea9-ac82-07ffa4d3916e": {"doc_hash": "36acae2de5f98093db1d85e696c29e808e45d186fd4dd2829488a0d1d15a7b91", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "d63d601e-7e8d-406e-bb1e-18a084747c37": {"doc_hash": "b31f2234d574ac0e3b9232c40d5724c82a2e81abfd0f4cebcce2ffb12ca740a5", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "8043fc55-be49-498a-9447-1002d39af3e2": {"doc_hash": "6c3a840263636593b59c5a90ae2d3c64b5aa8c6fb8511efc93d18fd9889885e9", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "d785f811-648a-47f3-ae7d-28617c1026d4": {"doc_hash": "1262a8044ea63e3eeb0fedb7f4a020a7b8230a4463e97960de320c2b58caaf02", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "58dfc7d5-0d29-4dac-aa84-fa08b73f9112": {"doc_hash": "69879ed2e9d54650737e945f85b99cf5ed08baa12ca84db1d0032a7a48b6c760", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "b8b51bd7-1b03-46ca-b8c7-75ee66846cee": {"doc_hash": "2278d88ddad8c73757f9f39cd42db67a2bf87bc54bd8d3202216ad5f63ecdd9f", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "cd4fd7ba-58c8-4329-b0fc-900a4251de92": {"doc_hash": "6a775d6496e1e71f81c1f2ada0e13b8706fc6262955fac230b04a2f485a5568e", "ref_doc_id": "583a4136-95fa-435e-b272-086d888555aa"}, "def37c16-d276-4ad1-ae81-b89f9e3467de": {"doc_hash": "eda035ed1afe22ad56acef6c37ce24ec2111b5424c83904682a751b40bf66cd4", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "0c131b54-ad6c-4f1b-aa46-deead7cca7c8": {"doc_hash": "a2088c8aa21a5a7f66f3b1317fb48f897d810ce3a3c2425e98629f4c3cf279d5", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "bba58b63-1740-47e0-bf0a-5d7f854214b8": {"doc_hash": "a70d2dbd42ddbee6c603aaf3fe1741f6912d9fa1da5dc16fc6adeb788e4c3644", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "f588fc84-d775-4752-911d-afded57ab07a": {"doc_hash": "630ec45dec6308c9ea2c2b0196ef76267ae78d30a8919cebb87f588749099d5a", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "5a50d428-8016-4dc0-babc-eb73dc2c4fc4": {"doc_hash": "ba11deb6a741c9ada1396d2019834bf64f8950e3267ac2f655a34bc44d5aa883", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "40e27841-fe33-4032-ad35-bf01cb593dfa": {"doc_hash": "e666acbb0d06b4ceaaea98e7db2b1cf1bc695667f1b46be20ca09e80446b64bb", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "5385341e-847d-4c20-a4da-2901cc6bb15a": {"doc_hash": "e5bfa09432c77c67d6772641b2a2572a6a1e6b2c412943530ac5a24fe5a67649", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "4db677e2-289a-476f-9dbb-617376b26f4a": {"doc_hash": "07836f26d8260b5672e253542e658b5fbf0ae406ce1178527a9af0285ad9a7d6", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "2137b0f3-044a-44eb-91bf-91f7e9e82908": {"doc_hash": "45620d04ac2628e16ff05e9d4b34967135f9edab010c074be538e808cb04c907", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "2f569bcc-cf3b-465d-8484-b9014538d57f": {"doc_hash": "7bdc773c66774d5b5ef87352ba3c6d451a3c40168603920e866aae2817b48832", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "1fba4314-dda4-4dbf-9838-40044393d3ab": {"doc_hash": "8e436dc57608b9da20a0acd4b22a7d65c49c6e8b413bb5e3a4755b383b61c105", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "9fa02a4f-0fe7-4407-89db-009c1d8edee6": {"doc_hash": "c35ae6c54764a830442fa6401cff60f2d38566bd6f93457a3691cc3eee514b8c", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "d6ec18aa-9e91-4618-9da7-12a4da0dae46": {"doc_hash": "e47e745842272cec34c2f922ade61aa5a2795105c37bebec4a90e829db0cfecf", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "55408135-3a12-4b26-9e8d-1d90298c703f": {"doc_hash": "d1a8a87c5d5068060e5fecfcee62edfa682bb1af6eaaa670e7e9c62d912d149c", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "22822b91-5e8c-4d16-ab69-90b535e94c1e": {"doc_hash": "26c29906c03d7841753e4763db435b1b6e19466804539d847852a6f38aaa7be9", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "7f54897e-ca86-4872-9354-37c4516ba08d": {"doc_hash": "a25a949e51338821d58203f5e8cddd6d4f9ad5e5dcdf24a4794df14c798e659d", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c": {"doc_hash": "0120eba7687e7587d01e6295dd23220994dc60cf8dfe8d0bd29a5c134b450e9d", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "21c7a587-bc07-4ec2-b848-f56dbf1e40f6": {"doc_hash": "f203e358089d7d652411a438d021b75f651099619cc92729107efa6e0d871f91", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "207da6bf-a917-4608-929f-e92119385a3f": {"doc_hash": "0ae60397d20143ca1d9d09e6933006f4eaae34fa3457ad6feae31f74a49d133f", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "850e71d0-4d08-4f77-a5e5-01ea008a65eb": {"doc_hash": "90715834c5273c3def4e66bbbcd55dfcc2f53c5669d5c4c8e9339b633096b0f6", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "77880587-1b8a-4afc-a128-e1d4ee80c9dc": {"doc_hash": "7af5134b59ff938062e89da6f84df970fdc1835598b3e2f700feec76c0760f3e", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "b1a8a0f9-df24-4d1f-b064-b06846f538e1": {"doc_hash": "cbc7d71ea7cded00bd7144a79c61777778a6f178cfdfa43ba33014657e10c1d5", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "430256e5-a139-4570-9f17-7a97615b6ff2": {"doc_hash": "ec848f3883e91215fe4bb2ae6f4143b57aef86e9719b8d0dc16687684da6f082", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "29a6eff8-5261-4d1c-a682-41313d7a8ec0": {"doc_hash": "8b82d51a35c0f73b4b50cce5f5c3870bd4ebd6e4bc4452f4618104e1acb03949", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a": {"doc_hash": "4d55db1f9d9709bc41d0aa1b45b626ce9dbf2a21cc934551fa679ed60a751c3f", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90": {"doc_hash": "6fd405d39be57edbc4e696ea52ca63c1b49a9e172bdffa358c44536b9f3b1424", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "f87d9b6b-a7e4-438b-ae94-8473f12883c6": {"doc_hash": "ae060d4215cc21803e6f346f194edaf11328546df9237b33c11b733486bab7ec", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "e5b6caeb-ee9a-42c2-ada3-967333509e14": {"doc_hash": "84fd0cb96214ea29ace36a599f336914d2131903bf0d5059818bcefe083d6849", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "681058e1-63f8-4bb3-946b-65cb06b59392": {"doc_hash": "874df9b2460289d015f1c036a45d66e33ae6e1c07d98b776e04a2add9613e1cb", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "1cb46e28-e8b5-49c5-a994-117427e95dfd": {"doc_hash": "b7bbd025725e09aa7dad97b55d4b17c2e46e0b7dd4f654ee5abc589a46165e15", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "ca772f96-9383-4668-a97e-ab1b043de843": {"doc_hash": "73b72068de3710ef687d798ab087dc7b96941fbd09338306b01e5941b7e3daba", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "51e785c9-4590-4bac-9966-7a7706034a7d": {"doc_hash": "d5cc29f4d8c6bcdfd98c79146dc95f57841e87e1471c02d4c66c65338fd83323", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d": {"doc_hash": "de78d57ac9a2d9c42702bf7043c8ba034ac5c463b6960005625778a91207e4a8", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530": {"doc_hash": "3e606d9de8a4a4a5914a1c7cae1dd8da2bc7b8ef10851b23cb15feb0a927678e", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "3d724f73-612b-4981-beba-a16f626e574d": {"doc_hash": "9cae9f7e8444a5a59fa43453b94943b08bbe00adfb68cef7392d47a46f3fa245", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "a2537069-940b-43a0-848f-b07ab4309033": {"doc_hash": "77670a8319b43da25cf9cc6495b1558d93036604077f86a6cfcc8966c7664fbd", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "9fc98085-ec85-4375-be24-0a7fd7086067": {"doc_hash": "efd74d4f1692897fbdd08c3231668706b031c040946caf01644e655d985e2a56", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455": {"doc_hash": "fa2a94bcad915793aa2f600f095d0bd687578404c72603d892e1f35c9d10ee19", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "a5ccafa7-8092-4a3c-9e0e-9667b919818d": {"doc_hash": "f36f5ca68d3d4b22624eb7fc26983f8135a7d38a79231d95a206b6f5e002b62b", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "7a59edbc-163a-496f-a952-cf50693d10c3": {"doc_hash": "9467b6b1c0842b2da922ab31ab32a8ff56feb339a765ee13765d1469f6ced3ba", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "e4dc3cef-6bda-4af2-9438-df6cfc763d6d": {"doc_hash": "df16226f7340bc6e65253a077a1aa7fac9e647250df7a5765d5edec015d3773e", "ref_doc_id": "256d8a9c-5e34-41c1-906c-a05ba84f9806"}, "ba54a53a-eec6-499e-a23f-392ddb84db11": {"doc_hash": "f6f6910fc6d54cb6862af8eda16691f2cf2c88757ba377d9c855bf9332025011", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "666f21a7-2dc6-4fbc-aba1-2a17af784435": {"doc_hash": "9073f26ef256aa53e53bc72cb656de835ae6a8e3cfb689f4321ad6142daac7a0", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e": {"doc_hash": "f7ef771e472d4d6552dd35087c43f567406cb610d0439253857e151f9c92db9e", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "62f82180-d4bd-42ce-8daa-bfb51b93189f": {"doc_hash": "cf2233eeecbe01930782defbe8d1ff6bc23c265a6f5a92fc9289a29eef958528", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "a064290d-f47e-4a38-932f-9987b00dcaec": {"doc_hash": "26c1948f37c6b2e1f77a831c97f154aff627dda3c94c12532352e89e25f58111", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "bdd175dd-4391-4024-bfc2-84fc6498b356": {"doc_hash": "1ad393f6a36c60cbf77bf7fbbaa800e7fa3881ce24503dc161a7acdfc9551ad1", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "eaddef56-5007-4d25-8172-6cc173aa9e46": {"doc_hash": "816ed31edd4d5bc36a84514785ed672b3b70d7dd61e58395e4839950d1e7ab9f", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "61f8ee6a-9aa1-4424-a3f3-1a093a73532f": {"doc_hash": "1f70ce630b683f0088818a54f35d273ca36746da673a38cc29052d8abd1cc599", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "46f368f2-6567-4762-aa50-b18707f5219b": {"doc_hash": "776b21ae9f60919ac5a5814ac8a5db42f0412ffd65ebb4e4572ea79e0dd3a49c", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "7da9b68e-9992-485b-8f78-b09bc4de6448": {"doc_hash": "ebb56c83c14c6d871c827e0b657caa39d3e1341f6e96722852ed23e8f4557e94", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "cff6925c-2e5e-41bf-9b81-290e36d24fd3": {"doc_hash": "70f1bafc9e3c429715b699bbf49f7efb51fce2dd42a2922837b95f623c0c5c24", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "480e2e63-0ecb-4af8-bdb8-f31d9e7283de": {"doc_hash": "54587c90b1ce53d98f4222955709b27eef4ecba6891c49e6d8d242ff5c8cc41b", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "178a3e5d-0b17-46cc-8b08-95a1936b54e3": {"doc_hash": "4d1d8ffb2d78478b4e6b9ef83a3638873d942564d2ab201e43050119738867e5", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "a41c38bf-efcc-4113-9e73-3d63337ceb3e": {"doc_hash": "f4aeec7ba3d98fd2add1385655a0cea30abfcd4f07dd26cfced155963d1c5ef9", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "6128da6c-4227-47dd-bc17-0cb49dd915ba": {"doc_hash": "344789fe692bbaf957c41895762dbb41f7be4d03d15f95714fe9c843a9f27019", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "131a347d-87fe-4960-bb0d-a63c9021cb86": {"doc_hash": "4de5840e32b1532e249c5dfd68ac898d3b5a2db8b8075d206596c9ee46d3c809", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "4d847bdf-2b40-41bd-9b43-829fc294ffbb": {"doc_hash": "cd3d22379e161a88f267e5e1da7f9087bb61f2cef62bb85640d715ad76e06cac", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "7a3f1674-f812-4b3b-abad-d614a6cb07f5": {"doc_hash": "6c2d20d5a45291ca1c9595f4dc3d3b4dcfaca644d14e91bf80fdedf0fb10e69e", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "97614a4b-bcd1-47c6-b491-3180efb18d06": {"doc_hash": "541cfd95be373ec476c34914a9fa0c01cd0e6ff6510e7f42a7ec0c5b81ffdd68", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "755a1a7b-e848-45b1-ba41-26d5b1f2d961": {"doc_hash": "fc3f7be24783a97207d77c69e30f1821309529639fb61713b17752cd5e19940a", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "e6a8785c-9c80-432c-aff7-cc9c33c5e89e": {"doc_hash": "1df43c7763a28a0ffdbf79437130ac02c1b77e5ec2778e4cb1516359b19b1b42", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "91f25c31-cc07-4555-8649-d01bb9e43541": {"doc_hash": "fa26ab0630126be0f1c9fbc598484de12b6f13e4d165df01993b4aa71a1cd3bb", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "a78a1031-1173-4cdf-8f95-23c9b160d829": {"doc_hash": "947c4f187ed0b7c27dc7af59db8c5c1c2c44a4ea20ef57cb790bf0c1f5de21f0", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe": {"doc_hash": "1af28bd9393efbf20aaada18201687de50975aadb5c4e1877bdda1c60dfa3f63", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "ad62c846-5cdc-406b-bfb6-7faf6387d93e": {"doc_hash": "69e0e0a10ac94326ea33cad2aca71a8a5624bea77a1c8a77bcc52d442b39f193", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "2492aecd-f9d3-447e-a904-836f3f5efb97": {"doc_hash": "5fd01d015b8925285592ea97d93eed0041a5204d4fbff3e7cc88f850e225c04f", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "beaa8262-c155-42fb-9d66-45351f293e72": {"doc_hash": "d2301e5fcd11e1cea66ac199481cf72bcb8c6a55445d124cd7a3484e30b35ee3", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "4f84127c-147b-4aa0-a89a-c5e823a2326e": {"doc_hash": "f72b0d424b31b143fc0647cf1d424d3f682e6884d9669d0698fc5db304fa2246", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "5b793907-f13b-477b-88bc-c79bc4a09328": {"doc_hash": "489b5054c895faff0a42503c2a5661eea42316a879d193d1d260a815670f2b08", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "8f016554-57bd-404c-abbe-131a6d053cc1": {"doc_hash": "1988181ebd1f55c5b3593ca0bc32385e3f27901994acd9e4dcab8ec202ba053c", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "ca184415-b10d-4660-be4a-f5cd66172646": {"doc_hash": "811b36366462602ae0c82116b4b70ceccf1ad2f97e130c09a4e875b666a42a89", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "77b827a6-cf68-4bec-b49c-f7dba7447068": {"doc_hash": "31c9ad2aef81e32320b88ca50ff48030ba96d91e5bcbbb23f6806d2e29e7c2de", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "a4517ada-2091-4e40-90c0-f2499f64b50a": {"doc_hash": "687e2793701e0e02ff6a1a0fb4f22b87e15df022487617b6e03224c35dcdac47", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668": {"doc_hash": "d30ee0bfb4f1e2b2bdcb8000769fd43a0f0d3b70eec2b46241f34fdb8619d7fe", "ref_doc_id": "32fdabc7-6624-46ed-8dba-39e6300a793c"}, "612d97bf-75a9-4cec-9b5f-454b2ae5102b": {"doc_hash": "586398dae7032cb1dfa0de706881fa8c72cdeea166310cc747957966038f9e70", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "944cf015-7afe-4e31-8e65-6ce68cdadb05": {"doc_hash": "06e7c8a73529a01323370d17feea998354c0db87f5e3ed5e9fccf85f16497549", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "6a464662-7c18-4007-b0a4-51a3390446d0": {"doc_hash": "27f41e0a272598f5aa79029b90a8e0e1c2e5f9dee87f7812f3c1d83e8e0afc0e", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd": {"doc_hash": "b71b1c52045efc5c43442ef82eec80f651e85ff6203ea6996dd67a25f38471d1", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "73277778-cfcf-4ffb-93c2-572503da11e8": {"doc_hash": "f4c2689e52f70a7c194254171f06b4279a45c1c3a0deb7cf1a22ff2fa7b3093b", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "f4aa8797-5214-44a1-864c-7ea819abcd79": {"doc_hash": "d498596158f413922dc8b99cbf2eb01c99b8cf7d3b0de4219ce40b58a6f9fb7c", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff": {"doc_hash": "fe47f9e62835559394aeeb8c7798dbe63030690067e7bdfdf03d947de2e89c08", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "b3c4cb82-c175-48ba-8578-ae97724b7526": {"doc_hash": "f4c7a9ffe8afaf28f4d4d6b79e33c46c1e7b58e5e21499209977159ea325e3b7", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "01f559af-c498-49df-bb21-73491491933f": {"doc_hash": "72c4c5e01f5df1ecc2af28d9267d78576ce0dce3e1f75fefdf9bbc8b41e17cf5", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "8ce9421c-4dff-40a5-8839-79e40ed409fe": {"doc_hash": "129c28653e6dc0b2e765898d0515e20efadd54df6567e95da1a775d4b3982245", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "67c9b484-13f2-483a-aeae-8c6663e7744f": {"doc_hash": "3a385bb6407695ed1ffa9af25fde1b6460601d5e417abf412a3b8ccc87f16539", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "1904f48a-436f-45eb-9529-c875b7462db0": {"doc_hash": "ae386a2bd68371ff5a08779dd725f1084f340e819be195afb04aa23016182672", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da": {"doc_hash": "4e0bade5e005526b215360c9ef132218b2ff66e1472c11a154f1e9b50600cc3a", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1": {"doc_hash": "9755c956d9b6c729cc4864bf24832eea4fa70bd7e0e617857467a6ab09220c51", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c": {"doc_hash": "9b6865e26c7c5cb75c5b2633fe69767b151a151b8aa7e1bd38798d96f23abfee", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "c4549a4f-861d-4de8-a316-0a9a8fe5449b": {"doc_hash": "e037a85ec90a309629778016be1c5f28391fafa708b70211fec2c173a35208e0", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "3508fe72-9527-4348-b20d-7d4e7b4abf90": {"doc_hash": "c8a0a1090527fa2a115528d00a9d514c8911d73d57d6b075a4d219206013c25c", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "3c189852-af7f-46d2-8a13-59f605c869bd": {"doc_hash": "07340b3d37834123111e1587b03788972b0d3db0e355aa34ad3ae6580c7f3abd", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "d6f4f168-2162-47bf-88ea-7d49ddcb1b89": {"doc_hash": "496c16eae6945de96d175394bb5b16d53514e1f1d03e77825df413d687ee9f8a", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "61a23bf6-5eb1-4652-bda6-e3d026292e2a": {"doc_hash": "062fa07842339d02acec75d8719ffe87954600e726844d85b208282644b52ff6", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "b0e24a25-4e59-4877-9d4e-3000964918ef": {"doc_hash": "37c667b141d6afe8c6f0b6309ef9988ed9f5ce323ed4e05ce0c1dfd67a1ee620", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "747b3b2b-6d17-4912-853a-f5aa15d4af0b": {"doc_hash": "3b672137a1a92549bd47d48c7c2f0992c7038c3ef4431f5c0dcceb20c7c2bf8d", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "f54027e8-c12c-4409-a95a-2b297e60416d": {"doc_hash": "268e65daa2d98814483be8eecf67262b62d916659009ab206529a945c40ddc6a", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "e4dd4516-e597-44db-8737-44d59108ea4a": {"doc_hash": "0d044322cbeaa5f81b1ca80f47bb0ae7a4e6f4a9fdea984fe75eafb47db96f4d", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "bf6520f4-2049-462e-87d9-dc0d16f2dcd9": {"doc_hash": "0945f3feec62ca56160febd5dbb53556a05eda2c4c15258535cc67b27c85c5fd", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "29123dc7-4108-44c0-b518-2add9d8ffb27": {"doc_hash": "550b430c53d6cf1d5cf4b031cc12ac0d772d734c9a9906cd92d1207e94396498", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "496b1b1c-3428-445a-9e75-061e97e26b34": {"doc_hash": "c05675ceec15d9f9638d91ec1ac9289d704829bba1d3014d1bba2e8e41767877", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "23a483d7-ca9c-4ff7-b740-d3a452f5e783": {"doc_hash": "2d7e54c36d46ad4fdcb236bbfb15db131f39abfd17a1a28aa27ac82cd77c53e6", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "f3f9fa52-28ba-4743-8553-ef0bc830ad86": {"doc_hash": "1462526a73b7eb956bc8a0df1e1f54cf2b4ac7e8d163c1029fe04510bd3808bc", "ref_doc_id": "57fb6302-0f70-41bd-974c-4700d10f9792"}, "7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c": {"doc_hash": "d65ea37648479d339484471a97e5c8e524c32d0d3271689194534f09229bef25", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "ff20df27-6df0-4ae9-bd90-6b1afa72c3be": {"doc_hash": "5a304d25d3b06d23da5aeb4f355492d8c27edd4792a666bab492ca37a72fa288", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "7bef3c43-0093-4113-b853-9b368900720e": {"doc_hash": "bcb6c15bb13eb6f8005553497e1a341cc9f1b67bfa483239a0aa5f327e4a9b1c", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d": {"doc_hash": "efcf6cc61dad56e10b75b526b45c80075df7a0d8bd11a5ee4d6a91e38e353e15", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "32fd547b-0885-419a-8850-a1f8a41ee111": {"doc_hash": "6c74db1ce6a736009c93eb6a7f2b23e870de832e8e4933c35f15638cfbb65d9c", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "c725811a-a895-4ea2-b866-580b299b2d75": {"doc_hash": "c12965907593f4a8e8f7b87b3bff432003ef0e8ea3715793846c841d6d3420ff", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "72206fe9-11cd-4f9e-98b7-7df419eaad72": {"doc_hash": "7d1162b26ac22524c192a292d26b67a16cef4ef60cabcf8c8dab4bab5bfc9526", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "82fbff9a-80a5-4575-a4e0-4cc02f6f383d": {"doc_hash": "3a1646027f62c4d1a6d9ffa33168a974c1885c8a6c7a3dfc49e7f5dda584a5e1", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "18b9ae79-2b3b-43a0-8476-4596d517b24e": {"doc_hash": "d4f8bd1b8f978920abb7e586f90178923a84a5b13acbf80bcc8df44e7ebfa66b", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "4932a5fb-f4a2-4b4b-bc20-dca4d5727026": {"doc_hash": "81a17fbc604783e5d42493d788bec6163084956cee1a57b0b8d572d9b449dd76", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "51c1c902-0d22-4467-8a63-3717faa3a227": {"doc_hash": "cf2b2f8cda6d9e365561620aeaf146232e757f653d26e07d5216f784492e05b6", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "47e19cdb-37bf-4e2d-949c-f10a6ea8a320": {"doc_hash": "faf9dd23dd7254a3d73389ff923d83882bc8db50a8ec98876e35ea5a81c19146", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "fa921067-a722-4ea3-a846-919959761dda": {"doc_hash": "8f35ba1c55c39d0d9c44066774594e2a14f01902f96bdcfd8aab1915bbe29ce9", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "f32bb6a0-bc45-4ad1-9602-0e02774e66be": {"doc_hash": "8cc952b12111de80850ad8565d2f6434ca22f9a55e90c89fd7e2ea0576539526", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "1c5bfb79-9635-4836-be0a-d5e1a903f1f7": {"doc_hash": "df87dd04c47108984cc5a5a26aba5706d5a686e6d07515a2975d3f0aeb98b490", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "d4fd3a87-1655-4e54-9a70-e930f20ecfd9": {"doc_hash": "18822a051c09b795c1fa2f352964cd9c09c02a912c6a7df7957f907044d88744", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "a4e2abed-964b-40ef-9b6a-50d8fc645db2": {"doc_hash": "f3adbef316424a209a6478a6dd5338b302cc878561184bd83dd7e10a231a0064", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "efd13549-6823-45fd-9b32-9d42b50c33f5": {"doc_hash": "b2714754e5b4b678463919291078ed18ccb52e26e907da5251ca64a6b247466f", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "eba1b936-d3d1-4472-94c3-0513de876214": {"doc_hash": "d344988386ef199843811301989965942a2c7af19f6942ab67ad5cc6463f9ec2", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed": {"doc_hash": "ff6fe828d1900669d06bc2964616829ebb1a1c2d80c36529d8805145ac496ed8", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "6528133f-d847-431f-9a79-6ac8841602a6": {"doc_hash": "ce9b7f0bfbeec157b111680255f1a76629e9bf8e471d44223c7f5a1e14954e6f", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "016dedb5-df60-4e72-97b4-4189389e59b2": {"doc_hash": "39db64ade9c5fbae21fb22f8c09d346c79eee5b8354361946485253c29c0eb2f", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "daf780bd-38cd-4868-9d6e-a2b090817655": {"doc_hash": "3f28a161eca32b1a33df09d8af20c48188b78818683ea84dbc3019e6ebdaf5bd", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "25d3a672-04d5-437f-ba9a-22b77d55bbe0": {"doc_hash": "7a8968dede19c356fa6ea34b3f2fdbf12b1543c42554f628a0b8a81dd7f2cf05", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2": {"doc_hash": "eaf85e939222f85965d725f48daf99bee258c05ff459e5495ffaa05ab740b303", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "6ef14a0f-9cbd-4293-8d20-e75729a1394e": {"doc_hash": "6d9b5b0cfafc6260869bb504eb9da149c397f6491857f130203beb6e1b1a4969", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "fbe74d38-7c39-45d3-8f95-26b658e64121": {"doc_hash": "e8c8fe6097faa235cfc6c586844667082146562b1a25a15bfd62d7a19af5e59a", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1": {"doc_hash": "537a6e502be1fef6839d0870e8058adfc48b46ff1f8a705ad27b9a2c185b4e1b", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "a180df14-e7e2-4617-81e9-f23c86ecdf7b": {"doc_hash": "70e5e03fb8661b576c41b679c81c541b32a781e3538d587bac5488205700d146", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "d1cd7436-46c9-4e52-8be2-d3ee66470ed5": {"doc_hash": "104880bc5cb5f1170c5af3d293eb8ccce4cfd970300cdff8667f8cb6de602094", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "70fbc380-241f-4491-ac19-29b784f5ac37": {"doc_hash": "592b81bd83510f46dff56c3736c12a161ace577c9f906dee9111e797891095b2", "ref_doc_id": "4863c1fe-d413-40b8-9259-2a1ec9b6b013"}, "44441188-4fbe-4a00-a3c5-2c777b6ffae9": {"doc_hash": "2ed1f810bd9c94db835eb162ff6772c2b6e220972e6e6fce319068661edb859f", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67": {"doc_hash": "062d3d5ba1f54c5840a063fb355648e9532fcd91531e37ac202a4621d83a8dd6", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "31d94e98-6604-445d-95f7-ee093c450ba9": {"doc_hash": "a4b80a16d0a2fa69ea399dc241711e6c7424ea3cb291ad30588aa19cc8e18d98", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "64a9bc0b-b0e0-4278-a26b-73796eb904e7": {"doc_hash": "67d7f7ba5a0a218b4de895b7f72f3a20d428405ccae65d915912f5a2b498bbf9", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "66092dcb-b49f-46bc-9a5e-ad05e856ee8a": {"doc_hash": "2f2f6b86005e33045ba2ef4d4b42d9c557e4f1a29f8342594be3c0ecd1a4a5bb", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "47061b9b-8e56-4f13-8aac-fe4338696347": {"doc_hash": "059ef1786499dcaedfe86110802b3f4c58639c1c9ce76469720eb834fc56d7b8", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "eb58f66f-4abf-4546-ac8d-f9842ed657d0": {"doc_hash": "aee5ebf0f454f31ebfe292e7710cbfef97a62ed08bee5525901ff52cb714df93", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "1dd1aee6-6f40-4299-8d79-24895b066a43": {"doc_hash": "8fb3e8000c8cf21804513905ecb7b86dbf55ec4dfcd2544d5418ee85fb857034", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "c4c450ba-e362-4427-8e36-f1a4c6c18d9e": {"doc_hash": "ad1fb25a4cd283fdf3508cfa48ebaaa3bbb93d5a45c3eac82a86f7c026236710", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc": {"doc_hash": "fa6497b72506afd754fe6928ec8b20cfacba02b4d0f26089861c23bbe351bdac", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "5ff218e9-ca17-4d4c-b1fd-b39c8098467d": {"doc_hash": "aa07622270dc0cd706a43f9548b388dac2b9eb19cb0d21004153d6fea57503e7", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "093e9060-ee6e-40d9-adf2-0a3bf20a9aae": {"doc_hash": "3d3bc3251af7e6e270107614348939570745f335c337b1974a85b4f2f1ec60d2", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f": {"doc_hash": "34d4c0e5ac20b713517ed1c788280708418f712c9b42644206f3d72bb361fd95", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "4c9208e2-7ac9-4be3-8551-f480d53ab37e": {"doc_hash": "5e53380d27dcd8ae4222eaa9d96d29cb9dbec8721b86522d30aaca2abb62c434", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "c30dd8de-33f3-4369-8cdf-a1be278dd7d4": {"doc_hash": "be4663c3309e193483069a671c5a83a6a183c9c458e4ff2bba629619e94f0c4e", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "a96f82a1-0894-4548-a329-1c2578aaa006": {"doc_hash": "152d204ea968c4f4e5272339da2606e752ea6f9c74a4100ea909dc1fe7f58e90", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "098c25e3-9a80-40d2-b16e-441dd8309ed5": {"doc_hash": "52eaab21cc8a50a979edd50ab30d26fbeb85f32890730fc4ebcac22a05177af4", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "7e8f9477-67b8-4762-88d3-7eb3df3f7142": {"doc_hash": "28568f067aad16c1a100c1c4879fb0c429004e0df6b89885e64273d738215348", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "138c20d5-9e10-4c2c-8bb4-8540f7c23885": {"doc_hash": "8cf14c9ffa8753105a0a5a3072afe4c001ae6cb6351f12fb91dff8b4fbac4e7c", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "67c208bd-0207-49b6-86f1-6f50d1778c74": {"doc_hash": "8b889f9eff3a165cf0ac51dd4c5ea86c4a5ca3688aaee04f6e771eaba88a1b8d", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "9043d293-8809-41d2-9fcf-846b2036490f": {"doc_hash": "e992d3049f4390fec1118d6ce7ed661018cde465e41d4853a991e5af53844052", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "a9467f47-d6c9-4f85-b216-1bdb79529f0f": {"doc_hash": "905e7f4d5d42bce7a43ba14607ebaae80b512fa32fc2efe991a09cd069a7c27d", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "68e74cea-1f89-4c05-8a07-ee61687ce22c": {"doc_hash": "1ca8d93573c7288109769b524afe0827a70432188db0f123258561eea335bc96", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "391b8bff-c6b7-435d-a581-950984f8686b": {"doc_hash": "d4ed6aa70daee7c25902d41ab6f9d431c2f2b8f55381abc801f7e7b7935deb11", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "3ec43f19-d7a0-4fe9-b02b-39c429e8727f": {"doc_hash": "73952189a56c2722aaa78d3996e08a0d22088d56fc01d44a3d9b787c7117e277", "ref_doc_id": "d1ae1264-4732-4177-936b-cd28f69fb016"}, "6391cc6e-a3f9-4e81-899e-61bbcf8b081f": {"doc_hash": "07a46490df30547123773b7a59501a2f54d2aaa8f1b9995ed10efd5a3fa87932", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "56d0b7b8-962b-4304-b5b5-c8a192fb22a6": {"doc_hash": "d558274d8aaa327a6187776aecccff50c8eedc45cc1d64a5f51b1631a2f74ebf", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "dd5a41bf-06b5-49f5-9eed-96778e2c539d": {"doc_hash": "e33f09c07b5360e164e23c1789c5bce141b4c6caed8e66eb8629f12f1bc72c99", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "6ed43fc5-438d-4444-b527-f1f1c4944086": {"doc_hash": "5c9914ad69dc0395dee3aebf17a4f138b75d78c0890524028f12921d029e26c9", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "b2767d92-6822-4469-9706-fc9752cae448": {"doc_hash": "2c8378ea0a60ec88955e98ccf4dcdfe81a87b626b8fc2722478b3ce36df79f3b", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "388a9fab-9edb-46d5-b2ac-062f48b004c3": {"doc_hash": "f2b4564a51169921e15936304d6e74e94b074a681f242752428194925c402aa3", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de": {"doc_hash": "86aff152052a37bcf3fb2b0bf46499bda6936efc5b687729655159dcf63ec71c", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "dd668294-fd5a-4eae-ad7f-45a833e0f2cc": {"doc_hash": "cac94a7360e3e419b16a8cdf7a7b373aefad56dec07f45016d011c1851371f89", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "cad9f854-3fea-498b-8840-e802193963ab": {"doc_hash": "b60c57982e749d5885607261febdfd4299f4ec4bfe3da55925af02725dc7071e", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7": {"doc_hash": "f43f52f56a2ce2393e64946a299c57b6eac622e4bac314c2b1d1d3528a3425e2", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "ac3102f3-46be-49b0-a729-17e49e6fd950": {"doc_hash": "3e352fdae7900798248ce1b9bfa62c33aa34889bfaa097b3c6c7cb4789512322", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "4493bf71-1160-4700-85ff-495850095cc4": {"doc_hash": "eefcc72979bf98b44d45be6d787993fb78a17dccf50c3c196434f7e69da44ab1", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "38561a4e-0e5b-4625-bd28-f02d52c88a11": {"doc_hash": "79687cad3b9d44015289ba1e7f8f3a008be5dce31f385345c26eb1c7023393b0", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "9b813436-5deb-470e-94b4-c7fe0aa1b1c2": {"doc_hash": "f79d086df345b8b03812ec1c9f24b91667e3b6032b16723a751bc031f493fffe", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "435950b2-528c-4a4b-8478-c60a73877603": {"doc_hash": "3ef91143bc286d0c240297d835363603350e07c92e8c5e3e5124ce8061d656a7", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "0ed75657-793d-452f-b727-a495283ffc07": {"doc_hash": "2c87ae4cc6dfa2c818f4fb2b377875132d8ed1deeb95cdd8d378be6e0c5e4c85", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118": {"doc_hash": "90b015e58dfe681bb58b3516452b3ed7dee6f7994d11a73c65d72db79bbadb46", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "551b90ae-1d33-42a1-83cb-518d1f058c71": {"doc_hash": "2b0a2c2a1e8c6344c3b9ad347e9c5e5eddfb8dfe408ac0740a35d0c9280a0067", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "caebd90e-6b8a-4221-8c8d-b965932e6e18": {"doc_hash": "0e92a157c5741772cd8c16fd4cfefe2fa86d7de4465ec58ae69903061cbb23af", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "74163fee-ee65-478a-b3a7-3bf4c0b75042": {"doc_hash": "8101e31b642ec9e2a79b14ea708f2b99dcb44c93c3e194b2de5582061814d393", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "46c12372-93b9-48b1-8d50-be880a060783": {"doc_hash": "02124a865bee75ff1f56c94dcd5640871ac4e7d78a152ebedfedb6a33a0b36dc", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "d6863459-7f7a-4e15-a14b-9afc3210dd96": {"doc_hash": "db56efbf085b643701ea3beff196c1e8883cfe762d66c1fe52aa151f696db284", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "3c7aece8-2d1b-4bd1-bd77-4af203362e97": {"doc_hash": "b0a105c162995ed9a8f2f5a109dad393c72f8eb1345cfe1cc0219283e5c76f07", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}, "963c4d3c-0cff-4257-b200-c5e80e57edfc": {"doc_hash": "2ac5206a44999ae56ec974c85841b2bd3282c8a7898e8f9e243c50e9ec0eceaf", "ref_doc_id": "a744e44c-75af-453a-8c6d-baf9da576fd5"}}, "docstore/ref_doc_info": {"4dcfea83-8c8b-4f2d-ab1e-40de6beee828": {"node_ids": ["41316b80-30ce-400c-8319-4b5b9a65544e", "d0cbf90e-e689-4154-9cb3-aefcbc3b5d58", "cb8e016c-f7d3-477c-8aa0-5c39f9d18a67", "88d9e3e4-2d6d-4039-a939-e84930b32699", "7964f2a6-b9ff-4e38-bb4f-45c60d57f81b", "3c6e526e-b38e-4e84-b1fc-5c50219eb411", "7e937027-1041-4c95-b8d5-c12ec234f856", "9e1a88a7-c2a7-489d-a64b-f43fb6a56de6", "38b53e2a-e72b-43da-a2b8-c4310ce8b6b2", "d448a807-bf5d-4b98-8d68-2f6e0537b1f1", "da81d20e-9b38-4a6f-9046-728898a30251", "cf175af5-9495-4f5d-ad14-a0644b9c7f1a", "ce5141aa-c6e8-4098-b431-cf3d4e59aeaf", "36e972bc-a93e-4e5d-92bb-6fef40446c80", "482a28d0-e57e-461e-a52c-f5da8d113860", "cdd08179-86fb-4a64-b6b6-d286ef58d146", "8236c2a3-ae41-4c98-bd37-bf2bff5640a8", "0f63f061-2dc9-4a60-a782-03291bd22955", "fe41a8c8-851d-4941-b98f-5eae7bd0f6e0", "aadeff19-5668-4197-82ff-60e6a403ce95", "580a089d-064b-4f95-9f48-ffd1e5b5de2d", "13351ad6-18c4-4edf-b783-59cc732822b0", "d1f72ce9-44d2-492f-b5d9-514c1c3ca00e", "ba7ebe22-f746-4016-8a3c-5d5d0f2a0e68", "e4dc5b93-bab6-4152-82bc-59fbd5714aa1", "81d5b8a8-4fde-49c0-8a29-4a256e974224", "1e14199d-38a3-4643-9959-9cfd67b9829e"], "metadata": {"window": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary  5th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Second Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded. ", "original_text": " \nPage 1 of 15 \n \nQ2 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d4db70c3-3b4b-48f3-84b5-5600da184518": {"node_ids": ["9096962c-e6de-453b-81f0-4f0a7c14c50d", "2e287777-3b67-4fa5-b368-15876ee589bb", "bf6f2b5d-02dd-413a-9ec5-9ebe24870787", "b0a3dd09-7b76-47ea-b5dc-effc051e43ce", "74ee92fb-a909-4e99-ab6a-ddb655a87e1e", "8b2df4e2-e8c2-4639-9ae6-5389fe4fec69", "8a7cff0c-7255-4537-93cc-ff3310bd5288", "587dd507-70ff-46d1-a6bd-058f34769e68", "c25b0ce2-4c77-4f2f-ac72-0eede3d16126", "42f2e63a-9af2-4851-a6d9-996e7650569a", "d42c2ca8-1b82-4989-8530-ce7b204a6eec", "7010d3ea-2f93-4a1f-b9f0-3b4ab11579ae", "e29ef39a-cf72-4fea-80f8-a3f12b361598", "f7d190be-0f24-4876-aa2a-3539fe9e9fda", "c21ae3a7-6c2f-44ac-9d32-7277f411e55a", "51ed658d-463f-4b41-86d5-e23fe4a5f44c", "f049eb98-69b3-4313-a3bb-7911a343b9f9", "029fd15a-6aa5-41be-aab0-fa3f6e91bfa5", "db083297-0a34-460b-b861-a785657f5b09", "869540b6-a772-4b4e-a5dc-5751328ee21e", "f3ed47ac-fa16-46ae-a082-4e321cf2bfd0", "3f170178-284f-4887-835c-f090af1a9e7e"], "metadata": {"window": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n  Across the company, we remain focused on doing our part to support ongoing pandemic relief \nefforts.   In Pharma, we partnered with the CDC to act as a network administrator, enabling retail \nindependent, small chain and long -term care pharmacy customers to participate in the vaccination \neffort.   And in Medical, we partnered with the state of Ohio to support vaccine distribution through our \nOptiFreigh t Logistics business.  \n \n ", "original_text": " \nPage 2 of 15 \n \nadversely impact volumes, mainly in gen erics and nuclear imaging, areas like Specialty and \nconsumer health are recovering and performing very well.  \n \n ", "page_label": "2", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3d4594b8-a6c9-4cc4-8c0e-690bca97fe74": {"node_ids": ["d3030068-d6c7-4974-8aea-f422050d5c81", "3c9c3045-d998-45d8-b928-033ebb9598b2", "0969bf37-5972-4827-a7fd-cd5926f77f3b", "4c6cf285-9348-4999-8ee8-2ee746f96589", "ba9d4dea-6a79-4a05-be69-55c28f812414", "37b111a1-83dd-412c-b72d-28b2f6f9e29b", "6a0ff9cc-47db-49ac-87c4-df3b18a5d029", "59199d16-ea90-4b4f-92f7-4e8f44f83a26", "aec4e766-d2f5-4b46-a914-74fd7978dd66", "c23717cc-1fa0-4021-9ff1-74262d576505", "34987c79-8cca-4fdf-a29c-2e245668fa8b", "6daa8ba2-40b6-47f5-9686-8e51b115d42d", "ac2768c5-a8e2-4526-8833-97045f5abdf2", "e9a5b043-67f4-4792-80c2-e3505f575fa0", "d9ebdb1b-9b8c-4df9-8772-134317c08b75", "fd72bfb2-a138-4d63-a88c-b3a552798d4e", "aafff343-a23e-4700-a0a6-cf368e04292f", "16808585-884f-415e-a130-c372c2047d65", "cf10b510-0416-4ad1-a5a5-d34916cc19c6", "93d454cb-6353-4710-bc4e-73b7136ab80a", "7c689f69-0266-43ee-b4f3-fe6b5709ca9d", "37e9dd54-3c4c-47c1-bcad-b22c27bb583c", "8af2f2cd-e31a-4310-8b53-051f33139850"], "metadata": {"window": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.   We generated robust operating cash flow of $1.2 \nbillion during the quarter.   As a reminder, the day of the week in whi ch the quarter ends affects point -\nin-time cash flows.   We ended the second quarter with a cash balance of $3.7 billion and no \noutstanding borrowings under our credit facilities.  \n \n ", "original_text": " \nPage 3 of 15 \n \n Turning to cash flow and the balance sheet.  ", "page_label": "3", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1473a07f-b10a-4654-a4f2-9dee46589993": {"node_ids": ["0f4c776f-89a2-49ae-871c-13849d846452", "0508242e-50ec-4d43-b991-7c4be367cea7", "45bb494a-afb8-47dd-b4a3-3491ca8bf1f3", "62dcb3eb-fe8c-4eb0-a981-222b72a57927", "fdf9a0c7-4d12-45d8-9f97-9c6a9b2c450e", "fa9f6497-f7fd-4520-b9ba-0658a714688b", "06ac2717-7976-40eb-a07c-3976c24371fb", "627bc1cb-a8cf-4c98-b7ce-216a392f08a4", "8e930669-9bb0-4c86-88f9-cce29285a825", "e73d18ba-67ae-4668-8c04-67cdd42fcf06", "ab1a7588-cf8d-417d-b1c5-03e43c707fdc", "f81b1ed6-a6cf-4ca8-b0d4-ae43f1abae0b", "1af2c304-98c0-4c94-8bf0-5f654b53abd0", "0bcae024-848f-4dfb-b0b8-2368b1495b0b", "c33f89dd-323b-4d77-879c-b625e6f4d2b4", "bb6fde54-0de6-4482-9ff0-d2f319acbb8b", "ca646af3-1473-4f33-9a63-d9dab9788a7c", "37cbbcfe-fa97-4e6f-9a70-c8e756054618", "cbbdf6ae-5c62-4ba9-b5c2-4d092c1b3720", "36da6d67-c689-4856-90e3-c2e012572d64"], "metadata": {"window": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.   Also, our generics program, when excluding the previously mentioned volume impact of \nCOVID -19, continued to see ge nerally consistent market dynamics.  \n \n  Next, on slide 8, I will review the updates to our fiscal 21 outlook.   Due to our solid first half \nperformance and better visibility into the back half of fiscal 21, we are raising and narrowing our EPS \nguidance ra nge to $5.85 to $6.10 per share, which at the midpoint, represents 10% year -over-year \nEPS growth.  ", "original_text": " \nPage 4 of 15 \n \n Our Specialty Solutions business continues to demonstrate r esilience, both downstream with \nproviders and upstream with biopharma manufacturers and again achieved strong overall growth in \nthe quarter.  ", "page_label": "4", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6f219db7-eaf2-4ecb-badd-b6060efd6a1c": {"node_ids": ["82385a61-136c-4a8c-86aa-6d6f9db4e4a9", "55982873-aed4-40b1-93a6-9bd3037c9988", "d5f4e526-340f-4681-acf1-5f3bc4c7ae1e", "5c62de11-5ddc-4d32-b1c6-3b7f3b19e185", "60a6a31c-124a-4e06-909b-c5359f3bcc4e", "ff62620c-20dd-444f-98b8-a16953d0651e", "daa83d76-489c-478a-b416-9dd833559298", "5c60d57f-beae-473a-aa98-8bcae190d704", "1a418c45-7adf-43a7-8816-48d08c69abb9", "f09dbee8-9dde-4e62-8db2-4fe248a64a56", "57772ff2-e4fb-42fe-bfa4-3e627a97f57d", "3a184cb5-4478-48a4-8970-55bd3cd70df9", "d3ef7458-f65a-4914-98ce-62d3a623631c", "12cec106-b471-4f95-b861-33cc4adeec37", "8958c496-13a0-418e-a2d3-fba6bf1cdaed", "417e1e19-2ba1-4462-b0f7-3dfcb70790c4", "2e5a667e-a179-4730-8119-83894dde3656", "9851d8d1-32cf-4282-9952-b09fdd4300f5", "1728d0c7-af0f-4fae-ac1b-8d74d6bf31a9"], "metadata": {"window": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n  First, as we've seen throughout the pandemic, we operate resilient business models that can \naddress today's challenges and adapt for the future.   For example, as Jason highlighted, our lab \nbusiness continues to enhance its offerings throughout the pandemic.   Through our Cardinal Health \nbrand portfolio and our distribution relationships, we supply instrumentation, reagents and \nconsumable s, enabling both independent and acute laboratories to support the health of patients.  \n \n ", "original_text": " \nPage 5 of 15 \n \nby efficiently operating resilient business models, deploying c apital with discipline and investing for \ngrowth, all while prioritizing the health, safety and development of our teams.  \n \n ", "page_label": "5", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6789be5e-f109-4922-8dd0-a62444fc7156": {"node_ids": ["584a41f2-9a5c-4dc5-9113-e2c32e6d6610", "c0624134-f566-4acc-8dc4-a08bf3cbda84", "65eabac1-8a23-449c-b09e-e896b7d05b04", "32ef4fe9-c622-4ffc-b4bc-44e722853dc5", "a9091641-1be6-473d-8401-eee06236cf4e", "3d4e3b31-4f0c-46de-aceb-fed3292ba26e", "fcce04ec-0644-40cb-a232-1535f70355e3", "2e917243-f96a-48b8-bfba-9c33c45bf54f", "186a1907-713c-4e8d-b6a8-448a1269f3b3", "cf13a671-f281-4d59-88af-f4bfbe0d43db", "6defaba3-963c-4aa1-8785-7b051ad3522a", "6e10bc90-db83-4678-b26c-1e67705abba1", "cc1dc365-7c84-4e9b-b0dc-13d304989b2a", "950acf64-ecc9-44a9-b795-924569c9635a", "329d4c24-8481-4f4f-b982-5c49a1851d61", "c85053ed-cd95-45c1-b42f-30d593254289", "6125400a-dada-4a21-afe5-607aa84d23ba", "7c59cdaa-c0cd-4370-a323-28c8b991786b", "4a63ffc0-272d-4e59-8d85-b6cbcd5aedd9", "c18337b3-0daf-4e57-8e8a-90c4d4da0b7f", "2db2c777-ab93-4e3f-9245-7bb93b7c00e3", "f579b64c-ee96-40f7-a5f3-b347da7bff64", "979c5c47-cf00-4c83-800e-7ed052deaf83"], "metadata": {"window": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.   From supporting manufacture developm ent of \nradiopharmaceuticals to commercialization and distribution, we are working together to change the \nway patient care is delivered.  \n \n  In addition, our recent customer loyalty survey results were excellent, showcasing our \ndifferentiated value propositio n in the market.   Our efforts over the past six years to transform our \nselling model, strengthen our world -class service levels and launch new products and services are \ndeeply appreciated by our customers, and we are excited about the mid  to long -term fut ure of this \nbusiness.  \n \n ", "original_text": " \nPage 6 of 15 \n \npharmaceutical innovators coming on board.  ", "page_label": "6", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "edfb9551-1ba0-4cd1-ad2c-fa77cd5c11bf": {"node_ids": ["b767b4bf-7909-4f08-bd49-fbd6a5f53672", "cd34ded4-edbe-4c8b-b6ae-b3af0d35d0a8", "3c6d330e-c8de-4687-8328-82f580635dfa", "5a2ce23c-c8e7-425e-a0be-fbe0872d2efd", "ec0b2a52-7ff5-4164-9a23-b0e3df2a3073", "404963e1-9e27-4689-bb67-58e0c5ed8413", "19db79da-6baa-43f6-b5c6-fe1ad3c84fa4", "852442b4-4eb1-4f0b-b51b-f5d96216af6f", "89a604d9-07bc-497e-a3a4-12c09a62eba7", "8f5fafc8-a48c-4b63-b26e-ff01b8f3c2eb", "85a8045a-8d42-48c3-a14b-da87dacb4bf0", "7db24b76-1eb9-4a4e-9c1e-95548879279d", "a479eeac-2946-4ed7-a583-4cb723996afd", "ca2d2d01-1e00-4a04-90f5-0dcacc9208bb", "2666daaf-2137-44a1-aba5-ad28d20ea76e", "97eeddee-b96e-416e-8dd1-67e8233fb477", "0d566364-47ba-4fbd-97ae-a0b205bb5ae9", "44542133-2a98-412d-b5a6-62802656aa42", "a46f37d3-ab13-4e5d-b41a-fa81c83eb99a", "adc0b8ab-d503-4eaf-b286-8f58f92f27b1", "e76b4230-71db-40ce-8eb1-0627e1763d08", "cf67efad-bf21-4e36-a058-f4e07a7c2774", "ffeaaee0-d9f1-4a2c-8153-a9b8eb9c9c7f", "747efa13-661f-47c6-8e88-85cc0871027e", "30ba9764-8b55-4d7b-b3eb-171141b95164", "677852d9-6ee1-45d2-b919-fc1e7333add8", "78566e42-6ccc-4cc0-8ec8-813214e13d1c", "4acd1ff2-dea6-4515-9bce-5c339800f04a", "2d78fe3d-98f4-4515-ac2b-fa1cc05c4cfd", "1567e5ed-5930-48f9-9bd4-9e62c59b7b32", "783ebae3-8a60-4a72-bf3e-fd04d42c6ebe", "08d52977-e156-4f81-9a35-774c0c9df496"], "metadata": {"window": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.   We feel like we're executing really well \non all our initiatives.   And also, from a cost saving standp oint, we're on track.   And then generics, \nwhich is always one of the -- could be one of the swing factors, we're not seeing anything inconsistent \nthere from what we've seen in prior quarters.  \n \n ", "original_text": " \nPage 7 of 15 \n \nthat's kind of off the table from what we've seen in January.  ", "page_label": "7", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "495936fd-d685-4b0c-b89c-4b6138ae239d": {"node_ids": ["6500bcc3-d258-49d2-a7fe-4d89c2cee269", "c0e05c87-1c2c-4887-8482-0d08efaf78ab", "48780eb7-9206-4a6c-b04e-0e4ad9687723", "84434f8d-6ca9-49ad-843a-9fcbcbb401f2", "cdbd9e75-0fbd-4c16-a99d-4f6e7c965dac", "e3450709-6f81-4c93-9394-efc0628c1da5", "e34e79fa-ead0-4351-adb1-0bf644cbd9d0", "03256936-c1fd-4080-8381-5d4b15584600", "48377fc6-3b71-4c41-a31f-15c29fec9fb6", "8307d0c3-2b4e-4c4f-aad5-f7477d34d1c8", "2a9d2d11-abde-414b-8a90-ce2770153515", "661b6b29-dd27-4513-99f6-4b7b38d32841", "fb677824-ca51-45ce-b3f8-d9d213a17532", "19e7dd46-16dc-4c96-b687-8f8cc4f21c4b", "68a52e8d-5115-4f16-923f-1088fa17dd64", "a1cc3470-889a-41d3-a2e7-80ccfef5eeae", "0f436e0c-3bb2-49b0-aa1a-e53aa1018f41", "59db0bd5-c660-453b-a48f-5be24ed9db95", "6135238c-a6c4-432c-a795-6fefa93112ad", "0de47365-6232-4b20-a05d-607fbbe39014", "a59ad682-c82a-4fa0-a067-9f22ce282b48", "581bd16e-c684-4d57-85a1-7f38ca789722", "8274f430-529d-46a8-a8d6-55043318f5f3", "bb13e3c4-aa14-4c57-8808-255fcdd7678a", "824771c2-87c4-4c03-b465-2d8c6facdb36", "93cac268-03b4-4ac1-8f5a-d608f9a3fe3b", "ae0f3473-f188-4784-9bc0-34142b6cf3e6", "dbf15ee1-fc99-4b88-84f0-6973507a5e89", "e165c5f8-b50e-4e1e-b1d1-421911888872", "0b7c67ec-59ec-4ab6-a430-624257ff07cf", "cf01853f-4907-4923-b3c2-32d5a38e8dc2", "6e4d20ff-c488-48f7-9d43-56b6a1d39fb5", "04755824-ca5b-4c57-9a55-87eb76a6b591", "a798bde6-ca31-45b8-aef1-ba1e8e44c822"], "metadata": {"window": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.   And so we wanted to make certain that we had a lot of flexibility going into the \nsecond half of the year.  \n \n  And then the third point I'd make is just that we do continue to make long -term investments in \nour business.   As we've hi ghlighted as our number one capital deployment priority is to invest in our \nstrong pipeline of organic growth opportunities.  ", "original_text": " \nPage 8 of 15 \n \n The other item that we talked about last quarter as well is that we continue to be very \naggressive with our cost control over the first half of the year here, a lot of uncertainty i n the \nunderlying volumes.  ", "page_label": "8", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "583a4136-95fa-435e-b272-086d888555aa": {"node_ids": ["b7ef5d7b-0fe9-487c-b7d2-9cd414622870", "0c3cfcb1-3576-4fb8-afcd-1e807aabd43a", "43a42134-88a4-45d4-9d4a-86218d4c55f0", "a26586fe-22b4-41b9-813e-82b5207e2280", "5f3e0ca6-8ac3-481f-a0dc-a6287c9a22a0", "7fa038cf-b2f1-432e-839c-afee7c0682ba", "be51034f-c8e0-45f5-aade-f9bfca0ee78a", "f9ed4f11-6330-4c00-b71a-24261afcadca", "b0ac6557-84bb-4216-9f17-67d8fec97d43", "79944b41-e5ed-4ffe-a777-f7befdf08eb8", "6bf65428-a692-47f9-b168-914a72c9b078", "0f3c956c-50a2-4017-9b32-16415d483311", "524ad625-806e-4290-a862-182ebfe79eb4", "bf27e2df-038a-4e9f-a039-df186e497372", "5684aec6-6fd9-4d4a-958a-bf7bdb628e07", "015ed896-be11-4f80-9e07-f909b872e9ab", "14eb0e67-f4fc-4338-8c33-5679b5d669ce", "e4c2c2ef-8c37-4a33-9d5c-de3e8bf62eae", "dd3335f1-f7c1-443c-a3b1-ae18c97cc756", "16321123-a2df-43e0-84da-cb7aabe33548", "bac13b59-cd26-4523-8a49-40b24646ecae", "281ab47f-4467-46cc-beaa-64ab3a12696d", "2eb59cff-035f-4e43-869c-6a9b91d6941f", "a11f3730-11a6-4cac-879c-2abaa6e7ce0c", "f9e472ad-a285-420e-b319-80669bb2646d", "5a1480d4-9b7e-4eba-a5ad-1b5b263e083b", "f0be2b1c-97bb-4404-80ed-92c03901b070", "84803eda-274b-49ea-97b8-13c942415c7f", "9b3cd2a1-5d2a-4604-82d3-a1967d70ac26", "16ec4829-a75f-4ea9-ac82-07ffa4d3916e", "d63d601e-7e8d-406e-bb1e-18a084747c37", "8043fc55-be49-498a-9447-1002d39af3e2", "d785f811-648a-47f3-ae7d-28617c1026d4", "58dfc7d5-0d29-4dac-aa84-fa08b73f9112", "b8b51bd7-1b03-46ca-b8c7-75ee66846cee", "cd4fd7ba-58c8-4329-b0fc-900a4251de92"], "metadata": {"window": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.   So it just becomes a \nbit of an uncertain combination of different influences that have driven some of these cost increases \nto be delayed then until later quarters.  \n \n  So overall, our key objective remains the same, to make sure we're mitigating all these cost \nincreases and working with our customers with the supply assurance program.   But the timing is \ngoing to vary, as we said last quarter, and we'll continue to manage that as appropriate . \n \n", "original_text": " \nPage 9 of 15 \n \nwith all the different timing elements of the cost increases and price increases.  ", "page_label": "9", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "256d8a9c-5e34-41c1-906c-a05ba84f9806": {"node_ids": ["def37c16-d276-4ad1-ae81-b89f9e3467de", "0c131b54-ad6c-4f1b-aa46-deead7cca7c8", "bba58b63-1740-47e0-bf0a-5d7f854214b8", "f588fc84-d775-4752-911d-afded57ab07a", "5a50d428-8016-4dc0-babc-eb73dc2c4fc4", "40e27841-fe33-4032-ad35-bf01cb593dfa", "5385341e-847d-4c20-a4da-2901cc6bb15a", "4db677e2-289a-476f-9dbb-617376b26f4a", "2137b0f3-044a-44eb-91bf-91f7e9e82908", "2f569bcc-cf3b-465d-8484-b9014538d57f", "1fba4314-dda4-4dbf-9838-40044393d3ab", "9fa02a4f-0fe7-4407-89db-009c1d8edee6", "d6ec18aa-9e91-4618-9da7-12a4da0dae46", "55408135-3a12-4b26-9e8d-1d90298c703f", "22822b91-5e8c-4d16-ab69-90b535e94c1e", "7f54897e-ca86-4872-9354-37c4516ba08d", "a7aeae1a-232e-4d0f-8f2c-fcf252bc6b3c", "21c7a587-bc07-4ec2-b848-f56dbf1e40f6", "207da6bf-a917-4608-929f-e92119385a3f", "850e71d0-4d08-4f77-a5e5-01ea008a65eb", "77880587-1b8a-4afc-a128-e1d4ee80c9dc", "b1a8a0f9-df24-4d1f-b064-b06846f538e1", "430256e5-a139-4570-9f17-7a97615b6ff2", "29a6eff8-5261-4d1c-a682-41313d7a8ec0", "eef91e4d-51c2-47c1-b5b4-6f14069c5e8a", "91ac4c4a-cbc7-4d1a-a06e-5428afafdb90", "f87d9b6b-a7e4-438b-ae94-8473f12883c6", "e5b6caeb-ee9a-42c2-ada3-967333509e14", "681058e1-63f8-4bb3-946b-65cb06b59392", "1cb46e28-e8b5-49c5-a994-117427e95dfd", "ca772f96-9383-4668-a97e-ab1b043de843", "51e785c9-4590-4bac-9966-7a7706034a7d", "204d73ef-9e0b-4f3b-9d6a-e17bdf306d3d", "5fee4be8-f2ce-4df0-bde8-1c9c9a7c0530", "3d724f73-612b-4981-beba-a16f626e574d", "a2537069-940b-43a0-848f-b07ab4309033", "9fc98085-ec85-4375-be24-0a7fd7086067", "f32ee4bf-a7b2-4feb-9a8c-f03d74b8a455", "a5ccafa7-8092-4a3c-9e0e-9667b919818d", "7a59edbc-163a-496f-a952-cf50693d10c3", "e4dc3cef-6bda-4af2-9438-df6cfc763d6d"], "metadata": {"window": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance.  It looks like you rais ed the share count guidance but you lowered the \ninterest expense guidance.   And I appreciate the comments you made with respect to the deferred \ncomp adjustments.   But I was just curious if you're changing at all your capital deployment priorities in \nthe ne ar term?  ", "original_text": " \nPage 10 of 15 \n \n \nGlen Santangelo:  Jason, I just wanted to ask a quick question about your share count guidance and \nyour interest expense guidance. ", "page_label": "10", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "32fdabc7-6624-46ed-8dba-39e6300a793c": {"node_ids": ["ba54a53a-eec6-499e-a23f-392ddb84db11", "666f21a7-2dc6-4fbc-aba1-2a17af784435", "6b3798a8-cd8f-4252-a121-fd8d4d2dd34e", "62f82180-d4bd-42ce-8daa-bfb51b93189f", "a064290d-f47e-4a38-932f-9987b00dcaec", "bdd175dd-4391-4024-bfc2-84fc6498b356", "eaddef56-5007-4d25-8172-6cc173aa9e46", "61f8ee6a-9aa1-4424-a3f3-1a093a73532f", "46f368f2-6567-4762-aa50-b18707f5219b", "7da9b68e-9992-485b-8f78-b09bc4de6448", "cff6925c-2e5e-41bf-9b81-290e36d24fd3", "480e2e63-0ecb-4af8-bdb8-f31d9e7283de", "178a3e5d-0b17-46cc-8b08-95a1936b54e3", "a41c38bf-efcc-4113-9e73-3d63337ceb3e", "6128da6c-4227-47dd-bc17-0cb49dd915ba", "131a347d-87fe-4960-bb0d-a63c9021cb86", "4d847bdf-2b40-41bd-9b43-829fc294ffbb", "7a3f1674-f812-4b3b-abad-d614a6cb07f5", "97614a4b-bcd1-47c6-b491-3180efb18d06", "755a1a7b-e848-45b1-ba41-26d5b1f2d961", "e6a8785c-9c80-432c-aff7-cc9c33c5e89e", "91f25c31-cc07-4555-8649-d01bb9e43541", "a78a1031-1173-4cdf-8f95-23c9b160d829", "0c929b1d-e40c-4b50-bcfa-cff3abaa31fe", "ad62c846-5cdc-406b-bfb6-7faf6387d93e", "2492aecd-f9d3-447e-a904-836f3f5efb97", "beaa8262-c155-42fb-9d66-45351f293e72", "4f84127c-147b-4aa0-a89a-c5e823a2326e", "5b793907-f13b-477b-88bc-c79bc4a09328", "8f016554-57bd-404c-abbe-131a6d053cc1", "ca184415-b10d-4660-be4a-f5cd66172646", "77b827a6-cf68-4bec-b49c-f7dba7447068", "a4517ada-2091-4e40-90c0-f2499f64b50a", "6bd6ce8c-905c-4bbd-b5a3-fe97eb421668"], "metadata": {"window": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.   Do we \nthink this is the new norm al or at some point in the future are we going to have to worry about PPE \nprice deflation?  \n \n Jason Hollar:  Yes.   So let me start, at least with the first part.  ", "original_text": " \nPage 11 of 15 \n \nAnd Mike, I guess, I'd be interested in your commentary on how long pricing stays elevated.  ", "page_label": "11", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "57fb6302-0f70-41bd-974c-4700d10f9792": {"node_ids": ["612d97bf-75a9-4cec-9b5f-454b2ae5102b", "944cf015-7afe-4e31-8e65-6ce68cdadb05", "6a464662-7c18-4007-b0a4-51a3390446d0", "bc1b9acd-9c85-4bf9-a33f-b27c26dc15cd", "73277778-cfcf-4ffb-93c2-572503da11e8", "f4aa8797-5214-44a1-864c-7ea819abcd79", "aaf47d3e-c231-4a9f-b4eb-91dba257a3ff", "b3c4cb82-c175-48ba-8578-ae97724b7526", "01f559af-c498-49df-bb21-73491491933f", "8ce9421c-4dff-40a5-8839-79e40ed409fe", "67c9b484-13f2-483a-aeae-8c6663e7744f", "1904f48a-436f-45eb-9529-c875b7462db0", "b93ee8f9-bc8b-422f-aeca-0b8cb4dd19da", "a13ec4a1-5f44-4d5e-9c9b-6b4093f893f1", "a8c9d54e-eb50-47ea-a6f7-0fc3061b8b7c", "c4549a4f-861d-4de8-a316-0a9a8fe5449b", "3508fe72-9527-4348-b20d-7d4e7b4abf90", "3c189852-af7f-46d2-8a13-59f605c869bd", "d6f4f168-2162-47bf-88ea-7d49ddcb1b89", "61a23bf6-5eb1-4652-bda6-e3d026292e2a", "b0e24a25-4e59-4877-9d4e-3000964918ef", "747b3b2b-6d17-4912-853a-f5aa15d4af0b", "f54027e8-c12c-4409-a95a-2b297e60416d", "e4dd4516-e597-44db-8737-44d59108ea4a", "bf6520f4-2049-462e-87d9-dc0d16f2dcd9", "29123dc7-4108-44c0-b518-2add9d8ffb27", "496b1b1c-3428-445a-9e75-061e97e26b34", "23a483d7-ca9c-4ff7-b740-d3a452f5e783", "f3f9fa52-28ba-4743-8553-ef0bc830ad86"], "metadata": {"window": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.   And so rest of the program continues to be as we \nexpected , we continue to see that program , all the various components that we have in it are \nessentially working as we expected with just COVID being the driver.   So again, as COVID begins to \nbe less and less of an impact, we would expect to see our volumes on  our generics program grow.  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 12 of 15 \n \n \n And then again, as far as generics go, yes, the main reason that we have seen that our \ngeneric volumes are off is because of COVID.  ", "page_label": "12", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4863c1fe-d413-40b8-9259-2a1ec9b6b013": {"node_ids": ["7fd67ea5-3fca-4308-9c37-4dc1d3e10e2c", "ff20df27-6df0-4ae9-bd90-6b1afa72c3be", "7bef3c43-0093-4113-b853-9b368900720e", "c2a4a86a-dd9c-4464-9cb1-3ee921ae8c7d", "32fd547b-0885-419a-8850-a1f8a41ee111", "c725811a-a895-4ea2-b866-580b299b2d75", "72206fe9-11cd-4f9e-98b7-7df419eaad72", "82fbff9a-80a5-4575-a4e0-4cc02f6f383d", "18b9ae79-2b3b-43a0-8476-4596d517b24e", "4932a5fb-f4a2-4b4b-bc20-dca4d5727026", "51c1c902-0d22-4467-8a63-3717faa3a227", "47e19cdb-37bf-4e2d-949c-f10a6ea8a320", "fa921067-a722-4ea3-a846-919959761dda", "f32bb6a0-bc45-4ad1-9602-0e02774e66be", "1c5bfb79-9635-4836-be0a-d5e1a903f1f7", "d4fd3a87-1655-4e54-9a70-e930f20ecfd9", "a4e2abed-964b-40ef-9b6a-50d8fc645db2", "efd13549-6823-45fd-9b32-9d42b50c33f5", "eba1b936-d3d1-4472-94c3-0513de876214", "a34894f1-bdaa-44e4-a6cb-caa4a23e0fed", "6528133f-d847-431f-9a79-6ac8841602a6", "016dedb5-df60-4e72-97b4-4189389e59b2", "daf780bd-38cd-4868-9d6e-a2b090817655", "25d3a672-04d5-437f-ba9a-22b77d55bbe0", "fc1f5d81-25dc-4fbf-a9fa-4469eeb415f2", "6ef14a0f-9cbd-4293-8d20-e75729a1394e", "fbe74d38-7c39-45d3-8f95-26b658e64121", "fdb1b0d0-24aa-4729-aff9-74d1ad580bd1", "a180df14-e7e2-4617-81e9-f23c86ecdf7b", "d1cd7436-46c9-4e52-8be2-d3ee66470ed5", "70fbc380-241f-4491-ac19-29b784f5ac37"], "metadata": {"window": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?   Just wanted to get more color \non the decline in profits in fiscal 2Q versus the f iscal 1Q?  \n \n Jason Hollar:  Yes.   As Mike mentioned earlier, we saw very consistent type of performance in a \nnumber of categories sequentially, Q1 to Q2 when we talked about the COVID impacts, we talked \nabout generics in general, the consistent market dynami cs. \n \n ", "original_text": " \nPage 13 of 15 \n \ncomp a little bit tougher in the December quarter that we overlooked?  ", "page_label": "13", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d1ae1264-4732-4177-936b-cd28f69fb016": {"node_ids": ["44441188-4fbe-4a00-a3c5-2c777b6ffae9", "c7822cc6-d984-46d5-a9a0-4d3b1fb17b67", "31d94e98-6604-445d-95f7-ee093c450ba9", "64a9bc0b-b0e0-4278-a26b-73796eb904e7", "66092dcb-b49f-46bc-9a5e-ad05e856ee8a", "47061b9b-8e56-4f13-8aac-fe4338696347", "eb58f66f-4abf-4546-ac8d-f9842ed657d0", "1dd1aee6-6f40-4299-8d79-24895b066a43", "c4c450ba-e362-4427-8e36-f1a4c6c18d9e", "86ef51fb-b0f1-4af4-acaa-8e74a6cd7efc", "5ff218e9-ca17-4d4c-b1fd-b39c8098467d", "093e9060-ee6e-40d9-adf2-0a3bf20a9aae", "b2ad8317-ffd3-4703-bc20-aaaa26ca3f8f", "4c9208e2-7ac9-4be3-8551-f480d53ab37e", "c30dd8de-33f3-4369-8cdf-a1be278dd7d4", "a96f82a1-0894-4548-a329-1c2578aaa006", "098c25e3-9a80-40d2-b16e-441dd8309ed5", "7e8f9477-67b8-4762-88d3-7eb3df3f7142", "138c20d5-9e10-4c2c-8bb4-8540f7c23885", "67c208bd-0207-49b6-86f1-6f50d1778c74", "9043d293-8809-41d2-9fcf-846b2036490f", "a9467f47-d6c9-4f85-b216-1bdb79529f0f", "68e74cea-1f89-4c05-8a07-ee61687ce22c", "391b8bff-c6b7-435d-a581-950984f8686b", "3ec43f19-d7a0-4fe9-b02b-39c429e8727f"], "metadata": {"window": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.   And as such, \nwe'd expect it to be permanent.  \n \n Mike Kaufmann:  Yes.   And the only thing I would add to that is, as Jason mentioned earlier, \nremember that because of some o f the strong performance we've had in Medical and in the business \nin the first half, there are some areas in Medical expenses where we are investing in the business, as \nwe've talked about from a capital standpoint.  \n \n ", "original_text": " \nPage 14 of 15 \n \nwithin our SG&A expense, it's within our global manufacturing and our supply chain.  ", "page_label": "14", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a744e44c-75af-453a-8c6d-baf9da576fd5": {"node_ids": ["6391cc6e-a3f9-4e81-899e-61bbcf8b081f", "56d0b7b8-962b-4304-b5b5-c8a192fb22a6", "dd5a41bf-06b5-49f5-9eed-96778e2c539d", "6ed43fc5-438d-4444-b527-f1f1c4944086", "b2767d92-6822-4469-9706-fc9752cae448", "388a9fab-9edb-46d5-b2ac-062f48b004c3", "30ac3f7a-22b5-42ae-9de0-d0558ff0c7de", "dd668294-fd5a-4eae-ad7f-45a833e0f2cc", "cad9f854-3fea-498b-8840-e802193963ab", "0ce9df47-edf0-4b07-bfff-b0a7d707b9e7", "ac3102f3-46be-49b0-a729-17e49e6fd950", "4493bf71-1160-4700-85ff-495850095cc4", "38561a4e-0e5b-4625-bd28-f02d52c88a11", "9b813436-5deb-470e-94b4-c7fe0aa1b1c2", "435950b2-528c-4a4b-8478-c60a73877603", "0ed75657-793d-452f-b727-a495283ffc07", "7f1ad774-8c9d-4ddf-bfa6-9246dbfe2118", "551b90ae-1d33-42a1-83cb-518d1f058c71", "caebd90e-6b8a-4221-8c8d-b965932e6e18", "74163fee-ee65-478a-b3a7-3bf4c0b75042", "46c12372-93b9-48b1-8d50-be880a060783", "d6863459-7f7a-4e15-a14b-9afc3210dd96", "3c7aece8-2d1b-4bd1-bd77-4af203362e97", "963c4d3c-0cff-4257-b200-c5e80e57edfc"], "metadata": {"window": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n And that can create some different opportunities for us to work with them.  \n \n  So I do think the entire supply chain will adjust over the next couple of years as it relates to \ninventory.   But the important thing to note is that as we work with our customers on this, we would -- \nand suppliers, we would expect to get compensated from both in order to provide that typ e of service.  \n \n", "original_text": " \nPage 15 of 15 \n \n \n But I also believe that customers are looking a t what they warehouse and don't warehouse and \nthat mix of what they warehouse may be more towards these PPE -related items versus other ones.  \n", "page_label": "15", "file_name": "CAH-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 182864, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}